

2026 ASCO[®]
ANNUAL MEETING



PROGRAM

THE SCIENCE AND PRACTICE OF TRANSLATION:

Improving Cancer Outcomes Worldwide

May 29–June 2, 2026

McCormick Place | Chicago, IL & Online

asco.org/am-program | [#ASCO26](https://twitter.com/ASCO26)

Wi-Fi Network: ASCO26 | No Password Required

Contents

Scientific Sessions	2
Annual Meeting Program Information and Access	4
CME, MOC, and Symposium Feedback	5
Conflict of Interest Disclosure	5
Policies	5
Ancillary Educational Events	5
Onsite Details	6
Planning Committees	8
Awards	12
Industry Expert Theater Schedule	14
Program by Day	17

Scientific Sessions

Breast Cancer—Local/Regional/Adjuvant

Oral Abstract Session	55
Rapid Oral Abstract Session	157
Poster Session	162

Breast Cancer—Metastatic

Oral Abstract Session	194
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: The Future of Immunotherapy for Breast Cancer	93
Rapid Oral Abstract Session	123
Poster Session	168

Care Delivery/Models of Care

Oral Abstract Session	188
Clinical Science Symposium: Global Strategies to Overcome Barriers in Cancer Care Access	53
Rapid Oral Abstract Session	19
Poster Session	28

Central Nervous System Tumors

Oral Abstract Session	82
Rapid Oral Abstract Session	125
Poster Session	174

Developmental Therapeutics—Immunotherapy

Oral Abstract Session	90
Clinical Science Symposium: Making It Personal: Targeting Tumor Neoantigens	187
Rapid Oral Abstract Session	26
Poster Session	55

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Oral Abstract Session	131
Rapid Oral Abstract Session	194
Poster Session	63

Gastrointestinal Cancer—Colorectal and Anal

Oral Abstract Session	91
Rapid Oral Abstract Session	193
Poster Session	34

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Oral Abstract Session	158
Rapid Oral Abstract Session	161
Poster Session	41

Genitourinary Cancer—Kidney and Bladder

Oral Abstract Session	20
Clinical Science Symposium: New Approaches to Curing Bladder and Kidney Cancer	26
Rapid Oral Abstract Session	131
Poster Session	94

Genitourinary Cancer—Prostate, Testicular, and Penile

Oral Abstract Session	83
Clinical Science Symposium: Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer	188
Rapid Oral Abstract Session	126
Poster Session	99

Gynecologic Cancer

Oral Abstract Session	21
Rapid Oral Abstract Session	27
Poster Session	132

Head and Neck Cancer

Oral Abstract Session	92
Clinical Science Symposium: Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer	130
Rapid Oral Abstract Session	189
Poster Session	70

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Oral Abstract Session	195
Rapid Oral Abstract Session	54
Poster Session	138

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Oral Abstract Session	84
Rapid Oral Abstract Session	18
Poster Session	141

Hematologic Malignancies—Plasma Cell Dyscrasia	
Oral Abstract Session	22
Rapid Oral Abstract Session	121
Poster Session	145
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other	
Oral Abstract Session	162
Rapid Oral Abstract Session	126
Poster Session	104
Lung Cancer—Non–Small Cell Metastatic	
Oral Abstract Session	18
Clinical Science Symposium: Is the Juice Worth the Squeeze: Challenges in Combination Therapy for Non–Small Cell Lung Cancer	26
Rapid Oral Abstract Session	54
Poster Session	109
Medical Education and Professional Development	
Clinical Science Symposium: Oncology 2.0: How Artificial Intelligence Is Closing the Information Gap—Or Is It?	121
Rapid Oral Abstract Session	20
Poster Session	148
Melanoma/Skin Cancers	
Oral Abstract Session	132
Clinical Science Symposium: Accelerating Adoptive Cell Therapy in Melanoma: Are We Sold on Cells?	189
Rapid Oral Abstract Session	85
Poster Session	116
Pediatric Oncology	
Oral Abstract Session I	92
Rapid Oral Abstract Session I	23
Rapid Oral Abstract Session II	27
Poster Session	178
Prevention, Risk Reduction, and Genetics	
Oral Abstract Session	196
Rapid Oral Abstract Session	122
Poster Session	179
Quality Care/Health Services Research	
Oral Abstract Session	93
Rapid Oral Abstract Session	82
Poster Session	149
Sarcoma	
Oral Abstract Session	84
Clinical Science Symposium: To Boldly Deliver Where No Drug Has Gone Before: Antibody-Drug Conjugates in Sarcoma	130
Rapid Oral Abstract Session	127
Poster Session	183
Symptom Science and Palliative Care	
Oral Abstract Session	159
Rapid Oral Abstract Session	90
Poster Session	75
Cross-Cutting Theme Sessions	
Highlights of the Year I	89
Highlights of the Year II	129
Highlights of the Year III	193
Plenary Session	124
Special Clinical Science Symposium: ctDNA in Clinical Practice: From Detection to Clinical Decision-Making	25
Special Clinical Science Symposium: Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials	121
Special Clinical Science Symposium: From Data to Decisions: Applying Artificial Intelligence for Smarter, More Accessible Cancer Care	157

Annual Meeting Program Information and Access

Stay up to date with the digital Annual Meeting program, accessible by website or app, which offers the latest session and speaker information.

Meetings App:

Download the ASCO Meetings Mobile App for Apple or Android devices. Scan the appropriate QR code below to access your device's app store:

Apple



Android



Abstract Key

Abstract numbers may include the following prefixes:

LBA: Late-Breaking Abstract

TPS: Trials in Progress Abstract

Cross-Cutting Tracks

The topics of artificial intelligence, clinical trials, geriatric oncology, global health, immunotherapy, survivorship, and value are important for all oncology professionals and cut across disease- and topic-based tracks. These cross-cutting themes have been incorporated into sessions of every track throughout the Meeting. For sessions that feature a cross-cutting track, search by track in the Program Guide.

Session Types

Scientific Program

Plenary Session

Abstract presentations in this session showcase scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field serve as discussants placing clinical research findings into perspective and sharing implications for future research.

Highlights Sessions

Expert discussants provide an overview of the most impactful and practice-changing updates within a specific disease track. Presentations focus on key findings and placing abstracts into clinical context.

Oral Abstract Sessions

Presenters summarize their novel research findings and provide background on their methodologies. Discussants analyze the significance of each abstract within the context of current knowledge, highlighting clinical application and implications for future research and practice. Abstract presenters and discussants answer questions during a moderated panel discussion.

Clinical Science Symposia

Presenters summarize research findings, while discussants place the abstracts in the appropriate context with a focus on how the findings apply to clinical practice. Abstracts in these sessions may span disease sites or disciplines, but they are unified by their focus on a key scientific topic.

Rapid Oral Abstract Sessions

Presenters give an overview of their novel research and answer questions during a moderated panel discussion.

Poster Sessions

Presenters outline their research via posters displayed throughout their assigned session(s). Authors are available to answer questions from attendees regarding the data presented. Electronic posters and supplemental materials are available online beginning on the day of their assigned Poster Session(s).

Educational Program

Education Sessions

Education Sessions offer interdisciplinary or multidisciplinary explorations of focused areas of clinical oncology. ASCO's Annual Meeting Education Committee determines the topics and format for these sessions that will best serve the educational needs of Annual Meeting attendees. Particular care is taken to ensure that these sessions address multidisciplinary issues, symptom management, health services research, international perspectives, and pathology, as appropriate.

Case-Based Panels

The Case-Based Panels will center on a case-based discussion and utilize interactive technology to poll the audience throughout the duration of the session.

Award Lectures

The Award Lectures will center on an exciting topic or research area related to the achievement of special award recipients.

Opening Session

The Opening Session includes the President's Address, presentations by guest speakers, recognition of top donors, David Karnofsky Science of Oncology Award lecture, and recognition of special award recipients and the Fellows of the American Society of Clinical Oncology (FASCO).

Workshops

Workshops are limited attendance, in-person-only sessions designed for interactive discussion and small group exercises. Please note: Workshops are not available on-demand after the Meeting.

Annual Business Meeting (ASCO Members Only)

The ASCO Annual Business Meeting is for ASCO Members to hear updates on the state of the Society. Members are encouraged to preregister online to attend this event. Please note: This session is not available on-demand after the Meeting.

CME, MOC, and Symposium Feedback

Sessions at the ASCO Annual Meeting will provide Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points for physicians.

Participants should use the ASCO Meetings app or online program to:

- Claim CME credit for sessions
- Request ABIM, ABP, ABS, ABOHNS, and/or ABS MOC points
- Provide feedback on sessions



Share Feedback on your Meeting Experience:
Download your Certificate of Attendance at profile.asco.org.

Please visit am.asco.org/continuing-education for more information about how to claim credit and request MOC points for ASCO Annual Meeting sessions.

CME claims and MOC requests are due by September 3, 2026.

For questions or assistance, contact customerservice@asco.org or visit ASCO Central onsite.

Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I=Immediate family member; Inst=My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

Please email coi@asco.org with specific questions or concerns.

Policies

Important policies for this Meeting, including the Attendee Code of Conduct, are available at am.asco.org.

Ancillary Educational Events

Ancillary educational events are hosted independently by other CME-accredited providers and are held adjunct to the 2026 ASCO Annual Meeting. They are not official events of the 2026 ASCO Annual Meeting and are not sponsored, endorsed, or accredited by ASCO, Association for Clinical Oncology, or Conquer Cancer, the ASCO Foundation.

For an up-to-date listing of events, please scan the QR code below.



The 2026 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors:

Meeting Sponsorship Platinum Level Donors: Daiichi Sankyo, Inc.; Genentech BioOncology; Johnson & Johnson; Novartis

ASCO and Conquer Cancer gratefully acknowledge the following major 2026 ASCO Annual Meeting Track donors:

Annual Meeting Track Donors (Conqueror): Genentech, a member of the Roche group; Johnson & Johnson; Merck & Co., Inc.

Annual Meeting Track Donors (Visionary): AbbVie, Inc.; AstraZeneca; BioNTech; Novartis

Onsite Details

ASCO Headquarters Office

Badge reprints and assistance is available in N427bc.

Emergency Response for Visitors

If an alarm sounds in McCormick Place:

- Horns and strobes will turn on
- Visitors will be directed over the public announcement system to exit through the closest "Emergency Exit"
- Doors marked as "Stairs" also serve as emergency exits

In the event of a power failure, all emergency systems will run on emergency power. Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place.

Faculty Registration and Ready Room

All faculty will check in at the Faculty Registration and Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty and oral abstract presenters should report to N426 to review their presentations at least 4 hours before their scheduled session.

Exhibit Hall

Located in the South Building, Level 3, Hall A, the Exhibit Hall hosts exhibits, posters, the Industry Expert Theaters, Innovation Hub, a Food Court, and ASCO Bistro. The exhibits highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet representatives from pharmaceutical companies, scientific publishers, and advocacy groups. Posters are located on the far-right side of the Exhibit Hall and can be accessed from the Grand Concourse entrance or from the S101 lobby. The Poster Pickup desk is in the S101 lobby.

A print copy of the Exhibitor Directory is available at materials pick up locations and the main entrance to the Exhibit Hall.

Exhibits are open Saturday through Monday, 9:00 AM–5:00 PM. Poster Sessions are open during the times listed in the program. Poster presenters can hang their posters 30 minutes prior to their Poster Session.

Industry Expert Theater

The Industry Expert Theater, located in the back of the Exhibit Hall, to the left of the Food Court, brings together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies. If the IET company chooses to post their in-person session recording online, the session audio and slides will be available for on-demand viewing after the Meeting at am.asco.org. Review the Theater schedule in this program or at am.asco.org.

Career Fair

Located in Hall C (North Building, Level 2), this area allows you to meet face to face with recruiters and engage in additional networking opportunities. The career fair is open Friday through Sunday.

Communities of Practice

ASCO Communities of Practice provide an opportunity for individuals to come together and build community, fellowship, networking, and goals collaboration, both onsite at the Annual Meeting and virtually throughout the year. Interested attendees are welcome to join.

- **Adolescent and Young Adult (AYA):** Sunday, May 31, 4:30-6:00 PM; E253ab
- **Alliance for the Support and Prevention of Immune-Related Events (ASPIRE):** Saturday, May 30, 4:30-6:00 PM; S501abc
- **Artificial Intelligence:** Sunday, May 31, 4:30-6:00 PM; S103
- **ASPO/Cancer Prevention:** Friday, May 29, 1:00-2:30 PM, E253cd
- **Cancer Care for Veterans:** Saturday, May 30, 10:00-11:30 AM; S103
- **Ethics:** Saturday, May 30, 8:00-9:30 AM; E253ab
- **Geriatric Oncology:** Sunday, May 31, 4:30-6:00 PM; E253cd
- **Global Oncology:** Sunday, May 31, 8:00-9:30 AM; E253cd
- **Health Policy:** Saturday, May 30, 8:00-9:30 AM; E253cd
- **Hospital-Based Oncology:** Monday, June 1, 8:00-9:30 AM; E253ab
- **International Medical Graduates (IMG):** Friday, May 29, 1:00-2:30 PM; E253ab
- **LGBTQ+:** Friday, May 29, 4:00-5:30 PM; E253cd
- **Medical Education:** Saturday, May 30, 8:00-9:30 AM; S103
- **Palliative Care:** Saturday, May 30, 4:30-6:00 PM; E253cd
- **Radiopharmaceutical Alliance and Information for Support and Education (RAISE):** Monday, June 1, 4:30-6:00 PM; E253cd
- **Survivorship:** Monday, June 1, 8:00-9:30 AM; E253cd

Services Available at McCormick Place

- **ASCO Store:** North Building, Level 3, ASCO Central
- **Customer Service, Technical Assistance, Continuing Education:** North Building, Level 3, ASCO Central
- **First Aid Stations:** South Building, Level 2.5 near Business Center; East Building, Level 1 near Arie Crown Theater
- **Headshots:** North Building, Level 3, outside Hall B1
- **Hotel Assistance Desk:** North Building, Level 3, ASCO Central
- **Interpreter Language Assistance:** North Building, Level 3, ASCO Central
- **Internet Stations With Printers:** North Building, Level 2.5
- **Member Services Desk:** Registration; ASCO Central; ASCO Booth
- **Nursing Room:** North Building, Room N227a
- **Prayer/Meditation Room:** North Building, Level 3, ASCO Central
- **Registration:** North Building, Level 2, Hall C
- **Wellness Zone:** South Building, Level 1 S103 lobby

Shuttle Bus Service

Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels, except those within walking distance. The complete shuttle schedule is available at am.asco.org. Please be sure to check the ASCO Shuttle sign in your hotel for any changes. Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes.

Hours of Operation

Friday 8:00 AM–7:00 PM*
Saturday-Monday 6:45 AM–7:00 PM*
Tuesday 6:45 AM–1:30 PM*

*Last shuttle departs McCormick Place at this time, and last shuttle departs hotels coming to McCormick Place approximately 90 minutes prior to this time.

If you have any questions regarding the shuttle or would like to make a reservation for a wheelchair-accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call Kushner & Associates at 312-808-2000.

Airport Shuttle

Shuttle service will be available from McCormick Place to O'Hare International Airport on Monday and Tuesday. Tickets can be purchased at the Airport Shuttle Desk at Gate 3 from Sunday to Tuesday.

Planning Committees

2025–2026 ASCO Board of Directors

Officers

Chair of the Board

Robin T. Zon, MD, FACP, FASCO

President

Eric J. Small, MD, FASCO

President-Elect

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO

Past President

Lynn M. Schuchter, MD, FASCO

Treasurer

Carolyn B. Hendricks, MD, FASCO

Treasurer-Elect

Kathleen N. Moore, MD, MS, FASCO

Directors

Fredrick Chite Asirwa, MD, MBChB, FASCO

Toni K. Choueiri, MD, FASCO

Melissa S. Dillmon, MD, FASCO

Jhanelle E. Gray, MD, FASCO

Clarissa Mathias, MD, PhD, FASCO

Ann H. Partridge, MD, MPH, FASCO

Debra A. Patt, MD, PhD, MBA, FASCO

Abby R. Rosenberg, MD, MS, MA, FAAP, FASCO

Sonali M. Smith, MD, FASCO

Jennifer S. Temel, MD, FASCO

Jason R. Westin, MD, MS, FACP, FASCO

Karen M. Winkfield, MD, PhD, FASCO

Ex-Officio Members

Clifford A. Hudis, MD, FACP, FASCO, ASCO Chief Executive Officer

Howard A. Burris III, MD, FACP, FASCO, Chair of the Conquer Cancer Board

2026 Conquer Cancer, the ASCO Foundation Board of Directors

Chair

Howard A. Burris III, MD, FACP, FASCO

Treasurer

Alexander Casdin, FASCO

Secretary

Amy C. Peterson, MD, FASCO

Chief Executive Officer

Nancy R. Daly, MS, MPH, ex-officio

Executive Vice Chair and ASCO Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO, ex-officio

ASCO President

Eric J. Small, MD, FASCO, ex-officio

Directors

Kathryn Beal, MD, FASCO

Bill Behnke

Riccardo Braglia, FASCO

Otis Webb Brawley, MD, MACP, FASCO

Lawrence H. Einhorn, MD, FASCO

Phillip G. Febbo, MD

Jasmine V. Ferrer, PhD, MPH

Raj Mantena, RPh, FASCO

Thomas A. Marsland, MD, FASCO

Robert J. Mayer, MD, FASCO

Gerald J. McDougall, FASCO

Steven T. Rosen, MD, FACP, FAIMBE, FRAP, FASCO

Alexandra E.F. Shapiro

Sandra M. Swain, MD, FACP, FASCO

Margaret Tempero, MD, FASCO

M. Teresa Alonso Thompson

Deanna B. van Gestel, FASCO

Cancer Communications Committee

Julie R. Gralow, MD, FACP, FASCO

Jane Lowe Meisel, MD, FASCO—Chair

Michael Lowe, MD, MA—Chair-Elect

David R. Spigel, MD, FASCO—Immediate Past Chair

April K.S. Salama, MD

Brian I. Rini, MD, FASCO

David Schiff, MD

Eleonora Teplinsky, MD, FASCO

Fumiko Chino, MD, FASCO

Glenn J. Hanna, MD

Ignacio Duran, MD, PhD

Jennifer F. Tseng, MD

Joel N. Saltzman, MD, FASCO

Julian C. Hong, MD, MS

Krish Patel, MD

Laura Vater, MD, MPH

Manmeet Singh Ahluwalia, MD, MBA, FASCO

Marcin Chwistek, MD, FAAHPM

Olatoyosi Odenike, MD, FASCO

Olga Kantor, MD

Oreofe Olukemi Odejide, MD, MPH

Rachna T. Shroff, MD, FASCO

Rebecca Alexandra Dent, MD, FASCO

Rodrigo Ramella Munhoz, MD, PhD

Samuel U. Takvorian, MD, MS

Steven Z. Merlin, BS

Tara Michelle Graff, MS, DO

Toby Christopher Campbell, MD, MS

Vishwanath Sathyanarayanan, MD

William K. Oh, MD

William Kevin Kelly, DO, FASCO

Annual Meeting Education Committee

Erika Ruiz-Garcia, MD, MS—Chair
Ethan Basch, MD, MSc, FASCO—Chair-Elect
Cardinale Smith, MD, PhD—Immediate Past Chair

Breast Cancer

David W. Cescon, MD, PhD, FRCPC—Track Leader
Bethany Marie Anderson, MD
Alexandru E. Eniu, MD, PhD
Cheryl Ann Ewing, MD
Henry Leonidas Gomez, MD, PhD, DHSc, MHA
Stephanie L. Graff, MD, FACP, FASCO
Sonya A. Reid, MD, MPH
Jennifer Shin, MD, MPH
Stephanie M. Wong, MD, MPH

Care Delivery and Quality Care

Jackson Orem, PhD, MBChB—Track Leader
Christopher M. Booth, MD
Dame Idossa, MD
Lisa A. Kottschade, APRN, MSN, CNP, NP
Estelamari Rodriguez, MD, MPH
Ramila Shilpakar, MD, DM
Dan Sayam Zuckerman, MD, FASCO

Central Nervous System Tumors

James A. Balogun, MBBS—Track Leader
Annick Desjardins, MD, FRCPC
Mark Charles Korpics, MD
Kathryn Sara Nevel, MD
Katherine B. Peters, MD, PhD, FAAN

Developmental Therapeutics—Immunotherapy

Raghav Sundar, MD, PhD—Track Leader
Matteo S. Carlino, PhD, FRACP, MBBS
Bridget P. Keenan, MD, PhD
Kristen Renee Spencer, DO, MPH
Naoko Takebe, MD, PhD

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Lola A. Fashoyin-Aje, MD, MPH—Track Leader
Allen Lee Cohn, MD
Giuseppe Curigliano, MD, PhD
Sarah Derks, MD, PhD
Janice M. Lu, MD, PhD

Gastrointestinal Cancer—Colorectal and Anal

Aaron J. Scott, MD—Track Leader
Prajnan Das, MD, MPH, MS
Sebastian Mondaca, MD
Priyadarshini Satyajit Pathak, MBBS
Benjamin Adam Weinberg, MD

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Do-Youn Oh, MD, PhD—Track Leader
Andrew S. Epstein, MD
Alexandra Gangi, MD, FACS
Pallavi Kumar, MD, MPH
Ryan David Nipp, MD, MBA, MPH, FASCO
Hongcheng Zhu, MD, PhD

Genitourinary Cancer—Kidney and Bladder

Chunkit Fung, MD, MSCE—Track Leader
Arpita Desai, MD
Félix Guerrero-Ramos, MD, PhD
Rana R. McKay, MD, FASCO
Adam C. Olson, MD

Genitourinary Cancer—Prostate, Testicular, and Penile

Silke Gillissen, MD—Track Leader
Nabil Adra, MD
Marie Carlo, MD
Curtiland Deville Jr, MD
Gustavo Villoldo Sr, MD

Gynecologic Cancer

Brittany Anne Davidson, MD—Track Leader
Michael Carney, MD
Shari Damast, MD
Sonia Mathai, MD, MPH

Head and Neck Cancer

Jessica R. Bauman, MD—Track Leader
Christine H. Chung, MD
Deepa Joseph, MD, DNB, MNAMS
Hyunseok Kang, MD, MPH, FACP

Hematologic Malignancies

Catherine Choy Smith, MD—Track Leader
Christianne Bourlon, MD, MHS, FCPS
Kavita Vyas Dharmarajan, MD
Catherine Lai, MD, MPH
Olalekan O. Oluwole, MBBS
Manju Sengar, MD

Lung Cancer

Kavitha Ramchandran, MD, FASCO—Track Leader
Toby Christopher Campbell, MD, MS
Kevin Lee Min Chua, MBBS, FRCR
José F. Corona-Cruz, MD
Kristin Ann Higgins, MD
Navneet Singh, MD, FRCP, DM, FASCO

Medical Education and Professional Development

Jennifer E. Schwartz, MD, FRCPC, FASCO—Track Leader
Tyler Paul Johnson, MD
Joseph William McCollom, DO
Bismarck Odei, MD
Vishwanath Sathyanarayanan, MD
Amishi Yogesh Shah, MD

Melanoma/Skin Cancers

Allison Betof, MD, PhD, FASCO—Track Leader
Tina J. Hieken, MD
Giorgos Constantine Karakousis, MD
Marlana M. Orloff, MD
Susan M. Swetter, MD

Pediatric Oncology

Adam J. Esbenshade, MD, MSCI—Track Leader
Sadhana Jackson, MD
Perry Morocco, MD
Kieuhoa Tran Vo, MD, MS

Prevention, Risk Reduction, and Genetics

Philip E. Castle, PhD, MPH—Track Leader
Foluso Olabisi Ademuyiwa, MD, MPH
Rosa Maria Alvarez-Gomez, MD, PhD, MSc
Judith Balmana Gelpi, MD, PhD
Maria Elena Martinez, PhD

Sarcoma

Jason K. Sicklick, MD—Track Leader
Dorian Yarih Garcia Ortega, MD, PhD, FACS, MSc, FSSO
Varun Monga, MBBS
Andrew Brian Smitherman, MD, MSc

Symptom Science and Palliative Care

Mazie Tsang, MD, MS—Track Leader
Michael Jordan Fisch, MD, MPH, FACP, FAAHPM, FASCO
Judith A. Paice, PhD, RN, FASCO
Michael W. Rabow, MD
Jennifer Malia Snaman, MD
Christopher B. Steer, MBBS, FRACP

Scientific Program Committee

Amy Jo Chien, MD—Chair
Mariana Chavez Mac Gregor, MD, MSc, FASCO—Chair-Elect
Erika Hamilton, MD—Immediate Past Chair

Biostatistics

Hao Wang, PhD—Track Leader
Dominik Hlauschek, MSc
Saskia Litiere, PhD
Baidehi Maiti, MD, PhD, FACP
Qian Shi, PhD
Francisco Emilio Vera Badillo, MD, FRCPC, MSc
Fengmin Zhao, PhD

Breast Cancer—Metastatic

Amy Sanders Clark, MD, MSCE—Track Leader
Aditya Bardia, MD, MPH, FASCO
Jose G. Bazan Jr, MD
Eva Maria Ciruelos, MD, PhD
Sharon H. Giordano, MD, FASCO
Matthew P. Goetz, MD
William John Gradishar, MD, FACP, FASCO
Laura Ann Huppert, MD
Mariana Chavez Mac Gregor, MD, MSc, FASCO
Gregory A. Vidal, MD, PhD

Breast Cancer—Local/Regional/Adjuvant

Kari Braun Wisinski, MD—Track Leader
Oluwadamilola Motunrayo Fayanju, MD, MA, FACS
Kevin Kalinsky, MD, MS, FASCO
Matteo Lambertini, MD, PhD
Rebecca Arielle Shatsky, MD
Simona Flora Shaitelman, MD
Mediget Teshome, MD, MPH, FACS

Care Delivery/Models of Care

Rebecca Jane DeBoer, MD, MA—Track Leader
Bishal Gyawali, MD, PhD, FASCO
Tufia C. Haddad, MD
Michael T. Halpern, MD, PhD, MPH, FASCO
Dawn L. Hershman, MD, MS, FASCO
Samilia Obeng-Gyasi, MPH
Ravi Bharat Parikh, MD, MPP
Alejandro Recio, MD

Central Nervous System Tumors

Iris C. Gibbs, MD—Track Leader
Philipp Karschnia, MD, MS
Priya Kumthekar, MD
Maryam Rahman, MD
Karisa C. Schreck, MD, PhD

Developmental Therapeutics—Immunotherapy

Hatem Hussein Soliman, MD—Track Leader
Juan Manuel O'Connor, MD
Daniel Olson, MD
Sandip Pravin Patel, MD, FASCO
Rachel E. Sanborn, MD
Mark Yarchoan, MD

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Timothy A. Yap, MD, PhD—Track Leader
Collin M. Blakely, MD, PhD
Carlos Gil Moreira Ferreira, MD, PhD
Jason Timothy Henry, MD
Shivaani Kummar, MD, MBBS, FACP
Cynthia X. Ma, MD, PhD
David Olmos, MD, PhD
Christos Vaklavas, MD

Gastrointestinal Cancer—Colorectal and Anal

Kristen Keon Ciombor, MD, MS, FASCO—Track Leader
Chloe E. Atreya, MD, PhD, FASCO
George J. Chang, MD, MS, MHCM, FASCO
Kyle Cuneo, MD
Elisa Fontana, MD, PhD
Najjia Mahmoud, MD
Wells A. Messersmith, MD, FACP, FASCO
Filippo Pietrantonio, MD
Takayuki Yoshino, MD, PhD

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Robin Kate Kelley, MD, FASCO—Track Leader
Stephen Lam Chan, MD, FRCP, MRCP
Sepideh Gholami, MD, FACS
Peter Joel Hosein, MD
Rohan Reddy Katipally, MD
Kelsey Klute, MD
Elizabeth S. Nakasone, MD, PhD
Kim Anna Reiss, MD
Kohei Shitara, MD
Elizabeth Catherine Smyth, MD
Nataliya V. Uboha, MD, PhD

Genitourinary Cancer—Kidney and Bladder

Thomas Powles, MD, PhD, FCRP—Track Leader
Peter Colin Black, MD
Elizabeth Henry, MD
Vadim S. Koshkin, MD
Ronac Mamtani, MD, MSCE
Tian Zhang, MD, MHS, FASCO

Genitourinary Cancer—Prostate, Testicular, and Penile

Rahul Raj Aggarwal, MD—Track Leader
Alan Haruo Bryce, MD
Daniel Castellano Gauna, MD
Sophia C. Kamran, MD
Dana Rathkopf, MD

Gynecologic Cancer

Gini F. Fleming, MD, FASCO—Track Leader
Jimmy A. Billod, MD, MHA, MT
Stephanie Lheureux, MD, PhD
Nathalie Dauphin McKenzie, MD, MSPH
Carolyn Muller, MD
Kathleen M. Schmeler, MD
William Small Jr, MD, FASCO

Head and Neck Cancer

Patrick Ha, MD—Track Leader
Aarti K. Bhatia, MD, MPH
Jason Y.K. Chan, MBBS
Renata Ferrarotto, MD
Kevin Joseph Harrington, PhD, MBBS
Quynh-Thu Xuan Le, MD

Hematologic Malignancies—Leukemia, MDS, and Allograft

Rita Assi, MD—Track Leader
Christine McMahon, MD
Sandrine Niyongere, MD
Eunice S. Wang, MD
Amer Methqal Zeidan, MBBS

Hematologic Malignancies—Lymphoma and CLL

Nathalie Johnson, MD—Track Leader
Charalambos Andreadis, MD, MSCE
Hetty E. Carraway, MD, MBA
Martin Hutchings, MD, PhD
Nidia Paulina Zapata, MD

Hematologic Malignancies—Plasma Cell Dyscrasia

Suzanne Lentzsch, MD, PhD—Track Leader
Rafat Abonour, MD
Brandon Jamaal Blue, MD
Ajai Chari, MD
Amrita Y. Krishnan, MD
Maria-Victoria Mateos, PhD

**Lung Cancer—Non–Small Cell Local-Regional/Small Cell/
Other Thoracic Cancers**

Patrick M. Forde, MD, PhD—Track Leader
C. S. Pramesh, MBBS, MS, FRCS
Mariano Provencio, MD, PhD
Abdul Rafeh Naqash, MD, FASCO
Melina Elpi Marmarelis, MD
Lecia V. Sequist, MD, MPH, FASCO
Misty Dawn Shields, MD, PhD
Meredith Elana Giuliani, PhD, MBBS, FRCP, MEd, FRCPC,
FASCO
Jonathan Villena-Vargas, MD

Lung Cancer—Non–Small Cell Metastatic

Ana I. Velazquez Manana, MD, MSc, FASCO—Track Leader
Angel Qin, MD
Nasser H. Hanna, MD, FASCO
Brian S. Henick, MD
Bruna Pellini, MD
Jonathan W. Riess, MD, MS
Adrian G. Sacher, MD, MMedSc, FRCPC
Natalie I. Vokes, MD

Medical Education and Professional Development

Maria Quintos Baggstrom, MD, FACP, FASCO—Track Leader
Aakash Desai, MD, MPH, FASCO
Jorge Gallardo, MD
Deepa Rangachari, MD, FASCO
Richard F. Riedel, MD, FASCO

Melanoma/Skin Cancers

Michael A. Postow, MD—Track Leader
Ravi K. Amaravadi, MD
Matias Rodrigo Chacon, MD
Siwen Hu-Lieskován, MD, PhD
Katy K. Tsai, MD

Pediatric Oncology

Sarah K. Tasian, MD, PhD—Track Leader
Anuradha Banerjee, MD
Shushan Hovsepyan, MD
Raya Saab, MD

Prevention, Risk Reduction, and Genetics

Payal Deepak Shah, MD—Track Leader
Andrea De Censi, MD
Jennifer Lee Caswell-Jin, MD
Anita Kinney, PhD, RN
Lisa A. Newman, MD, MPH, FASCO

Quality Care/Health Services Research

Mina S. Sedrak, MD, MS, FASCO—Track Leader
Caroline Chung, MD, FRCPC
Electra D. Paskett, PhD, MSPH, FASCO
Evangelia Razis, MD, PhD, FASCO
Stephen Matthew Schleicher, MD, MBA, FASCO
Gita Thanarajasingam, MD
Stephanie B. Wheeler, PhD, MPH

Sarcoma

Kristen Nooshin Ganjoo, MD—Track Leader
Abhijeet Kumar, MBBS
Alberto S. Pappo, MD, FASCO
Chandrajit P. Raut, MD

Symptom Science and Palliative Care

Carolyn J. Presley, MD, MHS—Track Leader
Peter Angelos, MD, PhD, FACS
Tracy A. Balboni, MD, MPH
Christopher Ryan Friese, PhD, RN, AOCN
Diah Martina, MD
Michelle E. Melisko, MD
Eric Roeland, MD, FAAHPM, FASCO
Nicholas Zdenkowski, PhD, MBBS, FRACP

Awards

ASCO 2026 SPECIAL AWARDS

Award recipients will be recognized during the Opening Session, Saturday, May 30, 9:45 AM, Hall B1.

Allen Lichter Visionary Leader Award

John D. Carpten, PhD

ASCO-American Cancer Society Cancer Prevention Award

Eduardo Vilar-Sanchez, MD, PhD

Session: Not Just for Cancer Immunotherapy: The Emergence of Cancer Immunoprevention

Presented on Sunday, May 31, 11:30 AM, S403

This award is generously supported by the American Cancer Society.

B.J. Kennedy Geriatric Oncology Award, Endowed by Dr. Tony and Mrs. Carrie Cheung

Enrique Soto Pérez de Celis MD, PhD, MSc, FASCO

Session: Geriatric Oncology: The Coming of Age of a Specialty—Its Distinct Principles, Practice, and Science in a Global Context

Presented on Saturday, May 30, 3:00 PM, E450a

This award is generously endowed by Dr. Tony and Mrs. Carrie Cheung.

David Karnofsky Science of Oncology Award

Nancy E. Davidson, MD, FASCO

Gianni Bonadonna Breast Cancer Award

Sharon H. Giordano, MD, MPH, FASCO

Session: Assessing Real-World Outcomes in Breast Cancer:

Opportunities, Challenges, and Lessons Learned

Presented on Monday, June 1, 11:30 AM, Hall D2

This award is generously supported by GSK.

Humanitarian Award

Michael J. Kelley, MD

Jamie Von Roenn Excellence in Teaching and Mentorship Award

Harvey Jay Cohen, MD

Patient Advocate Award

Beverly Canin

Diane Zipursky Quale, JD

Pediatric Oncology Award

Louis S. Constine MD, FASTRO, FACR

Session: Radiation Therapy, a Double-Edged Sword: Dulling the Normal Tissue Edge for Our Children With Cancer

Presented on Sunday, May 31, 11:30 AM, E450

Walther Cancer Foundation Supportive Oncology Award

Frank D. Ferris, MD, FAAHPM, FAACE, FASCO

Charles L. Loprinzi, MD, FASCO

Session: From Research to Bedside: Translating Symptom Science to Improve Cancer Outcomes

Presented on Friday, May 29, 4:30 PM, E350

This award is generously endowed by the Walther Cancer Foundation.

Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award

Katherine Van Loon, MD, MPH, FASCO

This award is generously supported by Hologic, Inc

International Women Who Conquer Cancer Mentorship Award

Manju Sengar, MD

This award is generously supported by Eisai Inc. and Bristol Myers Squibb.

Fellows of the American Society of Clinical Oncology (FASCO)

Presented during the Opening Session, Saturday, May 30, 9:45 AM, Hall B1.

Judith Abrams, PhD
Ranjana H. Advani, MD
Olatunji B. Alese, MD, FWACS, FASCO
Nicoleta Zenovia Antone, MD, FASCO
Andrea B. Apolo, MD, FASCO
Mark A. Applebaum, MD, FASCO
Chloe E. Atreya, MD, PhD, FASCO
Nilofer S. Azad, MD, FASCO
Julie E. Bauman, MD, MPH, FASCO
Lyudmila Bazhenova, MD, FASCO
Kathryn Beal, MD, FASCO
Tanios S. Bekaii-Saab, MD, FASCO
Cristiane Decat Bergerot, PhD, MS, FASCO
Allison Betof, MD, PhD, FASCO
Sibel Blau, MD, FASCO
Gabriel A. Brooks, MD, MPH, FASCO
Daniel R. Carrizosa, MD, MS, FACP, FASCO
Moshe Chasky, MD, FACP, FASCO
Ian Chau, MD, FASCO
Rashmi Chugh, MD, FASCO
Kristen K. Ciombor, MD, MS, FASCO
Alan S. Coates, MD, FRACP, FASCO
A. Dimitrios Colevas, MD, FASCO
Ibiayi Dagogo-Jack, MD, FASCO
Megan E. Daly, MD, FASCO
Devika G. Das, MD, MBBS, MS, FASCO
Niharika Dixit, MD, FASCO
Tanya B. Dorff, MD, FASCO
Janice P. Dutcher, MD, FASCO
Areej El-Jawahri, MD, FASCO
Jonathan W. Friedberg, MD, FASCO
Pauline Funchain, MD, FASCO
Ramaswamy Govindan, MD, FASCO
Jhanelle E. Gray, MD, FASCO
Erika P. Hamilton, MD, FASCO
David N. Hayes, MD, MPH, FASCO
Leslie J. Hinyard, PhD, MSW, FASCO
Richard T. Hoppe, MD, FASCO
Jimmy J. Hwang, MD, FASCO
Yelena Y. Janjigian, MD, FASCO
Komal L. Jhaveri, MD, FACP, FASCO
Robin Jones, MD, MBBS, MRCP, FASCO
Lee Jones, MBA, FASCO
Robin Kelley, MD, FASCO
William K. Kelly, DO, FASCO
David J. Kerr, MD, PhD, DSc, MA, FACP, FCRP, FASCO
Ali Raza Khaki, MD, MS, FASCO
Abhishek Kumar, MBBS, FASCO
Andrew B. Lassman, MD, FASCO
Lisa Y. Law, MD, FASCO
Raymond Liu, MD, FASCO
Dorothy Chilambe Lombe, MD, FASCO
Georgina V. Long, MD, PhD, FRACP, FASCO
Emil Lou, MD, PhD, FASCO
Adriana K. Malone, MD, FASCO
Kristen A. Marrone, MD, FASCO
Shearwood McClelland, MD, FASCO
Bradley A. McGregor, MD, FASCO
Mairead G. McNamara, PhD, MBBCh, FASCO
Jennifer L. McQuade, MD, FASCO
Joseph J. Merchant, MD, FACP, FASCO
Rodrigo Ramella Munhoz, MD, PhD, FASCO
Martina Cathryn Murphy, MD, FASCO
Abdul Rafeh Naqash, MD, FASCO
Prakash C. Neupane, MD, FASCO
Kimmie Ng, MD, MPH, FASCO
Deirdre O'Mahony, MD, FASCO
Martin Palmeri, MD, MBA, FASCO
Alberto S. Pappo, MD, FASCO
Electra D. Paskett, PhD, MSPH, FASCO

Dionisia M. Quiroga, DO, PhD, FASCO
Kavitha Ramchandran, MD, FASCO
Evangelia Razis, MD, PhD, FASCO
Mary Redman, PhD, FASCO
Richard F. Riedel, MD, FASCO
Mujahid A. Rizvi, MD, FRCP, MPH, FACP, FASCO
Nicholas J. Robert, MD, FASCO
Tracy L. Rose, MD, FASCO
Abby R. Rosenberg, MD, MS, MA, FAAP, FAAHPM, FASCO
Lori J. Rosenstein, MD, FASCO
Erika Ruiz-Garcia, MD, MS, FASCO
Joseph Kamel Salama, MD, FASCO
Sarah Schellhorn, MD, FASCO
Stephen M. Schleicher, MD, MBA, FASCO
Bryan P. Schneider, MD, FASCO
Nagashree Seetharamu, MD, FASCO
Nita L. Seibel, MD, FASCO
Carole Seigel, MBA, FASCO
Mikkael A. Sekeres, MD, MS, FASCO
Dhaval Shah, MD, FACP, MBA, FASCO
Priyanka Sharma, MD, FASCO
Shanthi Sivendran, MD, MBA, FASCO
William Small Jr, MD, FASCO
Heloisa P. Soares, MD, FASCO
Walter Stadler, MD, FASCO

Elena M. Stoffel, MD, MPH, FASCO
Latha Subramanian, MBChB, FASCO
Ryan J. Sullivan, MD, FASCO
Umang Swami, MD, FASCO
Banu Symington, MD, MACP, FASCO
Gevorg Tamamyan, MD, PhD, DSci, MSc, FASCO
Eleonora Teplinsky, MD, FASCO
Mylin A. Torres, MD, FASCO
Emily Z. Touloukian, DO, FASCO
Jonathan C. Trent, MD, PhD, FASCO
Reginald Tucker-Seeley, ScD, FASCO
Paul S. Unger, MD, FACP, FASCO
Deanna B. van Gestel, FASCO
Katherine Van Loon, MD, MPH, FASCO
Namrata Vijayvergia, MD, FASCO
Raymond C. Wadlow, MD, FASCO
Mark A. Walshauer, MD, FASCO
David M. Waterhouse, MD, MPH, FASCO
Julia R. White, MD, FASCO
Tanya M. Wildes, MD, MSCI, FASCO
Eddy Shih-Hsin Yang, MD, PhD, FASCO
Oladapo O. Yeku, MD, PhD, FACP, FASCO
Marjorie G. Zauderer, MD, MS, FACP, FASCO
Tian Zhang, MD, MHS, FASCO

Conquer Cancer[®], the ASCO Foundation, has a mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Through our Grants & Awards Program, we are building a pipeline of future leaders and are supporting and encouraging excellence in clinical and translational research in the field of oncology. Please visit [ASCO.org/grants-awards](https://www.asco.org/grants-awards) for a list of 2026 awards and recipients.

Industry Expert Theater Schedule

The Industry Expert Theaters (IETs), located in the back of the Exhibit Hall, to the left of the Food Court, bring together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies.

If the IET company chooses to post their in-person session recording online, the session audio and slides will be available for on-demand viewing after the Meeting at am.asco.org.

Industry Expert Theater sessions are not official presentations of the 2026 ASCO Annual Meeting and are not sponsored, endorsed, or accredited by ASCO, Association for Clinical Oncology, or Conquer Cancer, the ASCO Foundation. These sessions are not CME-accredited.

This schedule is subject to change. Information listed is current as of March 13, 2026. For the most up-to-date information, please visit am.asco.org.

Saturday, May 30

Time: 9:30 AM–10:30 AM

Title: Evolving Needs in RRMM and Understanding Emerging CELMoD Research

Description: Join us for a discussion on the evolving needs in the relapsed/refractory multiple myeloma landscape and the emerging research into the potential of Cereblon E3 Ligase modulation (CELMoD). This session will feature a panel discussion.

Company: Bristol Myers Squibb

Presenters:

Daniel Adamczyk, Director, US Iberdomide, Global Medical Oncology, Hematology, Bristol Myers Squibb
Brian Engelhardt, Director, US Multiple Myeloma, Medical Engagement Lead, Global Medical Oncology, Hematology, Bristol Myers Squibb
Michael Pourdehnad, SVP, Head of Early Clinical Development HOCT, Drug Development, Bristol Myers Squibb

Location: Theater 2

Time: 9:30 AM–10:30 AM

Title: Learn More About Inluriyo™ (imlunestrant) Followed By a Separate Presentation to Learn About Verzenio® (abemaciclib)

Description: During these back-to-back discussions, you'll learn which patients may be appropriate for Inluriyo or Verzenio and receive recommendations on how to manage specific side effects for each treatment. CMAT-16245 03/2026 © Lilly USA, LLC 2026. All rights reserved.

Company: Eli Lilly and Company

Presenter: Julia Perkins Smith, Vice President Global Clinical Development, Eli Lilly and Company

Location: Theater 1

Time: 12:30 PM–1:30 PM

Title: A Next-Generation 1L Approach in HR+/HER2- mBC: The Role of Early Intervention Upon Emergence of Endocrine Resistance

Description: Join AstraZeneca for a discussion on the clinical data and safety profile of a new approach and treatment option for HR+/HER2- mBC upon ESR1m emergence during 1L treatment with an AI + CDK4/6i.

Company: AstraZeneca

Presenter: Manuel Selvi Miralles, Global Clinical Program Lead - Camizestrant Degree, MD, MSc, Medical Oncologist Specialist, AstraZeneca

Location: Theater 1

Time: 12:30 PM–1:30 PM

Title: Evolution of Real-World Evidence

Description: Advances in prostate cancer are rapidly reshaping clinical practice. This session highlights recent developments including data releases and head to head real world evidence. Faculty will discuss how new evidence is informing clinical decision-making in an increasingly complex landscape.

Company: Johnson & Johnson

Presenter: Mark Wildgust, PhD, VP of Global Medical Affairs, Johnson & Johnson

Location: Theater 2

Time: 3:00 PM–4:00 PM

Title: New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Description: A discussion reviewing the latest clinical data and emerging evidence in HER2-expressing breast cancer, presented by Daiichi Sankyo, Inc. and AstraZeneca.

Company: Daiichi Sankyo, Inc. and AstraZeneca

Presenter: Jan-Willem Henning, MBChB, FRCPC, Director Global Medical Affairs Breast Cancer Strategy Head, AstraZeneca

Location: Theater 1

Time: 3:00 PM–4:00 PM

Title: No Patient Left Behind: AI, Diagnostic Insights and Foundation Models that Challenge the Status Quo

Description: Discover how our comprehensive diagnostic intelligence platform transforms vast datasets into insights to ensure that no patient is left behind in the pursuit of better outcomes. Beyond the clinic, our foundation models redefine the R&D landscape—de-risking discovery and accelerating drug development.

Company: Tempus

Presenters:

Kate Sasser, PhD, Chief Scientific Officer, Tempus
Ezra Cohen, MD, Chief Medical Officer, Tempus

Location: Theater 2

Sunday, May 31

Time: 9:30 AM–10:30 AM

Title: Ultra-Sensitive Molecular Residual Disease Detection with Myriad's Precise MRD™ Test

Description: Join Myriad Genetics for an introduction to the Precise MRD™ test. This session will present assay technical details and emerging clinical evidence across multiple solid tumors, including breast and colorectal cancers, and discuss the role of highly sensitive MRD detection across the care continuum.

Company: Myriad Genetics

Presenter: Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics

Location: Theater 1

Time: 11:30 AM–12:30 PM

Title: Efficacy & Safety from the Phase 3 Peak Study of Bezuclastinib + Sunitinib vs Sunitinib Monotherapy in Advanced Gastrointestinal Stromal Tumors (GIST)

Description: Review the novel combination of bezuclastinib + sunitinib from nonclinical TKI inhibition profiles and differentiated in vivo data through Peak trial results. Review efficacy & safety data and implications for how Peak may redefine the GIST treatment paradigm after decades of limited progress.

Company: Cogent Biosciences

Presenters:

John Robinson, PhD, Chief Scientific Officer, Cogent Biosciences
Jessica Sachs, MD, Chief Medical Officer, Cogent Biosciences

Location: Theater 2

Time: 11:30 AM–12:30 PM

Title: Evolving Strategies for Locally Advanced or Metastatic EGFR-mutated NSCLC and HR+/HER2– (IHC 0, IHC 1+, IHC 2+/ISH–) mBC

Description: Please join Daiichi Sankyo, Inc. and AstraZeneca for a discussion on a therapy for certain adults with previously treated, locally advanced or metastatic EGFRm NSCLC and unresectable or metastatic HR+/HER2– (IHC 0, IHC 1+, IHC 2+/ISH–) breast cancer. This program is intended for US healthcare professionals.

Company: Daiichi Sankyo, Inc. and AstraZeneca

Presenter: Jan-Willem Henning, MBChB, FRCPC, Director Global Medical Affairs Breast Cancer Strategy Head, AstraZeneca

Location: Theater 1

Time: 4:15 PM–5:15 PM

Title: A Treatment Option for Patients With Multiple Myeloma

Description: Explore the clinical data behind a multiple myeloma treatment. This session will cover efficacy and safety data, hypothetical patient profiles, and practical insights for multidisciplinary care coordination.

Company: GSK

Presenter: Elisabet Manasanch, MD, MHSc, Medical Director, GSK

Location: Theater 2

Time: 4:15 PM–5:15 PM

Title: Inside the Evidence: Using Multi-Cancer Early Detection (MCED) to Achieve Earlier Diagnosis

Description: GRAIL's multi-cancer early detection test analyzes cell-free DNA to screen for many of the deadliest cancers, including those without recommended screening. Explore evidence for MCED testing, from pivotal trials to real-world evidence, and review impact on early diagnosis and cancer care pathways.

Company: GRAIL, Inc.

Presenters:

Megan Hall, PhD, Vice President, Medical Affairs, GRAIL, Inc.
Eric Fung, MD, PhD, Senior Vice President, Clinical Development, GRAIL, Inc.
Sir Harpal Kumar, FRCR FMedSci, Chief Scientific Officer and President, International, GRAIL, Inc.

Location: Theater 1

Monday, June 1

Time: 9:30 AM–10:30 AM

Title: An Overview of an Immunotherapy Treatment Option Administered Subcutaneously

Description: Review clinical trial data for an immunotherapy administered subcutaneously; Discuss a hypothetical patient eligible for this immunotherapy treatment option administered subcutaneously.

Company: Merck & Co., Inc.

Presenter: Annette Griffith, MD, Sr. Dir, Medical Affairs, Merck & Co., Inc.

Location: Theater 2

Time: 9:30 AM–10:30 AM

Title: Unlocking the Benefits of Time Off Treatment with a New Combo Therapy with a BCL-2 Inhibitor as the Backbone of Targeted Fixed-Duration Therapy in 1L CLL

Description: Join AbbVie for a discussion on a new combination therapy for previously untreated CLL patients. We'll review the latest data on targeted, fixed-duration treatment from multiple trials.

Company: AbbVie

Presenter: Brianne Glenn, PharmD, BCOP, Scientific Director, Medical Affairs, AbbVie

Location: Theater 1

Time: 11:30 AM–12:30 PM

Title: A 2L+ Combination Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent

Description: Please join Johnson & Johnson to learn more about a combination therapy for adult patients with RRMM who have received at least one prior line of therapy.

Company: Johnson & Johnson

Presenter: Tonya Le Blanc, PhD, Medical Director, Johnson & Johnson

Location: Theater 2

Time: 11:30 AM–12:30 PM

Title: Treatment Approaches for Resectable Gastric/ Gastroesophageal Junction Cancers or Unresectable Hepatocellular Carcinoma

Description: Learn about the advancements in resectable GC/ GEJC, including an approved IO-based perioperative therapy and management options. In addition, learn about the long-term outcomes for IO therapy in uHCC.

Company: AstraZeneca

Presenter: Michael Baglio, US Oncology, Medical Lead, AstraZeneca

Location: Theater 1

Time: 3:00 PM– 4:00 PM

Title: Advancing Molecular Residual Disease (MRD) Detection: Analytical and Clinical Evidence Supporting the Oncodetect® Test

Description: Learn about Exact Sciences' Oncodetect® MRD test, including the personalized approach to detecting MRD in solid tumors and emerging clinical evidence in breast cancer.

Company: Exact Sciences

Presenters:

Rick Baehner, MD, Chief Medical Officer of Precision Oncology, Exact Sciences

Jennifer Racz, MD, MBA, Sr. Principal Medical Affairs Director, Exact Sciences

Location: Theater 2

Time: 3:00 PM–4:00 PM

Title: HYRNUO® (Sevabertinib): From Bench to Bedside

Description: Join to learn about the scientific journey, efficacy and safety profile of HYRNUO® (sevabertinib).

Company: Bayer

Presenters:

Franziska Siegel, PhD, Oncology Research Portfolio Lead, Bayer

Paolo Grassi, MD, Clinical Development Lead, Bayer

Nicoletta Brega, MD, Global Development Lead, Bayer

Location: Theater 1

1:00 PM-2:00 PM Education Session

ASCO Voices

Location: S100a

Erika Ruiz-Garcia, MD, MS, FASCO—Chair

Instituto Nacional De Cancerologia
Welcome and Introductions

Megan-Claire Chase

Advocates for Collaborative Education
When Representation Becomes Survival: Changing My Perspective on Clinical Trials

Jenna Benn Shersher

Twist Out Cancer
Finding Your Voice Through Illness

Boluwatife Adeola Aofolaju, BSc

The Dorcas Cancer Foundation
Healing Beyond the Scan

Amitabh Ray, MD, DNB

Chittaranjan National Cancer Institute
The Bridge of Beams: Connecting the Divide in Cancer Care

Onyinye Balogun, MD, MSc

NewYork-Presbyterian/Weill Cornell Medical Center
Borrowed Courage: How Others' Faith Sparks Our Boldest Moves

1:00 PM-2:15 PM Education Session

Cancer Care in Times of Crisis and in Immigrant and Displaced Populations

Location: E450b

Nazik Hammad, MD, MEd, FACP—Chair

University of Toronto
Cancer Control in Conflict Zones in Africa

Manali I. Patel, MD, MPH, MS, FASCO

Stanford University
Cancer Care When Natural Disaster Strikes

Patricia Mae Garcia Santos, MD, MS

Winship Cancer Institute, Emory University
Cancer Care in Immigrant Populations

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Complex Scenarios in Metastatic Breast Cancer

Location: Hall D1

Alexandru E. Eniu, MD, PhD—Chair

Clinique de Genolier
Endocrine Therapy in Metastatic Breast Cancer: Still the Foundation or Time to Move On?

Stephanie L. Graff, MD, FACP, FASCO

Brown University Health Cancer Institute, The Warren Alpert Medical School of Brown University
First Cytotoxic Therapy: Chemotherapy or Antibody-Drug Conjugates?

Steven J. Chmura, MD, PhD

University of Chicago
Stereotactic Body Radiotherapy for Oligometastatic and Oligoprogressive Hormone Receptor–Positive Breast Cancer: When and Why?

Stephanie Walker, RN

Metastatic Breast Cancer Alliance
Treatment Decisions in Hormone Receptor–Positive Metastatic Breast Cancer: What Patients Weigh and Why

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Detection and Implications of Novel Biomarkers in Pediatric Solid Tumors

Location: S504

Katherine A. Janeway, MD, MMedSc, FASCO—Chair

Dana-Farber Cancer Institute
Molecular Profiling of High-Risk Solid Malignancies to Identify Targeted Therapies

Stephen Gottschalk, MD

St. Jude Children's Research Hospital
Discovery of Immunotherapy Targets for Pediatric Solid and Brain Tumors by Exon-Level Expression

Ewa Koscielniak, MD

University of Tübingen
Exploring Biomarkers for Diagnostics and Disease Progression

Panel Question and Answer

1:00 PM-2:15 PM Education Session

State of the Art: Immunotherapy, Targeted Therapy, or Both?

Location: Arie Crown Theater

Myung-Ju Ahn, MD, PhD

Sungkyunkwan University School of Medicine
Advanced T-Cell Engager Strategies

Bernadett Emma Szabados, MD

Barts Cancer Institute, Queen Mary University of London
Integrating Immunotherapy and Targeted Therapy

Bridget P. Keenan, MD, PhD—Chair

University of California San Francisco
The Future of Personalized Immunotherapy

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe

Location: E350

Vanita Noronha, MD—Chair

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute
Dissemination of Immune Checkpoint Inhibitors: What High-Resource Settings Can Adopt From Global Partners

Kaysia Ludford, MD

The University of Texas MD Anderson Cancer Center
Navigating Gastrointestinal Toxicities: Timing, Severity, and Management

Susan Faye Dent, MD

University of Rochester
Practical Translation: Applying Cardiology Guidelines to Detect and Manage Cancer Therapy–Related Cardiac Dysfunction

Panel Question and Answer

Friday, May 29, 2026

1:00 PM-2:30 PM Rapid Oral Abstract Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: E450a

Nidia Paulina Zapata, MD—Chair

Instituto Nacional de Cancerologia, Mexico

Manali Kirtikumar Kamdar, MD—Chair

University of Colorado

- 1:00 PM Abstract 7009:** First-line odronextamab (Odro) plus chemotherapy (CHOP) in diffuse large B-cell lymphoma (DLBCL): OLYMPIA-3 Part 1B results. First Author: Matthew Matasar, MD
- 1:06 PM Abstract 7010:** Real-world outcomes of bispecific antibodies in relapsed/refractory (R/R) follicular lymphoma (FL). First Author: Jessica Allen, MD
- 1:12 PM Abstract 7011:** Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results. First Author: Marc S. Hoffmann, MD
- 1:18 PM Panel Question and Answer**
- 1:30 PM Abstract 7012:** Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy. First Author: Danielle Nicole Blunt, FRACP, FRCPA, MBBS
- 1:36 PM Abstract 7013:** REVO-U: A next-generation, gene-editing-free universal CAR-T platform to enable ultra-high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL. First Author: Di Wu, MD, PhD
- 1:42 PM Abstract 7014:** First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma. First Author: Xi Zhang
- 1:48 PM Panel Question and Answer**
- 2:00 PM Abstract 7015:** First-in-human novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies. First Author: Lu Haiyang, PhD
- 2:06 PM Abstract 7016:** Genetic signatures of CNS relapse in DLBCL patients profiled with next-generation sequencing (NGS). First Author: Jackson Thomas Bowers, MD
- 2:12 PM Abstract 7017:** Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial. First Author: R. Andrew Harkins, MD, MS
- 2:18 PM Panel Question and Answer**

1:00 PM-3:15 PM Workshop

JCO Workshop: The Ins and Outs of Medical Publishing—From Preparing Your Manuscript to Peer Review (Limited Attendance; First-Come, First-Served)

Location: S103

Kathy D. Miller, MD, FASCO—Chair

Indiana University Melvin and Bren Simon Cancer Center
Facing the Blank Page: How to Prepare Your Manuscript and Select the Right Journal in an Ever-Shifting Landscape

Elizabeth Goodwin Hill, PhD

The Medical University of South Carolina
How to Present Complex Computational or Analytical Methods and Results in Scientific Papers

Jonathan W. Friedberg, MD, FASCO

University of Rochester
Peer Review 101: What Happens to Your Manuscript After Submission and How Can You Get Involved in Peer Review? Tips for Success

Andrea Necchi, MD

Vita-Salute San Raffaele University and IRCCS Ospedale San Raffaele

Maryam B. Lustberg, MD, FASCO

Yale Cancer Center, Yale School of Medicine

James M. Ford, MD, FASCO

Stanford University School of Medicine

Jeffrey M. Peppercorn, MD, MPH, FASCO

Massachusetts General Hospital

Katherine Van Loon, MD, MPH, FASCO

University of California San Francisco

1:00 PM-3:15 PM Workshop

Genomics 101 for Oncologists Workshop (Limited Attendance; First-Come, First-Served)

Location: S501abc

Richard L. Haspel, MD, PhD—Chair

Beth Israel Deaconess Medical Center

Ramaswamy Govindan, MD, FASCO—Chair

Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis

Phillip Michaels, MD

Beth Israel Deaconess Medical Center
Molecular Pathologist Perspective

Alix D'Angelo, LCGC

Xavier University of Louisiana
Genetic Counselor Perspective

Deepa Rangachari, MD, FASCO

Dana-Farber Cancer Institute
Medical Oncologist Perspective

1:00 PM-4:00 PM Oral Abstract Session

Lung Cancer—Non-Small Cell Metastatic

Location: Hall D2

Jonathan W. Riess, MD, MS—Chair

University of California Davis Comprehensive Cancer Center

Nasser H. Hanna, MD, FASCO—Chair

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

- 1:00 PM Abstract LBA8500:** Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28). First Author: John V. Heymach, MD, PhD

- 1:12 PM** **Abstract 8501:** Overall survival of first-line amivantamab plus lazertinib in atypical *EGFR*-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
First Author: Joel W. Neal, MD, PhD
- 1:24 PM** **Abstract 8624:** Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
First Author: Anil Ramakant Tibdewal, MD, MBBS
- 1:36 PM** **Daniel Shao-Weng Tan, PhD, MBBS, MRCP**
National Cancer Centre Singapore and Duke-NUS Medical Centre
Discussion of Abstract(s) LBA8500-8624: Cracking the Rare Code: New Advances for Uncommon EGFR Mutations
- 1:48 PM** *Panel Question and Answer*
- 2:00 PM** **Abstract 8502:** Lorlatinib vs crizotinib as first-line treatment for advanced *ALK*+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
First Author: Tony S.K. Mok, MD, FRCPC, FASCO
- 2:12 PM** **Abstract 8503:** ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced *ALK*+ NSCLC.
First Author: Jessica Jiyeong Lin, MD
- 2:24 PM** **Abstract 8504:** Efficacy and safety of pralsetinib as first-line treatment of *RET* fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
First Author: Sanjay Popat, PhD, FRCP
- 2:36 PM** **Abstract 8505:** Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective *RET* inhibitor (SRI), from a pivotal phase II study in patients with advanced *RET* fusion-positive non-small cell lung cancer (NSCLC).
First Author: Qing Zhou, MD, PhD
- 2:48 PM** **Angel Qin, MD**
University of Michigan
Discussion of Abstract(s) 8502-8505: Raising the Bar in ALK and RET
- 3:00 PM** *Panel Question and Answer*
- 3:12 PM** **Abstract 8506:** Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
First Author: Caicun Zhou, MD, PhD, ABFT
- 3:24 PM** **Abstract LBA8507:** A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non-small cell lung cancer.
First Author: Yuankai Shi, MD, PhD
- 3:36 PM** **Natalie I. Vokes, MD**
The University of Texas MD Anderson Cancer Center
Discussion of Abstract(s) 8506-LBA8507: First but Not Alone: Novel Frontline Combinations With Checkpoint Inhibitors
- 3:48 PM** *Panel Question and Answer*

2:45 PM-3:45 PM Case-Based Panel**A Multidisciplinary Case-Based Approach to Non-Rhabdomyosarcoma Soft Tissue Sarcoma in Adolescent and Young Adults: Challenges and Emerging Strategies**

Location: S504

Aaron R. Weiss, DO—Chair
MaineHealth Maine Medical Center
Moderator

Fernando Augusto Batista Campos, MD, MSc
A.C. Camargo Cancer Center
Medical Oncologist Perspective

Suzanne L. Wolden, MD
Memorial Sloan Kettering Cancer Center
Radiation Oncologist Perspective

Thomas Scharschmidt, MD, FACS, MB
Nationwide Children's Hospital
Orthopedic Oncologist Perspective

*Panel Question and Answer***2:45 PM-4:15 PM Rapid Oral Abstract Session****Care Delivery/Models of Care**

Location: E350

Tufia C. Haddad, MD—Chair
Mayo Clinic Comprehensive Cancer Center

Dawn L. Hershman, MD, MS, FASCO—Chair
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

2:45 PM **Abstract 1513:** Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma.
First Author: Areej El-Jawahri, MD, FASCO

2:51 PM **Abstract 1514:** Use of a patient-facing digital tool for glioblastoma outside scheduled clinic visits.
First Author: Jason Binder

2:57 PM **Abstract 1515:** Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial.
First Author: Robert Michael Daly, MD, MBA, FASCO

Panel Question and Answer

3:15 PM **Abstract 1516:** Addressing geographic disparities in cancer care: An examination of the contributions of international medical graduates (IMGs).
First Author: Nazli Dizman, MD

3:21 PM **Abstract 1517:** Evaluation and appraisal of quality indicators for end-of-life cancer care in an African context.
First Author: Vivens Nsabimana

3:27 PM **Abstract 1518:** Timing of telepalliative care and end-of-life outcomes in advanced cancer: A multicenter retrospective cohort study.
First Author: Alexandra Mendes Barreto Arantes, MD

Panel Question and Answer

3:33 PM *Panel Question and Answer*

3:45 PM **Abstract 1519:** LLM-generated serious illness conversation summaries to improve care for hospitalized patients: A pilot clinical trial.
First Author: Christopher Manz, MD, MS

Friday, May 29, 2026

3:51 PM Abstract 1520: Effect of a financial navigation intervention on financial toxicity among patients with breast cancer: A randomized controlled trial in China.
First Author: Weijie Xing

3:57 PM Abstract 1521: Effect of group community health worker–led advance care planning education on advance care planning documentation, satisfaction, palliative care, and hospice: Results from a randomized clinical trial.
First Author: Olivia Viruet Quintero, BS

4:03 PM *Panel Question and Answer*

2:45 PM-4:15 PM Rapid Oral Abstract Session

Medical Education and Professional Development

Location: E450b

Jennifer E. Schwartz, MD, FRCPC, FASCO—Chair
Indiana University School of Medicine

Jorge Gallardo, MD—Chair
Fundación Chilena Desarrollo Oncología

2:45 PM Abstract 9003: Analyzing county-level factors of oncology fellowship program development from 2015-2025.
First Author: Ryan James Crowley, MPhil

2:51 PM Abstract 9004: Projecting 2050 oncology workforce through historical regional trends and economic stratification.
First Author: Arkadi Asaturyan, MD

2:57 PM Abstract 9005: Support of academic non-clinical efforts for cancer investigator faculty at Association of American Cancer Institutes.
First Author: Paula M. Fracasso, MD, PhD, FACP

3:03 PM *Panel Question and Answer*

3:15 PM Abstract 9006: Gender representation in first and senior authorship of phase III solid-tumor trials presented at the ASCO Annual Meeting, 2015-2025.
First Author: Sarbajit Mukherjee, MD, MS

3:21 PM Abstract 9007: Understanding the impact of gold and silver signals on ERAS applications: A survey of hematology/oncology fellowship program directors.
First Author: Courtney Nicole Miller-Chism, MD

3:27 PM Abstract 9008: Advancing career-focused training: Program leader perspectives on professional development pathways in hematology/oncology fellowships.
First Author: Lauren O'Loughlin, MD

3:33 PM *Panel Question and Answer*

3:45 PM Abstract 9009: Career fulfillment and intent to leave among oncology physicians: A global survey.
First Author: Coral Olazagasti, MD

3:51 PM Abstract 9010: Burnout (BO) among oncology professionals in the Middle East and North Africa (MENA): Meta-analysis of pre–post COVID trends, contributors, and predictive value of single-item screening tool.
First Author: Atial M. Abusanad, MD, MSc, FRCPC

3:57 PM Abstract 9011: Standardized mean differences of primary outcomes found in randomized controlled trials of wellness interventions among medical trainees: A systematic review and meta-analysis.
First Author: Andrew Irving Hearn, MD, MSc

4:03 PM *Panel Question and Answer*

2:45 PM-4:15 PM Education Session

New Drugs in Oncology: Incorporation Into Practice

Location: Hall D1

Romeo Angelo M. DeClaro, MD—Chair
U.S. Food and Drug Administration

Maria de Miguel, MD, PhD—Chair
START Madrid - CIOCC

Richard L. Schilsky, MD, FASCO
AAADV Workshop Foundation
Overview of FDA Review and Approval Pathways for New Drugs

David Ross Camidge, MD, PhD
University of Colorado Denver, Anschutz Medical Campus
Telisotuzumab Vedotin-Tilv for Locally Advanced or Metastatic, Nonsquamous Non–Small Cell Lung Cancer

Xiuning Le, MD, PhD
The University of Texas MD Anderson Cancer Center
Zongertinib and Sevabertinib for Nonsquamous Non–Small Cell Lung Cancer

Panel Question and Answer

Hans H. Shuhaiber, MD
University of Florida Clinical Research Center
Mirdametinib for Neurofibromatosis Type 1

Eunice S. Wang, MD
Roswell Park Cancer Center
Ziftomenib and Revumenib for Relapsed or Refractory Acute Myeloid Leukemia

Panel Question and Answer

2:45 PM-5:45 PM Oral Abstract Session

Genitourinary Cancer—Kidney and Bladder

Location: Arie Crown Theater

Ronac Mamtani, MD, MSCE—Chair
Abramson Cancer Center at the University of Pennsylvania

Kelly N. Fitzgerald, MD—Chair
University of California San Francisco

2:45 PM Abstract 4500: A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
First Author: Rana R. McKay, MD, FASCO

2:57 PM Abstract 4501: A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.
First Author: Xu Hu, MD

3:09 PM Abstract 4502: ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
First Author: Toni K. Choueiri, MD, FASCO

- 3:21 PM** **Martin H. Voss, MD**
 Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College
Discussion of Abstract(s) 4500-4502: Is the Best Yet to Come in Kidney Cancer?
- 3:33 PM** *Panel Question and Answer*
- 3:45 PM** **Abstract 4503:** Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.
 First Author: Richard Cathomas
- 3:57 PM** **To be determined**
- 4:09 PM** **Abstract 4513:** Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501).
 First Author: Ronald C. Chen, MD, MPH, FASCO
- 4:21 PM** **Melissa A. Reimers, MD**
 Washington University in St. Louis
Discussion of Abstract(s) 4503-4513: Curing Early Bladder Cancer With Multidisciplinary Approaches
- 4:33 PM** *Panel Question and Answer*
- 4:45 PM** **Abstract 4506:** Perioperative SHR-A2102, a novel nectin-4–targeted antibody-drug conjugate, in combination with adrelelimab for patients (pts) with muscle-invasive bladder cancer: Results from a phase 2/3 study.
 First Author: Dingwei Ye, MD
- 4:57 PM** **Abstract 4507:** Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
 First Author: Thomas Powles, MD, PhD, FCRP
- 5:09 PM** **Abstract 4508:** Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
 First Author: Gopa Iyer, MD
- 5:21 PM** **Andrea B. Apolo, MD, FASCO**
 National Cancer Institute, National Institutes of Health
Discussion of Abstract(s) 4506-4508: Nectin4 Antibody-Drug Conjugates: The Past, Present, and Future
- 5:33 PM** *Panel Question and Answer*

2:45 PM-5:45 PM Oral Abstract Session

Gynecologic Cancer

Location: S100bc

Brittany Anne Davidson, MD—Chair

Duke University

Katherine Kurnit, MD, MPH—Chair

University of Chicago Medicine

- 2:45 PM** **Abstract 5501:** Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
 First Author: Matthew A. Powell, MD
- 2:57 PM** **Abstract 5502:** Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
 First Author: Ramez Nassef Eskander, MD
- 3:09 PM** **Ana Oaknin, MD, PhD**
 Hospital Universitario Puerta de Hierro-Majadahonda
Discussion of Abstract(s) LBA5500-5502: Starting Strong: Contemporary Upfront Management of Endometrial Cancer
- 3:21 PM** *Panel Question and Answer*
- 3:33 PM** **Abstract 5503:** Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
 First Author: Lucy Gilbert, MD, MSc
- 3:45 PM** **Abstract LBA5504:** A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer.
 First Author: Xiaohua Wu, MD
- 3:57 PM** **Abstract 5505:** CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.
 First Author: Gwenael Ferron
- 4:09 PM** **Katherine Cynthia Fuh, MD, PhD**
 University of California San Francisco
Discussion of Abstract(s) 5503-5505: Refining the Approach to Advanced Ovarian Cancer
- 4:21 PM** *Panel Question and Answer*
- 4:33 PM** **Abstract 5506:** A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR α)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
 First Author: Philipp Harter, MD, PhD
- 4:45 PM** **Abstract 5507:** Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.
 First Author: Jianli Zhao, MD
- 4:57 PM** **Abstract 5508:** A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.
 First Author: Tudor-Eliade Ciuleanu, MD, PhD
- 5:09 PM** **Yvette Drew, PhD, MBBS, FRCPC**
 BC Cancer - Vancouver
Discussion of Abstract(s) 5506-5508: ABCs of ADCs
- 5:21 PM** *Panel Question and Answer*

Friday, May 29, 2026

2:45 PM-5:45 PM Oral Abstract Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: S100a

Suzanne Lentzsch, MD, PhD—Chair

Columbia University Irving Medical Center

Jesus G. Berdeja, MD—Chair

Tennessee Oncology

- 2:45 PM Abstract 7500:** Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.
First Author: Cyrille Touzeau, MD, PhD
- 2:57 PM Abstract 7501:** Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
First Author: Ashutosh D. Wechalekar, MD, MBBS, MRCP
- 3:09 PM Abstract 7502:** First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINV0) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.
First Author: Ashutosh D. Wechalekar, MD, MBBS, MRCP
- 3:21 PM Rafat Abonour, MD**
Sylvester Myeloma Institute, University of Miami, Sylvester Comprehensive Cancer Center
Discussion of Abstract(s) 7500-7502: Intercepting Plasma Cell Disorders: From Smoldering Multiple Myeloma to Amyloid Light-Chain Amyloidosis
- 3:33 PM Panel Question and Answer**
- 3:45 PM Abstract 7503:** DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).
First Author: Saad Z. Usmani, MD, MBA, FRCP, FASCO
- 3:57 PM Abstract 7504:** Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.
First Author: Mattia D'Agostino, MD
- 4:09 PM Abstract 7505:** New IMS/IMWG risk criteria by next-generation sequencing (NGS): Analysis of daratumumab benefit in both high- and standard-risk patients (pts) in the PERSEUS study.
First Author: Luca Bertamini
- 4:21 PM Amrita Y. Krishnan, MD**
City of Hope National Medical Center
Discussion of Abstract(s) 7503-7505: Raising the Bar in Newly Diagnosed Multiple Myeloma: Depth, Duration, and Risk
- 4:33 PM Panel Question and Answer**
- 4:45 PM Abstract LBA7506:** Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
First Author: Paul G. Richardson, MD

- 4:57 PM Abstract 7507:** MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).
First Author: Roberto Mina, MD
- 5:09 PM Abstract 7508:** Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy.
First Author: Saurabh Chhabra, MD, MS
- 5:21 PM Ajai Chari, MD**
University of California San Francisco
Discussion of Abstract(s) LBA7506-7508: Lines, Loops, and Beyond: Sequencing in the BCMA Era
- 5:33 PM Panel Question and Answer**

3:45 PM-6:00 PM Workshop

Communication in Late-Stage Cancer: Discussing Prognosis and Matching Care to Patients' Goals Workshop (Limited Attendance; First-Come, First-Served)

Location: S501abc

Gordon J. Wood, MD—Chair

Northwestern Medicine

Jillian Gustin, MD

The Ohio State University Wexner Medical Center

Andrew J. Lawton, MD, FAAHPM, FACP

Northwestern Medical Group

Abby R. Rosenberg, MD, MS, MA, FAAP, FAAHPM, FASCO

Dana-Farber Cancer Institute

Lyle Fettig, MD

Indiana University School of Medicine

4:30 PM-5:15 PM Award Lecture

From Research to Bedside: Translating Symptom Science to Improve Cancer Outcomes

Location: E350

Charles F. von Gunten, MD, PhD—Chair

The Elizabeth Hospice

Charles Loprinzi, MD, FASCO

Mayo Clinic

Walther Cancer Foundation Supportive Oncology Award Recipient

Frank D. Ferris, MD, FAAHPM, FASCO

The Elizabeth Hospice

Walther Cancer Foundation Supportive Oncology Award Recipient

4:30 PM-5:30 PM Case-Based Panel

Optimal Multidisciplinary Care for Patients With Nonmetastatic Exocrine Pancreatic Cancer

Location: Hall D1

Andrew S. Epstein, MD—Chair

Memorial Sloan Kettering Cancer Center

Moderator

Ashwin Somasundaram, MD
The University of North Carolina at Chapel Hill
Medical Oncologist Perspective

Melissa Hogg, MD
NorthShore University HealthSystem
Surgical Perspective

Makoto Shinoto, MD, PhD
QST Hospital
Radiation Oncologist Perspective
Panel Question and Answer

4:30 PM-5:45 PM Education Session

Driving Innovation in the Radiopharmaceutical Therapy Landscape to Improve Effectiveness, Access, and Reduce Risks

Location: E450b

To be determined
Key Regulatory Considerations for Approval of Radiopharmaceutical Therapies

Lisa Bodei, MD, PhD
Memorial Sloan Kettering Cancer Center
Innovation in Radiopharmaceutical Technology, Targets, and Treatment Delivery to Enhance Safety and Effectiveness

Emily K. Bergsland, MD, FASCO
University of California San Francisco
Improving Access to Radiopharmaceutical Therapies: Care Coordination, Patient Selection, and Toxicity Management
Panel Question and Answer

4:30 PM-5:45 PM Education Session

State-of-the-Art Updates for Incorporating Precision Medicine Approaches Into Every Stage of Lung Cancer

Location: Hall D2

Raymond U. Osarogiagbon, MBBS, FACP, FASCO
Baptist Cancer Center
Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer

Sameera Kumar, MD
Fox Chase Cancer Center
Treatment in Unresectable Stage III Non-Small Cell Lung Cancer

Ana I. Velazquez Manana, MD, MSc, FASCO—Chair
University of California San Francisco
Treatment in Advanced Non-Small Cell Lung Cancer With Driver Mutations
Panel Question and Answer

4:30 PM-5:45 PM Education Session

Updated Guidance on DPYD Testing to Prevent Severe and Fatal Toxicity From Fluoropyrimidine Chemotherapy

Location: E450a

Daniel Louis Hertz, PhD, PharmD—Chair
University of Michigan College of Pharmacy
Clinical Benefits and Risks of DPYD Testing

Karen Merritt
Advocates for Universal DPD/DPYD Testing
Patient Experience of Dihydropyrimidine Dehydrogenase Deficiency and Advocating for Improved Patient Care

Luis Abel Quiñones, PhD
Red Latinoamericana de Implementación y Validación de Guías Clínicas Farmacogenómicas (RELIVAF)
Implementing DPYD and Pharmacogenetic Testing in Lower-Resource Health Systems

Jeremy D. Kratz, MD
William S. Middleton Memorial Veterans Hospital, School of Medicine and Public Health, University of Wisconsin
Changing the Standard of Care by Recommending Pretreatment DPYD Testing in Veterans Affairs Oncology Clinical Pathways
Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Pediatric Oncology I

Location: S504

Adam J. Esbenshade, MD, MSCI—Chair
Vanderbilt University

Fariba Navid, MD—Chair
Children's Hospital Los Angeles

4:30 PM Abstract 10006: Primary breast malignancies in adolescents and young adults: The MD Anderson Cancer Center experience.
First Author: Samanta Catueno, MD

4:36 PM Abstract 10007: Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force.
First Author: Michael Mitchell, DO

4:42 PM Panel Question and Answer

4:57 PM Abstract 10008: Real-world experience of a pediatric precision oncology protocol utilizing paired somatic and germline sequencing at a single institution: Interim analysis.
First Author: Joshua Goldman, MD

5:03 PM Abstract 10009: Harnessing OMOP-CDM for multisite collaborations to measure cardiovascular risk factors and cardiovascular disease in the early survivorship period for children, adolescents, and young adults.
First Author: David H. Noyd, MD, FAAP, MPH

5:09 PM Panel Question and Answer

5:24 PM Abstract 10010: Association of neighborhood-level vulnerability with health behavior patterns in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE).
First Author: Amy Berkman, MD

5:30 PM Abstract 10011: Thematic game intervention as a novel psychosocial support to reduce sedation needs and anxiety in pediatric neuro-oncology patients during radiotherapy: A prospective cohort study (2020–2025).
First Author: Fuqiang Zhang

5:36 PM Panel Question and Answer

7:30 AM-9:30 AM Education Session

Oncology Division Chiefs and Department Chairs' Breakfast

Location: S501abc

Pavani Chalasani, MD, MPH—Chair

George Washington University
Welcome and Opening Remarks

Thomas J. Lynch, MD

Fred Hutch Cancer Center
Funding the Future of Academic Oncology: Challenges, Opportunities, and Successful Tactics

Blase N. Polite, MD, FASCO

University of Chicago
Funding the Future of Academic Oncology: Challenges, Opportunities, and Successful Tactics

Small Group Table Talk

Large Group Share

Pavani Chalasani, MD, MPH

George Washington University
Closing Remarks and Feedback

8:00 AM-9:00 AM Case-Based Panel

From Myelodysplastic Syndrome to Acute Myeloid Leukemia: Treatment-Related Myeloid Neoplasm Diagnosis and Therapeutic Strategies

Location: E450b

Rita Assi, MD—Chair

Indiana University
Moderator

Joshua F. Zeidner, MD

Lineberger Comprehensive Cancer Center, The University of North Carolina
Acute Myeloid Leukemia Specialist Perspective

Chun Yew Fong, PhD, MBBS

Austin Health and University of Melbourne
Myelodysplastic Syndromes Specialist Perspective

Stephen Strickland, MD

SCRI at TriStar Centennial
Transplant Specialist Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Oligometastatic Colorectal Cancer: Treating Pulmonary and Nodal Metastases

Location: S100a

Prajnan Das, MD, MPH, MS—Chair

The University of Texas MD Anderson Cancer Center
Moderator

Suresh Senan, PhD, MBBS

Amsterdam University Medical Center
Radiation Therapy Perspective

Stephen Barnett Solomon, MD

Memorial Sloan Kettering Cancer Center
Interventional Radiology Perspective

Erin Gillaspie, MD

Creighton University
Surgical Perspective

Panel Question and Answer

8:00 AM-9:15 AM Education Session

From Novel Agents to Novel Adverse Events: Getting Comfortable With Toxicity Profiles of Emerging Systemic Anticancer Therapy

Location: S403

Sydney Yolande Barsed, MD—Chair

Anne Arundel Medical Center
When Does Acceptable Become Unacceptable: A Patient's Perspective on Toxicities

Lauren A. Dalvin, MD

Mayo Clinic
Seeing the Signs: Recognizing and Managing Eye Toxicities From Novel Therapies

Lucie Heinzerling, MD, PhD, MPH

Ludwig Maximilians University Hospital
Itching for Answers: Cutaneous Toxicities and Management Panel Question and Answer

8:00 AM-9:15 AM Education Session

Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health

Location: S102

Amy H. Comander, MD—Chair

Massachusetts General Hospital Cancer Center, Harvard Medical School
Lifestyle Medicine in Survivorship: What Is It, Why It Matters, and How to Do It Without a Structured Clinic

Sophie Lebel, PhD

University of Ottawa
When the Cancer's Gone but the Fear Remains: Identifying and Managing Fear of Cancer Recurrence

Sherry Shen, MD

Memorial Sloan Kettering Cancer Center
Tackling Obesity After a Breast Cancer Diagnosis: From Behavior Change to Understanding the Potential for GLP-1 Therapies

Laura Carfang, EdD

Surviving Breast Cancer
An Advocate's View on Navigating Life After Breast Cancer Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

ctDNA in Clinical Practice: From Detection to Clinical Decision-Making

Location: Hall D1

Erika Ruiz-Garcia, MD, MS, FASCO—Chair

Instituto Nacional De Cancerología

David W. Cescon, MD, PhD, FRCPC—Chair

Princess Margaret Cancer Centre/University Health Network

8:00 AM Valsamo Anagnostou, MD, PhD

The Johns Hopkins University School of Medicine
The Role of ctDNA Across the Spectrum of Cancer Care From Early Detection to Treatment

8:12 AM Abstract LBA100: NHS-Galleri: Primary results

from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.
First Author: Robert Charles Swanton, MD, PhD, FCRP

Saturday, May 30, 2026

- 8:24 AM** **Mark Robson, MD, FASCO**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) LBA100: Multicancer Early Detection: Potential Versus Proof
- 8:40 AM** **Abstract LBA101:** Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).
First Author: Zhijie Wang
- 8:52 AM** **Abstract 102:** Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
First Author: Mitsuru Yokota, MD, PhD
- 9:04 AM** **Erika Ruiz-Garcia, MD, MS, FASCO**
Instituto Nacional De Cancerología
Discussion of Abstract(s) LBA101-102: The Clinical Utility of ctDNA in Oncology: From Molecular Test to Global Practice
- 9:16 AM** *Panel Question and Answer*

8:00 AM-9:30 AM Clinical Science Symposium

Is the Juice Worth the Squeeze: Challenges in Combination Therapy for Non-Small Cell Lung Cancer

Location: Arie Crown Theater

Mihaela Aldea, MD, PhD—Chair

Gustave Roussy and Paris-Saclay University

Jonathan Villena-Vargas, MD—Chair

Weill Cornell Medicine

- 8:00 AM** **Silvia Novello, MD, PhD**
University of Turin
Collision Course: Target Inhibition Meets Immune Activation
- 8:12 AM** **Abstract 8509:** Neoadjuvant almonertinib followed by chemo-immunotherapy in II-IIIb EGFR-mutant NSCLC: A single arm, phase II study (NEOVADE).
First Author: Jun-Tao Lin
- 8:24 AM** **Pilar Garrido, MD, PhD**
Hospital Universitario Ramón y Cajal, Universidad de Alcalá
Discussion of Abstract(s) 8509: EGFR and Immunotherapy: Is the Science Settled?
- 8:36 AM** **Abstract 8510:** First-line (1L) divarasil plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non-small cell lung cancer (NSCLC): Results from the Krascendo-170 study.
First Author: Ferdinandos Skoulidis, MD, PhD
- 8:48 AM** **Abstract 8511:** Elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor, as first-line therapy for KRAS G12C mutation-positive non-small cell lung cancer (NSCLC).
First Author: Shun Lu, MD, PhD
- 9:00 AM** **Bruna Pellini, MD**
Miami Cancer Institute, Baptist Health South Florida
Discussion of Abstract(s) 8510-8511: Double Trouble or Double Benefit? The Toxicity Tradeoffs of Targeted Therapy-Immunotherapy Combinations
- 9:12 AM** *Panel Question and Answer*

8:00 AM-9:30 AM Clinical Science Symposium

New Approaches to Curing Bladder and Kidney Cancer

Location: Hall D2

Vadim S. Koshkin, MD—Chair

UCSF Helen Diller Family Comprehensive Cancer Center

Qian Qin, MD—Chair

UT Southwestern

- 8:00 AM** **Srikala S. Sridhar, MD, MSc, FRCPC**
Princess Margaret Cancer Centre
New Approaches to Curing Bladder and Kidney Cancers: Where Do We Stand Today?
- 8:12 AM** **Abstract 4510:** Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.
First Author: Peter H. O'Donnell, MD
- 8:24 AM** **Abstract LBA4511:** Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
First Author: James M.G. Larkin, MD, PhD
- 8:36 AM** **Abstract 4512:** Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
First Author: Elizabeth Nally, MBBS
- 8:48 AM** **Abstract 4504:** Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
First Author: Nicholas David James, PhD, MBBS, FRCP
- 9:00 AM** **Brian I. Rini, MD, FASCO**
Vanderbilt University Medical Center
Discussion of Abstract(s) 4504-4512: Living Longer, Living Better: Can We Have It All?
- 9:12 AM** *Panel Question and Answer*

8:00 AM-9:30 AM Rapid Oral Abstract Session

Developmental Therapeutics—Immunotherapy

Location: E451

Juan Manuel O'Connor, MD—Chair

Instituto Alexander Fleming

So Yeon Kim, MD—Chair

Yale School of Medicine - Smilow Cancer Hospital Care Centers

- 8:00 AM** **Abstract 2512:** Phase 2 trial of TIL therapy for metastatic uveal melanoma: Evaluation of T cell potency and an in situ precision biomarker.
First Author: Shravan Leonard-Murali, MD, MSc
- 8:06 AM** **Abstract 2513:** Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC: A prospective, randomized, open-label, biomarker-driven, phase 2 trial.
First Author: Xiangdong Cheng, MD

- 8:12 AM Abstract 2514:** A randomized prospective trial evaluating duration of PD-1 and PD-L1 inhibitor therapy in advanced solid tumors.
First Author: Vincent Edgar Reyes, MD, MMM
- 8:18 AM Panel Question and Answer**
- 8:30 AM Abstract 2515:** Clinical and translational study of p38 inhibitor pexmetinib plus nivolumab following anti-PD-1/L1 failure in advanced solid tumors.
First Author: Matthew Nguyen, MD
- 8:36 AM Abstract 2516:** PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort.
First Author: Yuehong Kong
- 8:42 AM Abstract 2517:** Evaluation of the combination of regorafenib + avelumab in patients with HPV-associated cancer: The phase II REGOMUNE study.
First Author: Sophie Cousin, MD
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 2518:** Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.
First Author: Sarina A. Piha-Paul, MD, MS
- 9:06 AM Abstract 2519:** KEYNOTE-B59: An open-label, multicenter, phase 1/2 study of efdelikofusp alfa (GI-101A; CD80-IgG4 Fc-IL2v2) in advanced solid tumors (part E & F of GII-101-P101).
First Author: Jae Lyun Lee, MD, PhD
- 9:12 AM Panel Question and Answer**

8:00 AM-9:30 AM Rapid Oral Abstract Session

Gynecologic Cancer

Location: E450a

Carolyn Muller, MD—Chair

University of New Mexico Health Sciences Center

William Small Jr, MD, FASCO—Chair

Loyola University Medical Center

- 8:00 AM Abstract 5509:** Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer.
First Author: Antonia Busse, MD
- 8:06 AM Abstract 5510:** The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial.
First Author: Alexandra Leary, MD, PhD
- 8:12 AM Abstract 5511:** Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab.
First Author: Joyce N. Barlin, MD
- 8:18 AM Panel Question and Answer**

- 8:30 AM Abstract 5512:** Safety and efficacy of BAT8006 in combination with BAT1308 in patients with advanced endometrial cancer.
First Author: Xingtao Long, PhD
- 8:36 AM Abstract 5513:** NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC).
First Author: Toon Van Gorp, MD, PhD
- 8:42 AM Abstract 5514:** Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
First Author: Gini F. Fleming, MD, FASCO
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 5515:** Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
First Author: Linda R. Mileshekin, MD, MBBS, FRACP
- 9:06 AM Abstract 5516:** Updated efficacy, safety, and exploratory biomarker analyses of a phase II trial of abemaciclib plus hormonal therapy in recurrent ovarian (OC) and endometrial cancer (EC).
First Author: Jordyn Silverstein, MD
- 9:12 AM Abstract 5517:** Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.
First Author: Claudia Marchetti
- 9:18 AM Panel Question and Answer**

8:00 AM-9:30 AM Rapid Oral Abstract Session

Pediatric Oncology II

Location: S504

Shushan Hovsepian, MD—Chair

Yerevan State Medical University, Immune Oncology Research Institute

Raya Saab, MD—Chair

Stanford University School of Medicine

- 8:00 AM Abstract 10012:** Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs).
First Author: Yizhuo Zhang, MD
- 8:06 AM Abstract 10013:** RAPID: A pilot feasibility study of rapid dinutuximab infusion in patients with relapsed/refractory (RR) high-risk neuroblastoma (HRNBL).
First Author: Sara-Jane N. Onyeama, MD
- 8:12 AM Panel Question and Answer**
- 8:27 AM Abstract 10014:** Interim analysis of CaboMain: A prospective, single-arm phase 2 clinical trial of cabozantinib as maintenance therapy for patients with “ultra-high-risk” pediatric solid tumors.
First Author: Nilay Shah, MD

Saturday, May 30, 2026

- 8:33 AM** **Abstract 10015:** Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.
First Author: Suzanne J. Forrest, MD
- 8:39 AM** *Panel Question and Answer*
- 8:54 AM** **Abstract 10016:** Characterization and validation of a methylation signature as a prognostic marker in osteosarcoma.
First Author: Rachel M. Hurley, MD, PhD
- 9:00 AM** **Abstract 10017:** Dexamethasone-free antiemetic prophylaxis with olanzapine in children and adolescents receiving highly emetogenic chemotherapy: A multicenter, phase III non-inferiority randomized trial.
First Author: Venkatraman Radhakrishnan, MD, MBBS, MSc, DM
- 9:06 AM** *Panel Question and Answer*

9:00 AM-12:00 PM Poster Session

Care Delivery/Models of Care

Location: Hall A—Posters and Exhibits

Posters by Topic

Access to Care: Board(s) 246-481, 594a-594b

Care Delivery/Models of Care/Implementation Science:

Board(s) 482-505, 595a-596b

Care Delivery in Global Settings: Board(s) 506-526

Clinical Informatics/Artificial Intelligence/Data Science:

Board(s) 527-548, 597a

Digital Technology/Telemedicine/Remote Care: Board(s) 549-556, 597b

Discrepancies in Care: Board(s) 557-573

Geriatric Care Delivery: Board(s) 574-583

Survivorship Care Delivery: Board(s) 586-593

- Board 246 **Abstract 1522:** Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation.
First Author: Chaewon Hwang, MD
- Board 247 **Abstract 1523:** Intersecting rural, racial, and Medicaid disparities in cervical cancer outcomes across North Carolina, 2019–2023.
First Author: Vaidehi Mujumdar, MD
- Board 248 **Abstract 1524:** Lost in translation? Evaluating associations between English proficiency and next generation sequencing completion, and comparing understandability across different translation modalities among Spanish speakers with metastatic breast cancer.
First Author: Daniela Tovar
- Board 249 **Abstract 1525:** Mapping access to retinoblastoma care: Geographic disparities and service availability across Africa, and West and Central Asia.
First Author: Rima Torosyan, MD
- Board 250 **Abstract 1526:** Financial toxicity in early-phase cancer clinical trials: A review of sponsor-supplied information at a large trials unit.
First Author: Akul Purohit, MBChB

- Board 251 **Abstract 1527:** Geographic migration patterns of practicing medical oncologists in the United States, 2020-2025.
First Author: Jag S. Lally, MPhil
- Board 252 **Abstract 1528:** Scaling digital patient navigation to improve access to multidisciplinary melanoma care.
First Author: Govind Warriar, MD, MPH
- Board 253 **Abstract 1529:** Trends in biosimilar bevacizumab adoption and Medicare spending by socioeconomic deprivation and rurality, 2019-2023.
First Author: Taemin Kim, BS
- Board 254 **Abstract 1530:** Patient characteristics, treatment patterns, social determinants of health, and safety in patients prescribed nivolumab and hyaluronidase-nvhy by early adopters.
First Author: Lucio N. Gordan, MD
- Board 255 **Abstract 1531:** Impact of advanced practice provider-led new consults in community oncology: Expanding access and volume in benign hematology.
First Author: Eileen Vella, MS, PA-C
- Board 256 **Abstract 1532:** Transportation insecurity and RBC transfusion burden in multiple myeloma and related plasma cell disorders in New Mexico: A CRIIS statewide analysis (2013-2019).
First Author: Altamash Jawadi, DO
- Board 257 **Abstract 1533:** Neighborhood social vulnerability and clinical trial enrollment in colon cancer: Does age matter?
First Author: Shannon S. Yoo, DO
- Board 258 **Abstract 1534:** Accessibility of study contact information in ClinicalTrials.gov: A comprehensive analysis.
First Author: Fangdi Sun, MD
- Board 259 **Abstract 1535:** Hospital designation and survival disparities in young-onset gastrointestinal cancer.
First Author: Mrinalini Ramesh, DO
- Board 260 **Abstract 1536:** Transportation access as a structural determinant of quality of life and symptom burden among cancer patients.
First Author: Hailey Ivanson
- Board 261 **Abstract 1537:** Travel time to cancer care as it relates to care access, transportation distress, and financial toxicity: Findings from the Cancer Experience Registry.
First Author: Erica Fortune, PhD
- Board 262 **Abstract 1538:** Exploring transportation insecurity among cancer patients in urban cancer clinics in Ontario, Canada.
First Author: Clarissa Skorupski, MD
- Board 263 **Abstract 1539:** Access to trastuzumab deruxtecan for HER2-low metastatic breast cancer in Brazil's Unified Public Health System: A population-impact model.
First Author: Angela Theresa Zuffo Yabrude, MD
- Board 264 **Abstract 1540:** Geographic accessibility of recruiting clinical trials for rare and common gastrointestinal malignancies in the United States.
First Author: Rahul Kumar Thakur, MD

- Board 265 **Abstract 1541:** Validation of prognostic scores in Hispanic patients with advanced solid tumors enrolled in a single-center phase I clinical trial program.
First Author: Darin Poei, MD
- Board 266 **Abstract 1542:** Breaking barriers: Evaluation of a low-threshold community-based HPV vaccination model for gender minorities and sex workers in Milan.
First Author: Nicla Maria La Verde, MD
- Board 267 **Abstract 1543:** Participation of older adults (aged ≥ 65 years) in SWOG cancer clinical trials.
First Author: Jyotsana Parajuli, PhD
- Board 268 **Abstract 1544:** Time to treatment initiation for triple-negative breast cancer in Brazil: A call for public health action.
First Author: Fernanda Madasi Pinheiro, MD
- Board 269 **Abstract 1545:** Impact of neighborhood socioeconomic deprivation and diet quality on immune checkpoint blockade outcomes.
First Author: Anushri Kulkarni, BS
- Board 270 **Abstract 1546:** CancerTrialsBR: An open-access, collaborative platform to improve visibility and access to cancer clinical trials in Brazil.
First Author: Felipe Lazar Neto, MD, PhD
- Board 271 **Abstract 1547:** Breast cancer patient navigation to identify individual needs and offer medical and supportive care referrals.
First Author: Fernanda Mesa-Chavez, MD, MSc
- Board 298 **Abstract 1548:** Impact of broadening trial eligibility criteria on the inclusion of patients infected with HIV in cancer clinical trials.
First Author: Hong Xiao, PhD
- Board 299 **Abstract 1549:** Impact of a centralized APP-led peer-to-peer program on patient access, provider burden, and institutional revenue.
First Author: Sarah J. Bottomley, DNP, MSN, PCNP
- Board 300 **Abstract 1550:** Operational and clinical drivers of subcutaneous PD-1/PD-L1 inhibitor adoption: A mixed-methods analysis of U.S. oncology practice patterns.
First Author: Kimberly Peihsi Ku, MD
- Board 301 **Abstract 1551:** Patient-reported barriers to treatment access and home delivery in rare cancers across five European countries.
First Author: Raymond A. Huml
- Board 302 **Abstract 1552:** Advancing health equity in oncology: Virtual collaborative behavioral health engagement and outcomes among Medicaid-insured and BIPOC patients.
First Author: Nina Balanchivadze, MD
- Board 303 **Abstract 1553:** FALCON-Lung: Evolving global real-world treatment choices and outcomes for metastatic NSCLC in different patient populations.
First Author: Annelies Verbiest, MD, PhD
- Board 304 **Abstract 1554:** Coverage of subcutaneous versus intravenous oncology therapies by US commercial health plans.
First Author: Sophie E. Knox, MPharm
- Board 305 **Abstract 1555:** Inpatient financial toxicity among women hospitalized with breast cancer in the United States, 2013–2022.
First Author: Fathima Shehnaz Ayoobkhan, MD
- Board 306 **Abstract 1556:** Geographic distribution of cancer treatment trials and population-level cancer outcomes in the U.S.
First Author: Hong Xiao, PhD
- Board 307 **Abstract 1557:** Access to immunotherapy and molecular diagnostics for lung adenocarcinoma in Syria: A mixed-methods study from the country's main cancer center.
First Author: Ayla Kouli, MD
- Board 308 **Abstract 1558:** Assessment of CAR-T clinical trial availability and accessibility in the United States.
First Author: Rahul Kumar Thakur, MD
- Board 309 **Abstract 1559:** 20-year trends in socioeconomic disparities in breast cancer care for patients aged < 65 years old.
First Author: Olivia Frances Lynch, MD, MPH
- Board 310 **Abstract 1560:** Clinical trial participation among adolescents and young adults diagnosed with cancer in the United States (2004–2021).
First Author: Vianessa Andion Camargo
- Board 479 **Abstract 1561:** Financial vulnerability among U.S. cancer survivors: Differences by veteran status and VA health care utilization in the National Health Interview Survey, 2020–2024.
First Author: Aimee Pehrson, MHA, MPH
- Board 480 **Abstract 1562:** Recovery with residual disparities: Real-world patterns of platinum chemotherapy use after the 2023 drug shortage.
First Author: Omer Sayed Ashruf, MD
- Board 481 **Abstract 1563:** Trends in incidence, survival, and cause of death in Kaposi sarcoma in the antiretroviral therapy era.
First Author: Joseph Antony Elengickal, MD, BS
- Board 482 **Abstract 1564:** Fertility concerns, counseling, and preservation in AYA females with early-stage breast cancer: Chemotherapy receipt and timing.
First Author: Bolun Liu, MD
- Board 483 **Abstract 1565:** Impact of the Taylor Cancer Research Center (TCRC) and Tempus AI TIME Partnership on clinical trial start-up and accrual.
First Author: John Nemunaitis, MD
- Board 484 **Abstract 1566:** User-centered design of a COPD care pathway embedded in oncology care for patients receiving immune checkpoint inhibitors.
First Author: Thomas William Lycan Jr., MHS, DO
- Board 485 **Abstract 1567:** Greening a chemotherapy day ward.
First Author: Alannah Kelly, MBBS
- Board 486 **Abstract 1568:** Accelerated diagnostic pathway for undifferentiated malignancy via interventional radiology triage: A comparative effectiveness study.
First Author: Suken Shah
- Board 487 **Abstract 1569:** Patient-reported performance status as a predictive tool for mortality and supportive care needs in patients with advanced cancer.
First Author: Manan P. Shah, MD

- Board 488 **Abstract 1570:** Impact of a patient-facing app to address surgical oncology patients' social determinants of health: Preliminary results of a phase II clinical trial.
First Author: Ying Sun
- Board 489 **Abstract 1571:** National implementation of electronic patient-reported outcomes (ePROs) for remote symptom monitoring in oncology: The OncoPRO initiative.
First Author: Ethan Basch, MD, MSc, FASCO
- Board 490 **Abstract 1572:** Achieving epidemiologically representative enrollment and social determinants of health in the phase III evERA Breast Cancer study (NCT05306340).
First Author: Gregory A. Vidal, MD, PhD
- Board 491 **Abstract 1573:** Implementation of an expedited cancer workup clinic for uninsured patients at a metropolitan safety net hospital.
First Author: Dominick Zheng, MD
- Board 492 **Abstract 1574:** PRiMAL (precision randomized clinical trial comparing MTB assisted care to usual care): Quality of life analysis in patients with newly diagnosed non-small cell lung cancer (NSCLC).
First Author: Jill M. Kolesar, PharmD, MS
- Board 493 **Abstract 1575:** Addressing health-related social needs for cancer patients: An implementation assessment.
First Author: Samuel Woo, BS
- Board 494 **Abstract 1576:** Identifying patients at risk for non-receipt of guideline-concordant treatment in pancreatic cancer using electronic health record data and machine learning.
First Author: Annabelle Fonseca, MD, MHS
- Board 495 **Abstract 1577:** Real-world implementation of an integrated exercise medicine model within routine oncology care.
First Author: Lauren Whiting, MBA
- Board 496 **Abstract 1578:** Therapeutic strategies and reduced drug spending as a signal of early impact of the Enhancing Oncology Model.
First Author: Rachel Mosher Henke
- Board 497 **Abstract 1579:** Association of routine electronic symptom monitoring with reduced opioid use in patients with head and neck cancers.
First Author: Laila A. Gharzai, MD
- Board 498 **Abstract 1580:** Rethinking cancer attribution in oncology VBC models: E&M vs treatment-based approach.
First Author: Haibei Liu, MPH
- Board 499 **Abstract 1581:** Modernizing injectable cancer care delivery: A telemedicine-supported home injection model for breast cancer care.
First Author: Erin Mary Bange, MD
- Board 500 **Abstract 1582:** Feasibility and implementation of remote geriatric assessment-guided supportive care (GAIN-S) in public oncology settings.
First Author: Cristiane Decat Bergerot, PhD, MS, FASCO
- Board 501 **Abstract 1583:** From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption.
First Author: Aaron B. Cohen, MD, MSCE
- Board 502 **Abstract 1584:** Unmet rehabilitation needs in cancer survivors: A population-level analysis.
First Author: Subha Hanif, MD
- Board 503 **Abstract 1585:** Implementing a clinical research coordinator-led care delivery model (CRC model) in an early-phase oncology program: A pilot to streamline workflow, improve collaboration, and enhance patient-centered trial conduct.
First Author: Christina Chukri, BS
- Board 504 **Abstract 1586:** Spatial heterogeneity of structural inequities in diagnostic delay and survival in early-onset colorectal cancer in a large urban catchment area.
First Author: Rohan K. Patel, MD, MPH
- Board 505 **Abstract 1587:** Effect of an EHR-facilitated symptom surveillance intervention on rehabilitation utilization in cancer patients.
First Author: Toure Barksdale, MD
- Board 506 **Abstract 1588:** Impact of the Navya Earthshot-enabled clinical decision support system on treatment turnaround time in oncology care: A real-world study from a tertiary cancer center in India.
First Author: Umesh Mahantshetty, MD, DNB
- Board 507 **Abstract 1589:** Trial characteristics and results reporting among oncology clinical trials involving African countries.
First Author: Oyepeju Folashade Abioye, MD, MSc
- Board 508 **Abstract 1590:** Cancer stigma in low- and middle-income countries: A scoping review of frameworks, measurement approaches, and interventions.
First Author: Emma Seevak, BA
- Board 509 **Abstract 1591:** Validation of pathology-based triage for the 21-gene recurrence score: A meta-analysis and qualitative synthesis of the Magee equations.
First Author: Thiti Susirwatananont, MD, MS
- Board 510 **Abstract 1592:** Representing people's experience of cancer and its treatment (ResPECT) pilot study: A global collaborative study to improve cancer care and outcomes as part of the Lancet Commission on Cancer and Health Systems.
First Author: André Pfb, MD
- Board 511 **Abstract 1593:** Understanding barriers to the clinical breast exam in Telangana, India: A survey study of participants and non-participants in underserved rural and urban areas.
First Author: Nina Tamirisa, MD
- Board 512 **Abstract 1594:** Interpretable machine learning to identify health system levers for survival outcomes of patients with breast cancer.
First Author: Erin Feliciano, MD
- Board 513 **Abstract 1595:** Interpretable machine learning to identify health system levers for survival outcomes of patients with prostate cancer.
First Author: Edward Christopher Dee, MD

- Board 514 **Abstract 1596:** Machine learning approach to identify country-specific drivers of global cancer outcomes.
First Author: Erin Feliciano, MD
- Board 515 **Abstract 1597:** Leukemia mortality in Latin America and the United States: A population-based analysis.
First Author: Leticia Campoverde, MD
- Board 516 **Abstract 1598:** Machine learning–based decision support for ICU admission in febrile oncology patients: Optimizing care delivery and resource allocation.
First Author: Aditya Venkat Iyer, BS
- Board 517 **Abstract 1599:** Oncology drug shortages and disruptions to cancer treatment delivery in Mexico: A national oncologist survey.
First Author: Francisco Guadarrama-Conzuelo, MD
- Board 518 **Abstract 1600:** Expanding access to tyrosine kinase inhibitors for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia in low- and middle-income countries.
First Author: Lauren Herzog, MPH
- Board 519 **Abstract 1601:** “Who even talks to her anymore?” Misalignment between cervical cancer care landscape and community awareness in Rwanda.
First Author: Eulade Rugengamanzi, MD, MMedSc
- Board 520 **Abstract 1602:** National analysis of cancer care for refugees in Moldova during the war in Ukraine (2022–2025).
First Author: Horia Vulpe, MDCM
- Board 521 **Abstract 1603:** Closing the gap in germline testing in patients with cancer through a clinic-based awareness initiative: From booth to patient’s agenda.
First Author: Luisina Ines Bruno, MD
- Board 522 **Abstract 1604:** Validation of a generative AI-based clinical decision support system for surgical extent in thyroid cancer in Brazil: Potential aid to de-escalating treatment to preserve function.
First Author: Sergio Ferreira Juacaba, PhD, MSc
- Board 523 **Abstract 1605:** Validation of an AI-based clinical decision support system for guideline-concordant prostate cancer treatment at a Brazilian cancer center.
First Author: Sergio Ferreira Juacaba, PhD, MSc
- Board 524 **Abstract 1606:** A clinical prediction score to identify symptomatic patients at high risk for colorectal cancer in South Africa.
First Author: Yoanna S. Pumpalova, MD
- Board 525 **Abstract 1607:** Delivering oncology care in Syria: Implementation lessons from conflict-affected and resource-limited settings.
First Author: Maria Hafez, MD, MS
- Board 526 **Abstract 1608:** Optimization of immunotherapy duration for advanced melanoma: The prospective OTIMAS trial.
First Author: Milena Perez Mak, MD, PhD
- Board 527 **Abstract 1609:** Optimization of geospatial oncologist placement: A maximum coverage problem approach.
First Author: Ryan James Crowley, MPhil
- Board 528 **Abstract 1610:** Scaling prior authorization for philanthropic funding with artificial intelligence (AI): Five-year outcomes from Indian Cancer Society Cancer Cure Fund (ICS-CCF) NavyaAI implementation.
First Author: Nehal Rishi Khanna, MD
- Board 529 **Abstract 1611:** Predicting immune-related adverse events (irAEs) with large language model (LLM) embeddings.
First Author: Tiffany Tian, BA
- Board 530 **Abstract 1612:** The use of generative AI tools by cancer patients and caregivers: A cross-sectional survey of awareness, attitudes, and experiences.
First Author: Rashad Ismayilov, MD
- Board 531 **Abstract 1613:** Identifying cancer cachexia using clinical reasoning artificial intelligence (AI).
First Author: Vibhor Gupta, PhD
- Board 532 **Abstract 1614:** Prospective evaluation of AI-assisted documentation and summarization in virtual multidisciplinary cancer conferences.
First Author: Luxiga Thanabalachandran
- Board 533 **Abstract 1615:** Assessing the true burden of immune-related colitis in lung cancer through large language model–enabled clinical phenotyping.
First Author: Himil Mahadevia, MBBS
- Board 534 **Abstract 1616:** Correlation of tumor-naïve methylation-based preoperative ctDNA testing with pathologic upstaging and occult metastasis in early-stage solid tumors.
First Author: Xiangnan Li
- Board 535 **Abstract 1617:** Sources matter: Learning to evaluate large language models for oncology treatment plans and changes observed by anchoring models to an oncology-specific database.
First Author: Connor Yost, DO
- Board 536 **Abstract 1618:** Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success.
First Author: Boleslaw Leszek Osinski, PhD
- Board 537 **Abstract 1619:** Validation of electronic phenotyping algorithms for prostate cancer in All of Us and their impact on genetic association studies.
First Author: Zachary Creech, MD
- Board 538 **Abstract 1620:** A context-constrained oncology agent for automated, guideline-concordant treatment decision support in precision oncology.
First Author: Deva Datta Reddy Jyothi
- Board 539 **Abstract 1621:** Comparing oncologists, a GPT-based model, and a SEER-based survival calculator for cancer prognostication.
First Author: Lyndon Huang, MD
- Board 540 **Abstract 1622:** Machine learning modeling for predicting 60-day prognosis in newly diagnosed advanced solid tumors.
First Author: Yakir Malyanker, MD
- Board 541 **Abstract 1623:** Evaluation of AI-guided questioning versus standard information delivery in a simulated newly diagnosed breast cancer population.
First Author: Emma Singel, BA

- Board 542 **Abstract 1624:** Age-dependent pathogenic variant risk in female breast cancer.
First Author: Lina Sulieman
- Board 543 **Abstract 1625:** Clinical utility analysis of a computational reasoning system on large-scale tumor genomic data.
First Author: Dora Lakatos, PhD, BSc, MSc
- Board 544 **Abstract 1626:** Resolving the ambiguity between genomic rearrangements and gene fusions: An AI-augmented structural framework to define therapeutic eligibility in kinase-driven cancers.
First Author: Kai Wang, MD, PhD
- Board 545 **Abstract 1627:** SMS message sentiment as a predictive indicator of quality of life and program adherence in oncology nutrition.
First Author: Mélanie Guirette, PhD, MS
- Board 546 **Abstract 1628:** Toxicity risk calculator for personalised prediction of irAEs in patients with solid tumours receiving ICIs, developed based on a clinical dataset and machine learning approaches.
First Author: Marina Lyadova, MD
- Board 547 **Abstract 1629:** Fitbit-derived activity and heart-rate patterns for predicting 12-month hospitalization in an NIH All of Us cancer cohort.
First Author: Kenan Najjar, BA
- Board 548 **Abstract 1630:** Evaluating AI decision support in a rapidly evolving therapeutic landscape: *EGFR*-mutant metastatic NSCLC.
First Author: Chinmay Jani, MBBS
- Board 549 **Abstract 1631:** Wearable-derived physical activity monitoring with AI-based detection of treatment-related adverse events during neoadjuvant chemotherapy for early breast cancer: TRACK-BC.
First Author: Nobuhiro Shibata, MD, PhD
- Board 550 **Abstract 1632:** Impact of remote symptom monitoring program on payor-specific healthcare costs.
First Author: Gabrielle Betty Rocque, MD, FASCO
- Board 551 **Abstract 1633:** Earlier CRS identification with continuous wearable monitoring in outpatient CAR Tcell therapy.
First Author: Jonas Paludo, MD
- Board 552 **Abstract 1634:** Validating a single-item screener for low digital health literacy among surgical oncology patients.
First Author: Thomas S. Gunning, MD, MPH
- Board 554 **Abstract 1636:** Conversational AI-assisted exploratory data analysis (CA-EDA): A comparative evaluation of commercial large language models for clinical trial analysis.
First Author: Yaacov Lawrence Lawrence, MA, MBBS, MRCP
- Board 555 **Abstract 1637:** Evaluating the organizational benefits of remote symptom monitoring during injectable outpatient cancer treatment: The final analysis of the randomized OPTIMACURE trial.
First Author: Audrey Faveyrial, MD
- Board 556 **Abstract 1638:** Feasibility and preliminary efficacy of a 12-week remotely delivered exercise program in patients receiving immunotherapy: A phase II randomized controlled trial.
First Author: Paulo Gustavo Bergerot, MD
- Board 557 **Abstract 1639:** Disparities in receipt of guideline-concordant adjuvant chemotherapy and survival outcomes among immigrant patients with colon cancer: Real-world evidence from Ontario.
First Author: Bishal Gyawali, MD, PhD, FASCO
- Board 558 **Abstract 1640:** Sociodemographic variation in live birth incidence and access to assisted reproductive services among female cancer patients in the United States.
First Author: Isabel Beshar, MD, MPhil
- Board 559 **Abstract 1641:** Comorbidity-related medical expenditures and health outcomes in cancer patients.
First Author: Panpan Xiao
- Board 560 **Abstract 1642:** Retrospective assessment of Duffy-Null associated neutrophil counts (DANC) status and impact on treatment among patients with and without cancer in an urban academic medical center.
First Author: Bhawneet Chadha, MD
- Board 561 **Abstract 1643:** Emergency department visits and hospitalizations in cancer survivors with disabilities: A national analysis.
First Author: Mariana Lilani Henry, MD, MPH
- Board 562 **Abstract 1644:** Healthcare resource use (HCRU) intensity prior to cancer diagnosis and real-world outcomes in early-stage cancers.
First Author: Syed Irteza Abbas Shamsi
- Board 563 **Abstract 1645:** Reframing access to innovative oncology medicines: The impact of policy and governance reform in a Bismarck-type system in Bosnia and Herzegovina.
First Author: Timur Ceric, MD, PhD
- Board 564 **Abstract 1646:** Association between physician characteristics and likelihood of caring for underserved patients with cancer.
First Author: William Roberts
- Board 565 **Abstract 1647:** Racial disparities and nonconcordance with endocrine and HER2 therapy for breast cancer: A sequential mediation analysis of neighborhood deprivation and insurance status.
First Author: Jay Patel, MD, BS
- Board 566 **Abstract 1648:** Survival outcomes with immune checkpoint inhibitors among patients with cancer from minoritized racial and ethnic groups: A systematic review and meta-analysis.
First Author: Alfredo Viray Chua Jr, MD
- Board 567 **Abstract 1649:** ZIP-code-level distress as a predictor for advanced stage and mortality in female breast cancer across a multiethnic cohort in Hawai'i.
First Author: Chalothorn Wannaphut, MD
- Board 568 **Abstract 1650:** Racial variation in pain medication prescriptions among breast, prostate, and pancreatic cancer patients treated in a large community oncology setting.
First Author: Ila Sruti, MPH
- Board 569 **Abstract 1651:** Racial representation in clinical trials supporting NCCN breast cancer guidelines: A retrospective analysis.
First Author: Shreya Motkur, MD

- Board 570 **Abstract 1652:** Are socio-economic status indicators barriers for enrollment in phase 1 clinical trials?
First Author: Reema Mody, DO
- Board 571 **Abstract 1653:** Early-onset gastrointestinal cancers: Racial disparities in stage and survival from large-scale community oncology data.
First Author: Saamir Pasha
- Board 572 **Abstract 1654:** Global sex-based disparities in pancreatic cancer clinical trial enrolment: A systematic review and meta-analysis.
First Author: Amir H. Sohail, MBBS
- Board 573 **Abstract 1655:** Who gets access? National discrepancies in clinical trial enrollment among patients with brain metastases.
First Author: Manuela Jaramillo
- Board 574 **Abstract 1656:** Validation of a 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) for predicting survival in older adults with cancer.
First Author: Tomohiro F. Nishijima, MD, PhD
- Board 575 **Abstract 1657:** Use of parsimonious Fitbit step metrics to improve frailty classification in adults ≥ 50 with cancer in NIH All of Us.
First Author: Kenan Najjar, BA
- Board 576 **Abstract 1658:** GRACE: A conversational AI platform for geriatric oncology risk and capability evaluation.
First Author: Arash Naeim, MD, PhD
- Board 577 **Abstract 1659:** Development of a composite risk score for chemotherapy toxicity and unplanned hospitalization in older adults with cancer: A prospective cohort study.
First Author: Lirong Yang, PharmD
- Board 578 **Abstract 1660:** Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: A national real-world data analysis.
First Author: James Robert Janopaul-Naylor, BSc
- Board 579 **Abstract 1661:** Evaluation of a co-designed nurse-led geriatric oncology multidisciplinary model in treatment-naive older adults with solid cancers.
First Author: Surein Arulananda, PhD, MBBS
- Board 580 **Abstract 1662:** Outcomes of mortality and health care utilization in frail older patients with cancer receiving target therapies and/or immunotherapy.
First Author: Amit Arora, MD, MBBS, MS
- Board 581 **Abstract 1663:** G8 screening-defined geriatric vulnerability as a predictor of survival and quality of life in older patients with advanced cancer treated with novel therapies.
First Author: Andrea De Giglio, MD, PhD
- Board 582 **Abstract 1664:** Age-related efficacy of antibody-drug conjugates in solid tumors: A meta-analysis.
First Author: Mariana Macambira Noronha, MS
- Board 583 **Abstract 1665:** Integrating objective sarcopenia assessment into geriatric screening as a predictor of treatment tolerance.
First Author: Hojung An, MD, PhD
- Board 586 **Abstract 1668:** Online peer support for breast cancer survivors: A decentralized multicenter non-blinded parallel-group pilot randomized controlled trial (HOPE-BC study).
First Author: Yoshie Hasegawa, MD, PhD
- Board 587 **Abstract 1669:** Evaluation of a remote electronic assessment of survivors with tailored follow-up recommendations and survivorship messaging (REASSURE) to improve the delivery of follow-up for low-risk breast cancer survivors.
First Author: Heather B. Neuman, MD
- Board 588 **Abstract 1670:** The Engage program for childhood cancer survivors: Results from a multidisciplinary, distance-delivered intervention.
First Author: Christina Signorelli
- Board 589 **Abstract 1671:** Survivorship-focused content at the American Society of Clinical Oncology (ASCO) 2022-2024 annual meetings.
First Author: Lauren Rynar, PhD
- Board 590 **Abstract 1672:** Impact of medically tailored meals plus nutrition counseling on treatment adherence in vulnerable lung cancer patients: Results from NutriCare randomized controlled trial.
First Author: Zhongyao Li
- Board 591 **Abstract 1673:** Performance of ChatGPT in generating patient-facing cancer survivorship care plans.
First Author: Kaili Du, MD, FACP
- Board 592 **Abstract 1674:** Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024.
First Author: Kerry Conlin, MSc
- Board 593 **Abstract 1675:** Rethinking MRI surveillance after breast cancer in the context of persistent racial disparities in mortality.
First Author: Elizabeth Susan McDonald, MD, PhD
- Board 594a **Abstract TPS1676:** CTNow pilot study: A multilevel clinical trial education and clinical trial referral coordination intervention for rural oncology providers and patients with cancer.
First Author: Izumi Okado, PhD
- Board 594b **Abstract TPS1677:** Genetic testing uptake through an enhanced oncology nurse-led intervention in patients with solid tumors (GENESIS): A pilot study.
First Author: Ranjan Pathak, MD
- Board 595a **Abstract TPS1678:** Patient preference for subcutaneous vs. intravenous immune therapy (PSI-Immune).
First Author: Vincent Edgar Reyes, MD
- Board 595b **Abstract TPS1679:** Cancer CARE (Connected Access and Remote Expertise) beyond walls: Pilot, phase 2 clinical trial to evaluate administration of cancer-directed therapy in the patient's homes versus in clinic in the Florida Panhandle and surrounding areas.
First Author: Dina Elantably, MD, MSc
- Board 596a **Abstract TPS1680:** Making telehealth delivery of cancer care at home effective and safe: A pragmatic cluster randomized trial.
First Author: Erin Mary Bange, MD

- Board 596b **Abstract TPS1681:** Implementation of a cancer-oriented geriatric assessment (COGA) clinic to promote age-friendly cancer care: A type III hybrid implementation–effectiveness method in community practice.
First Author: Ganesh Prasad Merugu, MD, MBBS
- Board 597a **Abstract TPS1682:** An EHR-embedded SmartForm (OncAssessment) paired with ePROs to enable real-time structured documentation of key oncologic data during routine cancer care: A pragmatic implementation study.
First Author: Aditi Puri Singh, MD
- Board 597b **Abstract TPS1683:** MATCHES-NOVEL: A randomized controlled trial in progress of hospital-at-home (HaH) versus inpatient hospitalization for post tarlatamab monitoring.
First Author: Robert Michael Daly, MD, MBA, FASCO

9:00 AM-12:00 PM Poster Session

Gastrointestinal Cancer—Colorectal and Anal

Location: Hall A—Posters and Exhibits

Posters by Topic

Anal Cancer: Board(s) 272-273

Artificial Intelligence: Board(s) 274-280

Colorectal Cancer—Advanced Disease: Board(s) 281-376, 439a-445a

Colorectal Cancer—Local-Regional Disease: Board(s) 377-422, 445b-447b

Epidemiology/Outcomes: Board(s) 423-432

Other Colorectal and Anal Cancer: Board(s) 433-438

- Board 272 **Abstract 3518:** Role of microbiota in response to treatment in anal squamous cell carcinoma.
First Author: Jaime Feliú, MD
- Board 273 **Abstract 3519:** TROP2 as an actionable biomarker for anal cancer.
First Author: Mir Lim, MD
- Board 274 **Abstract 3520:** H&E–based MSI/MMR testing with artificial intelligence in colorectal cancer: A blinded evaluation across diverse clinicopathological subgroups.
First Author: Pahini Pandya, PhD
- Board 275 **Abstract 3521:** Large language model–assisted decision-making in multidisciplinary tumor boards for colorectal cancer.
First Author: Aydan Farzaliyeva, MD
- Board 276 **Abstract 3522:** Inferring molecular signatures in colorectal cancer directly from routine whole-slide images.
First Author: Piotr Keller, MS
- Board 277 **Abstract 3523:** HistoChrome: Virtual multiplex immunohistochemistry from routine H&E in colorectal cancer.
First Author: Mark Eastwood
- Board 278 **Abstract 3524:** Validation of DiaSurv, an AI-based algorithm for stage II colon cancer risk stratification.
First Author: Lou Rouan

- Board 279 **Abstract 3525:** A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance).
First Author: Frank A. Sinicrope, MD
- Board 280 **Abstract 3526:** A large-scale, multi-target deep learning model for virtual genomic and molecular risk profiling in colorectal cancer.
First Author: Erik N. Bergstrom
- Board 281 **Abstract 3527:** The use of miR-5193 to predict oxaliplatin chemosensitivity in colorectal cancer: Integrated in silico, in vitro, and clinical evidence.
First Author: Jaime A. González Montero, MD, PhD
- Board 282 **Abstract 3528:** Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS-mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study.
First Author: Yun Xu
- Board 283 **Abstract 3529:** daNIS-3: A phase II platform study of NIS793 and anti-PD-1 combined with standard of care (SoC) anti-cancer therapy for the second-line (2L) treatment (tx) of microsatellite-stable colorectal cancer (MSS CRC).
First Author: Filippo Pietrantonio, MD
- Board 284 **Abstract 3530:** Tislelizumab plus cetuximab and irinotecan in relapsed/refractory RAS/BRAF wild-type and microsatellite stable metastatic colorectal cancer: A randomized, controlled, multicenter study (TEC2).
First Author: Xiaojing Xu
- Board 285 **Abstract 3531:** Association of progression-free survival (PFS) with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) status determined by single vs dual validated companion diagnostic (CDx) assays: CheckMate-8HW post hoc analyses.
First Author: Thierry Andre, MD
- Board 286 **Abstract 3532:** Nivolumab + ipilimumab (NIVO + IPI) vs NIVO in microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC): CheckMate 8HW subgroup analyses including treatment-free status and outcomes in long-term survivors.
First Author: Elena Elez, MD, PhD
- Board 287 **Abstract 3533:** Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).
First Author: Hazel Lote, MD
- Board 288 **Abstract 3534:** A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC).
First Author: Wenhua Li, PhD
- Board 290 **Abstract 3536:** Intravenous oncolytic virus IDOV-Safe in pMMR/MSS metastatic colorectal cancer.
First Author: Tong Xie, MD

- Board 291 **Abstract 3537:** Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in *RAS* wild-type metastatic colorectal cancer.
First Author: Hao Chen, MD
- Board 292 **Abstract 3538:** Zongertinib in HER2-altered colorectal cancer: A pooled analysis of colorectal cancer patients from two clinical trials.
First Author: Dirk Arnold, MD, PhD
- Board 293 **Abstract 3539:** First-line immune checkpoint inhibitors in elderly colorectal cancer patients in the real world: Retrospective phase of the multicenter ELDER CRC trial.
First Author: Martina Cassaniti, MD
- Board 294 **Abstract 3540:** Overall survival benefit of doublet versus triplet BRAF inhibitor-based therapy: Insights from the BEETS study (JACCRO CC-18).
First Author: Chiaki Inagaki, MD, PhD
- Board 296 **Abstract 3542:** Ultra-early-onset metastatic colorectal cancer (<35 years): RAS-driven, APC/TP53-depleted, TMB-low molecular features in a real-world analysis of 2,392 patients.
First Author: Andrea Pretta, MD
- Board 297 **Abstract 3543:** Survival outcomes of human epidermal growth factor receptor 2 (HER2)-amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).
First Author: Yu Jen Alexander Jan, MD
- Board 311 **Abstract 3544:** A phase Ib, open-label, clinical trial of JAB21822 combined with second-line chemotherapy for metastatic colorectal cancer with *KRAS* G12C mutation.
First Author: Zhenghang Wang, MD, PhD
- Board 312 **Abstract 3545:** A prospective randomized controlled trial of FAPI PET/CT-guided radiotherapy combined with second-line standard systemic treatment and cadonilimab versus second-line standard systemic treatment alone in patients with peritoneal metastasis from colorectal cancer (TORCH-PM01).
First Author: Juefeng Wan
- Board 313 **Abstract 3546:** A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with Neo*RAS* wild-type metastatic colorectal cancer (C-PROWESS trial).
First Author: Hiroki Osumi, MD, PhD
- Board 314 **Abstract 3547:** Serum VEGF-A concentrations as a predictive biomarker of immunotherapy response in refractory metastatic colorectal cancer (mCRC): An exploratory analysis of CCTG CO.26.
First Author: François Jobin Gervais, MD
- Board 315 **Abstract 3548:** Antitumor activity of amivantamab by consensus molecular subtypes in *RAS/BRAF* wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI1 study.
First Author: Marcia Roxana Cruz-Correa, MD, PhD
- Board 316 **Abstract 3549:** First-in-human study of cavitation-enhanced drug delivery (CEeDD) by sonosensitive particles and focused ultrasound applied to colorectal metastases in the liver.
First Author: Jeffrey Rubasingham, MBChB
- Board 317 **Abstract 3550:** Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS) *RAS* and *BRAF* wild-type (wt) and HER2- metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).
First Author: Marco Maria Germani, MD
- Board 319 **Abstract 3552:** A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases.
First Author: Mengzhou Guo
- Board 320 **Abstract 3553:** Detecting *MTAP* loss in liquid biopsies from patients with clinically advanced colorectal cancer (CRC).
First Author: Xuanyi Li, MD
- Board 321 **Abstract 3554:** Tumor cell-intrinsic programs of metabolic adaptation and immune evasion in colorectal cancer liver metastases (CRCLMs).
First Author: Xuanyi Li, MD
- Board 322 **Abstract 3555:** Tumor shrinkage and depth of response with fruquintinib in patients with metastatic colorectal cancer: Results from FRESKO and FRESKO-2.
First Author: Elena Elez, MD, PhD
- Board 323 **Abstract 3556:** Evaluation of circulating tumor DNA (ctDNA) following liver resection in a high-risk population with colorectal liver metastases.
First Author: John Neil Primrose, MD
- Board 324 **Abstract 3557:** Screening for intrinsic and acquired resistance mutations to anti-EGFR in real-world MSS colorectal cancer data.
First Author: Matthew B. Maxwell, PhD
- Board 326 **Abstract 3559:** BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with *BRAF*V600E-mutant metastatic colorectal cancer.
First Author: Takeshi Yamada, MD, PhD
- Board 327 **Abstract 3560:** FOLFOXIRI/bevacizumab in microsatellite stable (pMMR/MSS) *RAS* and *BRAF* wild-type "gene-altered" metastatic colorectal cancer (mCRC): The HYPERTRIBE study.
First Author: Marco Maria Germani, MD
- Board 328 **Abstract 3561:** Tumor load change as a functional biomarker for prognosis and treatment modulation in metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of 12 randomized trials.
First Author: Alexej Ballhausen, MD
- Board 329 **Abstract 3562:** Single-cell atlas of peripheral blood immune landscape in pMMR/MSS rectal cancer treated with neoadjuvant chemoradiotherapy and PD-1 blockade.
First Author: Leqi Zhou, DrPH

- Board 330 **Abstract LBA3563:** Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial.
First Author: Jianmin Xu, PhD
- Board 331 **Abstract 3564:** NALIRIFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer: A phase I study.
First Author: Xiaojing Xu
- Board 332 **Abstract 3565:** KMT2C mutation to identify an immunotherapy-sensitive subset of gastrointestinal cancers: A large real-world analysis.
First Author: Bruno Bockorny, MD
- Board 333 **Abstract 3566:** Efficacy and circulating protein biomarkers of second-line aflibercept plus FOLFIRI according to prior bevacizumab or cetuximab treatment in advanced colorectal cancer (KCSG CO21-21).
First Author: Hyunwook Kim, MD
- Board 334 **Abstract 3567:** A multicenter phase II trial of encorafenib, binimetinib, and cetuximab for early relapsed stage II/III *BRAF*^{V600E}-mutated colorectal cancer: TRESBIEN trial (OGSG 2101).
First Author: Toshihiro Kudo, MD, PhD
- Board 335 **Abstract 3568:** Clinical validation of red blood cell DNA for early detection of advanced colorectal neoplasia: A single-center prospective observational case-control clinical trial.
First Author: Xingyun Yao, PhD
- Board 336 **Abstract 3569:** SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study.
First Author: Ting Xu, MD
- Board 337 **Abstract 3570:** A transcriptomic signature to predict immune checkpoint inhibition efficacy in proficient mismatch repair metastatic colorectal cancer: Translational analysis of the AVETRIC and TRIPLETE studies.
First Author: Martina Carullo, MD
- Board 338 **Abstract 3571:** A phase II combination study of galunisertib and capecitabine in patients with chemotherapy-resistant colorectal cancer with peritoneal metastases.
First Author: Ashwini Kanhailal
- Board 339 **Abstract 3572:** Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer.
First Author: Guglielmo Vetere, MD
- Board 340 **Abstract 3573:** ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.
First Author: Kentaro Yamazaki, MD, PhD
- Board 341 **Abstract 3574:** Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial.
First Author: Anees Dauki, PhD
- Board 342 **Abstract 3575:** FIRE-4 (AIO KRK-0114): Efficacy of third-line rechallenge with cetuximab versus investigator's choice in relation to the interval between initial and third-line anti-EGFR therapy.
First Author: Lena Weiss, MD
- Board 343 **Abstract 3576:** Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.
First Author: David Berz, MD, PhD
- Board 344 **Abstract 3577:** Cadonilimab, a bispecific anti-PD-1/CTLA-4 antibody, for patients with dMMR/MSI-H metastatic colorectal cancer after progression on anti-PD-(L)1 therapy: A multicenter, single-arm, phase 2 trial (CSWOG-C03).
First Author: Huabin Hu, MD
- Board 345 **Abstract 3578:** Radiotherapy followed by systemic therapy and tislelizumab in microsatellite-stable rectal cancer with synchronous unresectable metastases: Updated results of the MIRACLE-2 study.
First Author: Menglong Zhou, MD
- Board 346 **Abstract 3579:** Indirect comparison of nivolumab-ipilimumab versus chemotherapy (Chemo) and/or immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) using reconstructed individual patient data (IPD).
First Author: Daniele Rossini, MD, PhD
- Board 347 **Abstract 3580:** Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies (ACT-GI): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.
First Author: Gerald A. Soff, MD
- Board 348 **Abstract 3581:** Propensity score-matched analysis of trifluridine-tipiracil plus bevacizumab (FTD/TPI+Bev) vs anti-EGFR re-treatment in pretreated metastatic colorectal cancer (mCRC).
First Author: Giovanni Trovato, MD
- Board 349 **Abstract 3582:** A multi-omic analysis of EO CRC: Divergent methylation and gene expression signatures in young patients.
First Author: Ning Jin, MD, MS
- Board 350 **Abstract 3583:** Long-term responders to trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer: Results from the BeTAS real-world study.
First Author: Nieves Martinez Lago, MD, PhD
- Board 351 **Abstract 3584:** Correlative analysis of ctDNA in CheckMate-9X8 study of frontline treatment with mFOLFOX6, bevacizumab with or without nivolumab in metastatic colorectal cancer.
First Author: Jin Yao, PhD
- Board 352 **Abstract 3585:** Circulating tumor DNA for characterizing intratumor heterogeneity and outcomes in metastatic colorectal cancer.
First Author: Cynthia Yeung, MD
- Board 353 **Abstract 3586:** Influence of neoadjuvant therapy on tumor-vascular-immune stromal networks in colorectal cancer liver metastases.
First Author: Pia J. Osterlund, MD, PhD

- Board 354 **Abstract 3587:** Clinical efficacy of laparoscopic hybrid surgery versus total open surgery for simultaneous resection of colorectal cancer liver metastases (CHLH trial).
First Author: Wei Zhang
- Board 355 **Abstract 3588:** A four-marker-protein signature to predict ramucirumab efficacy in combination with TAS-102 in advanced colorectal cancer: Translational analysis of the RAMTAS trial of the German AIO (AIO-KRK-0316/IKF643).
First Author: Thomas Seufferlein, MD, PhD
- Board 356 **Abstract 3589:** Real-world outcomes and recurrence risk factors of liver transplantation for permanently unresectable colorectal liver metastases following the TransMet trial.
First Author: Rene Adam, MD, PhD
- Board 357 **Abstract 3590:** Dynamic circulating tumor DNA profiling for prediction of long-term clinical benefit in pMMR locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy plus sintilimab.
First Author: Xiaobin Zheng, MD, PhD
- Board 358 **Abstract 3591:** Safety and efficacy of ifebemtinib combined with garsorasib in KRAS G12C mutant colorectal cancer from a randomized part of a phase Ib/II study.
First Author: Xiangdong Cheng, MD
- Board 359 **Abstract 3592:** Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis.
First Author: Wallace Klein Schwengber, MD
- Board 360 **Abstract 3593:** Data from a real-world study: Association of CDCP1 expression level with survival outcomes in mCRC patients treated with bevacizumab or cetuximab plus chemotherapy.
First Author: Yitzhar Efraim Goretsky, MD, BS
- Board 361 **Abstract 3594:** Multimodality neoadjuvant downstaging therapy before liver transplantation for colorectal liver metastasis: Real-world data from the Cleveland Clinic.
First Author: Mazhar Khalil, MD
- Board 362 **Abstract 3595:** Tumor-informed versus tumor-agnostic ctDNA assays for molecular residual disease detection in colorectal cancer: A systematic review and meta-analysis.
First Author: Nain Tara, MD
- Board 363 **Abstract 3596:** The efficacy and safety of sosimerasib monotherapy in pretreated colorectal cancer with KRAS G12C mutation: Results from a phase 1b study.
First Author: Lihui Liu
- Board 364 **Abstract 3597:** TAMS in appendiceal cancer: Association with metabolic remodeling, prognosis, and response to intra-tumoral therapy.
First Author: Patrick Wagner, MD
- Board 365 **Abstract 3598:** A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for *RAS/BRAF* wild-type metastatic colorectal cancer: Updated results from the CAPCET study.
First Author: Qiu Meng
- Board 366 **Abstract 3599:** Prediction of hematotoxicity using CT-derived body composition in rectal cancer patients receiving immunotherapy-based total neoadjuvant therapy.
First Author: Ruone Xu
- Board 367 **Abstract 3600:** An early on-treatment “coordinated inflammatory niche” plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).
First Author: Yi Yin, MD
- Board 368 **Abstract 3601:** Clinical implications of primary and metastatic tumor-informed clonal tracking for MRD assessment in oligometastatic colorectal cancer.
First Author: Hyun Jin Bang, MD
- Board 369 **Abstract 3602:** Multiplexed immunohistochemistry (mIHC) analysis and clinical outcomes of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in patients with refractory colorectal cancer (phase 1b/2).
First Author: Soohyeon Lee, MD, PhD
- Board 370 **Abstract 3603:** Phase 1, FIH study of cabotamig, a TCE CDH17 X CD3, in CDH17-expressing GI malignancies.
First Author: Roland Ching-Yu Leung, MBChB, MRCP
- Board 371 **Abstract 3604:** The CONVERGE study: A phase II, single-arm trial of adabelimab combined with targeted therapy and liposomal irinotecan-based chemotherapy for conversion surgery in unresectable MSS colorectal cancer liver metastases.
First Author: Wenhui Yang
- Board 372 **Abstract 3605:** Association of concurrent GLP-1 receptor agonist use with survival outcomes in patients with metastatic colorectal cancer receiving immune checkpoint inhibitors.
First Author: Shalin Rawal, MD
- Board 373 **Abstract 3606:** Dynamics of circulating monomeric C-reactive protein (mCRP) to predict outcomes with first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC).
First Author: Anniken Joerlo Fuglestad
- Board 374 **Abstract 3607:** The SERPENTINE trial: A phase II clinical study decoding immune responses by scRNA-seq and TCR-seq analysis in patients with MSS metastatic colorectal cancer (mCRC) with and without liver metastases treated with durvalumab and tremelimumab.
First Author: Iosune Baraibar, MD, PhD
- Board 375 **Abstract 3608:** Liver transplantation (LT) in liver limited metastatic colorectal cancer (CRC): Insights and opportunities.
First Author: Jonathan W. Lee, MD, MSc
- Board 376 **Abstract 3609:** Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The MD Anderson INTERCEPT experience.
First Author: Soumya Shekhar, MD

- Board 377 **Abstract 3610:** Long-term survival and biomarker analysis of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. First Author: Weiwei Xiao, MD
- Board 378 **Abstract 3611:** Dual-microbial signature as a predictor of postoperative colorectal cancer recurrence. First Author: Pancheng Chen
- Board 379 **Abstract 3612:** Targeting the Warburg effect: Mitochondrial metabolic modulation with intermittent fasting during neoadjuvant chemoradiation in rectal cancer compared with standard neoadjuvant chemoradiation and total neoadjuvant therapy. First Author: Krithikaa Sekar, MD
- Board 381 **Abstract 3614:** Predicting neoadjuvant chemoradiotherapy response and postoperative recurrence in locally advanced rectal cancer using a preoperative large language model. First Author: Xiaoxi Chen
- Board 382 **Abstract 3615:** Association between circulating tumor DNA and local tumor regrowth and distant metastasis during nonoperative management in stage I–III rectal cancer. First Author: Kentaro Ochiai, MD, PhD
- Board 383 **Abstract 3616:** Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) to stratify recurrence risk and adjuvant treatment benefit in a real-world colorectal cancer (CRC) cohort. First Author: Mariem Galuia, MD
- Board 384 **Abstract 3617:** Safety, immunogenicity, and efficacy of Ad5.F35-GUCY2C-PADRE vaccine in patients with GI cancers at high risk of relapse: Results from a phase 2A trial. First Author: Babar Bashir, MD, FACP, MSc
- Board 385 **Abstract 3618:** SOCCER: A randomized phase II trial comparing complete clinical response after short course radiation or chemoradiation and consolidation chemotherapy in rectal cancer. First Author: Ramakrishnan Ayloor Seshadri, MCh, MNAMS, MS, MBBS
- Board 386 **Abstract 3619:** Prediction of localized rectal cancer outcomes with ctDNA analysis using a novel ultrasensitive structural variant (SV)-based method. First Author: Cecilia Merk, MD
- Board 387 **Abstract 3620:** Neoadjuvant treatment of QL1706 in patients with resectable microsatellite instability-high/mismatch repair-deficient colon cancer: Results from a phase 1b trial. First Author: Zi-Xian Wang
- Board 388 **Abstract 3621:** Phase II trial of anti-PD-1 monoclonal antibody and FOLFOXIRI combined with long-course radiotherapy as the total neoadjuvant treatment for proficient, mismatch repair, locally advanced low rectal cancer (PANFORTE). First Author: Jianhong Peng
- Board 389 **Abstract 3622:** The role of adjuvant chemotherapy in high-risk stage II colon cancer with microsatellite instability-high or DNA mismatch repair deficiencies: A multicenter pooled analysis (KCSG-CO24-03). First Author: Joon Young Hur, MD, PhD
- Board 390 **Abstract 3623:** Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program. First Author: Emerik Osterlund, MD, PhD
- Board 391 **Abstract 3624:** Efficacy of probiotics combined with glutamine compound for acute radiation enteritis during neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A randomized controlled trial (NCT05406882). First Author: Qiaoli Wang
- Board 392 **Abstract 3625:** Circulating tumor DNA clearance of adjuvant chemotherapy in localized colorectal cancer using an ultrasensitive structural variant–based assay. First Author: Cecilia Merk, MD
- Board 393 **Abstract 3626:** Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC). First Author: Amylou C. Dueck, PhD
- Board 394 **Abstract 3627:** Neoadjuvant chemotherapy followed by transanal endoscopic surgery (TES) and selective chemoradiation or total mesorectal excision (TME) for early-stage rectal cancer: The Ottawa Hospital experience. First Author: Mohammed Al Darai, MD
- Board 395 **Abstract 3628:** Impact of postsurgical circulating tumor DNA (ctDNA) dynamics on eligibility of colorectal cancer (CRC) patients for randomized ALTAIR trial: Implications for treat-on-molecular-recurrence (TOMR) trials. First Author: Hideaki Bando, MD, PhD
- Board 396 **Abstract 3629:** Molecular residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: The VICTORI study. First Author: Joao Paulo Solar Vasconcelos, MD
- Board 397 **Abstract 3630:** Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702. First Author: Seohyuk Lee, MD
- Board 398 **Abstract 3631:** Effect of transanal vs. laparoscopic total mesorectal excision on 5-year overall survival in patients with rectal cancer: The TaLaR trial. First Author: Liang Kang, MD, PhD
- Board 399 **Abstract 3632:** Neoadjuvant (NA) chemoradiotherapy (CTRT) plus avelumab (Ave) in locally advanced rectal cancer (LARC): 4-year outcomes of the phase II AVANA trial and their association with computational pathology. First Author: Giovanni Trovato, MD

- Board 400 **Abstract 3633:** Clinical outcomes in curatively resected dMMR/MSI-H colon cancer: A retrospective analysis of a multicentric cohort. First Author: Sofie De Meulder, MD
- Board 401 **Abstract 3634:** Neoadjuvant immunotherapy combined with radiochemotherapy vs chemotherapy alone in pMMR colon cancers: The TORCH-C randomized phase 2 clinical trial. First Author: Hui Zhang
- Board 402 **Abstract 3635:** Clinicopathological characteristics of patients with minimal residual disease in stage II–III colon cancer: Interim results from the observational cohort of CLAUDIA study. First Author: Minsu Kang, MD
- Board 403 **Abstract 3636:** Relationship between GLP-1 receptor agonists on cancer recurrence and survival of patients with stage I-III colorectal cancer: A retrospective cohort study using the TriNetX database. First Author: Emily Noelle Kinsey, MD
- Board 404 **Abstract 3637:** Comparison of longitudinal circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) for post-operative risk stratification in colorectal cancer (CRC). First Author: Eiji Oki, MD, PhD, FACS
- Board 405 **Abstract 3638:** Neoadjuvant tislelizumab plus chemotherapy in MSS/pMMR high-risk locally advanced colon cancer: Updated analysis results from a phase 2 trial. First Author: Minglin Lin, PhD
- Board 406 **Abstract 3639:** Association of CT-based deep learning–derived consensus molecular subtypes with survival outcomes in locally advanced colon cancer: A secondary analysis of the phase III OPTICAL trial. First Author: Sifan Qi, MD
- Board 407 **Abstract 3640:** Neoadjuvant chemoradiotherapy with or without PD-1 blockade in pMMR/MSS low rectal cancer patients (CHOICE II): A multi-center, open-label, randomized controlled trial. First Author: Wei Zhang
- Board 409 **Abstract 3642:** The value of tumor deposits in prognosis evaluation and clinical stage optimization of colorectal cancer: A real-world population-based retrospective cohort study. First Author: Chang Wang
- Board 410 **Abstract 3643:** Updated 5-year survival outcomes of short-course radiation followed by mFOLFOX-6 plus avelumab in locally advanced microsatellite-stable rectal adenocarcinoma: The Averectal phase II study. First Author: Ali Shamseddine, MD, FRCP
- Board 411 **Abstract 3644:** Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT. First Author: Yaqi Wang
- Board 412 **Abstract 3645:** Impact of CAPOX combined with traditional Chinese medicine (TiaoPi AnChang Decoction) on disease-free survival in patients with stage III or high-risk stage II colorectal cancer: An updated report of a randomized, double-blind, placebo-controlled trial. First Author: Jincheng Zhang, MB, MMedSc
- Board 413 **Abstract 3646:** AI-derived tumor microenvironment features and recurrence risk in microsatellite-stable colon cancer after adjuvant chemotherapy. First Author: Changhee Park, MD
- Board 414 **Abstract 3647:** Single-cell profiling of the tumor microenvironment in pMMR/MSS rectal cancer treated with neoadjuvant PD-1 inhibitor combined with FOLFOXIRI and radiotherapy: Insights from the PANFORTE trial. First Author: Chi Zhou, MD
- Board 415 **Abstract 3648:** Rates of metachronous colorectal cancer or secondary Lynch syndrome–related cancers in patients with non-metastatic colorectal cancer. First Author: Emily M. Russell, PhD
- Board 416 **Abstract 3649:** TGF- β signaling alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–enabled precision oncology study in diverse populations. First Author: Erika Ruiz-Garcia, MD, MS, FASCO
- Board 417 **Abstract 3650:** Cost-effectiveness analysis of aspirin and structured exercise as adjuvant therapy in localized colorectal cancer. First Author: Malek B. Hannouf Jr, MD, PhD
- Board 418 **Abstract 3651:** Efficacy and safety of tislelizumab as neoadjuvant therapy combined with MRD monitoring in locally advanced dMMR/MSI-H colon cancer: A prospective pilot study. First Author: Miaoqing Wu
- Board 419 **Abstract 3652:** Consensus molecular subtypes, mutational features, and circulating tumor DNA dynamics in colorectal cancer: A real-world clinico-genomic analysis. First Author: Imad Shureiqi, MD, MS
- Board 420 **Abstract 3653:** Safety and efficacy of neoadjuvant chemotherapy (NAC) in older patients with locally advanced colon cancer (LACC): Results from FOxTROT 1 and the FOxTROT 2 safety cohort population. First Author: Janet Shirley Graham, PhD, MRCP, MBChB
- Board 422 **Abstract 3655:** Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes. First Author: Avihai Moscovici
- Board 423 **Abstract 3656:** Screening and trends: A Global Burden of Disease 2023 assessment of colorectal cancer mortality across G7 nations. First Author: Rana Uzair Ahmad, MBBS
- Board 424 **Abstract 3657:** Association of *FBXW7* mutation with prolonged survival in microsatellite instability–high colorectal cancer treated with immune checkpoint blockade. First Author: Margaret R. Pruitt, MD, PhD

- Board 425 **Abstract 3658:** Clinicopathologic features of South African colorectal cancer patients by HIV status in a retrospective cohort study.
First Author: Jacob Lee Dubner, BA
- Board 426 **Abstract 3659:** Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations, and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD).
First Author: Alicia Catania McDonald, PhD, MPH
- Board 427 **Abstract 3660:** Epidemiology of early-onset colorectal cancer in the WHO Eastern Mediterranean Region: Regional and global comparisons.
First Author: Fares A. Qtaishat
- Board 428 **Abstract 3661:** Impact of concomitant GLP-1 receptor agonist use on overall survival and chemotherapy-related adverse events in colorectal cancer: A real-world pharmacoepidemiologic cohort study.
First Author: Arunkumar Krishnan, MD, MS
- Board 429 **Abstract 3662:** Impact of social determinants of health on women with early-onset colorectal cancer: A retrospective study.
First Author: Elaine Ognjanovski, DO
- Board 430 **Abstract 3663:** Shifting dietary drivers of colorectal cancer mortality in the United States: A 33-year Global Burden of Disease analysis.
First Author: Jennifer Kate Beckerman, MD
- Board 431 **Abstract 3664:** Association of pre-diagnosis primary care utilization with metastatic disease, treatment adherence, and mortality in colorectal cancer.
First Author: Hieu Nguyen
- Board 432 **Abstract 3665:** Bowel function after sphincter-preserving treatment with neoadjuvant therapy for low rectal cancer.
First Author: Yuanshan Chen, MD
- Board 433 **Abstract 3666:** Genomic profiling to define molecular drivers of colorectal neuroendocrine carcinoma subtypes.
First Author: Jenny Xue, MD, PhD
- Board 434 **Abstract 3667:** Defining prostaglandin-driven dysregulation in *PIK3CA*-mutant colorectal cancers: A real-world multi-omic analysis.
First Author: Andrew M. Gaya, MD, FRCR, MRCP
- Board 435 **Abstract 3668:** Divergent transcriptomic signatures and microenvironmental markers of KRAS and BRAF mutations in colorectal cancer: A multi-omics integrative analysis.
First Author: Muzammil Shaikh
- Board 436 **Abstract 3669:** Development and validation of a National Database-derived nomogram for predicting postoperative survival in colorectal cancer.
First Author: Mohyeddine El Sayed, MD
- Board 437 **Abstract 3670:** Molecular differences between early- and later-onset colorectal cancer in a Chilean cohort: A retrospective MSI and NGS-based analysis.
First Author: Tamara Saumann, MD
- Board 438 **Abstract 3671:** Use of KMT2 family mutations to define a distinct epithelial-high, stromal-depleted, and interferon-active gene expression state in colorectal cancer.
First Author: Songwit Payapwattanawong, MD
- Board 439a **Abstract TPS3672:** Phase 2/3 trial of pumitamid (PD-L1 × VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203).
First Author: Tiago Biachi de Castria, MD, PhD
- Board 439b **Abstract TPS3673:** Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease.
First Author: William J. Chapin, MD, MSCE
- Board 440a **Abstract TPS3674:** A phase Ib/III randomized double-blinded placebo-controlled study of suvencitug combined with trifluridine/tipiracil for refractory metastatic colorectal cancer.
First Author: Ying Yuan, MD, PhD
- Board 440b **Abstract TPS3675:** Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
First Author: Cathy Eng, MD, FACP, FASCO
- Board 441a **Abstract TPS3676:** The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab + balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.
First Author: Jonathan M. Loree, MD, MS
- Board 441b **Abstract TPS3677:** A phase II exploratory study of iparomlimab and tuvonralimab (QL1706) combined with bevacizumab in patients with locally advanced or metastatic MSI-H/dMMR colorectal cancer.
First Author: Jun Wang, MD, PhD
- Board 442a **Abstract TPS3678:** A phase 1, first-in-human (FIH), dose-escalation and doseoptimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability-low (MSIL) colorectal cancer (CRC).
First Author: Alexander I. Spira, MD, PhD, FACP, FASCO
- Board 442b **Abstract TPS3679:** A study evaluating microbiome modulation therapy in patients undergoing first-line therapy for metastatic colorectal cancer.
First Author: Emily Noelle Kinsey, MD
- Board 443a **Abstract TPS3680:** CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR *RAS/BRAF* wild-type unresectable metastatic colorectal cancer.
First Author: Yue Liu, MD
- Board 443b **Abstract TPS3681:** Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).
First Author: Javier Ros Montaña, MD, PhD

- Board 444a **Abstract TPS3682:** A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONIGI3.
First Author: Aparna Raj Parikh, MD, FASCO
- Board 444b **Abstract TPS3683:** INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.
First Author: Van K. Morris II, MD
- Board 445a **Abstract TPS3684:** Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS trial.
First Author: Joseph Tintelnot, MD
- Board 445b **Abstract TPS3685:** NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.
First Author: Anwaar Saeed, MD
- Board 446a **Abstract TPS3686:** NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
First Author: Arvind Dasari, MD, MS
- Board 446b **Abstract TPS3687:** Node-sparing modified short-course radiotherapy combined with capecitabine and PD-1/CTLA-4 for MSS early, middle, and low rectal cancer (mRCAT-E): An open-label, single-arm, prospective multicenter clinical trial.
First Author: Zhangfa Song
- Board 447a **Abstract TPS3688:** A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.
First Author: Kanwal Pratap Singh Raghav, MD, MBBS
- Board 447b **Abstract TPS3689:** Phase 2 study of adjuvant botensilimab in combination with balstilimab in patients with microsatellite-stable colorectal cancer and persistent circulating tumor DNA following surgery and chemotherapy.
First Author: Neil Howard Segal, MD, PhD

9:00 AM-12:00 PM Poster Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 1-4

Esophageal or Gastric Cancer—Advanced/Metastatic Disease: Board(s) 5-48, 222a-226a

Esophageal or Gastric Cancer—Local-Regional Disease: Board(s) 50-86, 226b-227b

Hepatobiliary Cancer—Advanced/Metastatic Disease: Board(s) 87-147, 228a-231b

Hepatobiliary Cancer—Local-Regional Disease: Board(s) 149-152, 232a

Neuroendocrine/Carcinoid: Board(s) 153-167

Outcomes/Quality: Board(s) 168-169

Pancreatic Cancer—Advanced/Metastatic Disease: Board(s) 170-205, 232b-234b

Pancreatic Cancer—Local-Regional Disease: Board(s) 122, 206-17, 235a-236b

Other GI Cancer: Board(s) 218-221, 237a-238a

- Board 1 **Abstract 4018:** H&E 2.0: Artificial intelligence-driven prediction of N256-glycosylated CEACAM5/6 expression in esophageal and gastric adenocarcinomas.
First Author: Felicia Wee
- Board 2 **Abstract 4019:** A machine learning algorithm for optimizing treatment selection for patients with up to three hepatocellular carcinomas measuring ≤ 3 cm.
First Author: Takashi Kokudo
- Board 3 **Abstract 4020:** Multi-modal AI modeling to predict clinical trial outcomes and benchmarks pan-RAS versus KRAS G12D inhibition in KRAS G12D-mutant PDAC.
First Author: Marc Robert de Massy, PhD
- Board 4 **Abstract 4021:** Benchmarking the KEYNOTE-811 standard of care using AI-reconstructed external control arms in advanced gastric cancer.
First Author: Augustine Annan, PhD
- Board 5 **Abstract 4022:** First-line (1L) trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
First Author: Yelena Y. Janjigian, MD, FASCO
- Board 6 **Abstract 4023:** Sonesitateg vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2-positive (CLDN18.2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY-PanTumor01.
First Author: Kohei Shitara, MD
- Board 7 **Abstract 4024:** An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).
First Author: Yu Aoki, MD
- Board 8 **Abstract 4025:** Application of unsupervised genetic clustering to identify biologically distinct cholangiocarcinoma subtypes with differential survival.
First Author: Qianchen Zhang
- Board 9 **Abstract LBA4026:** Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.
First Author: Zhi Peng, MD
- Board 10 **Abstract 4027:** A phase 2 clinical study of nimotuzumab plus S-1 and concurrent radiotherapy in 75 years and older patients with esophageal squamous cell carcinoma.
First Author: Xiaojie Xia, MD, MS

- Board 11 **Abstract 4028:** Preclinical efficacy of the anti-EBV agent brincidofovir (BCV) in EBV-associated gastric carcinoma (EBVaGC).
First Author: Tetsu Kamitani, MD, PhD
- Board 12 **Abstract 4029:** Early treatment failure despite first-line immunotherapy in real-world MSI-H/dMMR gastroesophageal cancer.
First Author: Shannon L. Rhodes, PhD
- Board 13 **Abstract 4030:** Tislelizumab (Tisle) combined with POF1 (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023).
First Author: Jiajing Chen
- Board 14 **Abstract 4031:** CLDN18.2–targeting antibody-drug conjugate BA1301 in advanced solid tumors: Results from a phase I clinical trial.
First Author: Dan Su, MD, PhD
- Board 15 **Abstract 4032:** Prognostic impact of AXL expression in upper gastrointestinal cancer in MONSTAR-SCREEN-2: An international collaborative study between United States and Japan.
First Author: Kyosuke Seguchi
- Board 16 **Abstract 4033:** CDH17 expression and tumor microenvironment composition in gastric cancer.
First Author: Ammanuel Taye, MD
- Board 17 **Abstract 4034:** Quality-adjusted survival comparison for tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with peritoneal metastasis (PM): Long-term follow-up from RATIONALE-305.
First Author: Rutika Mehta, MD, MPH
- Board 18 **Abstract 4035:** Real-world adoption and sequencing of CLDN18.2, PD-L1, and HER2 testing in advanced gastric and gastroesophageal junction adenocarcinoma.
First Author: Yifei Zhang, MD
- Board 19 **Abstract 4036:** Phase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ.
First Author: Jifang Gong, MD
- Board 20 **Abstract 4037:** A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors.
First Author: Hongfeng Gou
- Board 21 **Abstract 4038:** Randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma: Final analysis of RETRIEVE study (WJOG 15822G).
First Author: Hirokazu Shoji, MD, PhD
- Board 22 **Abstract 4039:** Evaluation of homologous recombination deficiency (HRD) in gastric cancer: Real-world prevalence and outcomes with first-line (1L) platinum-based therapy.
First Author: Dani Ran Castillo, MD, MBBS
- Board 23 **Abstract 4040:** KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
First Author: Akihito Kawazoe, MD
- Board 24 **Abstract 4041:** Efficacy and safety of PD-1 inhibitor plus chemotherapy vs chemotherapy alone in advanced gastric cancer patients with low or negative PD-L1 expression.
First Author: Abdallah Al Ghnaimat
- Board 25 **Abstract 4042:** Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
First Author: Elena Elimova, MD
- Board 26 **Abstract 4043:** Clinicopathologic and molecular features of Krukenberg tumors from gastric cancer (GC): A single-institution experience.
First Author: Nancy Nguyen, DO
- Board 27 **Abstract 4044:** SYS6010 combined with SYH2051 in advanced solid tumors: Results from a phase Ib/II trial.
First Author: Rongbo Lin, MD
- Board 28 **Abstract 4045:** Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.
First Author: Jin Li, MD
- Board 30 **Abstract 4047:** Phase II trial of SYS6010, an EGFR antibody-drug conjugate (ADC) in patients with advanced esophageal squamous cell carcinoma (ESCC).
First Author: Rongbo Lin, MD
- Board 31 **Abstract 4048:** Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA): Updated results from an open-label phase II trial.
First Author: Guangyu Wang
- Board 33 **Abstract 4050:** Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA).
First Author: Elena Elimova, MD
- Board 34 **Abstract 4051:** Survival outcomes according to ramucirumab (RAM)-related hypertension (HTN) in patients (pts) with advanced HER2-negative gastric (G) or gastro-esophageal junction (GEJ) cancer: An exploratory analysis of the phase III ARMANI trial.
First Author: Roberta Fazio, MD

- Board 35 **Abstract 4052:** Genomic biomarkers of primary resistance to anti-EGFR monoclonal antibodies (mAbs) by comprehensive genomic profiling (CGP) in *EGFR*-amplified (ampl) advanced gastroesophageal adenocarcinoma (aGEA) and correlative analysis from a single-arm study with panitumumab.
First Author: Cecilia Villa, MD
- Board 36 **Abstract 4053:** Real-world treatment patterns and overall survival (OS) in patients (pts) with HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinomas (mGEA) in the US.
First Author: Farshid Dayyani, MD, PhD
- Board 37 **Abstract 4054:** Update results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial.
First Author: Yong-Xu Jia, PhD
- Board 38 **Abstract 4055:** Nimotuzumab combined with paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma: A prospective, multicenter, double-blind, randomized controlled clinical study.
First Author: Zhihao Lu
- Board 39 **Abstract 4056:** Heterogeneity in biomarkers for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) across regions: Insights from CheckMate-649.
First Author: Lin Shen, MD
- Board 40 **Abstract 4057:** Sintilimab combined with short-course intensified chemotherapy regimen nab-POF in the treatment of metastatic gastric cancer (FDZL-GC002): A single-arm, phase 2 trial.
First Author: Weijian Guo
- Board 41 **Abstract 4058:** Radiogenomic biomarkers for identifying surgery-sparing candidates in locally advanced gastric or gastro-esophageal junction cancer treated with perioperative immunochemotherapy: A discovery and validation study.
First Author: Song-Bin Guo
- Board 42 **Abstract 4059:** Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): Long-term outcomes of a single-arm phase II trial.
First Author: Fang Peng
- Board 43 **Abstract 4060:** Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.
First Author: Paolo Manca, MD
- Board 44 **Abstract 4061:** Comparison of CLDN18/CLDN18.2 IHC assays (43-14A vs EPR19202) and the correlation with clinical efficacy in patients with gastric/gastroesophageal junction adenocarcinoma treated by the novel antibody-drug conjugate XNW27011.
First Author: Jinming Yu, MD, PhD, ABFT
- Board 45 **Abstract 4062:** Phase II study of ceralasertib (ATR inhibitor) plus durvalumab in patients with advanced gastric cancer (AGC) who progressed on prior anti-PD-(L)1 therapy.
First Author: Sung Hee Lim, MD
- Board 46 **Abstract 4063:** Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study.
First Author: Xiaodong Zhu
- Board 47 **Abstract 4064:** Toripalimab plus chemotherapy and radiotherapy for treatment-naïve advanced esophageal squamous cell carcinoma: Long-term survival and recurrence patterns.
First Author: Lei Wu
- Board 48 **Abstract 4065:** Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial.
First Author: Lian Liu, MD
- Board 50 **Abstract 4067:** Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative locoregional recurrent esophageal squamous cell carcinoma: A phase II study.
First Author: Jialiang Zhou, MD
- Board 51 **Abstract 4068:** Survival outcome of sandwich therapy with induction chemoimmunotherapy followed by concurrent chemoradiotherapy and sequential immune maintenance therapy in locally advanced unresectable esophageal squamous cell carcinoma (ESCC) patients: A multi-center prospective study.
First Author: Zhichao Fu
- Board 52 **Abstract 4069:** Incidence and prognostic impact of recurrence in esophageal carcinoma patients achieving complete pathological response after neoadjuvant chemoradiotherapy or perioperative chemotherapy.
First Author: Sibgha Aimon, MBBS, FCPS
- Board 53 **Abstract 4070:** Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.
First Author: Zev A. Wainberg, MD
- Board 54 **Abstract 4071:** Non-invasive strategy for gastric cancer detection: Integration of cell-free DNA fragmentomics and protein biomarkers.
First Author: Lian Lian

- Board 56 **Abstract 4073:** Prevalence of CDH1 germline variants in gastric cancer patients with exome-inferred ancestry.
First Author: Skylar Nahi
- Board 57 **Abstract 4074:** Neoadjuvant and adjuvant pembrolizumab plus chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: Outcomes from the microsatellite instability-high population of the phase 3 KEYNOTE-585 study.
First Author: Sun Young Rha, MD, PhD
- Board 58 **Abstract LBA4075:** Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by D2 gastrectomy and adjuvant chemotherapy for locally advanced gastric cancer (Neo-CRAG): A randomized, multicenter, phase 3 trial.
First Author: Rui-Hua Xu, MD, PhD
- Board 59 **Abstract 4076:** A multicenter non-randomized phase III study of sentinel node navigation surgery for early gastric cancer.
First Author: Yuko Kitagawa, MD, PhD, FACS
- Board 60 **Abstract 4077:** FGF4-mediated resistance to combined anti-angiogenic and immunotherapy in esophageal squamous cell carcinoma via suppression of high endothelial venules and tertiary lymphoid structure formation.
First Author: Weixiong Yang
- Board 61 **Abstract 4078:** Non-operative management in mismatch repair deficient (dMMR) esophagogastric cancer (EGC) following immune checkpoint inhibition (ICI).
First Author: Charlton Tsai, MD
- Board 62 **Abstract 4079:** Total neoadjuvant immunotherapy plus chemotherapy in Borrmann type IV gastric cancer (PERISCOPE-01 study): An open-label, single-arm, phase 2 trial.
First Author: Haibo Qiu, MD, PhD
- Board 63 **Abstract 4080:** Perioperative chemotherapy plus disitamab vedotin (RC48) and toripalimab in HER2-overexpressed locally advanced gastric or gastroesophageal junction cancer (PERISCOPE-02): An open-label, single-arm, phase 2 trial.
First Author: Xiaojiang Chen
- Board 64 **Abstract 4081:** Whole-genome sequencing-based ultra-sensitive ctDNA molecular residual disease assessment in resectable gastric cancer: Results from MONSTAR-SCREEN-3.
First Author: Etsuro Bando, MD, PhD
- Board 65 **Abstract LBA4082:** Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy plus sintilimab in resectable locally advanced esophageal squamous cell carcinoma.
First Author: Xuefeng Leng, MD, PhD
- Board 66 **Abstract 4083:** Perioperative durvalumab plus neoadjuvant chemoradiotherapy (CROSS) with and without tremelimumab in esophageal adenocarcinoma: The prospective phase II RICE trial (NCT04159974).
First Author: Hans Anton Schloesser, MD
- Board 67 **Abstract 4084:** Paclitaxel/cisplatin (TP) vs cisplatin/5-fluorouracil (PF) neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC): A randomized trial.
First Author: Ta-Chen Huang, MD
- Board 68 **Abstract 4085:** Phase II study of adjuvant nab-paclitaxel plus S-1 after D2 resection in stage III diffuse gastric cancer (NORDICA study).
First Author: Ke Peng
- Board 69 **Abstract 4086:** Interim results from a prospective phase II study of stratified treatment of localized cervical esophageal squamous cell carcinoma by induction immunochemotherapy (SCENIC trial).
First Author: Chunguang Li, MD, PhD
- Board 70 **Abstract 4087:** Perioperative therapy with tificemailab plus toripalimab and chemotherapy for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective phase II study.
First Author: Chengzhi Ding
- Board 71 **Abstract 4088:** The early-onset paradox of gastric cancer: Assessment of geographic clustering, biology, treatment, and outcomes.
First Author: Pranati Dharmesh Shah, DO
- Board 72 **Abstract 4089:** Neoadjuvant cadonilimab plus CapeOX in patients with clinical stage III gastric or esophagogastric junction adenocarcinoma (GC/EGJC): A prospective, single-arm phase II study.
First Author: Liying Zhao, MD
- Board 73 **Abstract 4090:** Neoadjuvant adebrelimab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, phase II trial.
First Author: Chao Wu
- Board 74 **Abstract 4091:** Neoadjuvant tislelizumab plus oxaliplatin and S-1 for locally advanced Siewert type II esophagogastric junction adenocarcinoma: A prospective multicenter phase II study.
First Author: Yanzhao Xu
- Board 75 **Abstract 4092:** SCALE-2: A phase 2 trial evaluating neoadjuvant short-course radiotherapy combined with chemotherapy and toripalimab in resectable locally advanced esophageal squamous cell carcinoma.
First Author: Ning Jiang
- Board 76 **Abstract 4093:** Noninvasive detection of early gastric cancer via red blood cell DNA features associated with tumor-induced hematopoietic stress.
First Author: Xingyun Yao, PhD
- Board 77 **Abstract 4094:** Prognostic value of perioperative ctDNA monitoring in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy (NAC) and surgery.
First Author: Akinori Watanabe, MD, PhD

- Board 78 **Abstract 4095:** Individualized estimation of benefit from adjuvant docetaxel plus S-1 in stage III gastric cancer using deep learning–based counterfactual survival analysis of the START-2 trial.
First Author: Hiroki Sato, MD, DPhil, MS
- Board 79 **Abstract 4096:** Long-term survival results of perioperative chemioimmunotherapy with DCF and avelumab in locally advanced gastro-esophageal adenocarcinoma.
First Author: Thierry Alcindor, MD, MSc
- Board 81 **Abstract 4098:** Integrating tumor-infiltrating lymphocytes (TILs) In the biomarker landscape of gastroesophageal adenocarcinoma: Going beyond PD-L1.
First Author: Filip Van Herpe, MD
- Board 82 **Abstract 4099:** Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/ mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma: Long-term follow-up of the GERCOR NEONPIGA phase II study.
First Author: Thomas Samaille, BC
- Board 83 **Abstract 4100:** Neoadjuvant cadonilimab plus chemotherapy for locally advanced gastric/ gastroesophageal junction cancer: A single-arm, phase II trial.
First Author: Pengfei Zhang
- Board 84 **Abstract 4101:** Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
First Author: David Liu
- Board 85 **Abstract 4102:** Perioperative cadonilimab (AK104) in locally advanced MSI-H/dMMR gastric or gastroesophageal junction adenocarcinoma and colorectal adenocarcinoma: A basket study.
First Author: Jiafu Ji, MD, PhD, DrPH
- Board 86 **Abstract 4103:** Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: A prospective clinical trial.
First Author: Hongda Liu
- Board 87 **Abstract 4104:** CheckMate-9DW 4-year follow-up: Overall survival by depth of response and outcomes in long-term survivors.
First Author: Aiwu Ruth He, MD, PhD
- Board 88 **Abstract 4105:** First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A.
First Author: Jian Zhou, PhD
- Board 89 **Abstract 4106:** Safety and efficacy of puxitatumab (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).
First Author: Do-Youn Oh, MD, PhD
- Board 90 **Abstract 4107:** Efficacy and safety of transarterial chemoembolization combined with donafenib for hepatocellular carcinoma with rupture and bleeding: A retrospective, cohort study.
First Author: Qi Zhang
- Board 91 **Abstract 4108:** Dual BRAF/MEK inhibition in *BRAF*^{V600E}-mutated biliary tract cancer with exploratory histology-dependent response: A systematic review and meta-analysis.
First Author: Neel Parikh, MBBS
- Board 92 **Abstract 4109:** Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib.
First Author: Amit Mahipal, MPH, MBBS
- Board 93 **Abstract 4110:** Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.
First Author: Yiming Zhao
- Board 94 **Abstract 4111:** Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).
First Author: Kohei Shitara, MD
- Board 95 **Abstract 4112:** Bortezomib plus gemcitabine-cisplatin versus gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancers: A randomized phase II clinical trial with exploratory analysis of PTEN status.
First Author: Hui Wang
- Board 96 **Abstract 4113:** Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial.
First Author: Bin Shu, MD
- Board 97 **Abstract 4114:** QL1706 (PD-1/CTLA-4 bispecific antibody) plus bevacizumab specific for patients with hepatocellular carcinoma combined with lung metastasis: A secondary analysis of a prospective, single-arm, phase Ib/II study.
First Author: Kunlin Xie, MD, PhD
- Board 98 **Abstract 4115:** Hepatic arterial infusion chemotherapy plus either toripalimab or sorafenib as first-line therapy for non–high-risk, locally advanced hepatocellular carcinoma: A non-comparative, randomized phase 2 trial.
First Author: Ming Shi, PhD
- Board 99 **Abstract 4116:** Association of asynchronous, time-flexible digital multidisciplinary care with overall survival in advanced biliary tract cancer treated with immune checkpoint inhibitors.
First Author: Binhe Tian, MD
- Board 100 **Abstract 4117:** Impact of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes in hepatocellular carcinoma treated with atezolizumab–bevacizumab.
First Author: Costanza Winchler, MD

- Board 101 **Abstract 4118:** Envafolelimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial.
First Author: Shukui Qin, MD
- Board 102 **Abstract 4119:** Impact of HSPA6 on lenvatinib resistance in HCC via phase separation-mediated TXNRD1 stabilization and ferroptosis suppression.
First Author: Yi Niu
- Board 103 **Abstract 4120:** NALIRIFOX in combination with adrelelimab for advanced biliary tract cancer: A phase 2 NIOFA-01 clinical trial.
First Author: Qing Zhu
- Board 104 **Abstract 4121:** Three-month versus six-month duration of postoperative adjuvant therapy after R0 resection following conversion therapy in hepatocellular carcinoma patients achieving MPR or pCR: A prospective randomized study.
First Author: Jia-Yi Wu
- Board 105 **Abstract 4122:** Final results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated biliary tract cancer (NAPOLI-2).
First Author: Benjamin Adam Weinberg, MD
- Board 106 **Abstract 4123:** A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial.
First Author: Xue Han
- Board 107 **Abstract 4124:** Beyond fibroblast growth factor receptor 2 (FGFR2) fusions: Mutations and amplifications in intrahepatic cholangiocarcinoma.
First Author: Felicity K. Namayanja, MChB, MPH
- Board 108 **Abstract 4125:** First-line tislelizumab plus chemoradiotherapy for patients with advanced biliary tract cancer: A prospective, biomolecular exploratory, phase II trial.
First Author: Mingzhen Zhou
- Board 109 **Abstract 4126:** CXCL12⁺ pericytes as drivers of lymphatic dissemination in pancreatic cancer: Integrated single-cell and spatial analysis.
First Author: Xiangxu Wang
- Board 110 **Abstract 4127:** Distribution and density of tertiary lymphoid structures as predictors of clinical outcomes and immunotherapy responses in gallbladder cancer.
First Author: Rui Zhang
- Board 111 **Abstract 4128:** Real-world outcomes of microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) biliary tract cancers (BTC).
First Author: Madhulika Eluri, MD
- Board 112 **Abstract 4129:** A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.
First Author: Tim F. Greten, MD
- Board 114 **Abstract 4131:** Sequential bTAE-HAIC combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma: A single-center perspective.
First Author: Qunfang Zhou
- Board 115 **Abstract 4132:** Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416).
First Author: Jiayi Liu, MD
- Board 116 **Abstract 4133:** Tinengotinib (TT-00420) in advanced/metastatic FGFR2-altered cholangiocarcinoma following prior chemotherapy and FGFR inhibitor treatment: Results from a phase II study (FIRST-08).
First Author: Jun Zhou, MD, PhD
- Board 117 **Abstract 4134:** Correlation of immune remodeling linked to obesity with immunotherapy outcomes in cholangiocarcinoma: An externally validated international cohort study.
First Author: Antonella Cammarota, MD
- Board 118 **Abstract 4135:** Association of genomic and clinical factors with outcomes with front-line chemoimmunotherapy in patients with advanced biliary tract cancer.
First Author: Orla Maeve Fitzpatrick, MBBCh, MRCP
- Board 119 **Abstract 4136:** Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma.
First Author: Zhong Jingtao
- Board 120 **Abstract 4137:** Tracking genomic evolution in *ERBB2*-altered biliary tract cancer through longitudinal tumor profiling.
First Author: Orla Maeve Fitzpatrick, MBBCh, MRCP
- Board 121 **Abstract 4138:** Homologous recombination signature (HRDsig) in clinically advanced gallbladder adenocarcinoma (CAGAC): A genomic landscape study.
First Author: Myungwoo Nam, MD
- Board 122 **Abstract 4139:** Multi-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection.
First Author: Anna Bergamaschi, PhD
- Board 123 **Abstract 4140:** Sequencing in the post-immunotherapy era: Does second-line tyrosine kinase inhibitor choice impact survival and safety in advanced HCC?
First Author: Ansy Patel, MBBS
- Board 124 **Abstract 4141:** Global insights into survival outcomes and unmet therapeutic needs in *KRAS*-mutant gallbladder cancer: A comprehensive federated network analysis.
First Author: Zeeshan Solangi, MD

- Board 125 **Abstract 4142:** A phase 1b/2 study of AK130 (TIGIT/TGF- β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC).
First Author: Haitao Zhao, MD
- Board 126 **Abstract 4143:** Peritumoral stiffness as a novel noninvasive biomarker: Predicting TACE response in intermediate-stage hepatocellular carcinoma via 2D-shear wave elastography.
First Author: Yanqin Wu
- Board 127 **Abstract 4144:** Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm): A multicenter retrospective study.
First Author: Shao Minghua, PhD, DS
- Board 128 **Abstract 4145:** Time-toxicity of first-line systemic therapy for hepatocellular carcinoma in clinical practice.
First Author: Kenta Takaura, MD
- Board 129 **Abstract 4146:** Transcriptomic profiling in advanced hepatocellular carcinoma to identify biomarkers for immunotherapy response and mechanisms of acquired resistance.
First Author: Sunyoung S. Lee, MD, PhD
- Board 130 **Abstract 4147:** Comprehensive genomic profiling to identify molecular determinants of efficacy of IDH1 inhibition in intrahepatic cholangiocarcinoma.
First Author: Sunyoung S. Lee, MD, PhD
- Board 131 **Abstract 4148:** Effectiveness and safety of IBI310 combined with sintilimab versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, controlled, multicenter phase III clinical study.
First Author: Jia Fan, DrPH
- Board 132 **Abstract 4149:** Yttrium-90 SIRT followed by lenvatinib plus sintilimab for unresectable intermediate-to-advanced hepatocellular carcinoma: Phase II SIRLENS-90 trial.
First Author: Jingjun Huang
- Board 133 **Abstract 4150:** Tumor microenvironment phenotypes and survival in fibrolamellar carcinoma: An exploratory study.
First Author: Hilal Polat
- Board 134 **Abstract 4151:** Characteristics of *SMAD4* alterations in an immune-cold genomic subtype of biliary tract cancers in the Indian population.
First Author: Aditya V. Shreenivas, MD, MS
- Board 135 **Abstract 4152:** Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study).
First Author: Lixia Xu, PhD
- Board 136 **Abstract 4153:** Cyclin amplification in biliary tract cancer: Integrated profiling to evaluate immune exclusion, drug sensitivity, and prognosis.
First Author: Akhila Madulapalli Reddy, MD
- Board 137 **Abstract 4154:** Tumor microenvironment modulation by losartan in advanced gallbladder cancer (GBC): Results and genomic correlates from the phase 2 LAST study.
First Author: Amol Patel, MD, DM
- Board 138 **Abstract 4155:** Optimizing biliary drainage in malignant biliary obstruction: A systematic review and meta-analysis of transpapillary versus suprapapillary stent positioning.
First Author: Zainab Rafaqat
- Board 139 **Abstract 4156:** Knowledge distillation-enabled ResNet framework for hepatocellular carcinoma diagnosis on multiphase CT: Toward scalable global deployment.
First Author: Hammad Khan, MBBS
- Board 140 **Abstract 4157:** Correlative analysis of phase II trial of olaparib and durvalumab in patients with *IDH*-mutated cholangiocarcinoma.
First Author: Xin Wang, MD, PhD
- Board 141 **Abstract 4158:** The molecular landscape and clinical nomogram of cholangiocarcinoma harboring ESCAT I alterations.
First Author: George Laliotis, MD, PhD, MHA, MPH, MSc
- Board 142 **Abstract 4159:** First-line GemCis \pm immunotherapy vs FGFR inhibition in ctDNA-detected *FGFR2* fusion-positive advanced cholangiocarcinoma: A real-world analysis.
First Author: Richard D. Kim, MD
- Board 143 **Abstract 4160:** Durvalumab or pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for advanced cholangiocarcinoma: A meta-analysis.
First Author: Abdullah Esmail, MD
- Board 144 **Abstract 4161:** Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP.
First Author: Daniel Hintz
- Board 145 **Abstract 4162:** An immune-related pathologic response score as a predictor of survival after immune checkpoint inhibitor-based conversion therapy in hepatocellular carcinoma.
First Author: Yi-Jun Lu, PhD
- Board 146 **Abstract 4163:** Comparative outcomes of first-line atezolizumab plus bevacizumab (A+B) and durvalumab plus tremelimumab (D+T) in hepatocellular carcinoma (HCC).
First Author: Sarina Ailawadi, DO
- Board 147 **Abstract 4164:** DEB-TACE combined with apatinib and camrelizumab as second-line therapy for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II study.
First Author: Xuegang Yang, PhD
- Board 149 **Abstract 4166:** Outcomes of combined HCC-cholangiocarcinoma with adjuvant chemotherapy: An NCDB cohort.
First Author: Maria Diab, MD
- Board 151 **Abstract 4168:** Performance of a multi-cancer early detection test (MCED) for detecting small hepatocellular carcinoma (HCC) in a screening population.
First Author: Gangchao Xu
- Board 152 **Abstract 4169:** Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles.
First Author: Lei Zhang, MD

- Board 153 **Abstract 4170:** Lanreotide for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Korean population: A multicenter prospective observational study (AIM-NETs).
First Author: Changhoon Yoo, MD, PhD
- Board 154 **Abstract 4171:** Quality of life in patients with gastroenteropancreatic neuroendocrine tumors receiving ¹⁷⁷Lu-edotreotide or everolimus: Results from the COMPETE study.
First Author: Jaume Capdevila, MD, PhD
- Board 155 **Abstract 4172:** Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.
First Author: Sara Wallam, MD
- Board 156 **Abstract 4173:** Cohort-level safety and efficacy results for [²¹²Pb]VMT- α -NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.
First Author: Thorvardur Ragnar Halfdanarson, MD
- Board 157 **Abstract 4174:** DISCO update: Diagnostic performance of ⁶⁴Cu-SARTATE compared to ⁶⁸Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.
First Author: Eva Lengyelova
- Board 158 **Abstract 4175:** Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers.
First Author: Rohit Thummalapalli, MD
- Board 159 **Abstract 4176:** A multicenter single-arm study of induction EC/EP plus camrelizumab followed by maintenance camrelizumab plus apatinib in treatment-naïve advanced or metastatic extrapulmonary neuroendocrine carcinoma.
First Author: Yuhong Dai, MD
- Board 160 **Abstract 4177:** Postoperative pancreatic fistula after resection of pancreatic neuroendocrine tumors: Incidence, predictors, and clinical impact.
First Author: Oliver Overheu, MD
- Board 161 **Abstract 4178:** Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance A021602).
First Author: Nikolaos Trikalinos, MD, MS
- Board 163 **Abstract 4180:** Immune microenvironment signatures as prognostic biomarkers in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).
First Author: Ruoyu Miao, MD
- Board 164 **Abstract 4181:** Therapy-related myeloid neoplasms after radioligand therapy in neuroendocrine tumors: A multicenter real-world analysis.
First Author: Deevyashali Parekh, MBBS
- Board 165 **Abstract 4182:** Germline pathogenic/likely pathogenic (P/LP) variants in epithelial neuroendocrine neoplasms: The case for universal germline genetic testing.
First Author: Udhayvir Singh Grewal, MD
- Board 166 **Abstract 4183:** Cabozantinib in high-grade neuroendocrine neoplasms.
First Author: Nikolaos Trikalinos, MD, MS
- Board 167 **Abstract 4184:** Insurance, hospital, and racial disparities in surgical treatment and mortality among patients with neuroendocrine tumors: A national analysis.
First Author: Swamynathan Umamaheswaran, MS
- Board 168 **Abstract 4185:** Circulating tumor deoxyribonucleic acid (DNA) and treatment outcomes of gastroesophageal cancer: A systematic review and meta-analysis.
First Author: Thuraya Al-Sayegh, MD
- Board 169 **Abstract 4186:** Evaluation of clinical success and adverse events with endoscopic ultrasound-guided biliary drainage (EUS-BD) compared to percutaneous transhepatic biliary drainage (PTBD) after failed ERCP in malignant biliary obstruction: A systematic review and meta-analysis.
First Author: Era Gupta, MBBS
- Board 171 **Abstract 4188:** Prevalence and prognostic value of Claudin 18.2 expression in pancreatic ductal adenocarcinoma.
First Author: Kevin Zi Ming Lim, MD
- Board 172 **Abstract 4189:** Multicenter phase 2 study of hydroxychloroquine (HCQ) and chlorphenesin carbamate (CPC) in combination with mFOLFIRINOX in patients with advanced pancreatic adenocarcinoma (PDAC).
First Author: Hyehyun Jeong
- Board 173 **Abstract 4190:** HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Xianjun Yu, MD, PhD
- Board 174 **Abstract 4191:** SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation.
First Author: Jin Xu, MB
- Board 175 **Abstract 4192:** Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Anwaar Saeed, MD
- Board 176 **Abstract 4193:** Safety and efficacy of nesuparib (JPI-547) with gemcitabine-nab-paclitaxel (GemAbraxane) or modified FOLFIRINOX (mFOLFIRINOX) in patients with locally advanced or metastatic PDAC: Results from an ongoing phase Ib/II study.
First Author: Hye Jin Choi, MD, PhD
- Board 177 **Abstract 4194:** MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.
First Author: Yonghua Laura Bao, MD, PhD
- Board 178 **Abstract 4195:** First-line NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma and pre-existing diabetes: NAPOLI 3 post hoc analysis.
First Author: Sreenivasa R. Chandana, MD, PhD

- Board 179 **Abstract 4196:** Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial.
First Author: Eric Andrew Collisson, MD
- Board 180 **Abstract 4197:** LAP-NET1: Results of a phase 1b evaluating NP137, an inhibitor of the epithelial-to-mesenchymal transition, in combination with mFOLFIRINOX for the first-line treatment of locally advanced pancreatic ductal adenocarcinoma.
First Author: Gael Roth, MD, PhD
- Board 181 **Abstract 4198:** Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial.
First Author: Wen-Quan Wang
- Board 182 **Abstract 4199:** Precectabart tocentecan (Precect-TcT, M9140), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic pancreatic ductal carcinoma (mPDAC): Results from the phase 1b/2 PROCEADE-PanTumor PDAC substudy.
First Author: Zev A. Wainberg, MD
- Board 183 **Abstract 4200:** Phase Ib/II clinical study of adebrelimab combined with decitabine, nab-paclitaxel, and gemcitabine as first-line (IL) treatment for metastatic pancreatic cancer (mPC).
First Author: Rui Liu, MD, MBBS, MMedSc
- Board 184 **Abstract 4201:** BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.
First Author: Benjamin Adam Weinberg, MD
- Board 185 **Abstract 4202:** Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.
First Author: Jill P. Smith, MD
- Board 186 **Abstract 4203:** QL1706 combined with nab-paclitaxel and gemcitabine as first-line treatment for locally advanced or metastatic pancreatic adenocarcinoma: A prospective, multicenter, single-arm phase II study.
First Author: Biyang Cao, PhD
- Board 187 **Abstract 4204:** Multicentre trial of telemonitored circadian rhythms and electronic patient-reported outcomes (ePROs) for improving tolerability of initial mFOLFIRINOX cycles in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): MultiDom (NCT04263948).
First Author: Francis Albert Lévi, MD, PhD
- Board 188 **Abstract 4205:** Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NC110208).
First Author: Carlos Diego Holanda Lopes, MD
- Board 189 **Abstract 4206:** Ultra-refractory PD–PD pancreatic cancer: Clinical and molecular insights across first- and second-line therapy.
First Author: Natalia Soledad Tissera, MD
- Board 191 **Abstract 4208:** Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Li-Wei Wang, MD, PhD
- Board 192 **Abstract 4209:** Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases.
First Author: Chuntao Wu
- Board 193 **Abstract 4210:** AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.
First Author: Hannah J. Glover, PhD
- Board 194 **Abstract 4211:** The SPIN Score, a simple clinical score to predict pain response following celiac plexus radiosurgery for retroperitoneal cancer pain.
First Author: Yaacov Lawrence, MA, MBBS, MRCP
- Board 195 **Abstract 4212:** A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Priyadarshini Satyajit Pathak, MBBS
- Board 196 **Abstract 4213:** Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
First Author: Devalingam Mahalingam, MD, PhD
- Board 197 **Abstract 4214:** Time toxicity in patients with advanced pancreatic cancer in Mexico.
First Author: Cecilia Ximenez Camilli, MD
- Board 198 **Abstract 4215:** Combined safety and efficacy results from three clinical studies evaluating alpha radiotherapy for advanced pancreatic cancer.
First Author: Corey Miller, MD, MSc
- Board 199 **Abstract 4216:** Single-cell circulating tumor cell genomics of KRAS-independent oncogenic sub-populations and longitudinal clonal evolution in metastatic pancreatic adenocarcinoma.
First Author: Mandana Kamgar, MD, MPH
- Board 200 **Abstract 4217:** Knowledge distillation for pancreatic cancer diagnosis: EfficientNet-based deep learning for stage stratification with real-world deployment optimization.
First Author: Lalith Akaash Ramasamy, MBBS
- Board 201 **Abstract 4218:** Phase IIb randomized trial of FOLFIRINOX plus ibrilatazar (ABTL0812) versus placebo as first-line treatment in metastatic pancreatic cancer: An analysis from the PanC-ASAP study.
First Author: Davendra Sohal, MD, MPH, FASCO
- Board 202 **Abstract 4219:** A phase II trial of binimetinib in combination with encorafenib in patients with pancreatic malignancies and a somatic *BRAF*^{V600E} mutation.
First Author: Tara Tamar Arouchian, BS

- Board 203 **Abstract 4220:** TME-informed bioprinted 3D tissue model as used to characterize architecture-associated drug uptake and response in PDAC. First Author: Amr Mahmoud
- Board 204 **Abstract 4221:** Next-generation cancer organoids 2.0 in precision cancer medicine: Patient-derived pancreatic ductal adenocarcinoma organoids model to describe drug sensitivity and complexity of tumor biology. First Author: Joo Kyung Sophie Park, MD, PhD
- Board 205 **Abstract 4222:** Actionable genomic alterations and survival in *KRAS* wild-type pancreatic ductal adenocarcinoma: Analysis of the MSK-CHORD 2024 clinico-genomic cohort with spotlight on *NRG1* fusions. First Author: Ayham Al-Omari, MD
- Board 206 **Abstract 4223:** Exosomal miRNA signatures as predictors of response to neoadjuvant FOLFIRINOX and GEM/nab-paclitaxel in resectable pancreatic cancer: The PRECEPT study. First Author: Takayuki Noma, MD
- Board 207 **Abstract 4224:** Phase I clinical trial evaluating dual-targeting CAR-T cells (KD-496) against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers and pancreatic cancers. First Author: Panpan Zhang, MD
- Board 208 **Abstract 4225:** Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: A multicenter, open-label phase 2 study. First Author: Zhe Cao
- Board 209 **Abstract LBA4226:** A multicenter randomized phase II trial of AHCC combined with multidisciplinary treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma (JRCTs051200029). First Author: Suguru Yamada, MD, PhD, FACS
- Board 210 **Abstract 4227:** Plasma small extracellular vesicle microRNAs as non-invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma. First Author: Yue Zhang
- Board 211 **Abstract 4228:** Impact of radiologically identified embryological origin on recurrence patterns and survival in resectable pancreatic head adenocarcinoma. First Author: Imdat Eroglu, MD
- Board 212 **Abstract 4229:** Early detection of pancreatic ductal adenocarcinoma (PDAC) with a multiomic liquid biopsy. First Author: Holly Butler, PhD, MBA
- Board 213 **Abstract 4230:** A phase II multicenter study of NASOX regimen as adjuvant chemotherapy for patients with resected pancreatic ductal adenocarcinoma. First Author: Kuirong Jiang, FACS
- Board 214 **Abstract 4231:** Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adrelinimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC). First Author: Si Shi, MD, PhD
- Board 215 **Abstract 4232:** Experience of Spanish centers with echoendoscopically implanted ³²P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma. First Author: Carmen Guillen-Ponce, MD, PhD
- Board 217 **Abstract 4234:** Distinct multi-omic signatures that underlie *KRAS* variants and survival in *KRAS* G12R pancreatic cancer. First Author: Sargis Hovhannisyan
- Board 218 **Abstract 4235:** Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation. First Author: Hoang Tran Pham, MD
- Board 219 **Abstract 4236:** Donafenib plus immune checkpoint inhibitors with or without oral fluorouracil chemotherapy drugs (S-1/capecitabine) for patients with resected high-risk biliary tract tumor: A multi-center retrospective study. First Author: Huang Huaiyin
- Board 220 **Abstract 4237:** Deciphering the heterogeneity and cellular interactions of cancer-associated fibroblasts in extrahepatic cholangiocarcinoma by spatial transcriptomics. First Author: Giulia Petroni
- Board 221 **Abstract 4238:** Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy. First Author: Linda Albusoul, MD
- Board 222a **Abstract TPS4239:** Phase II study evaluating ivonescimab in combination with chemotherapy as first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients (UCGI 52 – GRACIE). First Author: Christelle De La Fouchardiere, MD
- Board 222b **Abstract TPS4240:** HIPEC combined with NIPS and tislelizumab for conversion therapy in gastric cancer with peritoneal metastasis (P0CY1 or PCI ≤10): A prospective, single-arm, phase II study. First Author: Honghai Guo
- Board 223a **Abstract TPS4241:** A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234. First Author: Maheswari Senthil, MD, FACS
- Board 223b **Abstract TPS4242:** A phase 1/2 study of BDC-4182, a Claudin 18.2–targeting next-generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer. First Author: Sophia Frentzas, PhD, MBBS, MRCP, FRACP
- Board 224a **Abstract TPS4243:** Phase II RAINSPOT: A multicentric open label trial of zolbetuximab-paclitaxel-ramucirumab in second-line setting for CLDN18.2-positive gastro-esophageal adenocarcinoma. First Author: Filip Van Herpe, MD

- Board 224b **Abstract TPS4244:** Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma: The phase II IKF-090/AIO ZANGEA trial with translational analysis. First Author: Joseph Tintelnot, MD
- Board 225a **Abstract TPS4245:** Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A randomized controlled phase 3 trial. First Author: Zhi Peng, MD
- Board 225b **Abstract TPS4246:** A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2-negative gastroesophageal adenocarcinomas. First Author: Sienna M. Durbin, MD
- Board 226a **Abstract TPS4247:** A multicenter, open-label, single-arm, dose-finding and -expansion phase 1b/2 study to evaluate the safety and tolerability of nesuparib (JPI-547) in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer. First Author: Sun Young Rha, MD, PhD
- Board 226b **Abstract TPS4248:** Chemoradiotherapy plus sintilimab versus chemoradiotherapy as neoadjuvant treatment in locally advanced esophageal squamous cell carcinoma (NEOCRTEC2101): A multicenter, randomized, phase III trial. First Author: Mian Xi
- Board 227a **Abstract TPS4249:** Adjuvant oxaliplatin plus S-1 versus docetaxel plus S-1 for stage III gastric cancer after D2 gastrectomy (DRAGON-Adjuvant): A multicenter, open-label, phase 3, randomized, non-inferiority study. First Author: Chenfei Zhou, PhD
- Board 227b **Abstract TPS4250:** Multicenter phase Ib/II study of neoadjuvant zolbetuximab plus docetaxel, oxaliplatin, and S-1 (DOS) followed by adjuvant zolbetuximab/S-1 in patients with CLDN18.2-positive resectable gastric or gastroesophageal junction adenocarcinoma (NEOCLAUD). First Author: Hyung-Don Kim, MD, PhD
- Board 228a **Abstract TPS4251:** A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with *FGFR2* fusion or rearrangement. First Author: Richard D. Kim, MD
- Board 228b **Abstract TPS4252:** A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer. First Author: Hiroto Matsui
- Board 229a **Abstract TPS4253:** ARTEMIDE-Biliary02: A phase 3, randomized, global study of rilvegostomig or durvalumab with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC). First Author: Lipika Goyal, MD
- Board 229b **Abstract TPS4254:** Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2). First Author: Yongjun Chen, MD
- Board 230a **Abstract TPS4255:** A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti-CTLA-4 combined with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or with first-line durvalumab in advanced biliary tract cancer (BTC). First Author: Richard D. Kim, MD
- Board 230b **Abstract TPS4256:** Fatty acid degradation (FAD)–guided comprehensive therapy for unresectable hepatocellular carcinoma: A prospective phase II study (FAD-HCC-01). First Author: Decai Yu
- Board 231a **Abstract TPS4257:** CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma. First Author: Linhui Peng, PhD, DM
- Board 231b **Abstract TPS4258:** A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy. First Author: Madison Conces, MD
- Board 232a **Abstract TPS4259:** Impact of immunonutrition in patients undergoing hepatectomies for liver tumors: A randomized controlled phase II trial. First Author: Shraddha Patkar, MD, MBBS, MCh
- Board 232b **Abstract TPS4260:** Phase II study of NC410 and FOLFIRINOX in combination with nivolumab with or without ipilimumab in patients with treatment-naive metastatic pancreatic cancer. First Author: Shriram K. Sundararaman, MD
- Board 233b **Abstract TPS4262:** Phase 1 faecal microbiota transplantation in patients with advanced pancreatic carcinoma (FMTPanc Trial). First Author: Timothy Jay Price, DHSc, MBBS, FRACP
- Board 234a **Abstract TPS4263:** TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. First Author: Erkut H. Borazanci, MD, MS
- Board 234b **Abstract TPS4264:** S2433: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced, or metastatic pancreatic adenocarcinoma. First Author: Rachael A. Safyan, MD
- Board 235a **Abstract TPS4265:** A prospective single-arm study of irinotecan liposome II combined with adebrelimab, gemcitabine, and nab-paclitaxel for conversion therapy in locally advanced pancreatic cancer. First Author: Wenwen Zhang

Saturday, May 30, 2026

- Board 235b **Abstract TPS4266:** Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer: UNITEPANC (AIO-PAK-0424), a prospective, multicenter, proof-of-concept trial of the AIO Pancreatic Cancer Group. First Author: Thomas Jens Ettrich, MD
- Board 236a **Abstract TPS4267:** Phase I light-dose escalation study in locally advanced pancreatic ductal adenocarcinoma: Intra-arterial (IA) padeliporfin vascular-targeted photodynamic therapy (VTP). First Author: Nadine Abi-Jaoudeh, MD, FSIR
- Board 236b **Abstract TPS4268:** Durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma: A window of opportunity trial (DORA). First Author: Erica Sophia Tsang, MD, MPH, FRCPC
- Board 237a **Abstract TPS4269:** ENVELOPE trial (NCCH2412): Enfortumab vedotin in patients with locally advanced or metastatic small bowel adenocarcinoma refractory or intolerant to platinum-based combination therapy—A multicenter, phase II trial (trial in progress). First Author: Hiroyuki Fujii, MD, PhD
- Board 237b **Abstract TPS4270:** FusionVAC22_02, a phase I clinical trial in progress: Adjuvant *DNAJB1-PRKACA* fusion transcript-based peptide T-cell activator for fibrolamellar hepatocellular carcinoma (FLC) and other tumor entities carrying the oncogenic driver fusion. First Author: Susanne Jung, MD
- Board 238a **Abstract TPS4271:** Sacituzumab govitecan in combination with capecitabine for the treatment of advanced gastrointestinal cancers after progression on standard therapy. First Author: Maria Diab, MD

9:45 AM-12:00 PM Opening Session

Location: Hall B1

Clifford A. Hudis, MD, FACP, FASCO

ASCO
Welcome

Anthony G. Letai, MD, PhD

National Cancer Institute, National Institutes of Health
NCI Director's Remarks

Clifford A. Hudis, MD, FACP, FASCO

ASCO
Introduction of Dr. Eric J. Small

Eric J. Small, MD, FASCO

University of California San Francisco
President's Address

David Kessler

Author
Guest Speaker Address

Julio Frenk, MD, PhD, MPH

University of California Los Angeles
Guest Speaker Address

Felicia Marie Knaul, PhD, MA

University of California Los Angeles
Guest Speaker Address

Howard A. Burris III, MD, FACP, FASCO

Sarah Cannon Research Institute
Top Donor Recognition Ceremony

Nancy E. Davidson, MD, FASCO

University of Washington, Fred Hutch Cancer Research Center
David Karnofsky Science of Oncology Award Lecture

Lynn M. Schuchter, MD, FASCO

Perelman School of Medicine at the University of Pennsylvania
Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)

1:15 PM-2:15 PM Case-Based Panel

Management of High-Risk Stage II Melanoma and Beyond: A Case-Based Multidisciplinary Discussion

Location: E450b

Ines Esteves Domingues Pires da Silva, MD, PhD—Chair

The Champalimaud Centre for the Unknown
Moderator

Michael Lowe, MD, MA

Emory University School of Medicine
Surgical Oncologist Perspective

Christopher Andrew Barker, MD

Memorial Sloan Kettering Cancer Center
Radiation Oncologist Perspective

Sapna Pradyuman Patel, MD

University of Colorado Cancer Center
Medical Oncologist Perspective

Panel Question and Answer

1:15 PM-2:30 PM Education Session

ASCO/AACR Joint Session: The KRAS Journey—Perseverance Pays Off

Location: S100bc

Eric J. Small, MD, FASCO—Chair

University of California San Francisco
Welcome and Introductory Remarks From ASCO President

Lillian L. Siu, MD, FRCPC, FASCO—Chair

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Consortium, Marathon of Hope Cancer Centres Network
Welcome and Introductory Remarks From AACR President

Stephen Fesik, PhD

Vanderbilt
From Undruggable to Breakthrough: Lessons From the Longest Road in Targeted Therapy

Melissa Lynne Johnson, MD, FASCO

Sarah Cannon Research Institute
KRAS-Directed Therapy: A Clinical Update

Eileen M. O'Reilly, MD, FASCO

Memorial Sloan Kettering Cancer Center
Beyond KRAS G12C: Novel Approaches and Future Directions

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Integrating Systemic Therapy in Early- and Intermediate-Stage Hepatocellular Carcinoma

Location: E451

Adam Charles Yopp, MD

UT Southwestern Medical Center

Surgeon's Perspective: Is There a Role for Immunotherapy in Adjuvant/Neoadjuvant Hepatocellular Carcinoma Management?

Robin Kate Kelley, MD, FASCO—Chair

University of California San Francisco

Medical Oncologist's Perspective: How and When to Incorporate Immunotherapy With Locoregional Therapy?

Fan Xia, MD, PhD

Fudan University Shanghai Cancer Center

Radiation Oncologist's International Perspectives: How to Incorporate Radiotherapy With Systemic Therapy?

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Leadership Rx: Prescriptions for Effective Teams

Location: S504

Raymond Liu, MD, FASCO—Chair

Kaiser Permanente San Francisco

From Silos to Synergy: Building Resilient Multidisciplinary Oncology Teams

John Schneider, MD, MA

Washington University School of Medicine

From Friction to Function: Guiding Teams Through Conflict

Anees B. Chagpar, MD, MPH, MBA, MSc, MA, FACS, FRCS, FASCO

Yale School of Medicine

Uniting Across Time Zones: Building Teams for Global Cancer Care

Panel Question and Answer

1:15 PM-2:30 PM Education Session

State of the Art: Advances in Perioperative Management in Bladder and Kidney Cancers

Location: Hall D1

Rana R. McKay, MD, FASCO—Chair

UC San Diego Moores Cancer Center

Neoadjuvant Treatment Strategies in Renal Cell Carcinoma

Brendan John Guercio, MD

James P. Wilmot Cancer Center, University of Rochester Medical Center

Management in Bladder Cancer After Pathologic Complete Disease Response

Chien-Kuang Cornelia Ding, MD, PhD

University of California San Francisco

Clinical Applications of Pathologic Biomarkers in Genitourinary Cancers With an Emerging Focus for Integration of Artificial Intelligence-Driven Pathologic Biomarkers

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Unique Challenges in Sarcoma Care for Adolescents and Young Adults

Location: S102

Nita Louise Seibel, MD, FASCO—Chair

National Cancer Institute, National Institutes of Health

Narrowing the Gap on Clinical Trial Enrollment Among Adolescents and Young Adults With Sarcoma

Anita Villani, MD

The Hospital for Sick Children

Genetic Predisposition Among Adolescents and Young Adults With Sarcoma: From Diagnosis to Survivorship

Ursula Sansom-Daly, PhD

University of New South Wales

Early Access to Palliative Care Services for Adolescents and Young Adults With Sarcoma Improve Outcomes

Courtney Fullbright, BS

University of Chapel Hill AYA Cancer Program

Unique Impacts of Sarcoma: Insight From the Adolescent and Young Adult Perspective

Panel Question and Answer

1:15 PM-2:45 PM Clinical Science Symposium

Global Strategies to Overcome Barriers in Cancer Care Access

Location: E350

Jackson Orem, PhD, MBChB—Chair

Uganda Cancer Institute

Nashivai Elias Kivuyo, MD—Chair

Muhimbili University of Health and Allied Sciences

1:15 PM Glenda Ramos Martinez De Delgado, MD

Solca - Omni Hospital

Overcoming Barriers, Expanding Reach: Global Innovations in Cancer Care Access

1:27 PM Abstract 1509: Implementation science insights from a community-embedded cervical cancer screening program integrating high-risk human papillomavirus DNA testing with non-communicable disease screening in rural South India.

First Author: Shailendra Dandge, MD

1:39 PM Abstract LBA1510: Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial.

First Author: Nandini Sharrel Menon, MD, DNB, MBBS

1:51 PM Abstract 1511: Immunotherapy access disruptions in Mexico: Real-world delivery irregularities at a public cancer referral center.

First Author: Brenda Jimenez, MD

2:03 PM Abstract 1512: Sustaining oncology clinical trials under wartime conditions: Strategic lessons from Ukraine.

First Author: Igor Bondarenko, MD, PhD

2:15 PM Rebecca Jane DeBoer, MD, MA

University of California San Francisco

Discussion of Abstract(s) 1509-1512: Tailoring Solutions Across the Cancer Care Continuum in Resource-Limited Settings

2:27 PM Panel Question and Answer

1:15 PM-2:45 PM Rapid Oral Abstract Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Location: E450a

Christine McMahon, MD—Chair

University of Colorado School of Medicine

Gabriel N. Mannis, MD—Chair

Stanford Cancer Center

- 1:15 PM Abstract 6509:** A phase 2 study of fedratinib in patients with MDS/MPN and chronic neutrophilic leukemia.
First Author: Andrew Tucker Kuykendall, MD
- 1:21 PM Abstract 6510:** Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML).
First Author: Weiming Li
- 1:27 PM Abstract 6511:** A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).
First Author: Manju Sengar, MD
- 1:33 PM Panel Question and Answer**
- 1:45 PM Abstract 6512:** A randomized phase II study of selinexor added to standard induction and consolidation chemotherapy in adults with acute myeloid leukemia (AML).
First Author: Timothy S. Pardee, MD, PhD
- 1:51 PM Abstract 6513:** Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph⁺ BCP-ALL).
First Author: Elias Jabbour, MD
- 1:57 PM Abstract 6514:** Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.
First Author: Lewis Fady Nasr, MD, MSc
- 2:03 PM Panel Question and Answer**
- 2:15 PM Abstract 6515:** Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL.
First Author: Lewis Fady Nasr, MD, MSc
- 2:21 PM Abstract 6516:** The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.
First Author: Maria Hachem, MD, MS
- 2:27 PM Abstract 6517:** The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).
First Author: Jae Hong Park, MD
- 2:33 PM Panel Question and Answer**

1:15 PM-2:45 PM Rapid Oral Abstract Session

Lung Cancer—Non–Small Cell Metastatic

Location: Hall D2

Guilherme Harada, MD—Chair

Memorial Sloan Kettering Cancer Center

Brian S. Henick, MD—Chair

Irving Medical Center, Columbia University

- 1:15 PM Abstract 8512:** Efficacy and safety of HLX43 (anti-PD-L1 ADC) in patients with advanced non–small cell lung cancer.
First Author: Jie Wang, MD, PhD
- 1:21 PM Abstract 8513:** Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamidg (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC.
First Author: Solange Peters, MD, PhD
- 1:27 PM Abstract 8514:** Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Lin Wu, MD
- 1:33 PM Panel Question and Answer**
- 1:45 PM Abstract 8515:** Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with *STK11*, *KEAP1*, and/or *KRAS* mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
First Author: Ferdinandos Skoulidis, MD, PhD
- 1:51 PM Abstract 8516:** A phase 1/2 study of TSN1611, a highly selective oral *KRAS* G12D inhibitor, in solid tumors: Efficacy and safety in *KRAS* G12D–mutated NSCLC patients.
First Author: Yongfeng Yu, PhD
- 1:57 PM Panel Question and Answer**
- 2:09 PM Abstract 8517:** Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial.
First Author: Michael R. Conroy, MBCh
- 2:15 PM Abstract LBA8518:** Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L).
First Author: Naoki Haratake, MD, PhD
- 2:21 PM Abstract 8519:** Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
First Author: Julia K. Rotow, MD
- 2:27 PM Abstract 8520:** DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with *EGFR* C797X mutations: Results from phase 1/2 studies.
First Author: Mengzhao Wang, MD
- 2:33 PM Panel Question and Answer**

1:15 PM-4:15 PM Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall B1

Baidehi Maiti, MD, PhD, FACP—Chair

Cleveland Clinic Taussig Cancer Institute

Simona Flora Shaitelman, MD—Chair

The University of Texas MD Anderson Cancer Center

- 1:15 PM Abstract 500:** First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
First Author: Robert C. Stein, PhD, MBBChir, FRCPC
- 1:27 PM Abstract 501:** Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2- early breast cancer (EBC).
First Author: Stephen K.L. Chia, MD, FRCPC
- 1:39 PM Abstract 502:** Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2- eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
First Author: Peter Schmid, MD, PhD, FCRP
- 1:51 PM Martine J. Piccart-Gebhart, MD, PhD, FASCO**
Jules Bordet Institute, Université Libre de Bruxelles
Discussion of Abstract(s) 500-502: From Genomic Testing to Systemic Therapy: Personalizing Adjuvant Treatment for HR+/HER2- Breast Cancer
- 2:03 PM Panel Question and Answer**
- 2:15 PM Abstract LBA503:** Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.
First Author: Jana de Boniface
- 2:27 PM Abstract 504:** Surgical de-escalation of implant-based breast reconstruction (IBBR) after mastectomy for breast cancer treatment or prevention: The international randomized phase III PREPEC trial (OPBC-02).
First Author: Walter Weber
- 2:39 PM Abstract 505:** Prediction of axillary response in 5,262 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study.
First Author: Maggie Banys-Paluchowski, PhD
- 2:51 PM Judy Caroline Boughey, MD**
Mayo Clinic Rochester
Discussion of Abstract(s) LBA503-505: Optimizing the Surgical "Path": Operative Approaches in Early-Stage Breast Cancer
- 3:03 PM Panel Question and Answer**

- 3:15 PM Abstract 506:** Updated overall survival results from a randomized phase III trial of non-cross-resistant adjuvant chemotherapy plus endocrine therapy versus endocrine therapy alone in HR+/HER2-/lymph node-positive breast cancer with residual disease following neoadjuvant chemotherapy (NCT01019616).
First Author: Yang Yang
- 3:27 PM Abstract 507:** Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.
First Author: Peter Schmid, MD, PhD, FCRP
- 3:39 PM Abstract LBA660:** Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
First Author: Zhi-Ming Shao, PhD
- 3:51 PM Sarah L. Sammons, MD**
Dana-Farber Cancer Institute
Discussion of Abstract(s) 506-LBA660: Subtype-Specific Approaches to High-Risk Disease
- 4:03 PM Panel Question and Answer**

1:30 PM-4:30 PM Poster Session

Developmental Therapeutics—Immunotherapy

Location: Hall A—Posters and Exhibits

Posters by Topic

- Antibodies:** Board(s) 311-320, 455a-458b
- Artificial Intelligence:** Board(s) 321-325
- Cellular Immunotherapy:** Board(s) 326-355, 459a-459b
- Circulating Biomarkers:** Board(s) 356-368, 370
- Immunobiology:** Board(s) 371-381, 460a-461a
- Intratumoral/Tumor-Localized Treatment Modalities:** Board(s) 382-394, 461b-462a
- New Targets and New Technologies (IO):** Board(s) 395-400, 402-406, 408-409, 462b-467a
- PD1/PD-L1 Inhibitor Combinations:** Board(s) 410-428, 467b-470b
- PD1/PD-L1 Inhibitor Monotherapy:** Board(s) 429-431, 471a
- Tissue-Based Biomarkers:** Board(s) 432-440
- Vaccines:** Board(s) 441-444, 471b-472a
- Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination):** Board(s) 445-447
- Other Experimental IO-Related Topics:** Board(s) 448-454, 472b
- Board 311 **Abstract 2521:** CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.
First Author: Charlotte Rose Lemech, FRACP, MBBS
- Board 312 **Abstract 2522:** Pemivibart for prevention of COVID-19: Subset analysis of CANOPY participants with solid tumor or hematologic malignancies.
First Author: Meredith Leston

- Board 313 **Abstract 2523:** A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors.
First Author: Judith Raimbourg
- Board 314 **Abstract 2524:** Phase 1b dose-expansion study of IMC-002, a anti-CD47 monoclonal antibody, in patients with advanced triple negative breast cancer (TNBC).
First Author: Ji Hyung Hong, MD, PhD
- Board 315 **Abstract 2525:** Phase I trial of the anti-CAPRIN1 antibody TRK-950 alone or with nivolumab in Japanese patients with advanced solid tumors.
First Author: Takafumi Koyama, MD, PhD
- Board 316 **Abstract 2526:** Safety, pharmacokinetics, and immunogenicity of HLX6018, a monoclonal antibody targeting the GARP/TGF- β 1 complex, in healthy subjects: A randomized, double-blind, placebo-controlled, phase I clinical study.
First Author: Yanhua Ding
- Board 317 **Abstract 2527:** Safety and efficacy of a novel PD-L1/4-1BB bispecific antibody QLF31907 in previously-treated patients with advanced melanoma: Results from a phase 2 study.
First Author: Jun Guo, MD
- Board 318 **Abstract 2528:** Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced tumors.
First Author: Jermaine Ian George Coward, PhD, MBBS, MRCP, FRACP
- Board 319 **Abstract 2529:** A phase II study of perioperative cadonilimab (AK104) in patients with recurrent resectable head and neck squamous cell carcinoma.
First Author: Lei Liu, MD, PhD
- Board 320 **Abstract 2530:** Anti-tumor activity of Man 9 x PS targeting immunotherapies in diffuse intrinsic pontine glioma (DIPG) and pancreatic cancers.
First Author: Shabnam Samimi
- Board 321 **Abstract 2531:** Multiomic machine learning integration of DNA and RNA features to predict immunotherapy benefit in MSS-CRC and other rare cancers.
First Author: Michelle Ting-Lin, MD
- Board 322 **Abstract 2532:** AI-powered spatial tumor microenvironment analysis in metastatic microsatellite-stable colorectal cancer receiving immunotherapy.
First Author: Sojin Kim, MD
- Board 323 **Abstract 2533:** Multimodal immunoprofiling of peripheral blood using foundation models of the immune system for predicting immunotherapy response and toxicity in the RADIOHEAD pan-cancer cohort.
First Author: Artemii Nikitin, PhD
- Board 324 **Abstract 2534:** External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1-high metastatic non-small cell lung cancer.
First Author: Ravi Bharat Parikh, MD, MPP
- Board 325 **Abstract 2535:** Artificial intelligence (AI) foundation model as a predictor of efficacy of next-generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images.
First Author: Ryan Dalton
- Board 326 **Abstract 2536:** Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.
First Author: Jennifer Rachel Eads, MD
- Board 327 **Abstract 2537:** Tumor infiltrating lymphocytes (LM103 infusion) in solid tumors: A phase I trial evaluating clinical and immunological anti-tumor activity.
First Author: Fenge Li, MD, PhD
- Board 328 **Abstract 2538:** Extended monitoring and biomarker analysis in metastatic melanoma patients treated with TIL therapy and conditioning-replacing igrelimogene litadenorepvec virotherapy: Pre-infusion immune cell and cytokine profiles associated with survival.
First Author: Victor Cervera-Carrascon, PhD, PharmD
- Board 329 **Abstract 2539:** Immunologic and clinical outcomes of perfluoroalkyl substances (PFAS) exposure in solid tumors treated with pembrolizumab.
First Author: Charles Jeffrey Lay Tan, MD
- Board 330 **Abstract 2540:** GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01).
First Author: Jun Yu, MD, PhD
- Board 331 **Abstract 2541:** Longitudinal immune programs and association with toxicity burden and antitumor response during immunotherapy.
First Author: Mireille Diane Langouo Fontsa, MD
- Board 332 **Abstract 2542:** Phase 1 trial of a KRAS G12V/HLA-A*11:01-restricted TCR-engineered T-cell therapy in advanced solid tumors.
First Author: Ding Xiaoyan
- Board 333 **Abstract 2543:** Safety and preliminary efficacy of a novel armored mesothelin-targeted CAR-T therapy in advanced solid tumors.
First Author: Changsong Qi, MD, PharmD
- Board 334 **Abstract 2544:** Phase 1 dose escalation study of CD34 selected CD19 directed CAR T with metabolic programming in relapsed/refractory B-cell lymphoma.
First Author: Brian Hess, MD
- Board 335 **Abstract 2545:** Effects of resorcinol isoprenyl benzene derivative IPI201 on natural killer cell cytotoxicity and tumor cell viability in human colorectal adenocarcinoma cells.
First Author: Brett Lanier, BS
- Board 336 **Abstract 2546:** Epigenetic reprogramming of allogeneic NK cells via antigen-specific "training" to generate target-specific memory-like NK cells for B-cell lymphoma without genetic engineering.
First Author: Jialu Kang, MD

- Board 337 **Abstract 2547:** An LNP-mRNA-based in vivo cell engager as a producer of T macrophage tumor triads in situ for targeted anti-solid tumor therapies. First Author: Xudong Wang
- Board 338 **Abstract 2548:** Combining immune checkpoint inhibition and dendritic cell vaccination in advanced pleural and peritoneal mesothelioma: The phase 1b MESOVAX trial. First Author: Laura Ridolfi, MD, PhD
- Board 339 **Abstract 2549:** B cell responses in recurrent respiratory papillomatosis patients treated with DNA immunotherapy INO-3107. First Author: Nabil F. Saba, MD, FACP
- Board 340 **Abstract 2550:** Anitocabtagene autoleucl (anito-cel) clinical trial manufacturing experience in patients with relapsed/refractory (RR) or newly diagnosed (ND) multiple myeloma (MM). First Author: Krina K. Patel, MD, MSc
- Board 341 **Abstract 2551:** A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer. First Author: Hope S. Rugo, MD, FASCO
- Board 342 **Abstract 2552:** Phase 1 study of META 10-19, an IL-10-expressing, anti-CD19 CAR T cell product in patients with high-risk DLBCL. First Author: Qianwen Xu, MD
- Board 343 **Abstract 2553:** Erythrocyte-anti-PD-1 conjugates in patients with advanced solid tumors resistant to anti-PD-1/PD-L1 therapy: Long-term follow-up of a phase I trial. First Author: Xiaoqian Nie, MS
- Board 344 **Abstract 2554:** Single-cell multi-omics and TCR sequencing to identify early tumor cavity homing and phenotypic evolution of CAR-T cells in glioblastoma. First Author: Qi Zhu, MMedSc
- Board 345 **Abstract 2555:** Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer. First Author: Paras R. Sahani, BS
- Board 347 **Abstract 2557:** Long-term follow-up of satricabtagene autoleucl (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: A subgroup analysis. First Author: Chang Liu, MD
- Board 348 **Abstract 2558:** Concurrent chemoradiotherapy plus cytokine-induced killer cells therapy or observation in patients with locoregionally advanced nasopharyngeal carcinoma: A ten-year follow-up of a randomized, phase II study. First Author: Xiuyu Cai
- Board 349 **Abstract 2559:** Optimization of tumor-infiltrating lymphocyte (TIL) manufacturing in non-small cell lung cancer (NSCLC) using an IL-7/IL-15/IL-2 expansion protocol. First Author: Jorge Bartolome, MD
- Board 350 **Abstract 2560:** Preliminary phase 1 results of a MICA/B-targeted CAR T cell designed to overcome solid tumor escape mechanisms and avoid the requirement for conditioning chemotherapy. First Author: Manish Ramesh Patel, DO
- Board 351 **Abstract 2561:** Extreme persistence of polyclonal CD8⁺ CAR T cells as a driver of marrow failure, neurotoxicity, and fatal immune collapse after ciltacabtagene autoleucl. First Author: Djordje Atanackovic, MD
- Board 352 **Abstract 2562:** Influence of onboard, tethered IL-12 on potency of the Tmod NOT gate and selectivity. First Author: Jushen Liang
- Board 353 **Abstract 2563:** Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL). First Author: Paolo Fabrizio Caimi, MD, MBA
- Board 354 **Abstract 2564:** Depletion of T-regulatory cells by denileukin difitox-cxd1 (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results. First Author: Haider Mahdi, MD
- Board 355 **Abstract 2565:** Transposon-engineered hypoxia-inducible T cells for treatment of solid tumors. First Author: Yannick Schreiber, BS
- Board 356 **Abstract 2566:** Targeting MAN1A1 to address immune checkpoint inhibitors resistance: A novel mechanism of vascular-endothelial reprogramming in NSCLC. First Author: Ai Gao, PhD
- Board 357 **Abstract 2567:** Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 to inform resistance to immunotherapy in HCC. First Author: Joao Gorgulho, MD
- Board 358 **Abstract 2568:** Baseline peripheral blood activated-to-total CD8⁺ central memory T cell ratio to identify melanoma patients at high risk for severe toxicity but limited clinical benefit. First Author: Magdalena Kovacovics
- Board 359 **Abstract 2569:** Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients. First Author: Martin David Forster, MBBS
- Board 360 **Abstract 2570:** Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq-based prediction of severe adverse event risk and rheumatoid arthritis. First Author: Anatoly Bobe
- Board 361 **Abstract 2571:** Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1-positive non-small cell lung cancer (NSCLC) in AdvanTIG-105. First Author: Yan Yu
- Board 362 **Abstract 2572:** Molecular progression defined by longitudinal ctDNA dynamics for prediction of outcomes in immune checkpoint inhibitor-treated solid tumors. First Author: Muhammad Anees
- Board 363 **Abstract 2573:** Molecular pathways of immune checkpoint inhibitor-induced hepatitis. First Author: Erika Bushatsky, MD
- Board 364 **Abstract 2574:** Association of neutrophil percentage-to-albumin ratio with progression-free survival and overall survival in cancer patients treated with PD-1/PD-L1 inhibitors. First Author: Wenhui Liu, PhD, PharmD

- Board 365 **Abstract 2575:** Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study. First Author: Veronica Conca, MD
- Board 366 **Abstract 2576:** A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer. First Author: Katherine Cynthia Fuh, MD, PhD
- Board 367 **Abstract 2577:** Analysis of circulating small extracellular vesicle-associated miRNA in head and neck squamous cell carcinoma (HNSCC): Biomarker discovery in pre-operative neoadjuvant nivolumab. First Author: Joseph Patrick Flemming, DO, MS
- Board 368 **Abstract 2578:** T-cell stem-like memory cells as a novel biomarker to identify patients with sustained disease control during treatment with PD-(L)1 immunotherapy. First Author: Victor Joo
- Board 370 **Abstract 2580:** Real-world concordance of tumor mutational burden (TMB) between blood (circulating tumor DNA) and tissue, and its association with immunotherapy response. First Author: Kyle VanDommelen, MD
- Board 371 **Abstract 2581:** Functional binding of PD-1 ligands: Overcoming PD-L1 staining limitations to predict therapy response. First Author: Bar Kaufman, MD
- Board 372 **Abstract 2582:** Spatial immune profiling to identify GPNMB as a mediator of immune suppression that limits response to PD-1 blockade in TNBC. First Author: Anna-Maria Lazaratos, BSc
- Board 373 **Abstract 2583:** Age-associated genomic instability and inflammatory pathway activation: A pan-cancer multi-omics analysis of the TITANIA framework. First Author: Shugo Yajima, MD
- Board 374 **Abstract 2584:** A new HLA genotyping algorithm to show accuracy and concordance between tumor and normal samples. First Author: Ariane Lozac'hmeur
- Board 375 **Abstract 2585:** Pan-cancer analysis of STAT6 expression and its relationship with tumor microenvironment characteristics and survival. First Author: Hiba Narvel, MBBS
- Board 376 **Abstract 2586:** Beyond TMB: Characterizing tumor-intrinsic genomic architectures of immune resistance. First Author: Ashok K. Vaid, DM
- Board 377 **Abstract 2587:** Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R- $\beta\gamma$ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. First Author: Markus Joerger, MD, PhD
- Board 378 **Abstract 2588:** Multi-omics analysis from the IMMUcan consortium to identify predictors of chemo-immunotherapy response in early-stage triple-negative breast cancer. First Author: Andrea Joaquin Garcia, MS
- Board 379 **Abstract 2589:** Chemotherapy-induced gut microbiota taxonomic deviation and its association with outcomes and toxicities in breast cancer: CANTO microbiota. First Author: Joana M. Ribeiro, MD
- Board 380 **Abstract 2590:** Safety and preliminary efficacy of OH2 combined with BS006 sequential intratumoral injection in patients with advanced solid tumors: An open-label, dose-escalation phase Ib/II study. First Author: Han Wu
- Board 381 **Abstract 2591:** Association of SARS-CoV-2 vaccination with survival outcomes in patients with metastatic solid tumors treated with immune checkpoint inhibitors. First Author: Haris Sohail, MD
- Board 382 **Abstract 2592:** An exploratory, single-center, single-arm trial of R-ISV-FOLactis in situ vaccination for advanced soft tissue sarcoma. First Author: Qing Wang
- Board 383 **Abstract 2593:** Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101). First Author: Jong Chul Park, MD
- Board 384 **Abstract 2594:** Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial). First Author: Hyo S. Han, MD
- Board 385 **Abstract 2595:** First-in-human evaluation and preclinical mechanistic studies of targeted hyperthermia therapy. First Author: Carman Giacomantonio, MD, MSc
- Board 386 **Abstract 2596:** Evaluation of adnexal features and histological response to intralesional SP-002 in nodular basal cell carcinoma. First Author: Gregory Siller
- Board 387 **Abstract 2597:** Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases. First Author: Caroline Robert, MD, PhD
- Board 388 **Abstract 2598:** STING agonist JMKX000197 infusion in patients with malignant pleural effusion: Preliminary results from a prospective phase Ib study. First Author: Ning Li, MD
- Board 389 **Abstract 2599:** Clinical efficacy and safety of BM201 intra-tumoral injection and radiotherapy in advanced solid tumors: Results from the phase I/II study. First Author: Rutian Li, PhD
- Board 390 **Abstract 2600:** Hepatic arterial infusion chemotherapy combined with immunotherapy for unresectable intrahepatic cholangiocarcinoma: A single-arm, open-label, prospective clinical trial. First Author: Hongzhe Kang, MD

- Board 391 **Abstract 2601:** A phase I trial on the safety, tolerance, and preliminary efficacy of intracavitary injection of in situ vaccines (FOLactis) in patients with advanced solid tumors complicated with malignant pleural effusion.
First Author: Lifeng Wang
- Board 392 **Abstract 2602:** Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple-negative breast cancer (TNBC).
First Author: Stephane Dalle
- Board 393 **Abstract 2603:** A phase I window-of-opportunity trial of intraperitoneal, intratumoral lipopolysaccharide in peritoneal metastases: Safety and immune remodeling from the RIOT-1 study.
First Author: Christopher Sherry, DO
- Board 394 **Abstract 2604:** Clinical translation of PeptiCRAd-1: Interim clinical evaluation of a modular oncolytic adenovirus vaccine platform targeting NY-ESO-1 and MAGE-A3 in advanced solid tumors.
First Author: Lukasz Kuryk, PhD
- Board 395 **Abstract 2605:** BI1808 + pembrolizumab: Responses to a chemotherapy-free regimen in advanced ovarian cancer.
First Author: Anja Williams
- Board 396 **Abstract 2606:** Neoadjuvant chemokine modulation of the tumor microenvironment (TME) in resectable metastatic colorectal cancer: Results from a phase I study.
First Author: Sarbajit Mukherjee, MD, MS
- Board 397 **Abstract 2607:** Safety and efficacy results from a first-in-human, phase 1/2 study of ASKG915, an anti-PD-1/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors.
First Author: Jiajia Li
- Board 398 **Abstract 2608:** RAISIC-1: A phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256—Preliminary safety, tolerability, pharmacokinetic, and pharmacodynamic results.
First Author: Ganessan Kichenadasse, MD
- Board 399 **Abstract 2609:** Influence of pirfenidone on checkpoint inhibitor pneumonitis and antitumor efficacy in NSCLC: A multicenter study and mechanistic exploration.
First Author: Xiaohui Jia
- Board 400 **Abstract 2610:** Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).
First Author: Markus Joerger, MD, PhD
- Board 402 **Abstract 2612:** Potential effects of TGF- β inhibition on immune resistance by targeting immunosuppressive microenvironment in advanced gastric cancer (AGC): Multi-omics post-hoc analysis of the K-Umbrella-06 trial.
First Author: Choong-kun Lee, MD, PhD
- Board 403 **Abstract 2613:** Effects of SECN-15, a neuropilin-1–targeting antisense oligonucleotide, on resistance to immune checkpoint inhibitors in preclinical tumor models.
First Author: Richard Klar, PhD
- Board 404 **Abstract 2614:** Non-invasive characterization of intratumoral CD8+ T cells using standard-of-care (SOC) CT and ⁸⁹Zr-crefmirlimab berdoxam PET (CD8-PET) radiomic signature in solid tumors.
First Author: Jayant Narang, MD
- Board 405 **Abstract 2615:** PhaseX as a phase 0.9 translational platform to de-risk BiTE immunotherapy through mechanistic patient explant profiling.
First Author: Kanishka Fernando, PhD, MSc
- Board 406 **Abstract 2616:** Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.
First Author: Harriet M. Kluger, MD
- Board 408 **Abstract 2618:** First-in-class PD-1/IL-2^α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC): Updated results from a phase I study.
First Author: Jianya Zhou
- Board 409 **Abstract 2619:** Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
First Author: Eziafa Oduah, MD, PhD, MPH
- Board 410 **Abstract 2620:** Targeting PI3K- β to develop novel combinational therapies for melanoma.
First Author: Maegan Gabby, MS
- Board 411 **Abstract 2621:** Phase I/II study of concurrent intrathecal toripalimab and pemetrexed (PM) for leptomeningeal metastases (LM) from solid tumors.
First Author: Guozi Yang
- Board 412 **Abstract 2622:** Sequential or concurrent immunotherapy with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
First Author: Linfang Wu
- Board 413 **Abstract 2623:** Efficacy and safety of cadonilimab in patients with MSI-H/dMMR locally advanced or metastatic gastrointestinal malignancies: A real-world retrospective study.
First Author: Xiaoyuan Sun
- Board 414 **Abstract 2624:** Intrathecal (IT) PD-1/CTLA-4 antibody combined with pemetrexed (PM) for leptomeningeal metastases (LM) from solid tumors: Preliminary results of two single-center phase I studies.
First Author: Zhenyu Pan, MD, PhD
- Board 415 **Abstract 2625:** Evaluation of intravenous IPI201 in combination with anti-PD-1 therapy in a colorectal cancer mouse model.
First Author: Brett Lanier, BS
- Board 416 **Abstract 2626:** Phase I/II study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in combination with LB4330, a long-acting IL-10, in patients with advanced solid tumors.
First Author: Jiajian Liu, PhD

- Board 417 **Abstract 2627:** Low-dose intestinal irradiation to enhance the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer. First Author: Baiyang Huang
- Board 418 **Abstract 2628:** Personalized N-of-1 combinations based on molecular profiles in advanced malignancies: Immunotherapy group analysis of the I-PREDICT N-of-1 precision oncology study. First Author: Yuji Uehara, MD
- Board 419 **Abstract 2629:** Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition. First Author: Judy S. Wang, MD
- Board 420 **Abstract 2630:** Clinical efficacy of tislelizumab in combination with gemcitabine and nab-paclitaxel and chemoresistance analysis in borderline resectable pancreatic cancer: A prospective pilot study. First Author: Yonggang He
- Board 421 **Abstract 2631:** A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety. First Author: Chang Wang
- Board 422 **Abstract 2632:** A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced/metastatic breast cancer or NSCLC. First Author: Anwen Xiong
- Board 423 **Abstract 2633:** Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without lung and/or liver metastases (NCI/SWOG S1609). First Author: Megan Othus, PhD
- Board 424 **Abstract 2634:** Prior CTLA-4 blockade as associated with a hyperactive immunosuppressive signature and limited response to subsequent immunotherapy in melanoma. First Author: Omid Hamid, MD
- Board 425 **Abstract 2635:** Phase IIa study of toposertib, a dual TGFβRI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). First Author: Hye Ryun Kim, MD, PhD
- Board 426 **Abstract 2636:** Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis. First Author: Changchuan Jiang, MD, MPH
- Board 427 **Abstract 2637:** Impact of COVID-19 mRNA vaccines on survival outcomes in patients with solid tumors receiving immunotherapy: A large-scale retrospective study. First Author: Bayan Khasawneh, MD
- Board 428 **Abstract 2638:** Distinct T-cell subsets as drivers of response to different neoadjuvant treatments in esophageal squamous cell carcinoma. First Author: Xin-yun Song, MD
- Board 429 **Abstract 2639:** Phase I study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors. First Author: Jiajian Liu, PhD
- Board 430 **Abstract 2640:** Immune checkpoint inhibitor (ICI) toxicity in a large prospective cohort of patients with solid tumors: The I-CHECKIT study (SWOG S2013). First Author: Krishna Soujanya Gunturu, MD
- Board 431 **Abstract 2641:** COVID-19 mRNA vaccination and risk of immune-related adverse events in ICI-treated cancer patients. First Author: Andrea Yun-En Sun, MD
- Board 432 **Abstract 2642:** Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial. First Author: Valentina Gambardella, PhD
- Board 433 **Abstract 2643:** Engineering tumor-infiltrating lymphocytes (TILs) via the T-Editor platform to enhance antitumor activity. First Author: Fenge Li, MD, PhD
- Board 434 **Abstract 2644:** Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with *ERBB2* alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. First Author: Timothy Lewis Cannon, MD, FASCO
- Board 435 **Abstract 2645:** Functional assessment of polymerase proofreading variants to define sensitivity to immune checkpoint blockade (ICB) pan-cancer. First Author: Amin Nassar, MD
- Board 436 **Abstract 2646:** Development and testing of an ex vivo, live tumor fragment platform for the prediction of immune checkpoint inhibitor response and relationship to approved biomarkers. First Author: David A. Braun, MD, PhD
- Board 437 **Abstract 2647:** Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC). First Author: Michela Bartolini, MD
- Board 438 **Abstract 2648:** Pan-cancer long mononucleotide repeat microsatellite instability testing for detection and immunotherapy selection. First Author: Ruchi Shah, BS
- Board 439 **Abstract 2649:** Are all tumor-agnostic biomarkers equally tissue-independent? Comparative cross-histology efficacy analysis of MSI-H/dMMR versus *BRAF* V600E. First Author: Victor Andres Castillo, MD
- Board 440 **Abstract 2650:** Pan-cancer landscape of oncogenic *POLE* and *POLD1* alterations. First Author: Lawrence W. Wu, MD
- Board 441 **Abstract 2651:** Phase Ib evaluation of a recombinant overlapping peptide survivin immunotherapy: Safety, immunogenicity, and immune-clinical associations in advanced solid tumours. First Author: Shisong Jiang, PhD, MBBS

- Board 442 **Abstract 2652:** Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. First Author: Daniel L Adams, BS
- Board 443 **Abstract 2653:** Off-target HLA matches for prediction of response in personalised cancer vaccines: A multi-trial retrospective analysis. First Author: Om H. Gandhi, MS
- Board 444 **Abstract 2654:** Ranking neoantigens for escape-resilience rather than predicted immunogenicity: Associated changes in vaccine design. First Author: Michael E. Bryan, BSc
- Board 445 **Abstract 2655:** The differentiated SIRP α -IgG4 Fc fusion protein HCB101 in monotherapy and combination therapy. First Author: Fangling Ning
- Board 446 **Abstract 2656:** Lowdose nivolumab in patients at high risk of immunerelated adverse events: A retrospective cohort study. First Author: Lisa May Ling Tachiki, MD
- Board 447 **Abstract 2657:** Association of PCSK9 inhibitors with clinical outcomes in patients with cancer receiving immune checkpoint inhibitors: A real-world analysis. First Author: Chuan Angel Lu, MD, MPH
- Board 448 **Abstract 2658:** Modulation of PD-1 and PD-L1 expression on peripheral blood T-cells by novel rotavirus variants. First Author: Svetlana Yu Filippova
- Board 449 **Abstract 2659:** Preclinical investigations and first-in-human phase I trial of KP-483 in solid tumors: Safety, antitumor activity, and preliminary efficacy. First Author: Noboru Yamamoto, MD, PhD
- Board 450 **Abstract 2660:** Enrichment of the germline *NLR5^{Pro191Leu}* variant in patients with immune checkpoint inhibitor-induced hepatitis. First Author: Shira Gabizon Peretz, MD
- Board 451 **Abstract 2661:** Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study. First Author: Ciara M. Kelly, MD, MBCh
- Board 452 **Abstract 2662:** Effect of IL7 on ImmTAC-mediated killing by T cells in vitro and T-cell fitness in patients. First Author: Joseph J. Sacco, PhD, MBChB
- Board 453 **Abstract 2663:** A phase I study of pomalidomide and nivolumab (Pom/Nivo) in patients with virus-associated malignancies with and without HIV. First Author: Jose Mercado-Matos, MD, PhD
- Board 454 **Abstract 2664:** Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion. First Author: Richard Trauger, PhD
- Board 455a **Abstract TPS2665:** ASP2998, a trophoblast cell-surface antigen 2 (TROP2)-targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study. First Author: Guru P. Sonpavde, MD
- Board 455b **Abstract TPS2666:** Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors. First Author: Drew W. Rasco, MD
- Board 456a **Abstract TPS2667:** A phase I trial evaluating an optimized B7-H3xCD3 T cell engager for treatment of solid cancer. First Author: Jonas S. Heitmann, MD
- Board 456b **Abstract TPS2668:** First-in-human phase 1a/1b study of LB-LR1109, an anti-LILRB1 monoclonal antibody, as monotherapy in advanced solid tumors and in combination with atezolizumab in advanced NSCLC. First Author: Hyungjin Cho, MD
- Board 457a **Abstract TPS2669:** Phase 1 first-in-human trial of AGO1, a recombinant humanized monoclonal antibody to progranulin/glycoprotein 88 (GP88) to determine the safety, tolerability, pharmacokinetics, and preliminary antitumor activity in subjects with advanced solid tumor malignancies. First Author: Katherine H.R. Tkaczuk, MD
- Board 457b **Abstract TPS2670:** A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors. First Author: Rom S. Leidner, MD
- Board 458a **Abstract TPS2671:** A phase I/IIa dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety and preliminary efficacy of tri-specific antibody (SOA101) in subjects with advanced solid tumors. First Author: Jennifer Ho, MD, PhD
- Board 458b **Abstract TPS2672:** Phase 1, open-label clinical trial to treat stage IV cancer patients harboring multiple patient-specific mutated cell surface proteins with chimeric antibodies. First Author: Monika Joshi, MD
- Board 459a **Abstract TPS2673:** A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study. First Author: Salman Rafi Puneekar, MD
- Board 459b **Abstract TPS2674:** A phase I, open-label, dose-escalation study of CAR001 (mRNA-engineered Nb-CAR.BiTE- $\gamma\delta$ T cells) in patients with relapsed or refractory solid tumors. First Author: Der-Yang Cho
- Board 460a **Abstract TPS2675:** A phase 1/2 dose-escalation/expansion study of REGN10597 (anti-PD-1-IL2R α -IL2) in patients with advanced solid tumors. First Author: Kyri Papdopoulos
- Board 460b **Abstract TPS2676:** Biomarker study of BND-22 in combination with cemiplimab in solid tumors. First Author: Mohamed H. Derbala, MD

- Board 461a **Abstract TPS2677:** The TIME trial: Phase II randomized controlled trial of time-of-day–specified nivolumab and ipilimumab for advanced melanoma. First Author: Michael Lowe, MD, MA
- Board 461b **Abstract TPS2678:** A phase 1b, two-arm study of tolotodokin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC). First Author: Thomas Urban Marron, MD, PhD
- Board 462a **Abstract TPS2679:** OP-NEU-101: A phase 1/2 open-label, dose finding and expansion study to investigate the safety and effectiveness and determine the optimal dose of N17350 administered intratumorally in participants with advanced solid tumors. First Author: Matteo S. Carlino, PhD, MBBS, FRACP
- Board 462b **Abstract TPS2680:** A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay (NMD) inhibitor in patients with advanced/metastatic solid tumors (parts 1 and 2). First Author: Shiraj Sen, MD, PhD
- Board 463a **Abstract TPS2681:** Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors. First Author: Stephane Champiat, MD, PhD
- Board 463b **Abstract TPS2682:** Eiu-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T-cell engager, in advanced urothelial and squamous cell carcinomas. First Author: Tony Fiorino, MD, PhD
- Board 464a **Abstract TPS2683:** POLARIS: Polymetastatic lesion ablative radiotherapy with immunotherapy study. First Author: Evan Garrad, MD
- Board 464b **Abstract TPS2684:** Pharmacokinetics and pharmacodynamics evaluation in phase I trial of APX-343A, selective NOX inhibitor targeting CAF-mediated immunosuppression in patients with advanced solid tumors. First Author: Sung Hwan Moon, PhD
- Board 465a **Abstract TPS2685:** A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors. First Author: Ulka N. Vaishampayan, MD, FASCO
- Board 465b **Abstract TPS2686:** A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors. First Author: Jordan Ellis Cohen, MBBS, MMedSc
- Board 466a **Abstract TPS2687:** Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488). First Author: Harriet M. Kluger, MD
- Board 466b **Abstract TPS2688:** A phase I/IIa study to evaluate the safety and tolerability, activity, and PK of a potential novel CNTN4-targeted checkpoint inhibitor, EP0089, in patients with advanced solid tumors. First Author: Hendrik-Tobias Arkenau, MD, PhD
- Board 467a **Abstract TPS2689:** TREGCHECK 102: A study of tagmokitug (CHS-114) in combination with toripalimab and/or other treatments in participants with advanced solid tumors. First Author: Dani Ran Castillo, MD, MBBS
- Board 467b **Abstract TPS2690:** Cohort expansion of a phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1 integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI). First Author: Timothy A. Yap, MD, PhD
- Board 468a **Abstract TPS2691:** Phase II open-label trial of neoadjuvant immunotherapy in combination with CAPOX for resectable non-metastatic proficient mismatch repair (pMMR) colon cancer: NICER study. First Author: Atif Iqbal, MD
- Board 468b **Abstract TPS2692:** Induction adebrelimab combined with chemotherapy followed by response-adaptive concurrent chemoradiotherapy guided by PET-CT in locally advanced unresectable esophageal squamous cell carcinoma: A prospective, single-arm, phase II study. First Author: Jun Wang, MD
- Board 469a **Abstract TPS2693:** ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors. First Author: Meredith Pelster, MD, MSc
- Board 469b **Abstract TPS2694:** Efficacy and safety of QL1706-based combination therapy in recurrent or metastatic endometrial carcinoma previously treated with chemotherapy and immune checkpoint inhibitors: A single-arm, prospective, phase II trial. First Author: Lu Sun
- Board 470a **Abstract TPS2695:** SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies. First Author: Omid Hamid, MD
- Board 470b **Abstract TPS2696:** Phase I study of zeaxanthin alone or in combination with pembrolizumab in metastatic solid tumors. First Author: Philip Adam Friedlander, MD, PhD
- Board 471a **Abstract TPS2697:** Organ preservation strategy using dostarlimab for dMMR/MSI-H resectable solid tumors with whole-genome–based MRD monitoring (D-CURE: EPOC2401). First Author: Yuki Matsubara, MD
- Board 471b **Abstract TPS2698:** A phase II study of the DNA plasmid-based vaccine STEMVAC in patients with metastatic triple-negative breast cancer (mTNBC). First Author: Brie Chun, MD

- Board 472a **Abstract TPS2699:** A clinical study of a prototype DAA/TAA vaccine targeting MUC1 for immune interception and prevention in ductal carcinoma in situ.
First Author: Emilia Diego, MD
- Board 472b **Abstract TPS2700:** A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.
First Author: Chinmay Jani, MBBS

1:30 PM-4:30 PM Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 155-159

Chemotherapy and Antibody-Drug Conjugates: Board(s) 160-177, 292a-296a

Circulating Biomarkers: Board(s) 178-200

Molecular Diagnostics and Imaging: Board(s) 201-214

New Targets and New Technologies (Non-IO): Board(s) 215-228, 296b-301a

Pharmacology/Pharmacodynamics/Pharmacogenetics: Board(s) 229-231

Radiopharmaceuticals: Board(s) 232-236, 301b-302b

Small Molecules: Board(s) 238-253, 303a-306a

Tissue-Based Biomarkers: Board(s) 254-279, 306b

Other Developmental Therapeutics: Board(s) 280-291, 307a

- Board 155 **Abstract 3018:** The efficacy and safety of azvudine (FNC) in phase 1 investigator-initiated study in patients with advanced solid tumors.
First Author: Xuemei Zhu, MD, PhD
- Board 156 **Abstract 3019:** Discovery from single-cell RNA sequencing profiles of 18 CPTAC glioblastoma patients and validation in bulk profiles of 138 TCGA patients and two human-derived cell lines of a whole-transcriptome predictor of overall survival and drug targets by using quantum mechanics–based AI/ML.
First Author: Orly Alter, PhD
- Board 157 **Abstract 3020:** Quantum mechanics-based multi-tensor AI/ML as predictor of patients' overall survival, gene targets, and drug responses from their glioblastoma tumors' whole genomes.
First Author: Orly Alter, PhD
- Board 158 **Abstract 3021:** Development and clinical utility of an H&E-based tumor origin prediction model.
First Author: Qiyuan Hu
- Board 159 **Abstract 3022:** Prospective prediction of alisertib-induced Aurora-A kinase resistance mutations in patients with metastatic ER+ breast cancer using an innovative artificial intelligence approach.
First Author: Andrew Takchi, MD
- Board 160 **Abstract 3023:** Light-activated EGFR antibody–drug conjugate: Analysis of selectivity and translational profile for first-in-human evaluation.
First Author: Shirlin Xiao, PhD
- Board 162 **Abstract 3025:** First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.
First Author: Dan-yun Ruan, MD, PhD
- Board 163 **Abstract 3026:** Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis.
First Author: Yanqiao Zhang, DM
- Board 164 **Abstract 3027:** Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.
First Author: Chirayu Mohindroo, MD, MBBS
- Board 165 **Abstract 3028:** First-in-human phase I/II study of MRG006A, a first-in-class Glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: Hong Zhao, PhD
- Board 166 **Abstract 3029:** Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4–targeting ADC) from pharmacokinetics, efficacy, and safety perspectives.
First Author: Hugh Giovinazzo
- Board 167 **Abstract 3030:** Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors.
First Author: Siyuan Cheng
- Board 168 **Abstract 3031:** HER2-independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors.
First Author: Sarah Shin, MD, MPH
- Board 169 **Abstract 3032:** First-in-human phase 1 study of TQB6411, an EGFR/c-Met bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.
First Author: Shengxiang Ren, PhD
- Board 170 **Abstract 3033:** Clinical outcomes in phase 1 study of EBC-129, a first-in-class, anti-N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with gastroesophageal adenocarcinomas.
First Author: Wei-Peng Yong, MBChB
- Board 171 **Abstract 3034:** Real-world effectiveness of sacituzumab govitecan (SG) versus trastuzumab deruxtecan (T-DXd) in HER2-negative (HER2) metastatic breast cancer (MBC) in China: A propensity-score–matched study.
First Author: Biyun Wang
- Board 172 **Abstract 3035:** BC3195, a novel ADC targeting cadherin-3 (CDH3): Preliminary results of a phase I study in patients with advanced solid malignancies (study BC3195-102).
First Author: Madison Conces, MD

- Board 173 **Abstract 3036:** XNW27011, a Claudin 18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A phase 2 study.
First Author: Linlin Wang, DrPH
- Board 174 **Abstract 3037:** First-in-human study of DM002, an anti-MUC1/HER3 bispecific antibody-drug conjugate, in patients with advanced solid tumors.
First Author: Xian Jun Yu
- Board 175 **Abstract 3038:** A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.
First Author: Omar Saavedra, MD
- Board 176 **Abstract 3039:** Efficacy and safety of XNW27011, a Claudin-18.2 targeted (CLDN18.2) ADC, in advanced pancreatic ductal adenocarcinoma: A phase 2 study.
First Author: Linlin Wang, DrPH
- Board 177 **Abstract 3040:** Safety, efficacy, and pharmacokinetics of XNW28012, a tissue factor antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor (TOP1i) payload, in patients with advanced solid tumors: Results from a phase I/II study.
First Author: Miaoyan Wei, MD
- Board 178 **Abstract 3041:** Non-invasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boards.
First Author: Lavanya Ranganathan, MS
- Board 179 **Abstract 3042:** Performance of a tissue-free, molecular residual disease assay in colorectal, breast, and lung cancers from circulating tumor DNA.
First Author: Princy Parsana, PhD
- Board 180 **Abstract 3043:** Extracellular matrix-derived liquid biopsy for predicting response in patients with biliary tract cancer treated with nivolumab with or without ipilimumab combined with stereotactic body radiotherapy: Insights from the CheckPAC trial.
First Author: Martin Birkmose Rasmussen, PhD, MS
- Board 181 **Abstract 3044:** Prognostic impact of MRD positivity at ultra-sensitive ctDNA levels using a WGS-based personalized assay: A pan-cancer analysis from MONSTAR-SCREEN-3.
First Author: Tadayoshi Hashimoto, MD, PhD
- Board 182 **Abstract 3045:** Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial.
First Author: Rini Pauly, PhD, DPhil
- Board 183 **Abstract 3046:** Incremental clinical yield of serial large NGS panel liquid biopsies in routine care: Analysis of the STING study.
First Author: Camille Mazza
- Board 184 **Abstract 3047:** Cell-free DNA (cfDNA) methylation-based multi-cancer early detection (MCED) assay to enable subtyping of lung cancer, breast cancer, and non-Hodgkin lymphoma (NHL).
First Author: Kezhong Chen, MD
- Board 185 **Abstract 3048:** Correlation of presurgical circulating tumor DNA (ctDNA) levels with pathologic (p) stage and lymph node (LN) burden in localized colon cancer.
First Author: Masahito Kotaka, MD, PhD
- Board 186 **Abstract 3049:** Clinical utility of liquid *KRAS*-mutation screening in advanced pancreatic cancer patients referred for early-phase trials.
First Author: Erick F. Saldanha, MD
- Board 187 **Abstract 3050:** ctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: Retrospective analysis of PADA-1 samples.
First Author: Luc Cabel, MD, PhD
- Board 188 **Abstract 3051:** Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME).
First Author: Ankur Bahl, MD, MBBS
- Board 189 **Abstract 3052:** Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: A real-world study.
First Author: Saranya Chumsri, MD
- Board 190 **Abstract 3053:** Early ctDNA dynamics assessed by a personalized whole-genome sequencing-based assay as a predictor of outcomes with immune checkpoint blockade in advanced melanoma.
First Author: Mora Guardamagna, MD, PhD, MSc
- Board 191 **Abstract 3054:** A population tumor kinetics analysis for early-cycle ctDNA-guided therapy decisions in DLBCL.
First Author: Kunhee Kim, MD, MSc
- Board 192 **Abstract 3055:** Multi-omics discovery and clinical validation of COL1A2 alternative splicing isoforms as liquid biopsy markers for metastasis surveillance in osteosarcoma.
First Author: Junqiang Yin, MD
- Board 193 **Abstract 3056:** Integrating tumor mutation profiles, preoperative circulating tumor DNA (ctDNA), and clinical features to a predicting model for early peritoneal recurrence in stage II-III gastric cancer following curative gastrectomy.
First Author: Quang Thong Dang, MSc
- Board 194 **Abstract 3057:** A prospective study of tumor-informed ctDNA minimal residual disease detection in bone and soft tissue sarcomas.
First Author: Junqiang Yin, MD
- Board 195 **Abstract 3058:** Leveraging a hybrid tumor-informed and tumor-agnostic ctDNA assay for optimal ctDNA-MRD detection: A real-world study in Southeast Asia.
First Author: Anh Nguyen
- Board 196 **Abstract 3059:** Cell-free DNA fragmentomics as an enabler of tumor-of-origin classification using a commercial targeted cfDNA panel.
First Author: Kyle Helzer
- Board 197 **Abstract 3060:** Ultrasensitive tumor-informed ctDNA MRD detection to identify metastatic relapse and as predictor of recurrence-free survival following resection of early-stage NSCLC.
First Author: Fernando Pikabea Díaz, MD

- Board 198 **Abstract 3061:** cfDNA sequencing as a cutting-edge technology to identify pathogenic germline variants from 8353 patients with advanced tumors at the Gustave Roussy Institute.
First Author: Hela Sassi, MD, MSc
- Board 199 **Abstract 3062:** *ESR1* mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard-of-care hormonal therapy.
First Author: Malvika Pillai, PhD
- Board 200 **Abstract 3063:** Quantitative assessment of tumor shedding using AI-derived radiographic tumor burden and quantified liquid biopsy in advanced gastrointestinal cancers.
First Author: Abdul Qahar K. Yasinzai, MBBS
- Board 201 **Abstract 3064:** Breast cancer screening is heating up: A novel thermophysics-based AI modality for screening subjects with BIRADS 4 or 5 mammograms.
First Author: Nedal Darwish, MD
- Board 202 **Abstract 3065:** ⁶⁸Ga-NODAGA-SNA014 whole-body PET imaging to detect Claudin18.2-positive pancreatic cancer lesions.
First Author: Jihui Hao, MD, PhD
- Board 203 **Abstract 3066:** Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.
First Author: Ryan Gimple, MD, PhD
- Board 204 **Abstract 3067:** Application of long-read sequencing to resolve cryptic genomic instability across cancer types.
First Author: Josh Vo
- Board 205 **Abstract 3068:** CLERAD-PROBE: Dosimetric analysis of I-124 PET-guided remnant radioiodine ablation in differentiated thyroid carcinoma.
First Author: Kerstin Michalski
- Board 206 **Abstract 3069:** iPREDICT: Phase II study of CD8 PET in patients with immunoresponsive solid tumors—Imaging characteristics and correlation with RECIST response.
First Author: Kim Allyson Margolin, MD, FASCO
- Board 207 **Abstract 3070:** Cellfree DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients.
First Author: Laura Tung, PhD
- Board 208 **Abstract 3071:** Multicenter clinical study of [¹⁸F]AlF-HER2-BCH PET/CT as a molecular pathology tool for linear quantification of HER2 expression levels in breast cancer.
First Author: Xiaoyi Guo
- Board 209 **Abstract 3072:** FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
First Author: Tharani Sivakumaran, MBBS
- Board 210 **Abstract 3073:** Integrated imaging cytology profiling system for rapid point-of-care molecular diagnosis of leptomeningeal metastasis in breast cancer.
First Author: Hyungsoon Im, PhD
- Board 211 **Abstract 3074:** Diagnostic performance, safety, and biodistribution of [⁶⁸Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial.
First Author: Cristiano Pini
- Board 212 **Abstract 3075:** Diagnostic performance, safety, and biodistribution of [⁶⁸Ga]Ga-OncoCAIX for PET/CT imaging: A first-in-human phase I clinical trial in clear cell renal cell carcinoma.
First Author: Fabrizia Gelardi, MD, PhD
- Board 213 **Abstract 3076:** Molecular characteristics and outcomes of a real-world cohort of carcinoma of unknown primary determined by tissue-of-origin assays.
First Author: Nisha Ramamurthy, BS
- Board 214 **Abstract 3077:** Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling.
First Author: Brett Kennedy, PhD
- Board 215 **Abstract 3078:** Farnesyl transferase inhibitor (FTI) darlifarib (KO-2806) in combination with adagrasib in *KRAS* G12C mutated (mut) advanced solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial.
First Author: Andrea Zivi, MD
- Board 216 **Abstract 3079:** A phase 2 multi-center pharmacodynamic study of the fatty acid synthase (FASN) inhibitor TVB-2640 in advanced *KRAS*-mutant non-small cell lung cancer.
First Author: Arthi Sridhar, MD
- Board 217 **Abstract 3080:** Pan-cancer landscape and real-world management of BRAF non-V600E and MAP2K1 alterations: Analysis from the WAYFIND-R registry.
First Author: Esranur Aydın, PhD
- Board 218 **Abstract 3081:** First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.
First Author: Timothy A. Yap, MD, PhD
- Board 219 **Abstract 3082:** Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors.
First Author: Afshin Dowlati, MD
- Board 220 **Abstract 3083:** Convenience vs. complexity: Adoption of subcutaneous PD-(L)1s in lung cancer in EU4+UK.
First Author: Federico Gallo, PhD, DPhil
- Board 221 **Abstract 3084:** Targeting cancer stem cells with a novel virus-like drug conjugate.
First Author: Stevie Fawcett
- Board 222 **Abstract 3085:** Targeting TP53 pathologic variants for cancer immunotherapy using a self-replicating mRNA vaccine strategy.
First Author: Changgan Chen
- Board 223 **Abstract 3086:** TSY-310, a novel bispecific EGFR×ROR1 ADC: Assessment of antitumor activity in heterogeneous breast tumors through enhanced internalization and bystander cytotoxicity.
First Author: Kuo-Ming Yu, PhD

Saturday, May 30, 2026

- Board 224 **Abstract 3087:** Influence of genetic ancestry on UV mutational signatures linked to immunotherapy response in melanoma, beyond TMB.
First Author: Kevin Magnaye
- Board 225 **Abstract 3088:** A phase 1, first-in-human study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy in advanced solid tumors and in combination with endocrine therapy in ER+, HER2-advanced breast cancer (ABC): Preliminary results.
First Author: Amita Patnaik, MD, FRCPC
- Board 226 **Abstract 3089:** A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer.
First Author: Alan Loh Ho, MD, PhD
- Board 227 **Abstract 3090:** Genomic landscape of ERBB3 alterations in 5,416 metastatic solid tumors: Real-world evidence regarding biomarker-agnostic ADC strategies.
First Author: Minsuk Kwon, MD, PhD
- Board 228 **Abstract 3091:** Phase Ib expansion and dose optimization study of CX-5461 in patients with solid tumours enriched for DNA-repair deficiencies.
First Author: Ana Veneziani, MD
- Board 229 **Abstract 3092:** Topoisomerase 1 and DNA damage: Pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors.
First Author: Deborah Wilsker, PhD
- Board 230 **Abstract 3093:** Chemotherapy as a shaper of immune communication in the triple-negative breast cancer microenvironment.
First Author: David Ohtoinoyi, MD, PhD
- Board 231 **Abstract 3094:** Sex-associated differences in osimertinib pharmacokinetics among Asian patients with non-small cell lung cancer.
First Author: Sylvia Chen, PhD
- Board 232 **Abstract 3095:** NeoRay phase IIa results: A study of [¹⁷⁷Lu]Lu-NeoB (¹⁷⁷Lu-NeoB) in pts with advanced solid tumors overexpressing gastrin-releasing peptide receptor (GRPR).
First Author: Erik Mittra, MD, PhD
- Board 233 **Abstract 3096:** ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.
First Author: Jyoti Malhotra, MD, MPH
- Board 234 **Abstract 3097:** AKY-2519, a novel B7-H3-targeted radioconjugate, and its biodistribution profile in patients with mCRPC.
First Author: Michael Sathekge
- Board 235 **Abstract 3098:** First-in-human PET/CT imaging with ⁶⁸Ga-AKY-2519, a B7-H3 targeted miniprotein radioconjugate, to demonstrate tumor uptake and normal tissue exposure across various advanced solid tumors.
First Author: Josephine Enste
- Board 236 **Abstract 3099:** Final results of a first-in-human study of the MC1R-targeting radiopharmaceutical ²²⁵actinium MTI-201 (²²⁵Ac-MTI-201) in metastatic uveal melanoma (mUM).
First Author: Nikhil I. Khushalani, MD
- Board 238 **Abstract 3101:** First-in-class DIO3 inhibitor as a novel treatment strategy in ovarian cancer.
First Author: Sarit Batsir, PhD
- Board 239 **Abstract 3102:** EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors.
First Author: Martin Hojgaard, MD, PhD
- Board 241 **Abstract 3104:** Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with *ERBB2* alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.
First Author: Tareq Al Baghdadi, MD
- Board 242 **Abstract 3105:** Phase II basket trial of brigatinib for *ALK* fusion-positive solid tumors: ALLBREAK trial (WJOG15221M).
First Author: Tomoki Sakakida, MD, PhD
- Board 243 **Abstract 3106:** Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.
First Author: Izuma Nakayama, MD, PhD
- Board 244 **Abstract 3107:** Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).
First Author: Shiraj Sen, MD, PhD
- Board 245 **Abstract 3108:** Zidesamtinib efficacy and safety in patients with advanced *ROS1*-positive solid tumors other than NSCLC in the ARROS-1 study.
First Author: Benjamin J. Solomon, PhD, MBBS
- Board 246 **Abstract 3109:** First-in-human phase 1/2 study of ETX-19477, an oral, potent, and selective PARG inhibitor, in patients with advanced solid tumors (ERADIC8).
First Author: Ezra Rosen, MD, PhD
- Board 247 **Abstract 3110:** Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.
First Author: Alice P. Chen, MD
- Board 248 **Abstract 3111:** First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).
First Author: Johann S. De Bono, MD, PhD, MB, MSc
- Board 249 **Abstract 3112:** HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.
First Author: Wei Xue
- Board 250 **Abstract 3113:** Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS^{G12C} mutant solid tumors from a phase Ib/II study: 2-year follow-up from single-arm of non-small-cell lung cancer (NSCLC).
First Author: Yanling Wang
- Board 251 **Abstract 3114:** First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring *FGFR2* alterations.
First Author: Jiajia Yuan

- Board 252 **Abstract 3115:** A first-in-human phase I/II study evaluating CTS3497, an MTA-cooperative PRMT5 inhibitor, in advanced or metastatic *MTAP*-deficient solid tumors.
First Author: Dan Liu, MD
- Board 253 **Abstract 3116:** Efficacy of targeting replication stress in neuroblastoma.
First Author: Carla Sofia Sampaio, PhD
- Board 254 **Abstract 3117:** *MTAP* deletions and co-mutational landscape from whole genome sequencing in primary CNS tumors.
First Author: Lise Høj Omland, MD, PhD
- Board 255 **Abstract 3118:** Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.
First Author: Mayukhmala Jana, BSc
- Board 256 **Abstract 3119:** Spatial transcriptomic profiling of the tumor microenvironment associated with sunitinib response in metastatic renal cell carcinoma.
First Author: Shriya Deshmukh, MD, PhD
- Board 257 **Abstract 3120:** Developing harmonized tumor microenvironment subtypes for patient stratification in clinical trials.
First Author: Nadezhda Lukashovich
- Board 258 **Abstract 3121:** Identification of high-grade neuroendocrine carcinoma (HGNEC) biology across tumor types through transcriptomic profiling and validation in lung cancer.
First Author: Yatian Yang
- Board 259 **Abstract 3122:** ILF2 as a predictor of cisplatin resistance and clinical outcomes in intrahepatic cholangiocarcinoma.
First Author: Kodai Abe, MD, PhD
- Board 260 **Abstract 3123:** Target-specific therapy for actionable and approved tumor-agnostic biomarkers: Influence on survival in rare cancers.
First Author: Razelle Kurzrock, MD
- Board 261 **Abstract 3124:** Pan-cancer computational analysis of adaptive immune and vascular changes in primary versus metastatic tumors.
First Author: Neil Arya Babu, BS
- Board 262 **Abstract 3125:** Pan-cancer prevalence, molecular landscape, and prognostic impact of *CCNE1* amplification across 76,046 malignancies.
First Author: Ricardo Dahmer Tiecher, MD
- Board 263 **Abstract 3126:** Early-onset cancer signature (EOCS): Pan-cancer molecular alterations with prognostic significance in early-onset (EOC) and late-onset (LOC) cancer.
First Author: Mahesh Iddawela, PhD, MBBS, MRCP, FRACP
- Board 264 **Abstract 3127:** Clinical utility of whole transcriptome sequencing for fusion detection in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2.
First Author: Takao Fujisawa, MD, PhD
- Board 265 **Abstract 3128:** Pan-cancer *KRAS* atlas of 9,056 Chinese patients: Subtype-specific immunogenomic profiling to guide G12C, G12D, and pan-*KRAS* strategies.
First Author: Panli Peng, MD
- Board 266 **Abstract 3129:** Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: Exploratory analyses from the phase 2 EPOC2003 study.
First Author: Akihito Kawazoe, MD
- Board 267 **Abstract 3130:** APOBEC mutational signatures to predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.
First Author: Adar Yaacov, MD
- Board 268 **Abstract 3131:** Dynamics of nectin-4 (N4) expression in urothelial carcinoma (UC): Across disease states.
First Author: Hiba Narvel, MBBS
- Board 269 **Abstract 3132:** Implementing clinical-scale multiscale spatial transcriptomics: Tumor architecture profiling in SCRUM-Japan MONSTAR-SCREEN-3.
First Author: Mitsuho Imai, MD, PhD
- Board 270 **Abstract 3133:** AACR GENIE analysis of 211,526 patients to evaluate hormone receptor alterations across solid tumors: Rationale for tissue-agnostic basket trials.
First Author: Niamh Coleman, MD, PhD
- Board 271 **Abstract 3134:** Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.
First Author: Sadakatsu Ikeda, MD, PhD
- Board 272 **Abstract 3135:** Carcinomas of unknown primary treated with molecularly guided therapies and immune checkpoint inhibitors: A subset from the I-PREDICT N-of-1 Precision Oncology study.
First Author: Eric Roth, MD, PhD
- Board 273 **Abstract 3136:** Association of treatment-induced decrease of tumor chromosome Y and prognosis.
First Author: Dan Theodorescu, MD, PhD
- Board 274 **Abstract 3137:** Detection of mutational signatures in advanced cancer patients using clinical-grade specimens.
First Author: Samantha Rueckeis, MSc
- Board 275 **Abstract 3138:** Validation of SNHG11 as a prognostic and predictive biomarker for anti-EGFR benefit in colorectal cancer using real-world data.
First Author: Michela Bartolini, MD
- Board 276 **Abstract 3139:** Sensitivity of portal vein ctDNA versus peripheral blood in predicting postoperative liver metastasis adjuvant therapy in colorectal cancer.
First Author: Jin Gu
- Board 277 **Abstract 3140:** Spatial mapping of human colorectal cancer cell states to identify co-targeting opportunities and determinants of drug response.
First Author: Gertjan Rasschaert, MD

- Board 278 **Abstract 3141:** Phase 1/2 trial of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment-mediated pathways of resistance from correlative data.
First Author: Patrick Glen Pilié, MD
- Board 279 **Abstract 3142:** Genomic and transcriptomic correlates of HER3 expression in prostate cancer.
First Author: Syed Saqib Balkhi, MD, MBBS
- Board 280 **Abstract 3143:** Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.
First Author: Mark David Orland, MD
- Board 281 **Abstract 3144:** Efficacy and safety of pralsetinib in *RET* fusion-positive solid tumors: Data from the TAPISTRY trial.
First Author: Chia-Chi Lin, MD, PhD
- Board 282 **Abstract 3145:** Efficacy and safety of larotrectinib in patients with non-primary central nervous system *TRK* fusion cancer: An updated analysis.
First Author: Alexander E. Drilon, MD
- Board 283 **Abstract 3146:** BMS-986504 in patients (pts) with advanced solid tumors with homozygous *MTAP* deletion (*MTAP*-del): Exploratory pharmacodynamic (PD) and biomarker analyses from CA240-0007.
First Author: Jason Timothy Henry, MD
- Board 284 **Abstract 3147:** Fast-TRACKing precision oncology for rare cancers: A national decentralized trial offering comprehensive genomic profiling and a molecular tumor board.
First Author: Jim Palma, BA
- Board 285 **Abstract 3148:** Multi-modal molecular profiling of CDH1 and CLDN18.2 to identify predictive biomarkers for zolbetuximab efficacy in patients with advanced gastric adenocarcinoma: The ZOL-C3 study.
First Author: Shuhei Suzuki, MD, PhD
- Board 286 **Abstract 3149:** Clinical outcomes of patients with cell cycle alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
First Author: Abhijit Chakraborty, PhD, MS
- Board 287 **Abstract 3150:** Clinical outcomes of patients with PI3K pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
First Author: Apostolia Maria Tsimberidou, MD, PhD, FAAAS, FASCO
- Board 288 **Abstract 3151:** Clinical outcomes of patients with RTK-RAS pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
First Author: Mehmet A. Baysal, MD
- Board 289 **Abstract 3152:** Clinical outcomes of patients with TP53 pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
First Author: Jacopo Venturini, MD
- Board 290 **Abstract 3153:** Impact of dual inhibition of iNOS and COX2 on antitumor immunity and response to immune checkpoint blockade in hepatocellular carcinoma.
First Author: Yuzhen Li, MD
- Board 291 **Abstract 3154:** Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.
First Author: Carlos Roberto Becerra, MD
- Board 292a **Abstract TPS3155:** A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8+ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.
First Author: Anthony J. Olszanski, MD
- Board 292b **Abstract TPS3156:** A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
First Author: Manish R. Sharma, MD
- Board 293a **Abstract TPS3157:** A phase 2 study of telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with advanced solid tumors harboring *MET* amplification.
First Author: Manish R. Sharma, MD
- Board 293b **Abstract TPS3158:** A phase I, multi-center study of KIVU-107, a novel PTK7-targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors.
First Author: Jeffrey C. Goh, MD, FRACP, MBBS
- Board 294a **Abstract TPS3159:** A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody-drug conjugate (ADC), in patients with advanced/metastatic solid tumors.
First Author: Shigehiro Koganemaru, MD, PhD
- Board 294b **Abstract TPS3160:** BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamid (anti-PD-L1 x VEGF bsAb) in patients with advanced solid tumors.
First Author: Siqing Fu, MD, PhD
- Board 295a **Abstract TPS3161:** A phase 1, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors.
First Author: Charlotte Rose Lemech, FRACP, MBBS
- Board 295b **Abstract TPS3162:** Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.
First Author: Timothy A. Yap, MD, PhD
- Board 296a **Abstract TPS3163:** Phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGW101 in patients with advanced solid tumors.
First Author: Anthony W. Tolcher, MD, FASCO
- Board 296b **Abstract TPS3164:** First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.
First Author: Eric Keith Rowinsky, MD

- Board 297a **Abstract TPS3165:** A phase 1/2 first-in-human study of TH9619 in patients with advanced refractory solid tumors (ODIN).
First Author: Victor Moreno, MD, PhD
- Board 297b **Abstract TPS3166:** TAGNOT: A phase 1b/2 tumor-agnostic study of the selective anti-FGFR1 monoclonal antibody OM-RCA-01 in FGFR1-expressing advanced solid tumors.
First Author: Igor A. Utyashev, MD, PhD
- Board 298a **Abstract TPS3167:** A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.
First Author: Judy S. Wang, MD
- Board 298b **Abstract TPS3168:** First-in-human phase 1 dose escalation and expansion study of PIN-5018, a CK1 α -selective molecular glue degrader, in patients with advanced solid tumors.
First Author: Bhumsuk Keam, MD, PhD
- Board 299a **Abstract TPS3169:** An open-label, multicenter study of DPTX3186 to evaluate safety, tolerability, and pharmacokinetics in subjects with known Wnt pathway-activated solid tumors where no other treatments exist.
First Author: Alexander I. Spira, MD, PhD, FACP, FASCO
- Board 299b **Abstract TPS3170:** Phase 1/2 study of the novel Werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors.
First Author: Timothy A. Yap, MD, PhD
- Board 300a **Abstract TPS3171:** Phase 1, multi-center clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of PQ203, a first-in-class peptide drug conjugate targeting SORT1 in patients with advanced solid tumor malignancies (NCT07190469).
First Author: Philippe Bedard, MD, FRCPC
- Board 300b **Abstract TPS3172:** A phase 1 first-in-human study of BGM-2121 in patients with advanced solid tumors.
First Author: Chien-Chih Ou, PhD, PharmD
- Board 301a **Abstract TPS3173:** A multicenter phase 1/1b study of AMG 436 as monotherapy and combination therapy in patients with advanced MSI-H/dMMR solid tumors.
First Author: Elizabeth Won, MD
- Board 301b **Abstract TPS3174:** Phase I study of [²²⁵Ac] Ac-ETN029, a DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors.
First Author: Cristiano Ferrario, MD
- Board 302a **Abstract TPS3175:** Alpha-emitting radionuclide or beta-emitting radionuclide combined with metastasis-directed stereotactic body radiotherapy for oligorecurrent prostate adenocarcinoma (ANDROMEDA): A phase II trial.
First Author: Kekoa Taparra, MD, PhD, MPH
- Board 302b **Abstract TPS3176:** [²¹²Pb] Pb-MP0712 in patients with small cell lung cancer and other Delta-like ligand 3-expressing solid tumors: A phase 1/2a study to assess safety, tolerability, and efficacy.
First Author: Ticiana Leal, MD
- Board 303a **Abstract TPS3177:** Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC).
First Author: Kohei Shitara, MD
- Board 303b **Abstract TPS3178:** A study of MT-4561 in patients with various advanced solid tumors (NCT06943521).
First Author: Kimberly Lynne Futch, MBA
- Board 304a **Abstract TPS3179:** A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma (ACC) or metastatic castration-resistant prostate cancer (mCRPC).
First Author: Manish R. Patel, MD
- Board 304b **Abstract TPS3180:** A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.
First Author: Anthony J. Olszanski, MD
- Board 305a **Abstract TPS3181:** Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors.
First Author: Hongxia Wang
- Board 305b **Abstract TPS3182:** IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted (MTAP-Del) advanced solid tumors (IDE892001): Phase 1 trial.
First Author: Benjamin Garmez, MD
- Board 306a **Abstract TPS3183:** Study design of OMAHA-015: A phase 2 basket study of steroidogenesis inhibitor opevosostat in participants with selected solid tumors.
First Author: Virginia G. Kaklamani, MD
- Board 306b **Abstract TPS3184:** STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.
First Author: Kim Anna Reiss, MD
- Board 307a **Abstract TPS3185:** KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors.
First Author: Nehal J. Lakhani, MD, PhD

1:30 PM-4:30 PM Poster Session

Head and Neck Cancer

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 479-481

Advanced/Metastatic Disease: Board(s) 482-522, 582a-586a

Biologic Correlates: Board(s) 523-533

Local-Regional Disease: Board(s) 534-562, 586b-588b

Outcomes/Quality: Board(s) 563-571, 589a

Rare Head and Neck Cancers: Board(s) 572-581, 589b

- Board 479 **Abstract 6022:** Whole slide imaging–based prediction of immunohistochemistry markers and surgical pathological features.
First Author: Yusuf Sadek
- Board 480 **Abstract 6023:** Development and multicenter validation of a machine learning framework for predicting severe myelosuppression in nasopharyngeal carcinoma: Evidence from large-scale real-world data and prospective clinical trials.
First Author: Tingxi Tang
- Board 481 **Abstract 6024:** AI-powered assessment of tertiary lymphoid structures (TLS) from H&E whole-slide images as a prognostic tool in HNSCC.
First Author: Jiyeon Lim, MD
- Board 482 **Abstract 6025:** Volrustomig monotherapy for recurrent/metastatic HNSCC: Substudy 2 of the eVOLVE-02 phase 2 study.
First Author: Ye Guo, MD
- Board 483 **Abstract 6026:** An open-label, randomized phase 2 trial of ramucirumab and pembrolizumab versus pembrolizumab as first-line therapy for PD-L1–positive, recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC).
First Author: Christine Auberle, MD
- Board 484 **Abstract 6027:** Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC).
First Author: Victoria Meucci Villaflor, MD
- Board 485 **Abstract 6028:** Efficacy and safety of pralsetinib in advanced or metastatic *RET*-altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.
First Author: Vivek Subbiah, MD
- Board 486 **Abstract 6029:** Penpulimab (AK105) combined with cetuximab as first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
First Author: Shu Tian, MD
- Board 487 **Abstract 6030:** Real-world efficacy and safety of photoimmunotherapy for recurrent nasopharyngeal carcinoma: A nationwide multicenter study in Japan.
First Author: Hideki Tanaka
- Board 488 **Abstract 6031:** *Bacteroides sp. DH3716P* and mediation of immunotherapy response in oligometastatic nasopharyngeal carcinoma via the gut–nasopharyngeal axis.
First Author: Zhenhua Zhou, MD
- Board 489 **Abstract 6032:** Stereotactic body radiotherapy combined with chemotherapy and PD-1 inhibitor in oligometastatic nasopharyngeal carcinoma (STOMP): A prospective phase II clinical trial.
First Author: Jingjing Miao, MD, PhD, MBBS, MSc, MMed
- Board 490 **Abstract 6033:** Cadonilimab in combination with chemotherapy versus chemotherapy alone in patients with immunotherapy-refractory recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, phase III trial the CONQUEST trial).
First Author: Shuiqing He
- Board 491 **Abstract 6034:** Reirradiation with NBTXR3/SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma (HNSCC) in the phase I trial study 1100.
First Author: Colette Shen, MD, PhD
- Board 492 **Abstract 6035:** Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis.
First Author: Ronit Sethi, BS
- Board 493 **Abstract 6036:** Penpulimab plus oral anlotinib and capecitabine as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial.
First Author: Jun Ma, MD
- Board 494 **Abstract 6037:** Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.
First Author: Robert I. Haddad, MD, FASCO
- Board 495 **Abstract 6038:** Real-world treatment patterns and overall survival in recurrent/metastatic head and neck squamous cell carcinoma following treatment with immune checkpoint inhibitor and platinum-based chemotherapy.
First Author: Ari Joseph Rosenberg, MD
- Board 496 **Abstract 6039:** Defining the role of locoregional radiotherapy for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era: A systematic review and meta-analysis.
First Author: Kunpeng Wu, MMM
- Board 497 **Abstract 6040:** Depth and durability of response with TGF- β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab.
First Author: Deborah J.L. Wong, MD, PhD
- Board 498 **Abstract 6041:** First-in-class Trop2-targeted PET imaging with ⁶⁸Ga-MY6349 for diagnostic accuracy and altered management in recurrent/metastatic thyroid cancer compared to standard ¹⁸F-FDG PET/CT.
First Author: Haojun Chen, MD, PhD

- Board 499 **Abstract 6042:** First-line HLX07 vs placebo combined with serplulimab and chemotherapy for nasopharyngeal carcinoma: A randomized, double-blind, multicenter phase 2 study.
First Author: Wenfeng Fang, MD, PhD
- Board 500 **Abstract 6043:** Expansion of circulating NKG7⁺ cytotoxic CD4⁺ T cells as a predictor of response to PD-1 blockade in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective phase II study with translational analysis.
First Author: Chang Gon Kim, MD, PhD
- Board 501 **Abstract 6044:** Cytokine dynamics in a phase II trial of metronomic carboplatin/paclitaxel combined with cemiplimab in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Marcelo Raul Bonomi, MD
- Board 502 **Abstract 6045:** Updated results of benmelstobart combined with anlotinib and chemotherapy as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma: A single-arm, open-label phase II clinical trial.
First Author: Yiqian Liu, MD
- Board 503 **Abstract 6046:** Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
First Author: Jennifer Dorcas Hwang, MD
- Board 504 **Abstract 6047:** An open-label, single-center phase II trial of mitoxantrone hydrochloride liposome combined with programmed death-1 (PD-1) inhibitors for pretreated recurrent or metastatic nasopharyngeal carcinoma.
First Author: You Rui, MD
- Board 505 **Abstract 6048:** A prospective, single-arm, phase II exploratory clinical study on the efficacy and safety of neoadjuvant adabrelimab combined with cisplatin and docetaxel in patients with clinical stage IVB oral squamous cell carcinoma.
First Author: Zi-Li Yu
- Board 506 **Abstract 6049:** Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer.
First Author: Pin Wang, PhD
- Board 507 **Abstract 6050:** Defining a long-term benefit phenotype to PD-1 inhibitors in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A multicentre retrospective study.
First Author: Justin Panasci, MD
- Board 508 **Abstract 6051:** Preliminary efficacy and safety of intratumoral long-acting cisplatin-SRGel (TumoCure) in refractory locally advanced head and neck squamous cell carcinoma: Phase Ib CLPR-001.
First Author: Arnon Aharon, MD
- Board 509 **Abstract 6052:** First-line lenvatinib versus dabrafenib plus trametinib (D+T) in *BRAF*-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
First Author: Wilson Ngai, PharmD, MSC
- Board 510 **Abstract 6053:** The association of nutritional factors on disease control and survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) treated with anti-PD-1 monoclonal antibody.
First Author: Jessica Zheng, BA
- Board 511 **Abstract 6054:** Four-year landmark survival analysis of low-dose nivolumab added to metronomic chemotherapy in advanced head and neck squamous cell carcinoma: A phase III randomized trial.
First Author: Mehak Trikha, MD, DM
- Board 512 **Abstract 6055:** Second-line cetuximab monotherapy following PD-1 inhibitor treatments in patients with recurrent/metastatic head and neck carcinoma.
First Author: Mercedes Porosnicu, MD
- Board 513 **Abstract 6056:** Evaluation of the impact of regional lymph node depletion on response to immune checkpoint blockade in recurrent and metastatic head and neck squamous cell carcinoma.
First Author: Joshua D. Smith, MD
- Board 514 **Abstract 6057:** Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
First Author: Douglas Adkins, MD
- Board 515 **Abstract 6058:** The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck carcinoma (HNSCC).
First Author: John M. Kaczmar, MD
- Board 516 **Abstract 6059:** Outcomes of PD-(L)1 inhibitor continuation or rechallenge after first-line progression in recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Jong Chul Park, MD
- Board 517 **Abstract 6060:** Efficacy and safety of HLX43 (an anti-PD-L1 ADC) in previously treated recurrent/metastatic nasopharyngeal carcinoma: A multicenter, randomized phase 2 study.
First Author: Jun Ma, MD
- Board 518 **Abstract 6061:** A prospective phase II clinical study of different time-delivered drugs combined with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma.
First Author: Feng Jin
- Board 519 **Abstract 6062:** A phase 1/2 study of the next-generation nectin-4-targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Charlene Mantia, MD

- Board 520 **Abstract 6063:** PD-L1 CPS \geq 10 population subgroup analysis of KEYNOTE-412: Pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma.
First Author: Barbara Burtness, MD, FASCO
- Board 521 **Abstract 6064:** Clonal hematopoiesis in head and neck carcinomas receiving immunotherapy.
First Author: Niki Gavrielatou, MD
- Board 522 **Abstract 6065:** Prognostic impact of tumor suppressor and DNA damage repair gene mutations in oral cavity squamous cell carcinoma: A clinico-genomic analysis from a real-world database.
First Author: Parisa Abedi
- Board 523 **Abstract 6066:** Clinical validation of ultra-sensitive WGS-based MRD detection in head and neck squamous cell carcinoma: Results from MONSTAR-SCREEN-3.
First Author: Naoki Akisada, MD, PhD
- Board 524 **Abstract 6067:** Integrated proteogenomic profiling to reveal prognostic subtypes and actionable targets in adenoid cystic carcinoma.
First Author: Jiawei Zhou
- Board 525 **Abstract 6068:** Baseline spatial tumor microenvironment states to define response and primary resistance to immune checkpoint inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Armando Di Bello, MD
- Board 526 **Abstract 6069:** Circulating HPV DNA for early detection of minimal residual disease after definitive therapy in oropharyngeal cancer: A phase II biomarker-driven study.
First Author: Luana Guimaraes de Sousa, MD
- Board 527 **Abstract 6070:** Identification of tumor repopulating-like epithelial cells and a repair-dominant niche in pathological responders after neoadjuvant chem-immunotherapy for HNSCC.
First Author: Yongchao Yu
- Board 528 **Abstract 6071:** Inferring optimal detection of homozygous loss (homozygous deletion) in head and neck cancer: Associations with HPV status, primary disease site, and clinical outcomes.
First Author: Jessica Lyn Geiger, MD
- Board 529 **Abstract 6072:** Comprehensive genomic profiling of adenoid cystic carcinoma using the AACR Genie Database.
First Author: Madeline Patrick, BA
- Board 530 **Abstract 6073:** Environmental exposure and prevalence of papillary thyroid cancer in West Virginia: An ecological analysis of per and polyfluoroalkyl substances (PFAS)-impacted regions.
First Author: Sanjana Nethagani, MD
- Board 531 **Abstract 6074:** Discovery of gene set-based biomarkers and therapeutic targets for papillary thyroid cancer based on circulating DNA and tissue RNA.
First Author: Hsih-Te Yang, PhD
- Board 532 **Abstract 6075:** Inpatient comparative analysis of tumor-informed ctDNA and ctHPV-DNA in patients with HPV-driven OPSCC.
First Author: Evgeny Izumchenko, PhD, MSc
- Board 533 **Abstract 6076:** Biologic and clinical implications of HPV genome state variation in oropharyngeal cancers.
First Author: Vikram Vasan, MD
- Board 534 **Abstract 6077:** Validation of Immunoscore for prognostic stratification in HPV-associated oropharyngeal cancer: An international multicenter study.
First Author: Dac Hung Nguyen, MD
- Board 535 **Abstract 6078:** Prognostic value and role in guiding individualized treatment of imaging extranodal extension (iENE) in nasopharyngeal carcinoma.
First Author: Chuanrun Zhang
- Board 536 **Abstract 6079:** Prognostic significance of imaging-detected extranodal extension (iENE) in pathological ENE-negative head and neck squamous cell carcinoma.
First Author: Ryo Kuboki, MD
- Board 537 **Abstract 6080:** A phase 3, randomized, double-arm, open-label, controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician's choice standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma (HNSCC).
First Author: Anastasios Maniakas, MD, PhD
- Board 538 **Abstract 6081:** Efficacy of neoadjuvant immunochemotherapy followed by surgery in locally advanced buccal squamous cell carcinoma: A single-center real-world study.
First Author: Haolei Tan
- Board 539 **Abstract 6082:** Phase II randomised controlled trial on postoperative radiotherapy, in high-risk, resected, non-medullary, non-anaplastic thyroid cancers (THYRO-RT).
First Author: Gouri Pantvaidya, MBBS
- Board 540 **Abstract 6083:** C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
First Author: Danny Rischin, MD
- Board 541 **Abstract 6084:** Evaluation of a tissue-free genome-wide methylome enrichment assay for detecting molecular residual disease (MRD) in patients with head and neck squamous cell carcinoma (HNSCC).
First Author: Geoffrey Liu, MD
- Board 542 **Abstract 6085:** Neoadjuvant chemotherapy with/without PD-1i in locally advanced laryngeal/hypopharyngeal cancer: A multicentered retrospective study.
First Author: Xiaomin Ou, MD
- Board 543 **Abstract 6086:** Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: 3-year follow-up of the INSIGHT study.
First Author: Xiaomin Ou, MD

- Board 544 **Abstract 6087:** A prospective trial of single-dose neoadjuvant PD-1 blockade with or without a CD40 agonist in HPV-negative HNSCC.
First Author: Lova Sun, MD
- Board 545 **Abstract 6088:** Baseline skeletal muscle index as an independent prognostic factor in locally advanced head and neck squamous cell carcinoma: A post hoc analysis of the REACH trial.
First Author: Florian Clatot, MD, PhD
- Board 546 **Abstract 6089:** Four cycles of tislelizumab plus GP regimen as neoadjuvant therapy for high-risk (T4/N3) locally advanced nasopharyngeal carcinoma.
First Author: Qinhua Zhang Sr., MSc
- Board 547 **Abstract 6090:** Mandibular preservation with neoadjuvant tislelizumab plus platinum-doublet chemotherapy in locally advanced resectable oral squamous cell carcinoma: A prospective phase II trial.
First Author: Zhongyu Wang, MD
- Board 548 **Abstract 6091:** Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: Updated efficacy and safety data from a randomized phase II trial.
First Author: Lei Liu, MD, PhD
- Board 549 **Abstract 6092:** Adjuvant nivolumab in addition to postoperative radiation therapy in locally advanced head and neck cancer: Results of the phase II NadiHN trial.
First Author: Peter Brossart, MD
- Board 550 **Abstract 6093:** PD-1 inhibitor combined with nab-paclitaxel and cisplatin in neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma: 3-year follow-up from the randomized phase II study.
First Author: Hongling Wang, MD
- Board 551 **Abstract 6094:** Real-world evidence on definitive chemoradiotherapy following neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma.
First Author: Ya-Ni Zhang
- Board 552 **Abstract 6095:** Larynx preservation via chemotherapy-free neoadjuvant sintilimab-cetuximab-SBRT and response-adapted treatment in locally advanced laryngeal cancer: A phase II, single-arm clinical trial (the NeoVOICE study).
First Author: Shida Yan, MD
- Board 553 **Abstract 6096:** Niraparib and dostarlimab in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with (chemo)radiotherapy (CRT): Results from the phase IB-II TTCC-2022-01 RADIANT trial.
First Author: Marc Oliva, MD
- Board 554 **Abstract 6097:** Neoadjuvant HPV16-specific viral immunotherapy (HB200) plus chemotherapy with response-adapted de-escalation in HPV16+ oropharyngeal squamous cell carcinoma: TARGET-HPV trial.
First Author: Ari Joseph Rosenberg, MD
- Board 555 **Abstract 6098:** Patterns of tumor regression after neoadjuvant immunochemotherapy in oral squamous cell carcinoma and their surgical margin implications.
First Author: Haotian Cao, PhD, MB
- Board 556 **Abstract 6099:** GDF-15 levels and clinical correlates in head and neck cancer patients: Developing a risk model for cachexia.
First Author: Connor Maxwell Douglas Williams
- Board 557 **Abstract 6100:** A multicenter, randomized controlled phase III trial of TPF induction chemotherapy versus PF adjuvant chemotherapy combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: Long-term follow-up analysis.
First Author: Huajing Wu
- Board 558 **Abstract 6101:** Comparison of efficacy between 2 and 3 cycles of neoadjuvant immunotherapy combined with chemotherapy for LA HNSCC.
First Author: Xiaohong Chen, MD
- Board 559 **Abstract 6102:** Five-year follow-up of neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma.
First Author: Kunyu Yang, PhD
- Board 560 **Abstract 6103:** Induction chemotherapy response-guided selection for hypoxia-directed major radiation de-escalation in T3–T4 HPV-positive oropharyngeal cancer.
First Author: Eric Jeffrey Sherman, MD
- Board 561 **Abstract 6104:** Zopapogene imadenovec-drba, a novel non-replicating adenoviral vector-based immunotherapy: Effects on complete and durable responses in recurrent respiratory papillomatosis pivotal trial.
First Author: Scott Norberg, DO
- Board 562 **Abstract 6105:** Omitting postoperative radiotherapy after pathologic complete response to neoadjuvant immunochemotherapy for patients with locally advanced head and neck squamous cell carcinoma: Survival and patient-reported outcomes.
First Author: Shuwei Chen
- Board 563 **Abstract 6106:** Neoadjuvant adebrelimab plus chemotherapy in untreated locally advanced head and neck squamous cell carcinoma: Efficacy and biomarker insights from a single-arm phase 2 trial.
First Author: Ruihua Fang, MD
- Board 564 **Abstract 6107:** Long term functional survivorship in oral cavity cancer: Quality of life (QOL) outcomes by return to work (RTW) status.
First Author: Karthika Chettuvatti, MCh
- Board 565 **Abstract 6108:** Barriers and variability in lymphedema therapy for head and neck cancer survivors: Secondary analysis from a randomized trial.
First Author: Cristina Kline-Quiroz, DO
- Board 566 **Abstract 6109:** Impact of advanced pneumatic compression devices and usual care on psychosocial outcomes in head and neck cancer survivors with lymphedema.
First Author: Cristina Kline-Quiroz, DO

- Board 567 **Abstract 6110:** GDF-15 in oropharyngeal squamous cell carcinoma (OPSCC): Association of an HPV-dependent biomarker with malnutrition and low skeletal muscle.
First Author: Lorena Arribas
- Board 568 **Abstract 6111:** Nonoperative management of locally advanced resectable cutaneous squamous cell cancer of the head and neck with PD-1 blockade.
First Author: Fergal Kavanagh
- Board 569 **Abstract 6112:** Dynamic biological and metabolic response by EBV DNA and ¹⁸F-FDG-PET-CT to induction chemotherapy (IC) to enhance prognostication in endemic nasopharyngeal carcinoma (NPC).
First Author: Jialing Neo, BSc
- Board 570 **Abstract 6113:** Chrono-chemotherapy combined with IMRT in locoregionally advanced nasopharyngeal carcinoma: A prospective randomized study.
First Author: Feng Jin
- Board 571 **Abstract 6114:** Survival implications of context-dependent oncogenic PIK3CA mutations in HNSCC.
First Author: Jeremiah Ray Holt, PhD
- Board 572 **Abstract 6115:** Survival outcomes with contemporary treatments including immunotherapy for poorly differentiated neuroendocrine carcinomas of the head and neck.
First Author: Rushabh Gujarathi, MBBS
- Board 573 **Abstract 6116:** CCL3⁺ neutrophil signature as a predictor of response to neoadjuvant toripalimab plus chemotherapy in hypopharyngeal squamous cell carcinoma: A phase II trial.
First Author: Zhenghua Lv, MD
- Board 574 **Abstract 6117:** Palliative neck radiation therapy (RT) in combination with lenvatinib/pembrolizumab (L/P) in BRAF wild-type anaplastic thyroid cancer (BRAF-WT ATC).
First Author: Anna Lawless, MBBS, MPH
- Board 575 **Abstract 6118:** Detection, quantification, and subtyping of adenoid cystic carcinoma (ACC) using methylation from liquid biopsies.
First Author: Felipe Lazar Neto, MD, PhD
- Board 576 **Abstract 6119:** Window of opportunity study of the Notch inhibitor AL101 in Notch1 activated adenoid cystic carcinoma (ACC): Biological effects and biomarker correlates.
First Author: Daniel McGrail, PhD
- Board 577 **Abstract 6120:** Long-term outcomes of SINTART 1 and SINTART 2: Two phase II trials of multimodal treatments in patients with locally advanced sinonasal carcinomas.
First Author: Arianna Ottini
- Board 578 **Abstract 6121:** Clinicopathologic characteristics and treatment outcomes of adenoid cystic carcinoma (ACC) by different primary sites.
First Author: Larissa Passarini, MD
- Board 579 **Abstract 6122:** Artificial intelligence-powered spatial analysis of endothelial cells and tumor-infiltrating lymphocytes to predict response to axitinib in adenoid cystic carcinoma.
First Author: Dong Hyun Kim, MD
- Board 580 **Abstract 6123:** A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort.
First Author: Katharine Andress Rowe Price, MD
- Board 581 **Abstract 6124:** Anti-PD-1 immunotherapy with chemotherapy for poorly chemo-responsive thyroid and salivary gland tumors: The iPRIME study.
First Author: Faith Abodunrin, MD
- Board 582a **Abstract TPS6125:** Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).
First Author: Dongmei Ji, MD
- Board 582b **Abstract TPS6126:** MC240701: Decentralized pilot study of triple oral metronomic chemotherapy in recurrent/metastatic oral cavity cancer.
First Author: Binav Baral, MBBS
- Board 583a **Abstract TPS6127:** OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.
First Author: Robert I. Haddad, MD, FASCO
- Board 583b **Abstract TPS6128:** NRG-HN015: A phase II randomized trial of neoadjuvant chemotherapy or chemo-immunotherapy in patients with recurrent/persistent PD-L1-positive squamous cell carcinoma of the head and neck undergoing salvage surgery.
First Author: Nabil F. Saba, MD, FACP
- Board 584a **Abstract TPS6129:** A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1-positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
First Author: Renata Ferrarotto, MD
- Board 584b **Abstract TPS6130:** Becotatug vedotin plus pucotenlimab as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
First Author: Lei Liu, MD, PhD
- Board 585a **Abstract TPS6131:** ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Marc Oliva, MD

- Board 585b **Abstract TPS6132:** FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman, MD, MPH, FASCO
- Board 586a **Abstract TPS6133:** A phase III multicenter randomized non-inferiority trial comparing selective versus modified neck dissection in node-positive oral squamous cell carcinoma (SND vs MND).
First Author: Rakesh Katna
- Board 586b **Abstract TPS6134:** Phase 1 study of VLPONC-01, a novel IL-12–encoding saRNA viral replicon particle, alone and in combination with pembrolizumab in head and neck cancer patients: Protocol summary.
First Author: Summer F. Acevedo, PhD
- Board 587a **Abstract TPS6135:** A randomized, non-comparative, multicenter phase II trial of neoadjuvant becotatug vedotin alone or combined with immune checkpoint inhibitors (penpulimab/ivonescimab) in resectable locally advanced head and neck squamous cell carcinoma.
First Author: Xiaoyuan Wei
- Board 587b **Abstract TPS6136:** Neoadjuvant cemiplimab plus cetuximab prior to salvage surgery for recurrent oral cavity squamous cell carcinoma.
First Author: Luana Guimaraes de Sousa, MD
- Board 588a **Abstract TPS6137:** GP regimen chronomodulated induction chemotherapy combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A phase III, multicenter, randomized controlled study.
First Author: Feng Jin
- Board 588b **Abstract TPS6138:** NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.
First Author: Stephen Yenzen Lai, MD, PhD
- Board 589a **Abstract TPS6139:** Neoadjuvant therapy for head and neck squamous cell carcinoma based on hyperprogression genotyping: Cetuximab beta combined with chemotherapy with or without camrelizumab.
First Author: Ziyu Jiang Jr
- Board 589b **Abstract TPS6140:** EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with *BRAF* V600Em.
First Author: Lova Sun, MD

1:30 PM-4:30 PM Poster Session

Symptom Science and Palliative Care

Location: Hall A—Posters and Exhibits

Posters by Topic

Cardio-Oncology: Board(s) 1-13

End-of-Life Care: Board(s) 14-19

Oncology Rehabilitation: Board(s) 21-24, 144a

Palliative Care and Symptom Management: Board(s) 25-64, 144b-145b

Psychosocial, Behavioral, and Communication Research:

Board(s) 65-86, 146a-146b

Survivorship/Late and Long-Term Adverse Effects: Board(s) 87-106, 147a-148a

Toxicities—Prevention and Management Strategies: Board(s) 107-141, 143, 148b-150b

- Board 1 **Abstract 12018:** Cardiovascular disease incidence in women with early-onset breast cancer.
First Author: Vidhya Nair, DO
- Board 2 **Abstract 12019:** Machine learning (ML)-based prediction of fatal immune checkpoint inhibitor (ICI)-associated myocarditis (MC) with multi-cohort validation.
First Author: Hassan M. Abushukair, MD, MS
- Board 3 **Abstract 12020:** Artificial intelligence surrogate models to predict long-term cardiovascular effects of immune checkpoint inhibitor therapies using electrocardiograms.
First Author: Frances Dean, MA
- Board 4 **Abstract 12021:** The impact of body composition on cardiac function in women with early breast cancer taking cardiotoxic chemotherapy.
First Author: Gabriel Aleixo, MD
- Board 5 **Abstract 12022:** Exercise and cardiovascular risk among breast cancer patients.
First Author: Erika Libiar Estrada, MPH, MPP
- Board 6 **Abstract 12023:** Time-resolved cardiovascular risk after immune checkpoint inhibitors: A large real-world cancer cohort study.
First Author: Yibin Jia, MD, PhD
- Board 7 **Abstract 12024:** The genetic polymorphism underlying immune checkpoint inhibitor–induced endocrine toxicity.
First Author: Ming-Hua Cong, PhD, PhD
- Board 8 **Abstract 12025:** Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis.
First Author: Robert C. Shepard, MD, FACP
- Board 9 **Abstract 12026:** The association between cardiovascular disease risk and breast arterial calcifications identified on screening mammography: A retrospective study.
First Author: Tae Hoon Kim, MD
- Board 10 **Abstract 12027:** Differences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status.
First Author: Reed Mszar, MPH, MS
- Board 11 **Abstract 12028:** Efficacy of primary cardioprotection with perindopril, bisoprolol, and trimetazidine in high-risk patients with breast and gastric cancer receiving anthracycline- and trastuzumab-containing therapy.
First Author: Evgenia Khatkova, PhD
- Board 12 **Abstract 12029:** Lipid-lowering therapy use among cancer survivors undergoing lung cancer screening: A cross-sectional analysis.
First Author: Sri Gopalsamy Ramaswamy
- Board 13 **Abstract 12030:** Predicting fluoropyrimidine cardiotoxicity using a focus beyond routine cardiovascular risk assessment.
First Author: Aminat Maaz Yusupova, MD

- Board 14 **Abstract 12031:** Cost-effectiveness of post-discharge home care for reducing potentially avoidable readmissions in stage IV cancer.
First Author: Amal AlJuhani, MD, MBBS
- Board 15 **Abstract 12032:** County-level palliative care physician density and socioeconomic determinants of place of cancer death in the United States, 2021-2023.
First Author: Ruoxi Teng
- Board 16 **Abstract 12033:** Palliative care involvement at the end of life in advanced cancer.
First Author: Rhea Sehgal
- Board 17 **Abstract 12034:** End-of-life anti-cancer treatment (Rx) patterns in patients (pts) with the six most common cancers in the USA.
First Author: Umang Swami, MD, FASCO
- Board 18 **Abstract 12035:** Temporal trends and sociodemographic disparities in place of death among adults with pancreatic cancer in the United States (1999–2023).
First Author: Ali Mushtaq, MD
- Board 19 **Abstract 12036:** Impact of social vulnerability on end-of-life care in hematologic malignancies.
First Author: Jude O. Ossai, MD
- Board 21 **Abstract 12038:** Effects of tai chi qigong on gene expression profiles in older male cancer survivors with fatigue.
First Author: Anita Kinney, PhD, RN
- Board 22 **Abstract 12039:** Digital prehabilitation and functional performance signals in older adults undergoing hepatobiliary cancer surgery: A pilot study.
First Author: Mohammed Al-Jumayli, MD
- Board 23 **Abstract 12040:** Real-world feasibility and efficacy of a tailored exercise program in patients with cancer.
First Author: Alice Avancini
- Board 24 **Abstract 12041:** Dyadic exercise intervention for LGBTQ+ cancer survivors: Associations with health-related quality of life, fatigue, and inflammation biomarkers.
First Author: Hala Awad, PhD, MS, MSc, PharmD
- Board 25 **Abstract 12042:** Circulating heat shock protein 90 alpha (Hsp90α) as a biomarker for cancer cachexia.
First Author: Syed Hasan Raza Jafri, MBBS
- Board 26 **Abstract 12043:** Tele-nutritional collaborative care in patients with stage IV gastrointestinal cancer receiving chemotherapy: A randomized clinical trial.
First Author: Shihong Xu
- Board 27 **Abstract 12044:** A mediation analysis of neurocognitive deficits and patient-reported mood among patients with lung cancer with brain metastases.
First Author: Mary Catherine Boulanger, MD
- Board 28 **Abstract 12045:** ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose without erythropoiesis-stimulating agents for iron deficiency anemia in patients with gastric/colorectal cancer receiving chemotherapy.
First Author: Ryohei Kawabata, MD, PhD
- Board 29 **Abstract 12046:** Correlation of University of Texas Cancer Cachexia Staging (UTCCS) with clinical variables of systemic inflammation, nutritional status, and physical function in patients with cancer cachexia.
First Author: Harshit Khosla, MD
- Board 30 **Abstract 12047:** A retrospective cohort studying integrative palliative care in a community oncology practice: Impact and outcomes.
First Author: Summiya Nasim, MD
- Board 31 **Abstract 12048:** Behavioral predictors of pain control among adult cancer survivors: Examining the impact of smoking, physical activity, and alcohol consumption.
First Author: Clifford A. Aturi, MD, MPH
- Board 32 **Abstract 12049:** Utilisation of the Henry score in malignant bowel obstruction and characterisation of management approaches and outcomes: Experience from a New Zealand regional centre.
First Author: Nicole London, MBChB
- Board 33 **Abstract 12050:** Genetic associations with chemotherapy-induced nausea and vomiting: A genome-wide association study.
First Author: Aasha I. Hoogland, PhD
- Board 34 **Abstract 12051:** Early outpatient palliative care for patients with multiple myeloma: A randomized pilot study.
First Author: Breffni Hannon, MD
- Board 35 **Abstract 12052:** Using IPOS to trigger advance care planning in outpatient palliative oncology: A multicenter real-world study.
First Author: Sarah Ananda Gomes, MD
- Board 36 **Abstract 12053:** Early symptom signals preceding end-of-life decline in outpatient palliative oncology.
First Author: Flavia Santos Dumont Sorice, MBBS
- Board 37 **Abstract 12054:** Prognostic stratification using baseline objective clinical information in patients with stage IV lung cancer receiving best supportive care alone as initial treatment: A multicenter retrospective study (WJOG20824L).
First Author: Shunichi Kataoka, MD
- Board 38 **Abstract 12055:** A first-in-human (FiH) phase I study of GFS202A, a GDF15/IL-6 bispecific antibody, in advanced cancer patients (pts) with pre-cachexia or cachexia.
First Author: Hongyun Zhao, PhD
- Board 39 **Abstract 12056:** In-person versus telehealth outpatient palliative care visits in oncology: A multicenter study.
First Author: Sarah Ananda Gomes, MD
- Board 40 **Abstract 12057:** Phase II study of mirogabalin for oxaliplatin-associated chemotherapy-induced peripheral neuropathy in gastrointestinal cancer: The SmiliNg trial.
First Author: Reiko Ando Makihara, BS, BPharm
- Board 41 **Abstract 12058:** An automated, EHR-integrated intervention system for patient-reported insomnia symptoms.
First Author: Eric S. Zhou, PhD

- Board 42 **Abstract 12059:** Negative effect of malignant pleural effusion on the efficacy of immunotherapy via IL-6–mediated abscopal immunosuppression in advanced non-small cell lung cancer.
First Author: Yaping Guan, MD
- Board 43 **Abstract 12060:** Guard-01: A randomized, open-label trial of efbemalenograstim alfa as primary prophylaxis for neutropenia during definitive concurrent chemo-radiotherapy.
First Author: Yuanyuan Chen, MD
- Board 44 **Abstract 12061:** An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion due to NSCLC: A prospective randomized controlled phase II trial.
First Author: Zhengbo Song
- Board 45 **Abstract 12062:** Performance of the NutriPal nutritional screening algorithm in advanced cancer palliative care: A multicenter study.
First Author: Jesse Lopes da Silva, PhD
- Board 46 **Abstract 12063:** Role of palliative care nurse coordination in symptom control and care planning.
First Author: Suwana Rinchai, BSN
- Board 47 **Abstract 12064:** Patterns and timing of palliative care consultation in patients with newly diagnosed metastatic cancer.
First Author: Thomas Wayne Butler, MD
- Board 48 **Abstract 12065:** Olanzapine for chemotherapy-related anorexia: Impact on body composition.
First Author: Sandhya Singuluri, MD, DM
- Board 49 **Abstract 12066:** Clinical outcomes of gabapentinoids for oncologic pruritus: A retrospective cohort study.
First Author: Alim Osman, MS
- Board 50 **Abstract 12067:** Cancer cachexia and symptomatic toxicity among 706 older adults with advanced cancer receiving treatment: A URCC NCORP nationwide study.
First Author: Lindsey Jean Mattick, PhD
- Board 51 **Abstract 12068:** Enhancing supportive care in malignant bowel obstruction: A QI project using virtual dietitian-led low-fiber diet education.
First Author: Bojan Macanovic, MD
- Board 52 **Abstract 12069:** Fatigue and psychostimulant use in patients with advanced cancer in an oncology palliative care clinic: A retrospective cohort study.
First Author: Nicolas Chin-Yee, MD
- Board 53 **Abstract 12070:** Association of iterative cannabis care plans with rates of symptom relief and side effect burden in oncology patients.
First Author: Brooke Worster, MD
- Board 54 **Abstract 12071:** Meaning, distress, and desire for hastened death in homebound adults with advanced cancer: A cluster analysis.
First Author: Addison Dean Monroe, PhD
- Board 55 **Abstract 12072:** Race/ethnicity-stratified survival differences associated with psychotropic medication use in pancreatic cancer.
First Author: Hussein Khalil, PhD, BPharm, MS
- Board 56 **Abstract 12073:** National trends in palliative care use among hospitalized cancer patients: A seven-year analysis of demographic and socioeconomic disparities.
First Author: Aishwarya Ramesh, MD
- Board 57 **Abstract 12074:** Pilot trial of virtual and in-person symptom screening with targeted early palliative care (STEP2).
First Author: Camilla Zimmermann, MD, PhD, FRCPC
- Board 58 **Abstract 12075:** Integrated assessment of cachexia, body composition, and patient-reported outcomes in unplanned hospitalizations of patients with metastatic cancer (PRO-HAND study).
First Author: Enes Yeşilbaş, MD
- Board 59 **Abstract 12076:** Dermatologic adverse events (dAEs) and emotional quality of life (QoL) in patients (pts) with breast cancer: A mixed-methods study.
First Author: Elyssa Kim, BA
- Board 60 **Abstract 12077:** Sociodemographic determinants of end-of-life care settings and place of death among patients with lung cancer in the United States.
First Author: Ali Mushtaq, MD
- Board 61 **Abstract 12078:** More than pain relief: Associations between provider compassion, anxiety, and burnout in ED oncology care.
First Author: Christopher John Coyne, MD, MPH
- Board 62 **Abstract 12079:** Denosumab versus zoledronic acid in patients with breast cancer: A propensity-matched real-world time-to-event analysis.
First Author: Mohammad Salameh, MD
- Board 63 **Abstract 12080:** BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
First Author: Tariq Arshad, MD, MBA
- Board 64 **Abstract 12081:** Results from a pilot feasibility study of a novel community health worker–led intervention delivering stepped palliative care and care navigation for patients with pancreatic ductal adenocarcinoma.
First Author: Nikhil Ravi Thiruvengadam, MD
- Board 65 **Abstract 12082:** Expressive writing for body image distress and anxiety in adolescent and young adult cancer survivors: A pilot, randomized controlled trial.
First Author: Victoria A. Wytiaz, MD, MA
- Board 66 **Abstract 12083:** The psychosocial status of children who have a parent with cancer.
First Author: Erdinc Nayir
- Board 67 **Abstract 12084:** Hearing/vestibular dysfunction and longitudinal changes in psychosocial well-being among breast cancer survivors.
First Author: Jincong Q. Freeman, MPH, MS
- Board 68 **Abstract 12085:** Cognitive impairment during anti-EGFR targeted therapy in metastatic colorectal cancer patients.
First Author: Liubov Yu Vladimirova, MD, PhD

Saturday, May 30, 2026

- Board 69 **Abstract 12086:** Burnout among caregivers of hospitalized medical oncology patients: A cross-sectional survey study.
First Author: Suleyman Sami Guzel, MD
- Board 70 **Abstract 12087:** Longitudinal associations between patient and caregiver quality of life following hematopoietic stem cell transplantation.
First Author: Daniel Yang, BS
- Board 71 **Abstract 12088:** Closing the depression gap in community oncology: Real-world outcomes from collaborative care.
First Author: Tyler Jones, MD, MBA
- Board 72 **Abstract 12089:** Impact of structured oncologist-led home visits on psychological distress and resilience in patients with solid tumors undergoing chemotherapy: A comparative study.
First Author: Sonya Kircheva Draganova, MD
- Board 73 **Abstract 12090:** Impact of volunteer-integrated palliative home visits on psychological well-being among metastatic breast cancer patients in northern Malaysia.
First Author: Siti Khairizan Binti Rahim, MBBS
- Board 74 **Abstract 12091:** Influence of socioeconomic factors on patient-reported provider communication among patients with cancer.
First Author: Nishwant Swami, MD, MPH
- Board 75 **Abstract 12092:** Pilot RCT of a patient-centered communication intervention to promote values-based treatment decision-making in older adults with AML.
First Author: Rachel Rodenbach, MD, MS
- Board 76 **Abstract 12093:** Using the NCCN distress thermometer to evaluate clinically elevated levels of distress among caregivers of HSCT patients.
First Author: Christine Vinci, PhD
- Board 77 **Abstract 12094:** A digital educational and decision-support intervention for patients with advanced lung cancer receiving immunotherapy: Results of a multi-phase, mixed-methods study.
First Author: Matthias Villalobos, MD
- Board 78 **Abstract 12095:** Protective factors supporting caregiver well-being in glioblastoma.
First Author: Desiree Reinken, PhD, NP, MSN
- Board 79 **Abstract 12096:** "When I'm translating, I'm a daughter as well": Perspectives of caregivers supporting patients with limited language proficiency.
First Author: Rinat Nissim
- Board 80 **Abstract 12097:** Assessing loneliness in glioblastoma patients and caregivers using a nationwide survey.
First Author: Jacob Ellen, MS
- Board 81 **Abstract 12098:** Parent willingness to enroll children with acute lymphoblastic leukemia in escalation and de-escalation clinical trials.
First Author: Kellee Nicole Parker, DO
- Board 82 **Abstract 12099:** New paradigms of cancer and new language: A qualitative study exploring language around goals of cancer surgery.
First Author: Bonnie Odelia Wong, MD, PhD
- Board 83 **Abstract 12100:** Assessing the efficacy of cognitive behavioral therapy on anxiety, depression, and distress in people with cancer.
First Author: Daniela Tregnago
- Board 84 **Abstract 12101:** Baseline predictors of treatment response in the bounce back mind-body resiliency trial for AYA cancer survivors.
First Author: Lucy Finkelstein-Fox, PhD
- Board 85 **Abstract 12102:** COMFORT Survey: A comparison of the comfort level of hematologic and solid tumor oncology specialists with serious illness conversations.
First Author: Michael J. Tang, MD
- Board 86 **Abstract 12103:** Defining when and how to support palliative care communication: International consensus on timing and clinician training priorities for adolescents and young adults with cancer.
First Author: Ursula Sansom-Daly, PhD
- Board 87 **Abstract 12104:** Reproductive and pregnancy-related outcomes among adolescent and young adult female cancer survivors (15–39 years): A nationwide population-based study in South Korea.
First Author: Ja Yoon Heo, MD
- Board 88 **Abstract 12105:** Standardized birth rates and access to assisted reproductive technology among female cancer patients in the United States.
First Author: Isabel Beshar, MD, MPhil
- Board 89 **Abstract 12106:** National trends and disparities in early-onset non-colorectal cancer mortality in the United States, 1999–2023: A population-based analysis of 240,190 deaths.
First Author: Kumail Mustafa Ali
- Board 90 **Abstract 12107:** Bone mineral density changes in patients treated with anti-PD-1 immune checkpoint inhibitors.
First Author: Roma A. Kankaria, BS, BA
- Board 91 **Abstract 12108:** Conditional survival in advanced melanoma treated with immune checkpoint inhibitors.
First Author: Chloe Lim, MD
- Board 92 **Abstract 12109:** Impact of prior malignancy on cardiac complications and mortality in patients with COVID-19.
First Author: Samuel Condon, MD
- Board 93 **Abstract 12110:** Microbiome associations with chemotherapy-induced nausea and vomiting: A metagenomic shotgun sequencing study.
First Author: Aasha I. Hoogland, PhD
- Board 94 **Abstract 12111:** Longitudinal physical activity patterns and patient-reported cognitive function among patients with lymphoma receiving chemotherapy in a nationwide prospective cohort.
First Author: Tianming Zhao, MS
- Board 95 **Abstract 12112:** Organ-specific proteomic aging clocks (PACs) and mortality in cancer survivors.
First Author: Shuo Wang, PhD, MPH
- Board 96 **Abstract 12113:** Common symptoms, quality of life, and lifestyle factors reported by cancer survivors attending the Sydney Cancer Survivorship Multidisciplinary Clinic.
First Author: Janette L. Vardy, MD, PhD, FRACP

- Board 97 **Abstract 12114:** Prevalence and financial burden of WHO-defined disability among childhood cancer survivors: A report from the St. Jude Lifetime Cohort study (SJLIFE).
First Author: Joshua Burns, PhD
- Board 98 **Abstract 12115:** The neurotoxicity rating scale: A novel patient-reported outcome (PRO) measure for neuro-psycho-behavioral late effects in head and neck cancer (HNC) survivors.
First Author: Matthew Stewart, MD
- Board 99 **Abstract 12116:** Effect of “watch and wait” on fear of recurrence in rectal cancer: A multicenter cross-sectional study.
First Author: Ahmet Oruc, MD
- Board 100 **Abstract 12117:** Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
First Author: Meghna S. Trivedi, MD, MS
- Board 101 **Abstract 12118:** Untargeted baseline metabolomic profiling to identify candidate markers of long-term severe cancer-related fatigue (CRF) in breast cancer (BC) survivors.
First Author: Antonio Di Meglio, MD, PhD
- Board 102 **Abstract 12119:** Social determinants of health and long-term outcomes in prostate cancer: Mortality, survival, and comorbidity risks in a propensity score-matched federated database analysis.
First Author: Ashu Singh, MBBS
- Board 103 **Abstract 12120:** Correlative analysis between external and internal lymphedema in head and neck cancer survivors.
First Author: Jessica Abene, BSN
- Board 104 **Abstract 12121:** Estimation of the impact of chemotherapy-induced biological age acceleration on breast cancer survivorship using multi-scale simulation modeling.
First Author: Swarnavo Sarkar, PhD
- Board 105 **Abstract 12122:** The effectiveness of a multidisciplinary pain program in improving adherence to the use of aromatase inhibitors in breast cancer survivors.
First Author: Panuch Eiamprapaporn, MD
- Board 106 **Abstract 12123:** Cardiac substructure dose signatures as predictors of late cardiovascular events in childhood cancer survivors.
First Author: Hrushikesh Reddy Pamreddy, MBBS
- Board 107 **Abstract 12124:** Toxicity assessment clinic as an efficacious tool to provide fast care to oncology patients on systemic therapy by minimizing emergency department visits and streamlining admissions directly from the cancer clinics.
First Author: Andrew R. Maher, MD
- Board 108 **Abstract 12125:** A prospective study of the early treatment of recombinant human thrombopoietin for chemoradiation-induced thrombocytopenia in cervical squamous cell carcinoma patients.
First Author: Lu Li, BMedSci
- Board 109 **Abstract 12126:** Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day versus next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized clinical trial (CONCISE, KCSG PC22-11).
First Author: Kwonoh Park, MD, PhD
- Board 110 **Abstract 12127:** Evaluating the impact of treatment timing with recombinant human thrombopoietin for cancer treatment-induced thrombocytopenia: A retrospective cohort study.
First Author: Xin Wang
- Board 111 **Abstract 12128:** AQP4 and MOG as definers of distinct autoantibody signatures in immune checkpoint inhibitor-induced optic neuritis.
First Author: Jingyao Zhang, MD, MS
- Board 112 **Abstract 12129:** Prevention of paclitaxel-induced neurotoxicity with lithium: Results from a multicenter, randomized, double-blind, placebo-controlled phase 2 trial (PREPARE).
First Author: Wolfgang Boehmerle, MD
- Board 113 **Abstract 12130:** Hetrombopag plus caffeic acid tablets for the treatment of chemotherapy-induced thrombocytopenia in solid tumors: A single-center, open-label, phase II trial.
First Author: Xiao Li Xiao, DHSc
- Board 114 **Abstract 12131:** Efficacy of surgical glove-compression therapy as a prevention of paclitaxel-induced peripheral neuropathy: Randomized controlled trial.
First Author: Saowani Thantaviraya, MD
- Board 115 **Abstract 12132:** Natural language processing chatbot and continuous activity monitoring in a phase II randomized trial: Impact on hospitalizations and quality of life.
First Author: Casey Hollawell
- Board 116 **Abstract 12133:** Applying a large language model to detect immune-related adverse events in electronic health records: Effect of integrating prescription and laboratory data on accuracy.
First Author: Yukiko Shimoda Igawa, MD, PhD
- Board 117 **Abstract 12134:** Prophylactic vedolizumab to facilitate use of immune-checkpoint inhibitors in cancer patients at high risk of immune-mediated colitis.
First Author: Hemant Khandelia, MBBS
- Board 118 **Abstract 12135:** Gabapentin plus intranasal ketamine for the prevention and treatment of pain in patients undergoing radiotherapy for head and neck cancer: Phase II trial results.
First Author: Natalie A. Lockney, MD
- Board 119 **Abstract 12136:** The role of pretreatment vitamin D insufficiency in racial disparity in taxane-induced peripheral neuropathy: Results from the SWOG S0221 trial.
First Author: Nam Nguyen-Hoang, MS
- Board 120 **Abstract 12137:** Value of risk-directed thromboprophylaxis in ambulatory lung and gastrointestinal cancer care: Economic evaluation of the TARGET-TP randomized trial.
First Author: Marliese Alexander, PhD, MPH

- Board 121 **Abstract 12138:** Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.
First Author: Yoshihiro Masui, MD
- Board 122 **Abstract 12139:** Impact of synbindin deficiency on immune checkpoint blocker–induced systemic inflammation and multi-organ damage.
First Author: Zhenghang Xu
- Board 123 **Abstract 12140:** A randomized controlled pilot study of aromatherapy to reduce anxiety and pain during bone marrow aspiration and biopsy.
First Author: Krisstina Gowin, DO
- Board 124 **Abstract 12141:** Cumulative toxicity assessed by area-under-the-curve (AUC) in targeted therapy versus chemotherapy for advanced *EGFR*-mutant NSCLC.
First Author: William J. Phillips, MD
- Board 125 **Abstract 12142:** The price of a breath: The economic and mortality burden of checkpoint inhibitor pneumonitis (2016–2020).
First Author: Milan Regmi, MD
- Board 126 **Abstract 12143:** A risk prediction model for severe, life-threatening, and fatal treatment-related toxicity.
First Author: Joseph M. Unger, PhD, MS
- Board 127 **Abstract 12144:** Dentist-led systematic oral education programs in the prevention of radiation-induced oral toxicities in patients with head and neck cancer (BRIGHT): A randomized clinical trial.
First Author: Yu Min, MD
- Board 128 **Abstract 12145:** Efficacy and safety of Meilian Fuxin liquid for radiation-induced oral mucositis in head and neck cancer: A multicenter randomized clinical trial.
First Author: Huaju Yang
- Board 129 **Abstract 12146:** Oral mannitol for chemotherapy-induced constipation (CIC): A randomized, multicenter, controlled study.
First Author: Chaomin Liu
- Board 130 **Abstract 12147:** Efficacy and safety of mixed formulation aprepitant and palonosetron (QLM2010) for prevention of cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized, double-blind, double-dummy, positive-controlled phase III study.
First Author: Jieer Ying
- Board 131 **Abstract 12148:** SARM1 inhibition to prevent chemotherapy-induced peripheral neuropathy: Translational and early clinical evaluation of SIR2501.
First Author: Linping Yu
- Board 132 **Abstract 12149:** Baseline telomere length and prediction of cognitive recovery after chemotherapy in patients with breast cancer: An NCORP prospective cohort study.
First Author: Jonas M. Ndeke, MD, PhD, MPH
- Board 133 **Abstract 12150:** Prophylactic vs reactive PEG tube placement in early-stage head and neck (H&N) cancer treated with curative-intent radiotherapy: Balancing benefit and burden in real-world practice.
First Author: Fayaz Aijaz Ahmed Khan, MBBS
- Board 134 **Abstract 12151:** The influence of exercise on the mediational relationship between chemotherapy-induced sensory neuropathy and cancer-related fatigue: A nationwide phase II RCT in 111 patients receiving chemotherapy.
First Author: Po-Ju Lin, PhD, RD, MPH
- Board 135 **Abstract 12152:** Trilaciclib for myeloprotection in adjuvant and first-line chemotherapy for advanced gastric/gastroesophageal junction adenocarcinoma: A multicohort study.
First Author: Wenhui Yang
- Board 136 **Abstract 12153:** Machine learning approach for prediction of immune-related pneumonitis.
First Author: Barliz Waissengrin, MD
- Board 137 **Abstract 12154:** Efficacy and safety of a temperature-controlled oral cryotherapy device in preventing oral mucositis among patients receiving high-risk anticancer regimens.
First Author: Xiaojia Wang, MD, PhD
- Board 138 **Abstract 12155:** Cardiovascular toxicity across epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in *EGFR*-mutated non–small cell lung cancer: A population-based retrospective cohort study.
First Author: Yun-Gyoo Lee, MD, PhD
- Board 139 **Abstract 12156:** Oncologic outcomes following biologic therapy for immune-related cutaneous adverse events.
First Author: Tara Maier, BS
- Board 140 **Abstract 12157:** Major adverse cardiovascular events among prostate cancer patients in the VA, stratified by HIV status and androgen deprivation therapy.
First Author: Debanjan Pain, MD, MS
- Board 141 **Abstract 12158:** Identification of nutritional risk in chimeric antigen receptor T-cell (CAR-T) therapy: Proteinenergy malnutrition and its impact on patient outcomes.
First Author: Anu Priyamvada Ramakrishnan, MBBS
- Board 143 **Abstract 12160:** Impact of corticosteroid exposure on long-term immune checkpoint inhibitor responses in solid tumors.
First Author: Theresa Medina, MD
- Board 144a **Abstract TPS12161:** Supporting treatment resilience with optimized nutrition and guided exercise (STRONGER) in head and neck cancer patients undergoing chemoradiation.
First Author: Anton Jose Agana, MD
- Board 144b **Abstract TPS12162:** Hetrombopag in patients with chemotherapy-induced thrombocytopenia: A global phase 3, randomized, double-blind study.
First Author: Jodi Victoria Mones, MD
- Board 145a **Abstract TPS12163:** A randomized, double-blind, placebo-controlled trial of antiviral prophylaxis and oral *Herpesviridae* dynamics during radiotherapy for head and neck cancer.
First Author: Renata Ferrari, BS

- Board 145b **Abstract TPS12164:** Symptom monitoring program linked to electronic referrals (SyMPLER): A single-arm pilot feasibility study of remote symptom monitoring with palliative care self-referral.
First Author: Julia L. Agne, MD
- Board 146a **Abstract TPS12165:** Structured interventional strategies to prevent and reduce burnout in medical oncologists: The Resilience–Spanish Society of Medical Oncology (SEOM) multicenter project.
First Author: Yago Garitaonaindia, MD, MSc
- Board 146b **Abstract TPS12166:** Enhancing communication about cancer management and cancer care delivery for older adults with dementia and their care partners.
First Author: Molly Wilgucki, DO
- Board 147a **Abstract TPS12167:** RISE trial: A novel virtually delivered supervised exercise intervention targeting cognitive impairment and gut microbiome in adolescent and young adult (AYA) brain tumor survivors.
First Author: Elizabeth Pan, BA
- Board 147b **Abstract TPS12168:** Targeting cellular senescence to enhance skeletal muscle recovery in survivors of breast cancer: An ancillary study of the phase II randomized PROFFi clinical trial.
First Author: Jingran Ji, MD
- Board 148a **Abstract TPS12169:** Exercise therapy in survivors of gastroesophageal cancer: A phase I, randomized dose-finding study of an individually tailored, remotely supervised exercise intervention.
First Author: Jingran Ji, MD
- Board 148b **Abstract TPS12170:** MPOWER: A pilot trial among men with prostate cancer—Optimizing wellness by enhanced relief from hot flashes with acupuncture.
First Author: Jeanny B. Aragon-Ching, MD, FACP, FASCO
- Board 149a **Abstract TPS12171:** SWIVEL: A randomized phase II trial of switching medications versus guideline-directed interventions for adjuvant aromatase inhibitor side effects in breast cancer patients.
First Author: Elaine Patricia Kuhn, MD, MS
- Board 149b **Abstract TPS12172:** A late-phase randomized open-label multi-cohort trial to evaluate immune-related adverse events with different standard-of-care dosing strategies of standard-of-care immunotherapies: ImmuRA trial.
First Author: Anup Kasi, MD, MPH
- Board 150a **Abstract TPS12173:** Interrupting sedentary time to improve cardiometabolic health and toxicity in patients with lymphoma receiving chemotherapy: The iSTAND trial.
First Author: Rebekah Wilson, PhD
- Board 150b **Abstract TPS12174:** WINSHIP 4468-18: Phase II evaluation of the effect of 2- versus 6-hour oxaliplatin infusions on neuropathy and pharmacokinetics in patients with gastrointestinal cancers.
First Author: Olumide B. Gbolahan, MBBS

3:00 PM-3:45 PM Award Lecture

Geriatric Oncology: The Coming of Age of a Specialty—Its Distinct Principles, Practice, and Science in a Global Context

Location: E450a

Ravindran Kanesvaran, MD—Chair
National Cancer Centre

Enrique Soto Pérez de Celis, MD, PhD, MSc, FASCO
University of Colorado Anschutz Medical Campus
B.J. Kennedy Geriatric Oncology Award Recipient

3:00 PM-4:15 PM Education Session

Beyond Routine Surveillance Imaging: Emerging Technologies for the Early Detection of Melanoma Recurrence

Location: E450b

Michael Farwell, MD

University of Pennsylvania Health System
Role of CD8-Targeted Positron Emission Tomography Imaging to Predict Early Response to Immunotherapy

April K.S. Salama, MD—Chair

Duke University
Where Do We Stand With ctDNA for Disease Monitoring and Recurrence Prediction in Melanoma?

Cicero Luiz Cunha De Sousa Martins, MD

Latin American Cooperative Oncology Group
Global Approaches to Melanoma Surveillance in the Modern Era: The Feasible, the Practical, and the Affordable

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Measurable Residual Disease in Pediatric Hematologic Malignancies: Current and Emerging Technologies

Location: S504

Alexandra Kovach, MD

Boston Children's Hospital
Acute Lymphoblastic Leukemia Flow Cytometry for Measurable Residual Disease

Jan Zuna, MD, PhD

Univerzita Karlova
Next Generation Sequencing in Pediatric Leukemia—How Best to Utilize This Technology

Lisa Eidenschink Brodersen, PhD—Chair

Children's Hospital of Philadelphia
Acute Myeloid Leukemia Flow Cytometry and Reverse-Transcription Polymerase Chain Reaction for Measurable Residual Disease and Prognostic Significance of Molecular Measurable Residual Disease

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers

Location: E451

Do-Youn Oh, MD, PhD—Chair

Seoul National University Hospital, Seoul National University College of Medicine
Peri-Operative Treatment With Immunotherapy in Resectable Gastroesophageal Cancer

Zev A. Wainberg, MD

University of California Los Angeles
Validated New Therapeutic Targets in Gastroesophageal Cancer

Elizabeth Catherine Smyth, MD

NIHR Oxford Biomedical Research Centre, Churchill Hospital
Promising New Drug Development Platform in Gastroesophageal Cancer

Panel Question and Answer

3:00 PM-4:15 PM Case-Based Panel

One Patient, Many Pathways: Management Options in ALK-Positive Non-Small Cell Lung Cancer From Early Stage to Advanced Disease

Location: Hall D2

Kristin Ann Higgins, MD—Chair

City of Hope
Moderator

Mara Antonoff, MD, FACS

The University of Texas MD Anderson Cancer Center
Surgical Oncologist Perspective

Kevin Lee Min Chua, MBBS, FRCR

National Cancer Centre Singapore
Radiation Oncologist Perspective

Clarissa Mathias, MD, PhD, FASCO

Oncoclinicas&Co and Hospital Santa Izabel
Medical Oncologist Perspective

Panel Question and Answer

3:00 PM-4:30 PM Rapid Oral Abstract Session

Quality Care/Health Services Research

Location: E350

Gita Thanarajasingam, MD—Chair

Mayo Clinic Rochester

Etienne Grégoire Cornélius Brain, MD, PhD—Chair

Institut Curie

3:00 PM Abstract 11009: The electronic frailty index used to identify high-risk older adults receiving chimeric antigen receptor T-cell therapy.
First Author: Justine P. Enns, MD

3:06 PM Abstract 11010: Association of early cognitive decline with compromised delivery of adjuvant chemotherapy.
First Author: Filippos Koinis, MD, PhD

3:12 PM Abstract 11011: Clinical impact of baseline and peri-treatment concomitant medication exposure and polypharmacy on outcomes of immune checkpoint inhibitor therapy: A real-world pan-tumor analysis.
First Author: Ali Awada

3:18 PM Panel Question and Answer

3:30 PM Abstract 11012: Telehealth use and end-of-life care outcomes among Medicare decedents with cancers.
First Author: Teresa M. Waters

3:36 PM Abstract 11013: Cancer during pregnancy and child health perspectives: Evidence from real-world data.
First Author: Samah Hayek, DrPH

3:42 PM Abstract 11014: Real-world evidence of the association between primary insomnia and early-onset hormone-related cancers.
First Author: Vineet Polineni, DO

3:48 PM Panel Question and Answer

4:00 PM Abstract 11015: Longitudinal changes in patient-reported quality of life (QOL) and hope among early phase cancer clinical trial (EPCT) participants.
First Author: Debra Lundquist, PhD, RN

4:06 PM Abstract 11016: Obesity paradox in gastrointestinal cancer patients on immunotherapy: A retrospective multi-institutional US cohort study.
First Author: Marwa Al Faraj, MBBS

4:12 PM Abstract 11017: GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort.
First Author: Ila Sruti, MPH

4:18 PM Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Central Nervous System Tumors

Location: S100a

Philipp Karschnia, MD, MS—Chair

Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuernberg

Priya Kumthekar, MD—Chair

Northwestern Memorial Hospital

3:00 PM Abstract LBA2000: Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.
First Author: Jeffrey S. Weinberg, MD

3:12 PM Abstract 2001: A multicenter randomized phase III study for newly diagnosed, maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide versus chemoradiotherapy alone: Japan Clinical Oncology Group study JCOG1703 (MACS study).
First Author: Ryuta Saito, MD, PhD

3:24 PM Abstract 2002: Connectome-sparing stereotactic radiosurgery: Results from the phase II COG-SRS trial.
First Author: Andrew Connor Puett, MD, PhD

3:36 PM Abstract 2003: Neoadjuvant fractionated stereotactic radiotherapy followed by surgical resection for brain metastases: A multicenter, single arm phase II trial (NEO-TACTICS).
First Author: Koichi Mitsuya, MD, PhD

3:48 PM Nduka Amankulor, MD
University of Pennsylvania Perelman School of Medicine
Discussion of Abstract(s) LBA2000-2003: Optimizing Local Tumor Treatment While Protecting Global Function

- 4:00 PM** *Panel Question and Answer*
- 4:12 PM** **Abstract 2004:** MAGMA: Multi-arm glioblastoma Australasia phase 3 trial.
First Author: Craig Gedye, PhD, MBChB, FRACP
- 4:24 PM** **Abstract 2005:** Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: Final results from the phase 2a step (OLA-TMZ-RTE-01).
First Author: Dinu Stefan
- 4:36 PM** **Abstract 2006:** A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma.
First Author: Jack Y. Ghannam
- 4:48 PM** **Roy E. Strowd, MD, MEd**
Atrium Health Wake Forest Baptist
Discussion of Abstract(s) 2004-2006: Old Tricks, New Trials in Brain Tumor Studies
- 5:00 PM** *Panel Question and Answer*
- 5:12 PM** **Abstract LBA2007:** Efficacy and safety of asandeutertinib versus osimertinib as first-line treatment in EGFR-mutated NSCLC patients with brain metastases: Interim analysis of an open-label, multicenter, randomized, pivotal phase II study (ESAONA).
First Author: Yuankai Shi, MD, PhD
- 5:24 PM** **Abstract 2008:** Correlation of ten-year survival with cell-free DNA methylation of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.
First Author: Anna Maria Di Giacomo, MD
- 5:36 PM** **Anna Sophie Berghoff, MD**
Medical University of Vienna
Discussion of Abstract(s) LBA2007-2008: Practical Translation of Next-Generation Tools
- 5:48 PM** *Panel Question and Answer*

3:00 PM-6:00 PM Oral Abstract Session

Genitourinary Cancer—Prostate, Testicular, and Penile
Location: Hall D1

Alan Haruo Bryce, MD—Chair
Mayo Clinic Arizona

Laura Graham, MD—Chair
University of Colorado Cancer Center, Anschutz Medical Campus

- 3:00 PM** **Abstract 5000:** Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.
First Author: Krishnan R. Patel, MD, MHS
- 3:12 PM** **Abstract 5001:** Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.
First Author: Christopher Sweeney, MBBS

- 3:24 PM** **Abstract 5002:** Spatial transcriptomics-guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHARTED trial (ECOG-ACRIN E3805).
First Author: Md Mamunur Rahaman
- 3:36 PM** **Abstract LBA5003:** First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
First Author: Lucia Nappi, MD, PhD, FRCPC
- 3:48 PM** **Joshua Michael Lang, MD, MS**
University of Wisconsin
Discussion of Abstract(s) 5000-LBA5003: Precision Oncology: How to Apply New Biomarkers in Clinical Practice
- 4:00 PM** *Panel Question and Answer*
- 4:12 PM** **Abstract 5004:** A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).
First Author: Atish Dipankar Choudhury, MD, PhD
- 4:24 PM** **Abstract 5005:** Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.
First Author: Alicia K. Morgans, MD, MPH, FASCO
- 4:36 PM** **Catherine Handy Marshall, MD, MPH**
Johns Hopkins University School of Medicine
Discussion of Abstract(s) 5004-5005: Minimizing Toxicity and Maximizing Patient Benefit in Prostate Cancer
- 4:48 PM** *Panel Question and Answer*
- 5:00 PM** **Abstract 5006:** Final results from ZZFIRST: A randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC).
First Author: Joaquin Mateo, MD, PhD
- 5:12 PM** **Abstract LBA5007:** TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
First Author: Neeraj Agarwal, MD, FASCO
- 5:24 PM** **Abstract 5008:** Fuzuparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
First Author: Dingwei Ye, MD
- 5:36 PM** **David Olmos, MD, PhD**
Hospital Universitario 12 de Octubre
Discussion of Abstract(s) 5006-5008: PArPi-Palooza: Sorting out the Many Options in Prostate Cancer
- 5:48 PM** *Panel Question and Answer*

3:00 PM-6:00 PM Oral Abstract Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: Arie Crown Theater

Nathalie Johnson, MD—Chair

Jewish General Hospital

Hetty E. Carraway, MD, MBA—Chair

Taussig Cancer Institute, Cleveland Clinic

- 3:00 PM Abstract LBA7000:** frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
First Author: Georg Lenz, MD
- 3:12 PM Abstract 7001:** Integrating BTK inhibition into R-da-EPOCH for HIV-related DLBCL.
First Author: Ida Wong-Sefidan, MD
- 3:24 PM Abstract 7002:** Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.
First Author: Dai Chihara, MD, PhD
- 3:36 PM Laurie Helen Sehn, MD, MPH**
BC Cancer Centre for Lymphoid Cancer and University of British Columbia
Discussion of Abstract(s) LBA7000-7002: Redefining Frontline Therapy in Diffuse Large B-Cell Lymphoma
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 7003:** A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).
First Author: Enrico Derenzini
- 4:12 PM Abstract 7004:** Linperlisib plus CHOP for newly diagnosed peripheral T-cell lymphoma: A single-arm, phase Ib/II study (LINCH trial).
First Author: Qingqing Cai, PhD
- 4:24 PM Abstract 7005:** Impact of VT-EBV-N on disease-free survival as post-remission therapy in EBV-positive extranodal NK/T-cell lymphoma: A randomized, double-blind, placebo-controlled phase 2 study.
First Author: Youngwoo Jeon, MD, PhD
- 4:36 PM Alison J. Moskowitz, MD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 7003-7005: Innovative Therapies for T-Cell Lymphoma and Relapsed Hodgkin Lymphoma
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 7006:** Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.
First Author: Yasmin Karimi, MD

- 5:12 PM Abstract 7007:** Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.
First Author: Wonseog Kim
- 5:24 PM Abstract 7008:** Mediterranean CD19 genetic variations and potential influence on CAR T-cell therapy efficacy: Implications for population-tailored immunotherapy.
First Author: Osama Alsmadi
- 5:36 PM Tycel J. Phillips, MD, FASCO**
City of Hope National Medical Center
Discussion of Abstract(s) 7006-7008: Tailoring Immunotherapy for Relapsed Lymphoma
- 5:48 PM Panel Question and Answer**

3:00 PM-6:00 PM Oral Abstract Session

Sarcoma

Location: S100bc

Chandrajit P. Raut, MD—Chair

Brigham and Women's Hospital and Harvard Medical School

Maggie Yuxi Zhou, MD—Chair

Stanford University School of Medicine

- 3:00 PM Abstract 11500:** Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).
First Author: Andrew J. Wagner, MD, PhD
- 3:12 PM Abstract 11501:** Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by *KIT* mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.
First Author: Robin Lewis Jones, MD, MBBS, BSc, MRCP, FASCO
- 3:24 PM Gabriel Tinoco, MD**
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Discussion of Abstract(s) 11500-11501: New Standards or Just More Options? Evolving Therapies for Gastrointestinal Stromal Tumors
- 3:36 PM Panel Question and Answer**
- 3:48 PM Abstract 11502:** Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
First Author: Silvia Stacchiotti, MD
- 4:00 PM Abstract 11503:** Efficacy and safety of vebreltinib in advanced clear cell sarcoma (VEBrant): A multicenter, phase II study.
First Author: Binghao Li, MD, PhD
- 4:12 PM Abstract 11504:** The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAGON study.
First Author: Hans Gelderblom, MD

- 4:24 PM Abstract 11505:** Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma.
First Author: Sandra P. D'Angelo, MD
- 4:36 PM Margaret von Mehren, MD**
Fox Chase Cancer Center
Discussion of Abstract(s) 11502-11505: New Targets, New Therapies: Every Nail Needs a Hammer
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 11506:** RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.
First Author: Mrinal M. Gounder, MD
- 5:12 PM Abstract 11507:** Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial—A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.
First Author: Rosa Maria Alvarez Alvarez, MD
- 5:24 PM Abstract 11508:** Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802.
First Author: Makoto Endo, MD, PhD
- 5:36 PM Herbert H. Loong, MBBS, FRCP, FASCO**
The Chinese University of Hong Kong
Discussion of Abstract(s) 11506-11508: One Drug, Two Drugs, Old Drug, New Drug
- 5:48 PM Panel Question and Answer**

4:30 PM-6:00 PM Rapid Oral Abstract Session

Melanoma/Skin Cancers

Location: E451

Siwen Hu-Lieskovan, MD, PhD—Chair

University of Utah Health

Russell William Jenkins, MD, PhD—Chair

MUSC Children's Hospital Child Abuse Pediatrics Division

- 4:30 PM Abstract 9512:** Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma.
First Author: Monica F. Chen, MD
- 4:36 PM Abstract 9513:** Combination of vemurafenib with cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.
First Author: Anne Sophie Blokland
- 4:42 PM Abstract LBA9514:** MATRiX: A randomized phase II trial of tivosertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
First Author: Rashmi Bhakuni, PhD, BSc, MSc
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 9515:** A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)-naive basal cell carcinoma of the head and neck.
First Author: Hannah L. Kenny, MD

- 5:06 PM Abstract 9516:** Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.
First Author: Lili Mao
- 5:12 PM Abstract LBA9517:** Neoadjuvant intralesional daromun (L191L2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial.
First Author: Katharina C. Kaehler, MD
- 5:18 PM Panel Question and Answer**
- 5:30 PM Abstract 9518:** A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGYTE clinical trial.
First Author: Michael K.K. Wong, MD, PhD
- 5:36 PM Abstract 9519:** A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.
First Author: James William Smithy, MD, MHS
- 5:42 PM Abstract 9520:** Response-focused analyses of the impact of circadian rhythm on efficacy of first-line immunotherapy in melanoma.
First Author: Hemant Khandelvia, MBBS
- 5:48 PM Panel Question and Answer**

4:45 PM-6:00 PM Education Session

Advancing Antibody-Drug Conjugates: From Bispecific Innovation to First-Line Therapy

Location: Hall D2

Patricia LoRusso, PhD, DO, FASCO

Yale Cancer Center

Synergy and Strategy: Combining and Sequencing Antibody-Drug Conjugates With Targeted Agents

Giuseppe Curigliano, MD, PhD—Chair

European Institute of Oncology, IRCCS, University of Milano

Shifting the Paradigm: Integrating Antibody-Drug Conjugates Into First-Line and Curative Strategies

Anthony W. Tolcher, MD, FASCO

NEXT Oncology San Antonio

Next-Generation Antibody-Drug Conjugates: Unlocking the Potential of Bispecific and Dual-Payload Designs in Oncology

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu

Location: E450b

Pan-Chyr Yang, MD, PhD—Chair

National Taiwan University College of Medicine

Screening for Lung Cancer in Individuals Who Have Never Smoked: Why, When, Who, All, and How?

Laura Mezquita, MD, PhD

Hospital Clinic de Barcelona, IDIBAPS

The Air We Breathe, the Food We Eat, and the Water We Drink—What All Matters for Lung Cancer

Saturday, May 30, 2026

Efren J. Flores, MD, FACP

Massachusetts General Hospital
Nonradiological Screening: Where Do We Stand Today?
Panel Question and Answer

4:45 PM-6:00 PM Education Session

The Best of JCO Global Oncology: Improving Affordability in Cancer Care for Resource-Limited Settings

Location: S403

Akhil Kapoor, MD, DM, MBBS, MRCP

Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre
Triple Oral Metronomic Chemotherapy in Advanced Head and Neck Cancer

Carlos Magliano, MD, PhD, MBA, MSc

Asas Avaliações Econômicas em Saúde Ltda
Evaluating Oncotypedx Testing in Early-Stage Breast Cancer in Brazil

Celine Hoyek, MD

Mayo Clinic Arizona
Overcoming Financial and Access Barriers in Global Cancer Care with Low-Dose Immunotherapy

Katherine Van Loon, MD, MPH, FASCO—Chair

University of California San Francisco
Interpreting Results for Clinical Impact in Resource-Constrained Settings

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Triple-Negative Breast Cancer in 2026: Translating New Data Into Clinical Decisions

Location: Hall B1

Roberto Antonio Leon-Ferre, MD

Mayo Clinic Rochester
Stage I Triple-Negative Breast Cancer: Who Needs What Treatment?

Heather L. McArthur, MD, MPH, FASCO—Chair

UT Southwestern Medical Center
Personalizing Curative Therapy in Stage 2-3 Triple-Negative Breast Cancer

Rita Nanda, MD, FASCO

University of Chicago Medicine
Advances in Systemic Treatment of Metastatic Triple-Negative Breast Cancer
Panel Question and Answer

4:45 PM-6:00 PM Education Session

Unique Considerations in Rare Gynecologic Tumors: Gestational Trophoblastic Neoplasia, Germ Cell Tumors, and Clear Cell Ovarian Cancers

Location: S504

John H. Farley, MD—Chair

St. Joseph's Hospital and Medical Center
Germ Cell Tumors From the Adult and Pediatric Perspective

Neil S. Horowitz

Dana-Farber Cancer Institute
Gestational Trophoblastic Neoplasia

Keiichi Fujiwara, MD, PhD

Saitama Medical University International Medical Center
Management of Clear Cell Ovarian Cancers
Panel Question and Answer

4:45 PM-6:00 PM Education Session

Value, Access, and Quality Care: Can We Have It All?

Location: E350

Ian Tannock, MD, PhD, FASCO—Chair

Princess Margaret Cancer Centre
The Cancer Value Crisis: Challenges and Solutions

Haydee Cristina Verduzco-Aguirre, MD, MSc

Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán
Opportunity Costs of Low-Value Cancer Care

Ajay Aggarwal, MD, MBBS, MSc, FRCR, MRCP

London School of Hygiene and Tropical Medicine
How Can We Make Cancer Care High Quality and Sustainable?

Brooke Wilson, MBBS, MSc

Kingston Health Sciences Centre
Economics 101: Where Are We Going With Cancer Medicines?
Panel Question and Answer

7:30 AM-9:30 AM Education Session

Training Program Directors' Breakfast

Location: S103

Lori J. Rosenstein, MD, FASCO—Chair

Gundersen Health System

Welcome and Opening Remarks

Optimizing Your Program's Match: A Data-Driven Approach

Leveraging Resources and Shared Experiences

Courtney Nicole Miller-Chism, MD

Baylor College of Medicine

Leveraging Data and Resources: Application Review

Jerome Dallas Winegarden, MD

Trinity Health Ann Arbor

Leveraging Shared Experiences: Interview Structures Panel

Laura Elizabeth Finn, MD

Ochsner Health System

Leveraging Shared Experiences: Interview Structures Panel

Tyler Paul Johnson, MD

Stanford University Hospital

Leveraging Shared Experiences: Interview Structures Panel

Lori J. Rosenstein, MD, FASCO

Gundersen Health System

Closing Remarks and Feedback

8:00 AM-9:00 AM Case-Based Panel

Biomarker Treatment Strategies for Bladder Cancer: Putting the Patient at the Center

Location: S102

Jonathan E. Rosenberg, MD—Chair

Memorial Sloan Kettering Cancer Center

Moderator

Mark Tyson, MD, MPH

Mayo Clinic Arizona

Surgical Oncologist Perspective

Leslie K. Ballas, MD

Cedars-Sinai Medical Center

Radiation Oncologist Perspective

Rick Bangs, PMP, MBA

Bladder Cancer Advocacy Network

Patient Perspective

Michiel S. Van Der Heijden, MD, PhD

Netherlands Cancer Institute

Medical Oncologist Perspective

Panel Question and Answer

8:00 AM-9:15 AM Highlights Session

Highlights of the Year I

Location: Hall D1

Cardinale B. Smith, MD, PhD, FASCO—Chair

Memorial Sloan Kettering Cancer Center

8:00 AM Tian Zhang, MD, MHS, FASCO

Simmons Comprehensive Cancer Center, UT

Southwestern Medical Center

Highlights in Genitourinary Cancer: Antibody-Drug

Conjugates Transforming Bladder Cancer

8:15 AM Stephanie Lheureux, MD, PhD

Princess Margaret Cancer Centre

Highlights in Ovarian Cancer: Immunotherapies,

Glucocorticoid Receptor Antagonism, and Up-and-

Coming Antibody-Drug Conjugates

8:30 AM Suzanne Lentzsch, MD, PhD

Columbia University Irving Medical Center

Highlights in Hematologic Malignancies:

Immunotherapy in Plasma Cell Disorders in 2026:

How Early, How Deep, and How to Sequence?

8:45 AM Maryam Rahman, MD

University of Florida

Highlights in Central Nervous System Tumors

9:00 AM Greg Andrew Durm, MD

Indiana University

Highlights in Non–Small Cell Metastatic Lung

Cancer

8:00 AM-9:15 AM Education Session

It's 2026: Updates in Small Cell Lung Cancer—No Longer Too Small to Ignore

Location: E451

Rami Manochakian, MD, FASCO—Chair

Mayo Clinic Florida

Systemic Therapy for Small-Cell Lung Cancer: Standard of Care

and Recent Therapeutic Advances

Fiona Hegi-Johnson, PhD, MBBS

Peter MacCallum Cancer Centre

Defining the Role of Radiation in Small Cell Lung Cancer: From

Early-Stage to Advanced Disease

Noemi Reguart, MD, PhD

Hospital Clinic de Barcelona, IDIBAPS

Future Directions for Small-Cell Lung Cancer: Emerging

Therapies and Sequencing Strategies

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Let's Debate: Upfront Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Location: E450b

Sven Mahner, MD

The Ludwig-Maximilians-University Hospital, Munich

Pro: Primary Surgery

Alexander Olawaiye, MD, FACOG, FACS

University of Pittsburgh Medical Center and Magee-Women's

Hospital of UPMC

Pro: Neoadjuvant Chemotherapy

Kristin Leigh Bixel, MD—Chair

Stanford University

Synthesizing the Data: Shared Decision-Making in Surgical

Timing

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Radiation Necrosis: Diagnostic and Management Strategies and Challenges

Location: E350

Michael Veronesi, MD, PhD

University of Wisconsin-Madison

Imaging Options and Artificial Intelligence for Determining Radiation Necrosis

Anca-Ligia Grosu, MD

Medical Center – University of Freiburg

Radiotherapy Techniques for Preventing Radiation Necrosis

Shawn L. Hervey-Jumper, MD—Chair

University of California San Francisco

Role of Resection in Suspected Radiation Necrosis Including Laser Ablation Therapy

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Smoldering Multiple Myeloma: To Treat or Not to Treat

Location: E450a

María-Victoria Mateos, PhD

University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC

Pro: Risk Stratification and Indications for Treatment

Nizar Jacques J. Bahlis, MD

Arnie Charbonneau Cancer Research Institute, University of Calgary

Con: Risk Versus Benefit—Treating Smoldering Multiple Myeloma in Frail and Older Patients

Ajay K. Nooka, MBBS—Chair

Winship Cancer Institute of Emory University

Smoldering Multiple Myeloma: Takeaways and Further Considerations

Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Symptom Science and Palliative Care

Location: S403

Mazie Tsang, MD, MS—Chair

Mayo Clinic Arizona

Lauren Chiec, MD—Chair

Case Western Reserve University; University Hospitals Seidman Cancer Center

8:00 AM Abstract 12009: Efficacy of YES, an mHealth intervention for adolescent and young adults (AYA) with breast cancer (BC), to address AYA survivorship concerns.
First Author: Shoshana M. Rosenberg, ScD

8:06 AM Abstract 12010: Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
First Author: Jennifer A. Ligibel, MD, FASCO

8:12 AM Abstract 12011: Association of social isolation with overall survival in cancer patients.
First Author: Danlin Zeng, BSc, MSc

8:18 AM Panel Question and Answer

8:30 AM Abstract 12012: Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714.
First Author: Nam Nguyen-Hoang, MS

8:36 AM Abstract 12013: An international phase III randomized, double-blind, double-dummy trial comparing duloxetine and pregabalin for opioid-refractory neuropathic cancer pain.
First Author: Hiromichi Matsuoka

8:42 AM Abstract 12014: A URCC NCCORP Research Base nationwide phase II randomized controlled trial (RCT) investigating the effect of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN).
First Author: Ian Kleckner, PhD, MPH

8:48 AM Panel Question and Answer

9:00 AM Abstract 12015: A multicenter randomized phase II trial of topical betamethasone ointment for preventing severe chemoradiotherapy-induced oral mucositis in head and neck cancer.
First Author: Sakiko Soutome, PhD, DDS

9:06 AM Abstract 12016: The efficacy and safety of add-on ruxolitinib for patients with severe checkpoint inhibitor pneumonitis management with corticosteroids: A multicenter, open-label, randomised phase 2 trial.
First Author: Yan Xu, MD

9:12 AM Abstract 12017: A randomized phase III trial of dexamethasone mouthwash to prevent chemotherapy-induced oral mucositis in patients with breast cancer.
First Author: Sayaka Kuba, PhD

9:18 AM Panel Question and Answer

8:00 AM-11:00 AM Oral Abstract Session

Developmental Therapeutics—Immunotherapy

Location: Arie Crown Theater

Rachel E. Sanborn, MD—Chair

Earle A. Childs Research Institute, Providence Cancer Institute

Lilit Karapetyan, MD, MSc—Chair

H. Lee Moffitt Cancer Center and Research Institute

8:00 AM Abstract 2500: EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti-PD-1 resistance or MSS-CRC.
First Author: Fiona Thistlethwaite

8:12 AM Abstract 2501: Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.
First Author: Stephen James Luen, PhD, MBChB

8:24 AM Abstract 2502: DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
First Author: Sandip Pravin Patel, MD, FASCO

- 8:36 AM** **E. Gabriela Chiorean, MD, FASCO**
University of Washington
Discussion of Abstract(s) 2500-2502: Checkpoint Matchmaking: Finding the Right Immunotherapeutic Combination
- 8:48 AM** *Panel Question and Answer*
- 9:00 AM** **Abstract 2503:** Desmocolin-3–directed immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Ranjan Das, MBBS
- 9:12 AM** **Abstract 2504:** RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.
First Author: Joseph J. Sacco, PhD, MBChB
- 9:24 AM** **Abstract 2505:** Phase 2 basket trial of precision TIL therapy for immunotherapy-resistant advanced cancers.
First Author: Shravan Leonard-Murali, MD, MSc
- 9:36 AM** **Hannah Carter, PhD**
University of California San Diego
Discussion of Abstract(s) 2503-2505: Finding the Right Immune Match
- 9:48 AM** *Panel Question and Answer*
- 10:00 AM** **Abstract 2506:** Initial phase 1 study results of NT-175 engineered T-cell therapy in *TP53* R175H–mutated unresectable advanced solid tumors.
First Author: Rishi Surana, MD, PhD
- 10:12 AM** **Abstract 2507:** First-in-human results with IMA401, a MAGEA4/8-targeted T-cell receptor–based bispecific T-cell engager (TCER) in recurrent or refractory solid tumors.
First Author: Martin Wermke
- 10:24 AM** **Abstract 2508:** Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: Updated results from the phase Ib BEACON study.
First Author: Jia Fan, DrPH
- 10:36 AM** **Harriet M. Kluger, MD**
Yale Cancer Center
Discussion of Abstract(s) 2506-2508: Finding the Right Cellular Immunotherapy
- 10:48 AM** *Panel Question and Answer*

8:00 AM-11:00 AM Oral Abstract Session

Gastrointestinal Cancer—Colorectal and Anal

Location: Hall D2

Najjia Mahmoud, MD—Chair

University of Pennsylvania

Wells A. Messersmith, MD, FACP, FASCO—Chair

University of Colorado

- 8:00 AM** **Abstract LBA3500:** Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.
First Author: Gunnar Folprecht, MD

- 8:12 AM** **Abstract 3501:** Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.
First Author: Hiroyuki Yamamoto
- 8:24 AM** **Jonathan M. Loree, MD, MS**
BCCA - Vancouver Cancer Centre, University of British Columbia
Discussion of Abstract(s) LBA3500-3501: Decision and Duration: Has ctDNA Landed in the Adjuvant Space?
- 8:36 AM** *Panel Question and Answer*
- 8:48 AM** **Abstract 3502:** Observation versus maintenance PD-1 inhibitor therapy after clinical complete response in dMMR/MSI-H colorectal cancer managed with non-operative management: A multicentre cohort study.
First Author: Xiaohang Gao, MS
- 9:00 AM** **Abstract LBA3503:** BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz, MD, PhD, FASCO
- 9:12 AM** **Abstract 3504:** SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF^{V600E} metastatic colorectal cancer (mCRC).
First Author: Van K. Morris II, MD
- 9:24 AM** **Abstract 3505:** Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC).
First Author: Jin Li, MD
- 9:36 AM** **Filippo Pietrantonio, MD**
Fondazione IRCCS Istituto Nazionale dei Tumori
Discussion of Abstract(s) 3502-3505: Break It, Block It, Boost It: BRAF, HER2, and MSI-H Targeted Approaches
- 9:48 AM** *Panel Question and Answer*
- 10:00 AM** **Abstract LBA3506:** Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.
First Author: Loubna Outmani
- 10:12 AM** **Abstract 3507:** Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.
First Author: Kelvin K. Chan, MD, PhD
- 10:24 AM** **Abstract LBA3508:** Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C).
First Author: Atsuo Takashima, MD, PhD
- 10:36 AM** **Alan P. Venook, MD, FASCO**
University of California San Francisco
Discussion of Abstract(s) LBA3506-LBA3508: CHALLENGE Accepted: Redefining Adjuvant Approaches
- 10:48 AM** *Panel Question and Answer*

8:00 AM-11:00 AM Oral Abstract Session

Head and Neck Cancer

Location: S100a

Renata Ferrarotto, MD—Chair

The University of Texas MD Anderson Cancer Center

Ben O’Leary, PhD, MBBS—Chair

The Institute of Cancer Research

- 8:00 AM Abstract 6000:** Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).
First Author: Sudhir Vasudevan Nair, MBBS, MS, MCh
- 8:12 AM Abstract 6001:** Impact of lymph node dissection extent on disease-free survival with postoperative nivolumab plus concurrent chemoradiotherapy in head and neck squamous cell carcinoma: A post-hoc analysis of the NIVOPOSTOP trial.
First Author: Ariane Lapierre, MD, PhD
- 8:24 AM Abstract 6002:** Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase III randomized controlled trial.
First Author: Pankaj Chaturvedi
- 8:36 AM Aarti K. Bhatia, MD, MPH**
Yale School of Medicine, Yale Cancer Center
Discussion of Abstract(s) 6000-6002: Beyond the Scalpel: Optimizing Adjuvant Therapy in Head and Neck Cancer
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 6003:** Two-cycle versus three-cycle induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase III randomized noninferiority trial.
First Author: Hu Liang, MD, PhD
- 9:12 AM Abstract 6004:** Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.
First Author: Xiaoqing Wang, MD
- 9:24 AM Abstract LBA6005:** Adjuvant sintilimab-capecitabine versus capecitabine alone in locoregionally advanced nasopharyngeal carcinoma with suboptimal response to induction chemotherapy: An open-label, randomized, controlled, phase 2 trial.
First Author: Li-Ting Liu, MD
- 9:36 AM Alexander Dimitrios Colevas, MD, FASCO**
Stanford University
Discussion of Abstract(s) 6003-LBA6005: From Frontline to Finish Line: Induction to Adjuvant Therapy in Nasopharyngeal Cancer
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 6006:** A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.
First Author: Jacob Stephen Thomas, MD

- 10:12 AM Abstract LBA6007:** Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
First Author: Minit Jalan Shah, DM
- 10:24 AM Abstract 6008:** Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
First Author: Barbara Burtness, MD, FASCO
- 10:36 AM Jessica R. Bauman, MD**
Fox Chase Cancer Center
Discussion of Abstract(s) 6006-6008: From Relapse to Response: Advances in Recurrent and Metastatic Head and Neck Cancer Treatment
- 10:48 AM Panel Question and Answer**

8:00 AM-11:00 AM Oral Abstract Session

Pediatric Oncology

Location: S504

Sarah K. Tasian, MD, PhD—Chair

Children’s Hospital of Philadelphia

Brittany L. Greene, MD, MA, FAAP—Chair

Seattle Children’s Research Institute

- 8:00 AM Abstract 10000:** Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC).
First Author: Shannon L. Maude, MD, PhD
- 8:12 AM Abstract 10001:** SPARTO: A phase I study of PD-1 inhibitor spartalizumab (PDR001) in combination with low dose of pazopanib in pediatric relapsed/refractory tumors.
First Author: Jordane Chaix
- 8:24 AM Abstract 10002:** Targeting metastatic sites with radiation and outcomes in high-risk pediatric rhabdomyosarcoma.
First Author: Rachel Mendelson, MD
- 8:36 AM Navin Pinto, MD**
Children’s Hospital Colorado
Discussion of Abstract(s) 10000-10002: New Immunotherapy or Radiotherapy Approaches for Children With High-Risk Cancers
- 8:48 AM Panel Question and Answer**
- 9:18 AM Abstract 10003:** Digital health intervention for comorbid insomnia and neurocognitive impairment in adult survivors of childhood cancer: Results from a randomized clinical trial.
First Author: Tara M. Brinkman, PhD
- 9:30 AM Abstract 10004:** The ASPIRES study: Promoting colorectal cancer surveillance in childhood cancer survivors—A randomized intervention trial from the Childhood Cancer Survivor study (CCSS).
First Author: Tara O. Henderson, MD, MPH, FASCO

- 9:42 AM Abstract 10005:** Prediction of anthracycline-related cardiomyopathy in long-term childhood cancer survivors: The power of survivor-specific polygenic risk score—A COG-ALTE03N1 study.
First Author: Noha Sharafeldin, MD, PhD, MSc
- 9:54 AM Lynda M. Vrooman, MD**
Dana-Farber Cancer Institute
Discussion of Abstract(s) 10003-10005: Advancing Knowledge in Childhood Cancer Survivorship
- 10:06 AM Panel Question and Answer**

8:00 AM-11:00 AM Oral Abstract Session

Quality Care/Health Services Research

Location: S100bc

Evangelia Razis, MD, PhD, FASCO—Chair

Hygeia Hospital

Jingran Ji, MD—Chair

UCLA Health Jonsson Comprehensive Cancer Center

- 8:00 AM Abstract 11000:** The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.
First Author: Salman Jajja, MD
- 8:12 AM Abstract 11001:** Impact of mRNA SARS-CoV-2 vaccination on CAR T-cell therapy outcomes in hematologic malignancies: A multi-center real-world analysis.
First Author: Jowan Al-Nusair, MD
- 8:24 AM Abstract 11002:** Frailty matters: Association of mFI-5 Index with odds of mortality, hospitalization, and toxicities with ADCs, BiTE, and CAR T-cell therapies in real-world data.
First Author: Anne-Laure Strong, PhD
- 8:36 AM Electra D. Paskett, PhD, MSPH, FASCO**
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Discussion of Abstract(s) 11000-11002: Looking Beyond Trials: Can Real-World Data Answer Questions That Matter?
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 11003:** Overall survival analysis of eSyM: A cluster randomized trial of an electronic patient-reported outcomes (ePRO)-based symptom management program.
First Author: Michael J. Hassett, MD, MPH, FASCO
- 9:12 AM Abstract 11004:** Multicenter open-label randomized trial of the utility of electronic patient-reported outcome monitoring system in patients with advanced solid tumors (PRO-MOTE).
First Author: Naomi Kiyota, MD, PhD
- 9:24 AM Abstract 11005:** Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.
First Author: James H. Essell, MD

- 9:36 AM Amylou C. Dueck, PhD**
Alliance Statistics and Data Management Center, Mayo Clinic Arizona
Discussion of Abstract(s) 11003-11005: Listening to Patients in Real Time: Do ePROs Change Outcomes or Just the Conversation?
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 11006:** Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
First Author: Li Zhang, MD
- 10:12 AM Abstract 11007:** Doubling cascade testing uptake for hereditary cancer syndromes: Results from a cluster randomized controlled trial of a registry-aided outreach approach.
First Author: Jianbang Chiang, MBBS, MRCP
- 10:24 AM Abstract 11008:** Impact of dedicated care coordination on access to multidimensional support services in young-onset colorectal cancer: A pragmatic trial.
First Author: Jeongyoon Moon, MD
- 10:36 AM Camilla Zimmermann, MD, PhD, FRCPC**
Princess Margaret Cancer Centre, University of Toronto
Discussion of Abstract(s) 11006-11008: Moving Beyond Efficacy: Can Nontherapeutic Trials Advance Care Delivery?
- 10:48 AM Panel Question and Answer**

8:30 AM-10:00 AM Clinical Science Symposium

The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: The Future of Immunotherapy for Breast Cancer

Location: Hall B1

Jose G. Bazan, MD—Chair

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Marleen Kok, MD, PhD—Chair

Netherlands Cancer Institute

- 8:30 AM Stephanie Downs-Canner, MD**
The University of North Carolina at Chapel Hill
Immunotherapy for Breast Cancer in 2026
- 8:42 AM Abstract 1009:** Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: The HELEN-Trio 011 randomized clinical trial.
First Author: Dechuang Jiao, MD
- 8:54 AM Abstract 1010:** Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial.
First Author: Maria Vittoria Dieci, MD

- 9:06 AM Abstract 1011:** Primary results from the triple-negative cohort of TBCRC-053 (P-RAD): A randomized trial of no, low, or high dose preoperative radiation with pembrolizumab and chemotherapy in node-positive breast cancer. First Author: Alice Yoosun Ho, MD, MBA
- 9:18 AM Abstract 1012:** Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07. First Author: Sherene Loi, MD, PhD
- 9:30 AM Shipra Gandhi, MD, MS**
Winship Cancer Institute of Emory University
Discussion of Abstract(s) 1009-1012: Expanding the Impact of Immunotherapy in Breast Cancer
- 9:42 AM Panel Question and Answer**

9:00 AM-12:00 PM Poster Session

Genitourinary Cancer—Kidney and Bladder

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 1-2

Kidney Cancer: Board(s) 3-38, 108a-112a

Outcomes/Quality: Board(s) 39-40

Urothelial Cancer—Advanced/Metastatic Disease: Board(s) 41-68, 112b-114b

Urothelial Cancer—Local-Regional Disease: Board(s) 69-102, 115a-115b

Other GU Kidney and Bladder Cancer: Board(s) 105-107

- Board 1 **Abstract 4522:** Artificial intelligence (AI)–augmented analysis of quantitative circulating tumor DNA (ctDNA) burden and longitudinal kinetics to identify prognostic risk stratification in metastatic clear cell renal cell carcinoma (ccRCC). First Author: Eric Martin, MD, PhD
- Board 2 **Abstract 4523:** Vessel branching patterns quantified by artificial intelligence as a novel prognostic biomarker in advanced renal cell carcinoma: A post-hoc analysis of the CM914 trial. First Author: Hannah Timm
- Board 3 **Abstract 4524:** Deciphering the genomic landscape of renal cell carcinoma brain metastases. First Author: Betul Gok Yavuz, MD, PhD
- Board 4 **Abstract 4525:** CheckMate-901: Association of tumor and peripheral biomarker profiles with durable disease control in metastatic urothelial carcinoma treated with nivolumab plus ipilimumab. First Author: Matthew D. Galsky, MD, FASCO
- Board 5 **Abstract 4526:** Machine learning–based transcriptomic signatures to predict treatment outcomes across targeted and immunotherapy regimens in renal cell carcinoma. First Author: Peng Li, MS
- Board 6 **Abstract 4527:** Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial. First Author: Viktor Grünwald, MD

- Board 7 **Abstract 4528:** Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial. First Author: Andrea B. Apolo, MD, FASCO
- Board 8 **Abstract 4529:** An external validation of the IMmotion151 molecular subtypes in patients with advanced renal cell carcinoma using the ORIEN database. First Author: Gautham Prakash, MD
- Board 9 **Abstract 4530:** Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial. First Author: Amishi Yogesh Shah, MD
- Board 10 **Abstract 4531:** Efficacy of fruquintinib (F) plus sintilimab (S) versus axitinib (A) or everolimus (E) by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma (RCC): A subgroup analysis of the FRUSICA-2 study. First Author: Kaiwei Yang, MD
- Board 11 **Abstract 4532:** Emotional health concerns due to kidney cancer (KC) and unmet needs in patient support: Results from the International Kidney Cancer Coalition (IKCC) Global Patient Survey (GPS). First Author: Eric Jonasch, MD
- Board 12 **Abstract 4533:** Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden. First Author: Yuan-Yuan Qu, PhD
- Board 13 **Abstract 4534:** A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma. First Author: Neil J. Shah, MD
- Board 14 **Abstract 4535:** Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study. First Author: Benjamin Garmez, MD
- Board 15 **Abstract 4536:** Neoadjuvant apatinib plus camrelizumab in renal cell carcinoma with inferior vena cava tumor thrombus: Results of a phase II study. First Author: RuiYang Xie, MD
- Board 16 **Abstract 4537:** [⁶⁸Ga] Ga-NYM096 PET/CT in patients with primary and metastatic clear cell renal cell carcinoma: A preliminary study. First Author: Yangyang Xue
- Board 17 **Abstract 4538:** Body composition and quality of life (QOL) with lenvatinib + everolimus (len + eve) versus cabozantinib (cabo) in metastatic clear cell renal cell carcinoma (ccRCC) after PD-1 inhibitor progression: Results from the randomized phase II LenCabo trial. First Author: Julia Moura, MD

- Board 18 **Abstract 4539:** Defining second-line sequencing in advanced renal cell carcinoma: A systematic review and meta-analysis.
First Author: Luisana Sisca, MD
- Board 19 **Abstract 4540:** Relationships between clinical stage, pathological stage, and disease-free (DFS) survival in renal cell carcinoma as used to inform future neoadjuvant study design: ECOG-ACRIN EA8143 PROSPER analysis.
First Author: James Owain Jones, PhD, MRCP, MBBCh
- Board 20 **Abstract 4541:** Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 150 RCC patients.
First Author: Harshitha Reddy Dudipala, MD
- Board 21 **Abstract 4542:** Early detection of kidney cancer using blood-based multi-gene mRNA profiling in a prospective clinical study.
First Author: Taigo Kato, MD, PhD
- Board 22 **Abstract 4543:** Comprehensive characterization of HIF-2 α and carbonic anhydrase IX expression and the genomic landscape in clear cell and *VHL*-altered renal cell carcinoma.
First Author: Yu-Wei Chen, MD, MS
- Board 23 **Abstract 4544:** A first-in-human phase 1 dose-escalation study of the oral HIF-2 α inhibitor JMKX003948 in patients with renal cell carcinoma.
First Author: Xieqiao Yan
- Board 24 **Abstract 4545:** Investigating mechanisms of resistance to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC).
First Author: Soki Kashima, MD, PhD
- Board 25 **Abstract 4546:** Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.
First Author: Koral U. Shah, MD
- Board 26 **Abstract 4547:** First-line tivozanib in favorable- and very favorable–risk metastatic renal cell carcinoma: Real-world evidence from the TIVOREAL-SOGUG study.
First Author: Cristina Pernaut Sanchez, MD
- Board 27 **Abstract 4548:** LIF expression as a predictive biomarker in metastatic renal cell carcinoma.
First Author: Mustafa Saleh, MD
- Board 28 **Abstract 4549:** Nivolumab and Ipilimumab (NIVO IPI) as first-line (1L) treatment for patients with metastatic renal-cell carcinoma (mRCC): A real-world benchmarking analysis from the International mRCC Database Consortium (IMDC).
First Author: Heber Tomas Reyes-Garcia, MD
- Board 29 **Abstract 4550:** Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease–associated neoplasms.
First Author: Ramaprasad Srinivasan, MD, PhD
- Board 30 **Abstract 4551:** Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma.
First Author: Juan Ruiz Bañobre
- Board 31 **Abstract 4552:** Impact of time-of-day of immune checkpoint inhibitor infusion on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC).
First Author: Soon Khai Low, MD
- Board 32 **Abstract 4553:** Correlation between *CARINH* expression and clinical outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).
First Author: Wassim Daoud Khatoun, MD
- Board 33 **Abstract 4554:** A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma.
First Author: Marc Machaalani, MD
- Board 34 **Abstract 4555:** Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Robert J. Motzer, MD
- Board 35 **Abstract 4556:** Explainable AI to predict molecular classes of renal cell carcinoma from digital pathology images.
First Author: Jordan Krull
- Board 36 **Abstract 4557:** Spatial multiomic profiling to identify de-differentiated tumor phenotypes and exhausted T cell niches in rhabdoid and sarcomatoid RCC.
First Author: Zachary Alan Yochum, MD, PhD
- Board 37 **Abstract 4558:** Loss of chromosome Y and tumor immune phenotypes in metastatic renal cell carcinoma.
First Author: Pablo Barrios, MD
- Board 38 **Abstract 4559:** Association of baseline quality of life (QOL) and early death in patients with metastatic renal cell carcinoma (mRCC) in the real-world prospective observational ODYSSEY study.
First Author: Michael R. Harrison, MD
- Board 39 **Abstract 4560:** Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
First Author: Elise Y. Cai, MD, PhD
- Board 40 **Abstract 4561:** Real-world overall survival outcomes of belzutifan treatment in advanced renal cell carcinoma.
First Author: Elshad Hasanov, MD, PhD
- Board 41 **Abstract 4562:** Real-world clinical outcomes by HER2 expression in locally advanced/metastatic urothelial carcinoma (la/mUC): Results from the global SGNDV-003 retrospective study.
First Author: Vadim S. Koshkin, MD
- Board 42 **Abstract 4563:** Zelenectide pevvedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1.
First Author: Oscar Reig Torras, MD, PhD
- Board 43 **Abstract 4564:** Zelenectide pevvedotin (BT8009) plus pembrolizumab in 1L cisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update on Duravelo-1 B7.
First Author: Ignacio Duran, MD, PhD

- Board 44 **Abstract 4565:** Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
First Author: Jeffrey Yinhong Zhong, MD
- Board 45 **Abstract 4566:** Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Daniel P. Petrylak, MD
- Board 46 **Abstract 4567:** Identifying optimized dosage for zelenectide pevedotin in locally advanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses.
First Author: Yasong Lu, PhD
- Board 47 **Abstract 4568:** Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.
First Author: Petros Grivas, MD, PhD, FASCO
- Board 48 **Abstract 4569:** Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab.
First Author: Adanma Ayanambakkam, MD, MS
- Board 49 **Abstract 4570:** Untreated advanced urothelial carcinoma (aUC) in the modern treatment era: Patterns of care from a decade-long national cohort.
First Author: Melanie Mayer, PhD
- Board 50 **Abstract 4571:** Characterizing the immune effects of enfortumab vedotin and pembrolizumab (EV+P) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).
First Author: Aditi Gupta, MD
- Board 51 **Abstract 4572:** Genomic determinants of metastatic burden and survival in metastatic urothelial carcinoma.
First Author: Milit S. Patel, BS
- Board 52 **Abstract 4573:** CXCL9:SPP1 ratio: Macrophage polarization and outcomes with pembrolizumab or enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.
First Author: Saad Omar Atiq, MD
- Board 53 **Abstract 4574:** The role of NECTIN4 in shaping the tumor microenvironment and potentiating the efficacy of immunotherapy in bladder cancer.
First Author: Kazuki Nishimura
- Board 54 **Abstract 4575:** Outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC) by *NECTIN4* and *HER2* RNA expression: Exploratory analyses from JAVELIN Bladder 100.
First Author: Niklas Klümper, MD
- Board 55 **Abstract 4576:** Treatment-free survival (TFS) in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV)-based therapy.
First Author: Salvador Jaime-Casas, MD
- Board 56 **Abstract 4577:** Quantitative pre-cystectomy ctDNA levels for identification of ctDNA-positive patients with surgically curable loco-regional disease versus those with occult micrometastatic progression.
First Author: Ruveyda Ayasun, MD, PhD
- Board 57 **Abstract 4578:** Outcomes with enfortumab vedotin (EV) rechallenge after disease progression in metastatic urothelial carcinoma.
First Author: Michal Sternschuss, MD
- Board 58 **Abstract 4579:** A phase 1b study of SYS6002 in advanced solid tumors.
First Author: Yao Zhu, MD
- Board 59 **Abstract 4580:** Proteomic profiling of circulating tumor cells (CTCs) in metastatic urothelial cancer (mUC) as associated with upregulation of EGFR, HER2, and B7-H3 in patients (pts) progressing on enfortumab vedotin (EV) plus pembrolizumab.
First Author: Wadih Issa, MD
- Board 60 **Abstract 4581:** Responses to trastuzumab deruxtecan (T-Dxd) in HER2 IHC spectrum 2+ versus 3+ urothelial carcinoma across lines of therapy.
First Author: Sara El Sarout, MD
- Board 61 **Abstract 4582:** Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
First Author: Mohammad Jad Moussa, MD, MSc
- Board 62 **Abstract 4583:** Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial.
First Author: Syed A. Hussain, MD
- Board 63 **Abstract 4584:** Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).
First Author: Rishi Raju Patel, MD
- Board 64 **Abstract 4585:** Long-term survival update of TRUCE-01: A phase 2 study of preoperative tislelizumab combined with low-dose nab-paclitaxel for muscle-invasive bladder cancer (MIBC).
First Author: Zhouliang Wu
- Board 65 **Abstract 4586:** Paired Nectin4 expression analysis pre and post enfortumab vedotin and pembrolizumab in urothelial carcinoma.
First Author: Michal Sternschuss, MD
- Board 66 **Abstract 4587:** Clinical outcomes for patients (pts) with synchronous versus metachronous metastatic urothelial cancer (mUC) treated with enfortumab vedotin and pembrolizumab (EV-P).
First Author: Libin Yan, MD, PhD
- Board 67 **Abstract 4588:** Use of *NECTIN4* expression inferred from circulating chromatin to predict response and survival to enfortumab vedotin (EV) in metastatic urothelial carcinoma.
First Author: Rashad Nawfal, MD
- Board 68 **Abstract 4589:** Cost-effectiveness analysis of first-line (1L) therapies for advanced urothelial carcinoma (aUC) from a U.S. payer perspective.
First Author: Prateek Jain, MBBS

- Board 69 **Abstract 4590:** A novel oncolytic vaccinia virus armed with IL-21 and 4-1BBL for intravesical treatment of NMIBC: Preclinical efficacy and first-in-human safety evaluation.
First Author: Shun Zhang, postgraduate
- Board 70 **Abstract 4591:** Keratin 19 (KRT19) as a circulating biomarker to measure disease burden and guide treatment in urothelial cancer.
First Author: Eric James Miller, MD
- Board 71 **Abstract 4592:** Preliminary results of a single-arm, multi-center, prospective clinical study of disitamab vedotin combined with toripalimab and pelvic lymph node dissection for bladder preservation in patients with cT2-4aN0M0 bladder urothelial carcinoma and HER2 expression $\geq 2+$ after maximal TURBT.
First Author: Tianhang Lan
- Board 72 **Abstract 4593:** Urinary tumor DNA-guided de-escalation of systemic immunotherapy in extensive very high risk non-muscle-invasive bladder cancer.
First Author: Yunkai Qie, MD
- Board 73 **Abstract 4594:** Evidence implicating human papillomavirus in bladder carcinogenesis: A case-control study.
First Author: Xueying Zhang, MD
- Board 74 **Abstract 4595:** Clinical outcomes with *ERBB2* gene amplification and activating mutations in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy.
First Author: Earle F. Burgess
- Board 75 **Abstract 4596:** Impact of FGFR3 pathway activation in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy.
First Author: Earle F. Burgess
- Board 76 **Abstract 4597:** PUNCH03: Preliminary results from a phase II study of disitamab vedotin combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang
- Board 77 **Abstract 4598:** Cost-effectiveness analysis in the era of systemic immunotherapy for BCG-naive high-risk non-muscle-invasive bladder cancer in the United States, the United Kingdom, and China.
First Author: Zihan Xue, MD
- Board 78 **Abstract 4599:** Final results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for high-risk non-muscle-invasive bladder cancer patients unresponsive to Bacillus Calmette-Guerin.
First Author: Zhiyong Li, MD
- Board 79 **Abstract 4600:** Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC).
First Author: Khilna Patel, PharmD
- Board 80 **Abstract 4601:** Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).
First Author: Sandip M. Prasad
- Board 81 **Abstract 4602:** Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.
First Author: Ruchika Talwar, MD
- Board 82 **Abstract 4603:** Influence of low-coverage whole-genome sequencing-based urinary tumor fraction and chromosomal instability on recurrence risk stratification in systemic immunotherapy-treated non-muscle-invasive bladder cancer.
First Author: Yunkai Qie, MD
- Board 83 **Abstract 4604:** UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
First Author: Abhishek Srivastava, MD
- Board 84 **Abstract 4605:** Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma.
First Author: Zihao Tao
- Board 85 **Abstract 4606:** Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Real-world evidence from the SOGUG-NIADY study of the Spanish Oncology Genitourinary Group (SOGUG).
First Author: Sara Perez Ramirez
- Board 86 **Abstract 4607:** Magnitude and timing of clinical benefit associated with pathologic complete response in perioperative muscle-invasive bladder cancer: A reconstructed IPD analysis of NIAGARA trial.
First Author: Andrea Malgeri, MD
- Board 87 **Abstract 4608:** Progress of phase II study of MVR-T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in high-risk BCG-unresponsive CIS and papillary NMIBC.
First Author: Dingwei Ye
- Board 88 **Abstract 4609:** Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.
First Author: Zhuowei Liu
- Board 89 **Abstract 4610:** Survival and treatment patterns of patients with metastatic urothelial cancer in France: Results of a cohort study using the French National Healthcare database (SNDS).
First Author: Philippe Barthelemy
- Board 90 **Abstract 4611:** Real-world effectiveness of disitamab vedotin plus PD-1 inhibitor versus platinum-based chemotherapy as postoperative adjuvant therapy in high-risk upper tract urothelial carcinoma: A comparative study.
First Author: Yudong Cao, MD
- Board 91 **Abstract 4612:** Real-world treatment patterns and clinical outcomes among US patients with non-muscle invasive bladder cancer (NMIBC) during the BCG shortage.
First Author: Suzanne Biehn Merrill, MD

- Board 92 **Abstract 4613:** Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905. First Author: Nabil Adra, MD
- Board 93 **Abstract 4614:** Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. First Author: Christopher J. Hoimes, DO
- Board 95 **Abstract 4616:** Adjuvant or rescue disitamab vedotin for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multicenter study. First Author: Junru Chen
- Board 96 **Abstract 4617:** Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC). First Author: Andrea Necchi, MD
- Board 97 **Abstract 4618:** TRUCE-11: An open-label, single-arm, multicenter phase II study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma. First Author: Zhouliang Wu
- Board 98 **Abstract 4619:** Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial. First Author: Brigida Anna Maiorano, MD
- Board 99 **Abstract 4620:** Association of GLP-1 receptor agonist therapy with BCG response in high-risk non-muscle invasive bladder cancer. First Author: Benyamin Yaniv, MD
- Board 100 **Abstract 4621:** Rethinking the role of tumor size in bladder preservation: Comparing survival outcomes of radical cystectomy (RC) and tri-modality therapy (TMT). First Author: Dawood Hasan Syed, MD
- Board 101 **Abstract 4622:** Exploration of biomarkers for TRUCE-01: Development of a urine-based efficacy prediction model. First Author: Yuda Lin
- Board 102 **Abstract 4623:** Chemoablation with oral erdafitinib in recurrent *FGFR3*-altered non-muscle-invasive bladder cancer: A phase II window-of-opportunity trial. First Author: Muhammad Hassan Alkazemi, MD, MS
- Board 105 **Abstract 4626:** Updated efficacy and safety of SHR-1501, an IL-15R α Fc superagonist, with or without Bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. First Author: Zhisong He, MD
- Board 106 **Abstract 4627:** Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct) DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC). First Author: Joaquim Bellmunt, MD
- Board 107 **Abstract 4628:** Molecular classification of neuroendocrine carcinoma of the bladder. First Author: Shijia Li, MD
- Board 108a **Abstract TPS4629:** A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC). First Author: Qian Qin, MD
- Board 108b **Abstract TPS4630:** A multicenter randomized controlled clinical study of neoadjuvant combination of axitinib plus toripalimab to improve disease-free survival of patients with renal cell carcinoma. First Author: Zhiling Zhang
- Board 109a **Abstract TPS4631:** Phase 3 study to assess the safety and efficacy of ¹⁷⁷Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON). First Author: David Cade, MD
- Board 110a **Abstract TPS4633:** LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti-PD-(L)1 therapy. First Author: Cristina Suárez, MD, PhD
- Board 110b **Abstract TPS4634:** ZAMBONI: A phase II study of zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases previously treated with immune checkpoint inhibitors. First Author: Kelly N. Fitzgerald, MD
- Board 111a **Abstract TPS4635:** First-in-human study of [¹¹¹In] XYIMSR-01 SPECT/CT, a novel carbonic anhydrase IX small molecule in patients with metastatic clear cell renal cell carcinoma. First Author: Yasser Ged, MBBS, MRCP
- Board 111b **Abstract TPS4636:** PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma. First Author: Toni K. Choueiri, MD, FASCO
- Board 112a **Abstract TPS4637:** Phase II study of cemiplimab ± fianlimab following SBRT for oligometastatic clear-cell RCC (LAG-BOOST). First Author: Abhirami Das, MBBS
- Board 112b **Abstract TPS4638:** A phase I, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activities of GenSci139 in patients with solid tumors. First Author: Jinming Yu
- Board 113a **Abstract TPS4639:** An open-label phase 1 study of DCC-2812 monotherapy in patients with advanced genitourinary cancers. First Author: Ildelfonso Ismael Rodriguez-Rivera, MD
- Board 113b **Abstract TPS4640:** RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a costimulatory bispecific antibody for the treatment of advanced bladder cancer and other Nectin-4-positive solid tumors. First Author: John D. Powderly II, MD

- Board 114a **Abstract TPS4641:** A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti-PD-(L)1-resistant advanced urothelial cancer: ECOG-ACRIN EA8231.
First Author: Monika Joshi, MD
- Board 114b **Abstract TPS4642:** TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab.
First Author: Matthew D. Galsky, MD, FASCO
- Board 115a **Abstract TPS4643:** Advancing treatment of low-grade upper tract urothelial carcinoma (LG UTUC) with padeliporfin vascular-targeted photodynamic therapy (VTP): The ENLIGHTED phase 3 trial.
First Author: Vitaly Margulis, MD
- Board 115b **Abstract TPS4644:** Selective bladder-sparing trial with sasanlimab as maintenance treatment based on clinical response to neoadjuvant treatment in molecularly categorized muscle invasive bladder cancer patients: SASAN-SPARING trial.
First Author: Elena Sevillano, MD

9:00 AM-12:00 PM Poster Session

Genitourinary Cancer—Prostate, Testicular, and Penile

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 116-119

Germ Cell/Testicular Cancer: Board(s) 120-125, 226a

Outcomes/Quality: Board(s) 126-128, 226b

Penile Cancer: Board(s) 129-130, 227a

Prostate Cancer—Advanced/Castrate-Resistant: Board(s) 131-174, 227b-233b

Prostate Cancer—Advanced/Hormone-Sensitive: Board(s) 175-203, 234a-235b

Prostate Cancer—Local-Regional Disease: Board(s) 204-221, 236a-236b

Other Prostate, Testicular, or Penile Cancer: Board(s) 222-225

- Board 116 **Abstract 5021:** Validation of prostate-specific antigen (PSA) decline among the Latin American subgroup of LIBERTAS: A phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Andrea Juliana Gomes, MD
- Board 117 **Abstract 5022:** Real-world genetic testing patterns in prostate cancer assessed via artificial intelligence: Implications for NCCN guideline implementation.
First Author: Mitchell Singstock, MD
- Board 118 **Abstract 5023:** Image-only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies.
First Author: Xinglei Shen, MD

- Board 119 **Abstract 5024:** AI-assisted preoperative communication in prostate cancer: A prospective, single-blinded, randomized phase II trial.
First Author: Zheng Liu, PhD
- Board 120 **Abstract 5025:** Implementation of serum microRNA-371a-3p testing for testicular germ-cell tumors in a pathology department: Real-world data from a comprehensive cancer center.
First Author: João Lobo
- Board 121 **Abstract 5026:** Comparative transcriptomic analysis of chemotherapy-naive and post-chemotherapy germ cell tumors.
First Author: Michal Mego, MD, PhD
- Board 122 **Abstract 5027:** Genomic determinants of cisplatin resistance in germ cell tumors.
First Author: Vincent D'Andrea, MD
- Board 123 **Abstract 5028:** Prognostic significance of teratoma components in germ cell tumor patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
First Author: Nurlan Mammadzada, MD
- Board 124 **Abstract 5029:** Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study.
First Author: Zachariah Thomas, MBBS
- Board 125 **Abstract 5030:** Regional trends in testicular cancer burden among adolescents and young adults (15–39 years), 1990–2023: A Global Burden of Disease analysis.
First Author: Vanshika Singh, MBBS
- Board 126 **Abstract 5031:** Metabolic and inflammatory marker elevations and associations with hormone therapy usage in prostate cancer patients of the All of Us Research Program cohort.
First Author: Yuanchu J. Yang, MD
- Board 127 **Abstract 5032:** Burden, mortality patterns, and treatment disparities of prostate cancer across G20 countries: Insights from the Global Burden of Disease 2023 study.
First Author: Kashish Magnani, MBBS
- Board 128 **Abstract 5033:** Real-world overall survival outcomes of lutetium (Lu¹⁷⁷) vipivotide tetraxetan treatment in prostate cancer.
First Author: Elshad Hasanov, MD, PhD
- Board 129 **Abstract 5034:** Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE).
First Author: Fang Yuan, MD, PhD
- Board 130 **Abstract 5035:** Spatial immune architecture as used to define progression and treatment response in penile squamous cell carcinoma.
First Author: Firas Hatoum, MD
- Board 131 **Abstract 5036:** HRS-1167 (M9466), a PARP1 inhibitor, combined with abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: A phase 1b/2 study.
First Author: Chaozhao Liang

- Board 132 **Abstract 5037:** Evaluation of the safety, efficacy and dosimetry of TRC003 in metastatic castration-resistant prostate cancer: A prospective, open-label, single-arm study.
First Author: Suping Li
- Board 133 **Abstract 5038:** Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study.
First Author: Valentina Boni, MD, PhD
- Board 134 **Abstract 5039:** Cell-free DNA nucleosome and genomic signatures as predictors of outcomes with radium-223 in metastatic castration-resistant prostate cancer.
First Author: David Dawei Chen, MD
- Board 135 **Abstract 5040:** Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE).
First Author: Rana R. McKay, MD, FASCO
- Board 136 **Abstract 5041:** Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
First Author: Ethan Lo, BS
- Board 138 **Abstract 5043:** Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: Extended follow-up.
First Author: Ugo De Giorgi, MD, PhD
- Board 139 **Abstract 5044:** Genomic landscape of *TP53* Y220C-mutated clinically advanced prostate carcinoma (CAPC).
First Author: Varun Nandakumar, MBBS
- Board 140 **Abstract 5045:** Clonal hematopoiesis-related outcomes associated with radioligand therapy in prostate cancer: A “real-world” analysis.
First Author: Robert Yuan, MD
- Board 141 **Abstract 5046:** Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.
First Author: Xinan Sheng, MD
- Board 142 **Abstract 5047:** Phase 1, multicenter, open-label study of HSK46575 in patients with metastatic castration-resistant prostate cancer progressing after next-generation hormonal agents and chemotherapy.
First Author: Qiang Wei
- Board 143 **Abstract 5048:** Integrated clinical and molecular characterization of WNT pathway alterations in metastatic castration-resistant prostate cancer (mCRPC) liver metastases (mets).
First Author: Elise Y. Cai, MD, PhD
- Board 144 **Abstract 5049:** Phase I dose-escalation results of ¹⁷⁷Lu-NYM032 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).
First Author: Yanjuan Wang
- Board 145 **Abstract 5050:** ProTACT: Preliminary data from a first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [²²⁵Ac] Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
First Author: Alison Yan Zhang, PhD, MMed, MBBS, FRACP
- Board 146 **Abstract 5051:** Analysis of genomic and clinical predictors of overall survival and PSA response: Results from the PRECISION registry.
First Author: Hyotae Kim, PhD
- Board 147 **Abstract 5052:** Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
First Author: Christopher Choi, MD
- Board 148 **Abstract 5053:** Regional disparities in prostate cancer mortality in the African Union: A retrospective analysis (1980-2023).
First Author: Abubakar Nazir, MBBS
- Board 149 **Abstract 5054:** Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in *BRCA*-mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
First Author: Srikala S. Sridhar, MD, MSc, FRCPC
- Board 150 **Abstract 5055:** Phase 1b/2 study of pembrolizumab plus lenvatinib or pembrolizumab coformulated with vibostolimab in participants (pts) with metastatic neuroendocrine prostate cancer (NEPC): KEYNOTE-365 cohorts F and H.
First Author: Gunhild Von Amsberg, MD
- Board 151 **Abstract 5056:** Can TGF-β inhibition (galunisertib) enhance response to enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)? Results from a randomized phase II trial.
First Author: Nicole Metri, MD
- Board 152 **Abstract 5057:** A randomized phase Ib/II study of enzalutamide (Enza) with and without ribociclib (Rib) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that retains RB expression: RiboX study.
First Author: Kevin Kayvan Zarrabi, MD, FACP, MS
- Board 153 **Abstract 5058:** Belzutifan in docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Phase 1b/2 KEYNOTE-365 cohort J.
First Author: Jose Angel Arranz Arijia, MD, PhD
- Board 154 **Abstract 5059:** Utidelone in heavily pretreated metastatic castration-resistant prostate cancer progressing after docetaxel and novel hormonal agents: Results of a completed phase II trial.
First Author: Meiting Chen
- Board 155 **Abstract 5060:** Rad2Nivo: Phase IB study of radium-223 (Rad) with nivolumab (Nivo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Georges Gebrael, MD

- Board 156 **Abstract 5061:** Mortality trends and disparities in prostate cancer with co-occurring cardiometabolic disorders among U.S. men aged ≥ 55 years, 1999–2024.
First Author: Mian Muinuddin Jamshed, MBBS
- Board 157 **Abstract 5062:** Efficacy, safety, and quality of life outcomes of ^{177}Lu -PSMA-617 in metastatic castration-resistant prostate cancer: A GRADE-assessed systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.
First Author: Moosa Mubarika, MBBS
- Board 158 **Abstract 5063:** A phase I study of ^{225}Ac Ac-PSMA-XT, a novel alpha-particle-emitting radioligand therapy, in patients with metastatic castration-resistant prostate cancer.
First Author: Xiaorong Sun, MD
- Board 159 **Abstract 5064:** Genomic biomarkers of sensitivity to bipolar androgen therapy (BAT) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Diogo Assed Bastos, MD
- Board 160 **Abstract 5065:** Early chemo-induced TME alterations as a predictor of response to PD-1 blockade in AVPC: Single-cell data from C3NIRA.
First Author: Anthos Christofides, MD
- Board 161 **Abstract 5066:** Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.
First Author: Peter D. Zang, MD
- Board 162 **Abstract 5067:** Correlation between dual FDG/PSMA PET mismatch and ctDNA genomic profiling in metastatic castration-resistant prostate cancer (mCRPC) patients screened for ^{177}Lu -PSMA.
First Author: Louise Lazerges, MD
- Board 163 **Abstract 5068:** Predicting response to ^{177}Lu -PSMA-617 in metastatic prostate cancer (mPC) using plasma-derived extracellular vesicles (EVs).
First Author: Albert Jang, MD
- Board 164 **Abstract 5069:** Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
First Author: Charles J. Ryan, MD
- Board 165 **Abstract 5070:** Initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate (AA) in patients (pts) with mCRPC.
First Author: Christopher Joseph Sumey, MD
- Board 166 **Abstract 5071:** Real-world use of olaparib in US veterans with metastatic castration-resistant prostate cancer: Treatment patterns and outcomes.
First Author: Christelle McFarland
- Board 167 **Abstract 5072:** Sequencing of PARP inhibitors and taxane chemotherapy in HRR-altered metastatic castration-resistant prostate cancer: A real-world VA analysis.
First Author: June K. Corrigan, MS
- Board 169 **Abstract 5074:** Dissecting metastatic castration-resistant prostate cancer using regulatory network analysis of tumor transcriptomes.
First Author: Aaron Timothy Griffin, MD, PhD
- Board 170 **Abstract 5075:** Clinical outcomes of sequential androgen receptor pathway inhibitors (ARPIs) versus novel therapies in metastatic castration-resistant prostate cancer after progression on second-generation ARPIs: A systematic review and meta-analysis.
First Author: Rohan Garje, MD
- Board 171 **Abstract 5076:** Androgen receptor (AR) gene dynamics in ctDNA post-abiraterone/enzalutamide: Longitudinal study in mCRPC with germline results.
First Author: Minqi Huang, MS
- Board 172 **Abstract 5077:** Effect of frailty measures on overall survival in prostate cancer: A systematic review and meta-analysis.
First Author: Nicole Sequeira, MBBS
- Board 173 **Abstract 5078:** Transient prostate-specific antigen flare induced by lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration resistant prostate cancer.
First Author: Tiewei Cheng, MD, PhD
- Board 174 **Abstract 5079:** Post-ARPI sequencing in mCRPC: A propensity-matched real-world comparison of ^{177}Lu -PSMA-617 versus docetaxel for early clinical outcomes.
First Author: Sooraj Srirangadhamu Gopu, MD
- Board 175 **Abstract 5080:** Real-world characteristics, homologous recombination repair mutation (HRRm) testing, treatment patterns, and outcomes of patients with metastatic castration-sensitive prostate cancer (mCSPC) in the US community oncology setting.
First Author: Manojkumar Bupathi, MD
- Board 176 **Abstract 5081:** Comparative efficacy and safety of systemic therapies in high-risk hormone-sensitive prostate cancer: A network meta-analysis of 13 phase III randomized trials.
First Author: Neel Ketankumar Parikh, MBBS
- Board 177 **Abstract 5082:** Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial.
First Author: Soumyajit Roy, MD, MBBS, MSc
- Board 178 **Abstract 5083:** Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED).
First Author: Atish Dipankar Choudhury, MD, PhD
- Board 179 **Abstract 5084:** Remote activity monitoring to detect physical function decline and unexpected medical events in patients with prostate cancer undergoing androgen deprivation therapy.
First Author: Brandon Noorvash, BA
- Board 180 **Abstract 5085:** Cognition of apalutamide + ADT treatment responders versus non-responders.
First Author: Arun Azad, PhD, MBBS, FRACP
- Board 182 **Abstract 5087:** Evaluation of concomitant medications in advanced prostate cancer patients receiving apalutamide: TITAN and SPARTAN post-hoc analysis.
First Author: Neeraj Agarwal, MD, FASCO

- Board 183 **Abstract 5088:** EMBARK: Testosterone recovery to >250 ng/dL following treatment suspension.
First Author: Stephen J. Freedland, MD
- Board 184 **Abstract 5089:** Genomic and transcriptomic correlates of deep PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Emmanuel S. Antonarakis, MD
- Board 185 **Abstract 5090:** Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial.
First Author: Dingwei Ye, MD
- Board 186 **Abstract 5091:** Does a statin a day keep prostate cancer (PC) away?: Statin use and disease progression in patients receiving androgen deprivation therapy (ADT) after radical prostatectomy (RP) in SEARCH.
First Author: Maria P. Mogollon, MD
- Board 187 **Abstract 5092:** Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.
First Author: Arnulf Stenzl, MD
- Board 188 **Abstract 5093:** Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.
First Author: Andrew J. Armstrong, MD, MS
- Board 189 **Abstract 5094:** Outcomes with androgen-deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: A subgroup analysis of enzalutamide and high-volume disease.
First Author: Martin W. Schoen, MD, MPH
- Board 190 **Abstract 5095:** Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry.
First Author: Alexandra Larkin, MPH
- Board 191 **Abstract 5096:** Correlation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.
First Author: Georges Gebrael, MD
- Board 192 **Abstract 5097:** Outcomes of radical radiotherapy in de novo low-burden metastatic hormone-sensitive prostate cancer vs prostate radiotherapy alone.
First Author: Kelvin Yan
- Board 193 **Abstract 5098:** Impact of a whole-food plant-based diet (WFPBD) on weight and metabo-inflammation in men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.
First Author: Nicole Jacobs
- Board 194 **Abstract 5099:** Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).
First Author: Anis Hamid, PhD, MBBS
- Board 195 **Abstract 5100:** Prognostic value of PSA nadir ≤ 0.2 ng/mL in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
First Author: Arjun Pon Avudaiappan
- Board 196 **Abstract 5101:** Clinical impact and molecular profiling of *PTEN* loss and *TMPRSS2:ERG* fusion in metastatic hormone-sensitive prostate cancer.
First Author: Carme Crous, MD
- Board 197 **Abstract 5102:** Quantitative results from PSMAtrack: A prospective study evaluating changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Praful Ravi, MBBChir, MRCP
- Board 198 **Abstract 5103:** Prostate-specific antigen outcomes of darolutamide and androgen deprivation therapy in patient subgroups by age, comorbidities, and concomitant medications: ARANOTE post hoc analyses.
First Author: Fred Saad, MD, FRCS
- Board 199 **Abstract 5104:** Prognostic potential of PROSTest for predicting outcome in ADT-treated Black South African prostate cancer patients.
First Author: Susanna Elizabeth Nagel, MD
- Board 200 **Abstract 5105:** Overall survival in veterans with metastatic hormone sensitive prostate cancer by initial therapy and STRATOS-P somatic tumor classification.
First Author: Robert Wilson, BA
- Board 201 **Abstract 5106:** STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.
First Author: Martin W. Schoen, MD, MPH
- Board 202 **Abstract 5107:** Major adverse cardiovascular events in androgen receptor signaling inhibitor-treated patients with metastatic castration-sensitive prostate cancer.
First Author: Linden Huhmann
- Board 203 **Abstract 5108:** Homologous recombination repair (HRR) genes and overall survival prognosis within the STRATOS-P classification in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Kara N. Maxwell, MD, PhD
- Board 204 **Abstract 5109:** Optimal prostate-specific antigen cutoff for prostate cancer detection: A prospective cohort study.
First Author: Yun-Gyoo Lee, MD, PhD
- Board 205 **Abstract 5110:** Large language model protein set generation for interpretable serum proteomics in localized prostate cancer.
First Author: Nicholas Robert Rydzewski, MD, MPH

- Board 206 **Abstract 5111:** Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080).
First Author: Md Mamunur Rahaman
- Board 207 **Abstract 5112:** External validation of new prostate cancer risk groups by PSMA-PET (PPP3).
First Author: Wolfgang Peter Fendler, MD
- Board 208 **Abstract 5113:** Is language barrier a mere proxy?: Psychological distress among non-English-speaking prostate cancer patients receiving radiation therapy—A prospective cohort study.
First Author: Teresia M. John, BS
- Board 209 **Abstract 5114:** Assessing the clinical and biological associations between multimodal artificial intelligence (MMAI) and 22-gene genomic classifier (GC) in localized prostate cancer (PCa).
First Author: Boon Hao Hong, MS
- Board 210 **Abstract 5115:** A prospective study of mpMRI-guided salvage radiotherapy with lesion-directed dose escalation after radical prostatectomy: 10-year follow-up results (MRI Study: UMIN 00009823).
First Author: Kenshiro Shiraishi, MD
- Board 212 **Abstract 5117:** Survival outcomes and subgroup efficacy analysis of Ga-68-NGUL and Lu-177-DGUL (pocuvotide satetraxetan) in patients with mCRPC: Results from a phase 1/2 study.
First Author: Chang Wook Jeong, MD, PhD
- Board 213 **Abstract 5118:** Spatially organized immune niches in high-grade primary prostate cancer.
First Author: Aishwarya Atmakuri, BS
- Board 214 **Abstract 5119:** Neoadjuvant androgen receptor pathway inhibition for patients with high-risk localized prostate cancer: 5-year survival update and PSMA PET correlatives of the randomized NeoPRO trial.
First Author: Gabriel Berlingieri Polho, MD
- Board 215 **Abstract 5120:** A head-to-head comparison of sextant-systematic biopsy versus extended-systematic biopsy for prostate cancer diagnosis in the era of MRI-targeted biopsy: Non-inferiority randomized clinical trial.
First Author: Ruiyi Deng, MD
- Board 216 **Abstract 5121:** Long-term oncologic outcomes of PSMA PET-guided salvage radiotherapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis.
First Author: Muhammad Moghis, MBBS
- Board 217 **Abstract 5122:** Evaluation of treatment outcomes in ductal and intraductal prostate cancer: Insights from the National Cancer Database.
First Author: Annabel Ricci
- Board 218 **Abstract 5123:** Association of cardiovascular outcomes with GnRH agonist and antagonist therapy in non-metastatic prostate cancer.
First Author: Abdulraof Ghiblawi, MD
- Board 219 **Abstract 5124:** Temporal evolution of prostate cancer incidence and incidence-based mortality from 2000 to 2022: A retrospective analysis by race and age at diagnosis based on USPSTF screening guidelines.
First Author: Charles Tobin, DO
- Board 220 **Abstract 5125:** Addition of 18F-DCFPyL PSMA PET to MRI to avoid unnecessary biopsy in men on active surveillance: Final results from a phase II diagnostic trial (PROMPT).
First Author: Marcelo Bigarella, MD
- Board 221 **Abstract 5126:** Leveraging spatial proteomics to identify epithelial cell subtypes driving poor prognosis in prostate cancer.
First Author: William Chen, MD
- Board 222 **Abstract 5127:** Clinical implications and diagnostic utility of ⁶⁸Gallium FAPI PET CT in patients with testicular germ cell tumors: The prospective phase Ib FAPI-TEST study.
First Author: Maximilian Peter Johannes Karl Brandt
- Board 223 **Abstract 5128:** First-in-human PET imaging of ⁶⁸Ga-FC516, a novel ACP3-targeted radiotracer for prostate cancer.
First Author: Kongzhen Hu, PhD
- Board 224 **Abstract 5129:** Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).
First Author: Sonia Macia, MD, PhD
- Board 225 **Abstract 5130:** cfDNA-based signatures of nucleosome organization to enable prostate cancer subtyping.
First Author: Weiwei Bian, PhD
- Board 226a **Abstract TPS5131:** Randomized phase 1 trial of cisplatin-based chemotherapy with or without sodium thiosulfate for men with metastatic germ cell tumor (GCT).
First Author: Koral U. Shah, MD
- Board 226b **Abstract TPS5132:** Protocol for ADHERE: A randomised controlled trial evaluating a digital exercise intervention with virtual supervised group exercise sessions compared to standard of care for patients receiving androgen deprivation therapy for prostate cancer.
First Author: Emily Curtis, BSc
- Board 227a **Abstract TPS5133:** DEPECA-1 (Defeating Penile Cancer 1): A phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma.
First Author: Igor Tsaur, MD
- Board 227b **Abstract TPS5134:** AcTFirst: A phase 3 trial of ²²⁵Ac-PSMA-617 plus ARPI versus standard of care in adults with PSMA-positive metastatic castration-resistant prostate cancer.
First Author: Alton Oliver Sartor, MD
- Board 228a **Abstract TPS5135:** OMAHA-004: Phase 3 trial of the steroidogenesis inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.
First Author: Donald Charles Vile, MD
- Board 228b **Abstract TPS5136:** A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.
First Author: Kim N. Chi, MD

- Board 229a **Abstract TPS5137:** BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).
First Author: Johann S. De Bono, MD, PhD, MB, MSc
- Board 229b **Abstract TPS5138:** A phase II clinical trial of ivonescimab (VEGFxPD-1 bispecific antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Bilal Ahmed Siddiqui, MD
- Board 230a **Abstract TPS5139:** A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.
First Author: Rana R. McKay, MD, FASCO
- Board 230b **Abstract TPS5140:** Phase 1/2 OMAHA-U01 substudy 01A: Oral steroidogenesis inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arif Hussain, MD, PhD
- Board 231a **Abstract TPS5141:** ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [²²⁵Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
First Author: Robert Dreicer, MD, MACP, MS, FASCO
- Board 231b **Abstract TPS5142:** TIDAL: A phase II study of the DLL3-directed t-cell engager tarlatamab in DLL3-positive metastatic prostate cancer.
First Author: Karen A. Autio, MD, MSc
- Board 232a **Abstract TPS5143:** A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.
First Author: Michael Ong, MD, FRCPC
- Board 232b **Abstract TPS5144:** XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator's choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
First Author: Tanya B. Dorff, MD, FASCO
- Board 233a **Abstract TPS5145:** TALENT: A randomized phase 2 study of talazoparib with or without enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) alterations after progression on abiraterone acetate.
First Author: Karen A. Autio, MD, MSc
- Board 233b **Abstract TPS5146:** Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).
First Author: Neeraj Agarwal, MD, FASCO

- Board 234a **Abstract TPS5147:** REINFORCE: A phase III randomized trial of treatment intensification with docetaxel in metastatic hormone-sensitive prostate cancer patients without deep PSA response after initial apalutamide therapy.
First Author: Enrique Gonzalez-Billalabeitia, MD, PhD
- Board 234b **Abstract TPS5148:** An open-label, parallel-cohort, multicenter clinical study of rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer.
First Author: Qi Lin, MD
- Board 235a **Abstract TPS5149:** TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
First Author: Michael Ong, MD, FRCPC
- Board 235b **Abstract TPS5150:** EORTC GUCG 2238: "Deescalate," a pragmatic trial to revisit intermittent androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in the era of new androgen receptor pathway inhibitors.
First Author: Fabio Turco, MD
- Board 236a **Abstract TPS5151:** AMPLIFY: A phase 3 study of ⁶⁴Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.
First Author: Luke Nordquist, MD
- Board 236b **Abstract TPS5152:** A phase 2 study of androgen deprivation therapy and the androgen receptor ligand-directed degrader (BMS-986365) prior to radical prostatectomy in patients with high-risk localized prostate cancer.
First Author: Kristine Peregrino Lacuna, MD

9:00 AM-12:00 PM Poster Session

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 492-498

Biologic Correlates: Board(s) 499-503

Local-Regional Non–Small Cell Lung Cancer: Board(s) 504-523, 597a-598a

Mesothelioma: Board(s) 524-527, 598b

Neoadjuvant, Perioperative, and Adjuvant Therapy: Board(s) 528-538, 599a-601b

Outcomes/Quality: Board(s) 539-550

Small Cell Lung Cancer: Board(s) 551-589, 602a-605a

Thymic Malignancies: Board(s) 590-596, 605b

Board 492 **Abstract 8018:** Lung cancer stage prediction using longitudinal CT imaging compared with single-timepoint assessment.
First Author: Amrik Majumdar

Board 493 **Abstract 8019:** Rapid multi-task intraoperative diagnosis of lung cancer via deep neural network-driven label-free femtosecond laser imaging (FLI).
First Author: Yin Li, MD

- Board 494 **Abstract 8020:** Noninvasive imaging biomarkers for survival risk stratification with tarlatamab in ES-SCLC.
First Author: Mohammadhadi Khorrami, PhD
- Board 495 **Abstract 8021:** Development and validation of an artificial intelligence–based deep learning imaging model for early lung cancer detection: DAVINCI, a retrospective study of 8,962 patients.
First Author: Syeda Hafsa Noor-AIN
- Board 496 **Abstract 8022:** Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non–small cell lung cancer.
First Author: Loïc Ferrer, PhD
- Board 497 **Abstract 8023:** Multimodal intraoperative diagnosis and grading system integrating macroscopic images, CT imaging, and textual reports for adenocarcinoma (MaCTex) in early-stage LUAD: A multicentric diagnostic study.
First Author: Yingwei Lu
- Board 498 **Abstract 8024:** A deep learning model for intraoperative diagnosis of lung adenocarcinoma using frozen section whole-slide images (CryoPath): A multicentric diagnostic study.
First Author: Jinqing Li
- Board 499 **Abstract 8025:** Intratumoral heterogeneity of *MTAP* loss by immunohistochemistry in non–small cell lung cancer: Implications for clinical outcomes.
First Author: Tsuyoshi Hirata, MD
- Board 500 **Abstract 8026:** Cancer-related overall survival for patients on durvalumab for stage III unresectable non–small cell lung cancer with PD-L1 positive and negative tumors.
First Author: Zohra Nooruddin, MD, MBBS
- Board 501 **Abstract 8027:** Chromosomal instability and integrated tumor-margin immune ecosystem remodeling as drivers of progression of pulmonary ground-glass nodules.
First Author: Ruoyi Jin
- Board 502 **Abstract 8028:** PSG copy number amplification and association with poor survival in early-stage female lung adenocarcinoma patients.
First Author: Jung Hun Oh
- Board 503 **Abstract 8029:** Breath analysis of volatile organic compounds with mid-infrared laser spectroscopy in a cohort of lung cancer patients and control subjects.
First Author: Boshi Duan, MD
- Board 504 **Abstract 8030:** Management of pulmonary nodules across Latin America: A real-world observational study.
First Author: Danilo Lopes
- Board 505 **Abstract 8031:** Prognostic stratification of early-stage NSCLC patients using preoperative circulating tumor DNA (ctDNA).
First Author: Zhicheng Huang
- Board 506 **Abstract 8032:** Pseudoprogression after neoadjuvant immunotherapy for resectable NSCLC: Incidence, PET/CT patterns, and differentiation.
First Author: Li-Bo Berlin Tang, MD, PhD
- Board 507 **Abstract 8033:** Class-specific clinical and molecular features of *SMARCA4* alterations in non–small cell lung cancer.
First Author: Chihiro Takemura, MD
- Board 508 **Abstract 8034:** Outcomes of atypical *EGFR* mutations in early-stage *EGFR*-mutated non-small cell lung cancer (NSCLC).
First Author: Jacqueline V. Aredo, MD, MS
- Board 509 **Abstract 8035:** Clinical impact of genomic co-mutation profiles including TP53 in resected early-stage *EGFR*-mutated NSCLC: LC-SCRUM-Advantage.
First Author: Kiyotaka Yoh, MD
- Board 510 **Abstract 8036:** Fusion-positive early-stage and locally advanced lung cancers: A real-world analysis of event-free, disease-free, and overall survival.
First Author: Sameh Nabeeh Daher, MD
- Board 511 **Abstract 8037:** Induction chemoimmunotherapy followed by hypofractionated radiotherapy and consolidation immunotherapy for locally advanced unresectable non–small cell lung cancer: A prospective phase II study.
First Author: Xiangzhi Zhu, MS
- Board 512 **Abstract 8038:** Analysis of recurrence and risk factors in resectable early-stage adenocarcinoma with uncommon *EGFR* mutations: A comprehensive cohort study in South Korea.
First Author: Insu Kim, MD, PhD
- Board 513 **Abstract 8039:** Socioeconomic focus in neoadjuvant chemoimmunotherapy: An analysis of pathologic complete response and overall survival in clinical stage II-III NSCLC patients.
First Author: Jack William Ibinson, BS
- Board 514 **Abstract 8040:** An integrated multidisciplinary analysis of pre-treatment cachexia in locally advanced non–small cell lung cancer.
First Author: Ernest Nadal, MD, PhD
- Board 515 **Abstract 8041:** Decomposing the co-mutational landscape of NSCLC by unsupervised learning to unveil components with impact on overall survival.
First Author: Chidiebube Ugwu, MD, MPH
- Board 516 **Abstract 8042:** Fraction genome altered to predict survival in early-stage non–small cell lung cancer.
First Author: Mobina Shrestha, MD
- Board 517 **Abstract 8043:** Realworld adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.
First Author: Brendan Heiden, MD, MS, MBA
- Board 518 **Abstract 8044:** Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC.
First Author: Melina Elpi Marmarelis, MD
- Board 519 **Abstract 8045:** Non-surgical management and outcome of 1,113 patients with stage I-II non-small cell lung cancer (NSCLC) in a 20-year cohort.
First Author: Ping Yang, MD, PhD

- Board 520 **Abstract 8046:** Influence of neoadjuvant spatially fractionated stereotactic body radiotherapy on antitumor immunity and pathological response to toripalimab-based immunochemotherapy in resectable stage IIA-IIIb non-small cell lung cancer. First Author: Xu Yaping, MD
- Board 521 **Abstract 8047:** Real-world outcomes and prognostic risk stratification of neoadjuvant immunotherapy for stage III lung squamous cell carcinoma. First Author: Wang Yishuo, MMedSc
- Board 522 **Abstract 8048:** Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study. First Author: Valentina Santo, MD
- Board 523 **Abstract 8049:** Nodulomics: Histopathologic and genomic heterogeneity among multiple malignant pulmonary nodules sampled by robotic-assisted bronchoscopy. First Author: Jamie Rowell
- Board 524 **Abstract 8050:** Sintilimab plus anlotinib and chemotherapy as first-line treatment for advanced malignant pleural mesothelioma (SACH-MPM): A prospective, single-arm, phase II trial. First Author: Yiyi Huang, MD
- Board 525 **Abstract 8051:** Machine learning-integrated transcriptomic clustering for prognostic stratification in epithelioid pleural mesothelioma. First Author: Mario Occhipinti, MD
- Board 526 **Abstract 8052:** Tumor methylation subtypes as a predictor of clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study. First Author: Luana Calabrò
- Board 527 **Abstract 8053:** The role of sarcopenia and adiposity in prognosis of pleural mesothelioma: A CT-based analysis. First Author: Senar Ebinc
- Board 528 **Abstract 8054:** Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer. First Author: Giorgio Caturegli, MD
- Board 529 **Abstract 8055:** Pathologic complete response with neoadjuvant chemoimmunotherapy in clinical stage II-III NSCLC: A large real-world analysis including older adults. First Author: Jorge Raul Vazquez Urrutia, MD
- Board 530 **Abstract 8056:** Prediction of survival outcome in clinical stage II-III non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy: Role of ypN status vs PCR. First Author: Hannah Hoang, MD
- Board 531 **Abstract 8057:** Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non-small cell lung cancer (NSCLC) study. First Author: David E. Kozono, MD, PhD
- Board 532 **Abstract 8058:** Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb EGFR-mutated non-small cell lung cancer: A single-arm, single-center, open-label phase II study. First Author: Jie Xu
- Board 533 **Abstract 8059:** RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy. First Author: Gustavo Schvartsman, MD
- Board 534 **Abstract 8060:** Survival outcomes between neoadjuvant and adjuvant chemo-immunotherapy in patients with stage II-III NSCLC undergoing surgical resection. First Author: Joseph Zouein, MD, MSc
- Board 535 **Abstract 8061:** Characteristics of patients with resectable early-stage non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy or surgery ± adjuvant therapy. First Author: Pragya Rai, PhD, MS
- Board 536 **Abstract 8062:** Impact of adjuvant immunotherapy after pathologic complete response to neoadjuvant chemo-immunotherapy in resected stage II-III non-small cell lung cancer. First Author: Joseph Zouein, MD, MSc
- Board 538 **Abstract 8064:** Postoperative re-profiling for identification of missed drivers and a high-risk fusion subgroup in non-pCR lung adenocarcinoma after neoadjuvant immunotherapy: A multicenter retrospective study. First Author: Xin Liu, PhD
- Board 539 **Abstract 8065:** CT-derived visceral fat phenotypes to reveal a metabolically defined TOFI subgroup in a lung cancer screening cohort: An imaging-based framework for evaluating the BMI paradox. First Author: Taofik Ahmed Suleiman, MS
- Board 540 **Abstract 8066:** Stage-dependent divergence of immune prognostic signatures in non-small cell lung cancer. First Author: Praveen Thapa, MBBS
- Board 541 **Abstract 8067:** Survival outcomes of young patients with non-small cell lung cancer in Latin America: A real-world cohort study. First Author: Cristina Torres-Mallma, MD
- Board 542 **Abstract 8068:** Immune aging within the tumor microenvironment as a predictor of survival in non-small cell lung cancer. First Author: Taeyun Kim, MD
- Board 543 **Abstract 8069:** Age-based differences in outcomes among small cell lung cancer patients treated with tarlatamab. First Author: Raymart Macasaet, MD
- Board 544 **Abstract 8070:** SPARK-Lung: A study of patterns and outcomes in young-onset lung cancer. First Author: Teja Voruganti, MD, PhD
- Board 545 **Abstract 8071:** Real-world impact of first immunotherapy infusion timing on outcomes in locally advanced non-small cell lung cancer. First Author: Mumtu Lalla, MD

- Board 546 **Abstract 8072:** Trends in income-related lung cancer disparities since the introduction of USPSTF screening guidelines.
First Author: Tyler Munchmeyer Healy, MD
- Board 547 **Abstract 8073:** A large prospective patient-advocacy assessment of fears, concerns, and challenges in patients diagnosed with lung cancer in the United States.
First Author: Lisa Spain, MEd
- Board 548 **Abstract 8074:** Regional and gender disparities in lung cancer mortality in Guatemala.
First Author: Natalia Pineda Grajeda, MD
- Board 549 **Abstract 8075:** Surgical resection versus stereotactic body radiation therapy in stage IV non-small cell lung cancer: A large, real-world, propensity-matched survival study.
First Author: Harshitha Bandaru, MBBS
- Board 550 **Abstract 8076:** Association of carbon tetrachloride with lung cancer incidence and mortality, including effects in low-smoking regions.
First Author: Ashish Samaddar, MD
- Board 551 **Abstract 8077:** Are lobectomy and neoadjuvant therapy the missing link in improving early-stage small cell lung cancer survival?
First Author: Yahya Alwatari, MBBS
- Board 552 **Abstract 8078:** Chemoimmunotherapy for large cell neuroendocrine carcinoma (LCNEC) of the lung: A multi-institutional prospective study (NEJ044).
First Author: Suguru Matsuda
- Board 553 **Abstract 8079:** Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402.
First Author: Firas Benyamine Badin, MD, MBA
- Board 554 **Abstract 8080:** A retrospective real-world study on the efficacy and safety of anlotinib in combination with immunotherapy as maintenance therapy after standard immunochemotherapy for extensive-stage small cell lung cancer (ALTER-L059).
First Author: Yong Fang, MD
- Board 555 **Abstract 8081:** A validation study of a novel biomarker-based scoring system (EAST score) for limited-stage small-cell lung cancer: A secondary analysis of JCOG0202 and JCOG1011.
First Author: Yu Ito
- Board 556 **Abstract 8082:** Prophylactic tocilizumab to mitigate cytokine release syndrome in patients receiving tarlatamab: A single-center exploratory experience informed by bispecific antibody safety data.
First Author: Feras Al Moussally, MD
- Board 557 **Abstract 8083:** Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era.
First Author: Catherine Rinaldi, PharmD
- Board 558 **Abstract 8084:** Antigen presentation suppression as a hallmark of immune evasion and poor outcomes in small cell lung cancer.
First Author: Triparna Sen, PhD
- Board 559 **Abstract 8085:** Multiomic spatial analysis of tumor microenvironment during neuroendocrine (NE) transformation in *EGFR*-mutant LUAD.
First Author: Elisa Gobbin, MD, PhD
- Board 560 **Abstract 8086:** IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC).
First Author: Hossein Borghaei, DO, MS
- Board 561 **Abstract 8087:** Impact of DLL3 expression and tumor subtype on response to tarlatamab.
First Author: Jessica Ross, MD
- Board 562 **Abstract 8088:** Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.
First Author: Ty Michael Moore, DO, MS
- Board 563 **Abstract 8089:** DAREON-8: Updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC).
First Author: Solange Peters, MD, PhD
- Board 564 **Abstract 8090:** Clinical outcomes of local treatments for oligoprogressive or oligorecurrent small cell lung cancer.
First Author: Adrien Mathieu
- Board 565 **Abstract 8091:** Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?
First Author: Denis Lucien Moro Sibilot, MD, MSc
- Board 566 **Abstract 8092:** Sexspecific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019–2024).
First Author: Pilar Garrido, MD, PhD
- Board 567 **Abstract 8093:** Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer.
First Author: Apar Kishor Ganti, MD, MS, FASCO
- Board 568 **Abstract 8094:** MC1923: Phase II durvalumab plus lurbinectedin in platinum-resistant relapsed extensive-stage small cell lung cancer after prior chemoimmunotherapy (cohort B).
First Author: Konstantinos Leventakos, MD, PhD
- Board 569 **Abstract 8095:** BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.
First Author: Shuhang Wang, MD, PhD
- Board 570 **Abstract 8096:** Updated results of the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
First Author: Qiming Wang, MD

- Board 571 **Abstract 8097:** Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis.
First Author: Graeme Fenton, MD
- Board 572 **Abstract 8098:** Monalizumab plus durvalumab plus platinum-based chemotherapy for first-line treatment of extensive stage small-cell lung cancer: Early efficacy results from MOZART trial.
First Author: Hirva Mamdani, MD
- Board 573 **Abstract 8099:** Multicenter phase II trial of atezolizumab plus carboplatin and etoposide for extensive-stage small cell lung cancer older patients who underwent geriatric assessment (OLCSG2002 EPAS Trial).
First Author: Yuka Kato, MD, PhD
- Board 574 **Abstract 8100:** Comparative real-world outcomes of tarlatamab and lurbinectedin in relapsed extensive-stage small cell lung cancer.
First Author: Daniyal Aziz Khan
- Board 576 **Abstract 8102:** Impact of lung cancer screening in patients diagnosed with small cell lung cancer.
First Author: Paresh Kumar, MBBS
- Board 577 **Abstract 8103:** Comparison by immunotherapy agent of real-world outcomes with chemoimmunotherapy in first-line extensive-stage small cell lung cancer.
First Author: Anthony Alfonso
- Board 578 **Abstract 8104:** Demographics and outcomes of individuals with young-onset small cell lung cancer.
First Author: Paresh Kumar, MBBS
- Board 579 **Abstract 8105:** A multi-institutional, single-arm, phase 2 study of durvalumab plus amrubicin in patients with relapsed extensive-stage small cell lung cancer (Aphrodite trial).
First Author: Yuka Kato, MD, PhD
- Board 580 **Abstract 8106:** Safety, pharmacokinetic, and preliminary efficacy of SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): A phase 1 study.
First Author: Tianqing Chu
- Board 581 **Abstract 8107:** Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.
First Author: Mikel Portu
- Board 582 **Abstract 8108:** Tarlatamab in small cell lung cancer with brain metastases: A real-world experience.
First Author: Santiago Sucre, MD
- Board 583 **Abstract 8109:** Updated results of the randomized phase 2 dose optimization study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with advanced small cell lung cancer.
First Author: Xinghao Ai
- Board 584 **Abstract 8110:** Evaluation of survival after chemo-immunotherapy in veterans with extensive-stage small cell lung cancer and brain metastases.
First Author: Jason Cham, MD
- Board 585 **Abstract 8111:** An innovative team approach to improve SCLC care across an integrated health system.
First Author: Melinda Laine Hsu, MD, MS
- Board 586 **Abstract 8112:** Predictive role of immune cell subsets and intestinal flora in immune-related adverse event of small cell lung cancer.
First Author: Mei-xi Lin, PhD
- Board 587 **Abstract 8113:** Real-world challenges in the adoption of emerging therapies for extensive-stage small cell lung cancer in community settings.
First Author: Jacob Sands, MD
- Board 588 **Abstract 8114:** Phenotypic heterogeneity in primary tumors and brain metastases of small cell lung cancer: Insights into tumor microenvironment and metastatic behavior.
First Author: Alan Amaral Oliveira, BA
- Board 589 **Abstract 8115:** Does treatment delay matter?: Impact of time to immunotherapy on survival in extensive-stage small cell lung cancer.
First Author: Anand Shah, MD
- Board 590 **Abstract 8116:** Efficacy and safety of second or further line KC1036 in patients with thymoma and thymic carcinoma: A multicenter, single-arm phase II trial.
First Author: Wentao Fang, MD
- Board 591 **Abstract 8117:** Platinum rechallenge versus non-platinum regimens as second-line treatment for advanced thymoma: Analysis of the largest retrospective cohort to date.
First Author: Go Saito, MD, PhD
- Board 592 **Abstract 8118:** Cell-free DNA fragmentomics and methylomics for thymic epithelial tumors.
First Author: Michael Daniels, PhD, MSc
- Board 593 **Abstract 8119:** Surufatinib for advanced or metastatic chemotherapy-refractory thymic epithelial tumor: A single-arm, single-center, phase II study.
First Author: Bei Xu, MD
- Board 594 **Abstract 8120:** Penpulimab (PD-1 inhibitor) combined with platinum-based chemotherapy as induction therapy for newly diagnosed thymic carcinoma: A multicenter, single-arm, phase II trial.
First Author: Weixiong Yang
- Board 595 **Abstract 8121:** Combining SBRT with GM-CSF and Peg-IFN α to induce abscopal effects in previously treated patients with metastatic thymic tumors: A single-institution, phase II trial.
First Author: Min Fan
- Board 596 **Abstract 8122:** Development and validation of a preoperative pathological risk prediction model for thymic tumors: A retrospective multicenter diagnostic study.
First Author: LuYu Huang
- Board 597a **Abstract TPS8123:** A multi-institutional, randomized, phase III trial comparing anatomical segmentectomy and lobectomy for clinical stage IA3 pure-solid non-small-cell lung cancer: West Japan Oncology Group study WJOG16923L (STEP UP trial).
First Author: Atsushi Kamigaichi, MD

- Board 597b **Abstract TPS8124:** CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non-small-cell lung cancer—A randomized phase III trial. First Author: Chiaojung Jillian Tsai, MD, PhD
- Board 598a **Abstract TPS8125:** InDuRanS: A randomized phase II trial on induction immunochemotherapy followed by surgery or chemoradiotherapy and consolidation durvalumab in stage III NSCLC. First Author: Eleni Gkika
- Board 598b **Abstract TPS8126:** Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma: Substudy 5 of the eVOLVE-02 phase 2 study. First Author: Michael Offin, MD
- Board 599a **Abstract TPS8127:** Neoadjuvant chemo-immunotherapy and surgical resection in locally advanced non-small cell lung cancer with N3 lymph node involvement (NEO-SURG). First Author: Joshua E. Reuss, MD
- Board 599b **Abstract TPS8128:** IFCT-2401 SPORADIC trial: Integrating cemiplimab to sequential hypofractionated chemoradiotherapy for unfit or elderly patients with unresectable stage III non-small cell lung cancer. First Author: Sébastien Thureau
- Board 600a **Abstract TPS8129:** Beamion LUNG-3: Zongertinib in resectable *HER2*-mutant NSCLC. First Author: Amy Lauren Cummings, MD, PhD
- Board 600b **Abstract TPS8130:** Randomized, double-blind, phase 3 TRUST-IV study of adjuvant taletrectinib vs placebo in patients with stage IB–IIIA ROS1+ non-small cell lung cancer (NSCLC). First Author: Alexander I. Spira, MD, PhD, FACP, FASCO
- Board 601a **Abstract TPS8131:** SWOG S2414 (INSIGHT): A randomized phase III trial incorporating pathologic complete response in participants with early-stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting. First Author: Jeremy Paul Cetnar, MD, MS
- Board 601b **Abstract TPS8132:** Randomized multicenter phase II trial of radioimmunotherapy versus chemoimmunotherapy followed by surgery for c-stage IB-III NSCLC (RICHIS trial). First Author: Jonathan Villena-Vargas, MD
- Board 602a **Abstract TPS8133:** A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tivozalimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). First Author: Linlin Wang, DrPH
- Board 602b **Abstract TPS8134:** TIGOS-LS, an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer. First Author: Melissa Lynne Johnson, MD, FASCO
- Board 603a **Abstract TPS8135:** SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC). First Author: Kristof Cuppens, MD, MSc
- Board 603b **Abstract TPS8136:** A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator's choice therapy in participants with relapsed small cell lung cancer (DLLEVATE). First Author: Afshin Dowlati, MD
- Board 604a **Abstract TPS8137:** A phase 3 study of sacituzumab govitecan in patients with previously treated extensive-stage small cell lung cancer. First Author: Afshin Dowlati, MD
- Board 604b **Abstract TPS8138:** Phase 3 study of zipaleritinib plus adjuvant chemotherapy in early-stage NSCLC harboring *EGFR* exon 20 insertion or other uncommon *EGFR* mutations (REZILIENT4). First Author: Jamie E. Chaft, MD, FASCO
- Board 605a **Abstract TPS8139:** Durvalumab plus chemotherapy prior to chemoradiotherapy and followed by durvalumab as consolidation for patients with limited-stage small cell lung cancer (CONCUR study). First Author: Qian Chu, MD, PhD
- Board 605b **Abstract TPS8140:** A phase II trial of ivonescimab for previously treated thymic carcinoma: UCLA L-11. First Author: Jonathan Boiarsky, MD

9:00 AM-12:00 PM Poster Session

Lung Cancer—Non-Small Cell Metastatic

Location: Hall A—Posters and Exhibits

Posters by Topic

Antibody-Drug Conjugates and Other Novel Therapies:

Board(s) 311-321, 449b-451a

Artificial Intelligence: Board(s) 322-326

Biologic Correlates: Board(s) 327-343

Immunotherapies: Board(s) 344-381, 451b-456b

Outcomes/Quality: Board(s) 382-393

Targeted (Non-Immunotherapy): Board(s) 394-445, 457a-460a

Other Lung Cancers: Board(s) 446-448

Board 311 **Abstract 8521:** Amivantamab in *EGFR*-mutated NSCLC with refractory brain or leptomeningeal metastases: A multi-center real-world study. First Author: Chang Lu

Board 312 **Abstract 8522:** Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)—directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001). First Author: Jesus Corral Jaime, MD

Board 313 **Abstract 8523:** Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors. First Author: Ziming Li

- Board 314 **Abstract 8524:** Impact of *MET* amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ) *EGFR* wild-type (WT) NSCLC with c-Met protein overexpression (OE).
First Author: Jair Bar, MD, PhD
- Board 315 **Abstract 8525:** SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study.
First Author: Longhua Sun, MD, PhD
- Board 317 **Abstract 8527:** SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.
First Author: Yi Hu
- Board 318 **Abstract 8528:** Necitumumab plus pembrolizumab and chemotherapy for untreated advanced squamous NSCLC: Phase I/II NEJ048A/NEXUS.
First Author: Tomoiki Aiba, MD, PhD
- Board 320 **Abstract 8530:** First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors.
First Author: Jinji Yang
- Board 321 **Abstract 8531:** The efficacy of trastuzumab deruxtecan after HER2-TKI exposure in HER2 exon 20 insertion-positive non-small cell lung cancer: Results from a large-scale nationwide genomic screening (LC-SCRUM-Asia).
First Author: Yu Tanaka, MD, PhD
- Board 322 **Abstract 8532:** Integrating tumor growth models to improve late-stage lung cancer outcome prediction using early-stage clinical trial data.
First Author: Janos Szalma
- Board 323 **Abstract 8533:** GEMINI-NSCLC: Multiomics and single-cell spatial profiling to benchmark, back-translate, and build digital twins of IO response.
First Author: Vincent Perez, PhD
- Board 324 **Abstract 8534:** AI-derived CD8⁺ cytotoxic T-cell immune signatures from baseline H&E images to predict immunotherapy benefit over chemotherapy in non-small cell lung cancer: Blinded validation in CheckMate-227 (CM227).
First Author: Cristian Barrera, PhD, MSc
- Board 325 **Abstract 8535:** Impact of NCCN-guided training on large language model performance in mNSCLC.
First Author: Andrew Gould
- Board 326 **Abstract 8536:** A triage-aware neuro-symbolic approach for clinical trial matching in oncology: Real-world validation in lung and genitourinary cancer.
First Author: Vittoria Peppoloni
- Board 327 **Abstract 8537:** Discrepancy between plasma cell-free DNA and tissue-based analysis for detection of gene amplifications in non-small cell lung cancer.
First Author: Haruka Nakatani, MD
- Board 328 **Abstract 8538:** Smoking signature as used to define a genomically distinct subset of class I BRAF-mutant NSCLC.
First Author: Shuai Wang, MD
- Board 329 **Abstract 8539:** A real-world analysis of ctDNA methylation-based histology prediction and associated clinical characteristics in non-small cell lung cancer (NSCLC).
First Author: Jessica Zhang, MD
- Board 330 **Abstract 8540:** Longitudinal circulating tumor DNA surveillance as predictor of progression in advanced non-small-cell lung cancer with long-term benefit to immunotherapy.
First Author: Fang Wu, MD
- Board 331 **Abstract 8541:** Association of gut microbiota and peri-initiation proton pump inhibitor/antibiotic exposure with outcomes of atezolizumab-bevacizumab-carboplatin-paclitaxel regimen in patients with advanced non-squamous NSCLC: Prospective phase II study (K-TAIL-201).
First Author: Hiroshi Wakui, MD, PhD
- Board 332 **Abstract 8542:** USP10 activity as sensitizer of lung adenocarcinoma to immune checkpoint inhibitors: Upregulating PD-L1 via the ANT3-mediated activation of the cGAS-STING pathway.
First Author: Aman Wang, MD
- Board 333 **Abstract 8543:** Smoking-genomic discordance in metastatic non-small cell lung cancer.
First Author: Ilit Turgeman, MD
- Board 334 **Abstract 8544:** STK11 and/or KEAP1 alterations in KRAS-mutant NSCLC treated with immune checkpoint inhibitors or chemotherapy: An episode-based Project GENIE analysis.
First Author: Aayushi Pareek, MD
- Board 335 **Abstract 8545:** AI-powered characterization of the tumor microenvironment landscape in HER2-overexpressing non-small cell lung cancer.
First Author: Woochan Hwang, MBBS
- Board 336 **Abstract 8546:** Comparing becotarug plus osimertinib with a real-world osimertinib therapy cohort in platinum-refractory, advanced non-small cell lung cancer with EGFR exon 20 insertion.
First Author: Jian Fang, MD
- Board 337 **Abstract 8547:** Genomic characterization of *SMARCA4*-mutant versus wild-type non-small cell lung cancer in a Chinese population: A large-scale next-generation sequencing study.
First Author: Tongguo Si
- Board 338 **Abstract 8548:** Effect of gut microbiota-derived testosterone on distant metastasis in non-small cell lung cancer.
First Author: Chen-Guang Liu, PhD
- Board 339 **Abstract 8549:** Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819.
First Author: Kai Zhang, PhD
- Board 340 **Abstract 8550:** Impact of *KRAS* co-mutations on the efficacy of durvalumab in patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (ChRT).
First Author: Jaime Rubio Perez, MD, PhD

- Board 341 **Abstract 8551:** Serial ctDNA genomic profiling integrated with a networked molecular tumor board in first-line advanced NSCLC: The COPE randomized phase II trial.
First Author: Antoine Italiano, MD, PhD
- Board 342 **Abstract 8552:** Clinico-genomic landscape and prognostic impact of APC/CTNNB1 oncogenic alterations in non-small cell lung cancer.
First Author: Leonardo Brunetti, MD
- Board 343 **Abstract 8553:** Use of LIF and LIFR expression to characterize survival and tumor microenvironment composition in lung adenocarcinoma.
First Author: Michael Borecky, MD, MA
- Board 344 **Abstract 8554:** A randomized phase III study of pembrolizumab versus pembrolizumab with carboplatin plus pemetrexed for locally advanced or metastatic nonsquamous non-small cell lung cancer with PD-L1 TPS \geq 50%: LAPLACE-50.
First Author: Yoshihito Kogure, MD, PhD
- Board 345 **Abstract 8555:** Combination of golidocitinib (a JAK1 inhibitor) with anti-PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study.
First Author: Jie Wang, MD, PhD
- Board 346 **Abstract 8556:** A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2R β selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
First Author: Kai Wang
- Board 347 **Abstract 8557:** Race-associated clinicogenomic predictors in non-small cell lung cancer treated with immune checkpoint inhibitors.
First Author: Nirosha Perera King, MD
- Board 348 **Abstract 8558:** Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.
First Author: Wei Li
- Board 349 **Abstract 8559:** A phase II study of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non-small cell lung cancer: TORG2241 (UBE-Q).
First Author: Akane Narumi
- Board 350 **Abstract 8560:** FF-10832 liposomal gemcitabine monotherapy or combination with pembrolizumab in patients with advanced non-small cell lung cancer.
First Author: Hamid Emamekhoo, MD
- Board 351 **Abstract 8561:** Disease kinetics and practice patterns in \geq 4-year long-term beneficiaries of immune checkpoint inhibitors for advanced non-small cell lung cancer.
First Author: Masahiro Torasawa, MD, PhD
- Board 352 **Abstract 8562:** Impact of immunotherapy era on survival in stage IV non-small cell lung cancer.
First Author: Tahreem Malik, DO
- Board 353 **Abstract 8563:** Ablation plus immunotherapy in advanced NSCLC patients who develop oligo-residual disease after anti-PD-1/L1 therapy: Updated results from the BOOSTER trial.
First Author: Shuo Yang
- Board 354 **Abstract 8564:** Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non-small cell lung cancer: A phase 1/2 study.
First Author: Wen Wee Ma, MBBS
- Board 355 **Abstract 8565:** Impact of *STK11/KEAP1/SMARCA4* co-mutations in RAS-activated *KRAS* wild-type metastatic NSCLC treated with immune checkpoint inhibitors.
First Author: Cassio Murilo Hidalgo-Filho, MD
- Board 356 **Abstract 8566:** Effect of dual immune checkpoint inhibitors (ICI) by the time of infusion in advanced non-small cell lung cancer (NSCLC): A secondary analysis of CCTG BR34 trial.
First Author: Sze Wah Samuel Chan, MD
- Board 357 **Abstract 8567:** A phase 2 study of plinabulin (Plin)/docetaxel (Doc) plus pembrolizumab (Pemb) in metastatic NSCLC (mNSCLC) after acquired resistance (AR) to anti-PD-1/L1 alone or in chemotherapy combination: Efficacy and immunophenotyping.
First Author: Yan Xu, MD
- Board 358 **Abstract 8568:** Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.
First Author: Bo Wang, MD
- Board 359 **Abstract 8569:** SHR-1701 combined with fuzuloparib and chemotherapy as first-line therapy for advanced lung squamous cell carcinoma: Efficacy and safety results from a phase II study.
First Author: Yongchang Zhang, MD
- Board 360 **Abstract 8570:** 1L olomorasib plus pembrolizumab +/- chemotherapy in *KRAS* G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.
First Author: Timothy F. Burns, MD, PhD
- Board 361 **Abstract 8571:** Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer: TRAP-OLIGO study (WJOG11118L).
First Author: Hideyuki Harada
- Board 362 **Abstract 8572:** Immune-related adverse event severity and clinical outcomes with immune checkpoint inhibitor immunotherapy in participants with non-small cell lung cancer: Analysis of the lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A.
First Author: Diane Tseng, MD, PhD
- Board 363 **Abstract 8573:** Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1-high advanced NSCLC: Final results of the phase II K-TAIL-202 study.
First Author: Atsushi Horiike, MD, PhD

- Board 364 **Abstract 8574:** A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC).
First Author: Lei Wang, MD
- Board 365 **Abstract 8575:** Chronotherapy in metastatic non-small cell lung cancer: Clinical outcomes according to immune checkpoint inhibitor administration time during the day in patients treated with first-line chemoimmunotherapy.
First Author: Bahadır Köylü, MD
- Board 366 **Abstract 8576:** Multi-omic ctDNA-based MRD for predicting clinical outcomes in advanced NSCLC receiving chemoimmunotherapy.
First Author: Yun Fan, MD
- Board 367 **Abstract 8577:** Real-world efficacy and safety of bispecific antibody ivonescimab-based regimens in EGFR-TKI-resistant advanced NSCLC.
First Author: Chuang Yang
- Board 368 **Abstract 8578:** Baseline characteristics of NSCLC first-line immunotherapy super-responders in three European lung cancer centers: An ENDEAVOUR-IMIGO project.
First Author: David Lang
- Board 369 **Abstract 8579:** Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)-targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).
First Author: Julian R. Molina, MD, PhD
- Board 370 **Abstract 8580:** Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC.
First Author: Xiaoqing Yu, MD
- Board 371 **Abstract 8581:** First-line serplulimab for locally advanced or metastatic squamous non-small cell lung cancer: Updated survival from the ASTRUM-004R trial.
First Author: Bo Shen, MD
- Board 372 **Abstract 8582:** Impact of genomic HLA class I allelic imbalance on enduring immunotherapy response in advanced non-small cell lung cancer.
First Author: Yiting Dong
- Board 373 **Abstract 8583:** Concomitant radiotherapy, tremelimumab, and durvalumab for advanced NSCLC patients progressing on first-line immunotherapy: A phase 2 study (CORAL-Lung).
First Author: Jair Bar, MD, PhD
- Board 374 **Abstract 8584:** Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)-based combination therapy for non-small cell lung cancer (NSCLC).
First Author: Martin Gutierrez, MD
- Board 375 **Abstract 8585:** Single-cell spatial analysis of the tumor immune microenvironment in NSCLC primary tumors and brain metastases.
First Author: Lauren Julia Brown, MBBS
- Board 376 **Abstract 8586:** IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC).
First Author: HaiYan Tu, MD
- Board 377 **Abstract 8587:** Immunonutrition intervention in driver gene-negative non-small cell lung cancer patients with sarcopenia: A randomized controlled trial.
First Author: Xiangliang Liu
- Board 378 **Abstract 8588:** Efficacy outcomes in first-line (1L) non-small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT2.023 randomized phase 3 study of IL15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.
First Author: John M. Wrangle, MD, MPH
- Board 379 **Abstract 8589:** Response to cancer immunotherapy for p53 antibody-positive non-small cell lung cancer according to treatment regimen.
First Author: Tetsuo Shimizu, MD, PhD
- Board 380 **Abstract 8590:** Indefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non-small cell lung cancer.
First Author: Biagio Ricciuti, MD, PhD
- Board 381 **Abstract 8591:** Comparison of a highly sensitive, tumor-informed Illumina whole genome sequencing research assay and a tumor-informed bespoke whole exome sequencing assay for molecular residual disease detection in CheckMate-77T (NCT 04025879).
First Author: Jonathan Beer
- Board 382 **Abstract 8592:** Efficacy and safety of anamorelin in patients with non-small cell lung cancer and cancer cachexia undergoing chemoimmunotherapy: A real-world prospective cohort study (SPIRAL-ANA).
First Author: Kenji Morimoto, MD
- Board 383 **Abstract 8593:** Disaggregated lung cancer mortality trends in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) patients by key sociodemographic features including sex, age, and smoking status.
First Author: Diya Jayram, BA
- Board 384 **Abstract 8594:** A phase 2 study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.
First Author: Badi Edmond El Osta, MD, FACP
- Board 385 **Abstract 8595:** Trends in lung cancer mortality among U.S. adults aged ≥55 before and after the introduction of immunotherapy: A CDC WONDER Joinpoint-style analysis.
First Author: Aura Calderon, MD
- Board 386 **Abstract 8596:** Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.
First Author: Ying Zhang

- Board 387 **Abstract 8597:** Early lipid-lowering therapy initiation after lorlatinib and clinical outcomes in non–small cell lung cancer: A propensity-matched real-world analysis.
First Author: Sooraj Srirangadhamu Gopu, MD
- Board 388 **Abstract 8598:** Glucagon-like peptide-1 receptor agonist use in lung cancer patients receiving immune checkpoint inhibitors: A real-world study.
First Author: Wern Lynn Ng, MD
- Board 389 **Abstract 8599:** A comprehensive evaluation of the effectiveness of the Geriatric 8 screening tool in Japanese patients with non–small cell lung cancer: Results from the ENSURE-GA study, a cluster-randomized phase III clinical trial.
First Author: Akihiro Tsukamoto, MD
- Board 390 **Abstract 8600:** Five-year overall survival in lung adenocarcinoma: Real-world results from three French nationwide cohorts (2000–2010–2020).
First Author: Didier Debievre, MD
- Board 391 **Abstract 8601:** Long-term survival outcomes of consolidative local ablative therapy after response to first-line systemic treatment in oligometastatic NSCLC.
First Author: Phurin Areesawangkit, MD
- Board 392 **Abstract 8602:** Impact of time-of-day (ToD) of single-agent immune-checkpoint inhibitor (ICI) on survival in advanced non–small cell lung cancer (aNSCLC) with PD-L1 \geq 50%: Analysis of the NOTCH collaborative REAL-SAIF study.
First Author: Alfred Chung Pui So, MBChB
- Board 393 **Abstract 8603:** Lung cancer burden in AYAs: Global and U.S. trends.
First Author: Ruchi Tusharkumar Jani
- Board 394 **Abstract 8604:** Resistance mechanisms and efficacy of first-line alectinib and sequential treatments in advanced *ALK*+ NSCLC: Real-world outcomes from a multicenter, observational study in Japan (ALCURE).
First Author: Hirotsugu Kenmotsu, MD, PhD
- Board 395 **Abstract 8605:** Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).
First Author: Yutaro Nagano, MD
- Board 396 **Abstract 8606:** Brigatinib after lorlatinib and/or chemotherapy following first-line alectinib in *ALK*-rearranged NSCLC: Cohort B of the WJOG11919L/ABRAID study.
First Author: Shuhei Teranishi, MD, PhD
- Board 397 **Abstract 8607:** High-dose furmonertinib in *EGFR*-mutated advanced NSCLC with brain metastases after *EGFR*-TKI resistance: The iFORCE phase II trial.
First Author: Mengxing You, MD
- Board 398 **Abstract 8608:** Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of *KRAS*-G12C mutated mNSCLC.
First Author: Adam Barsouk, MD
- Board 399 **Abstract 8609:** Reduction in circulating tumor DNA (ctDNA) in relation to radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC).
First Author: Ramy Saleh, MD, MSc, FRCPC
- Board 400 **Abstract 8610:** Firmonertinib combined with platinum-based chemotherapy in patients with *EGFR*-mutant advanced NSCLC following disease progression on first-line third-generation *EGFR*-TKI.
First Author: Jialei Wang, MD
- Board 401 **Abstract 8611:** Spatial transcriptomic profiling to identify stroma-based prognostic groups in oncogene-addicted lung cancer.
First Author: Helena Bote-de Cabo
- Board 402 **Abstract 8612:** Profiling patients with *MET* exon 14 (*MET*ex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.
First Author: Paul K. Paik, MD
- Board 403 **Abstract 8613:** COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in *EGFR*-mutated advanced NSCLC: Early safety results.
First Author: Sarah B. Goldberg, MD
- Board 404 **Abstract 8614:** COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in *EGFR*-mutated advanced NSCLC: Interim results.
First Author: Ticiana Leal, MD
- Board 405 **Abstract 8615:** RET fusion–positive lung adenocarcinoma: Partner-specific clinicopathological characteristics, co-mutation profiles, and implications for targeted and immunotherapy.
First Author: Zihan Sun, PhD
- Board 406 **Abstract 8616:** PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with *HER2*-mutant advanced NSCLC.
First Author: Joshua K. Sabari, MD
- Board 407 **Abstract 8617:** Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.
First Author: Shun Lu, MD, PhD
- Board 408 **Abstract 8618:** Efficacy and safety of larotrectinib in patients with *TRK* fusion lung cancer: An updated analysis.
First Author: Jessica Jiyeong Lin, MD
- Board 409 **Abstract 8619:** First-in-human dose-escalation study of the selective *EGFR*/*HER2* exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC.
First Author: Anas Gazzah, MD
- Board 410 **Abstract 8620:** Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S *EGFR* mutations.
First Author: Helena Alexandra Yu, MD

- Board 411 **Abstract 8621:** Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of *EGFR*-mutated advanced non-small cell lung cancer.
First Author: Pooja Gokhale
- Board 412 **Abstract 8622:** SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced *HER2*-mutant non-small cell lung cancer (NSCLC).
First Author: Herbert H. Loong, MBBS, FRCP, FASCO
- Board 413 **Abstract 8623:** Safety and antitumor activity of VRN110755, a brain-penetrant, selective *EGFR* inhibitor, in patients with *EGFR*-driven non-small cell lung cancer.
First Author: Min Hee Hong, MD, PhD
- Board 415 **Abstract 8625:** Osimertinib combined with bevacizumab and chemotherapy as 1L treatment in *EGFR*-mutated metastatic non-squamous non-small cell lung cancer (nsq NSCLC) with concurrent mutations.
First Author: Liang Liu, MD, PhD
- Board 416 **Abstract 8626:** Clinical utility of repeat next-generation sequencing in patients with driver-negative non-small cell lung cancer: A report from the LC-SCRUM-TRY screening platform.
First Author: Hiroki Izumi, MD, PhD
- Board 418 **Abstract 8628:** First-line (1L) olomorasib + pembrolizumab in patients with *KRAS* G12C-mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.
First Author: Bryan Anthony Chan, BPharm, MMed, FRACP, MBBS
- Board 419 **Abstract 8629:** Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) with taletrectinib in advanced ROS1+ non-small cell lung cancer (NSCLC) from the TRUST-II study.
First Author: Yasir Y. Elamin, MD
- Board 420 **Abstract 8630:** Hi-C sequencing to identify clinically actionable fusions in non-small cell lung cancer missed by other sequencing technologies.
First Author: Kevin Max Levine, MD, PhD
- Board 421 **Abstract 8631:** Prognostic impact of actionable driver alterations and efficacy of targeted therapy in lung squamous cell carcinoma: A large-scale nationwide genomic screening (LC-SCRUM-Asia).
First Author: Tetsuya Sakai, MD, PhD
- Board 422 **Abstract 8632:** Actionable genomic alterations and outcomes in lung squamous and adenosquamous cell carcinoma.
First Author: Simone E. Dekker, MD, PhD
- Board 423 **Abstract 8633:** Ablation of oligo-residual disease to prolong progression-free survival in *EGFR*-mutant advanced NSCLC patients treated with third-generation *EGFR*-TKIs.
First Author: Jizhong Yin
- Board 424 **Abstract 8634:** Clinicogenomic determinants of early progression on first-line osimertinib in *EGFR*-mutant NSCLC.
First Author: Federica Pecci, MD
- Board 425 **Abstract 8635:** *EGFR*-mutated lung cancer: A comparative analysis of common and uncommon variants.
First Author: Anas Mohammad Zayed, MD
- Board 426 **Abstract 8636:** The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on outcomes in metastatic non-small cell lung cancer (mNSCLC) patients treated with tyrosine kinase inhibitors (TKIs): Real-world retrospective analysis.
First Author: Khvaramze Shaverdashvili, MD
- Board 427 **Abstract 8637:** Plasma epigenomic profiling for identification of mechanisms of sensitivity, primary and acquired resistance to tepotinib in METex14 skipping metastatic NSCLC.
First Author: Sunny Das
- Board 428 **Abstract 8638:** Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non-small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.
First Author: Yunpeng Yang
- Board 429 **Abstract 8639:** Clinical efficacy and tolerability of the selective RET inhibitor soxatatinib (SY-5007) in advanced *RET* fusion-positive non-small cell lung cancer (NSCLC): Primary findings from a confirmatory phase III trial.
First Author: Anwen Xiong
- Board 430 **Abstract 8640:** Results from OCEAN II: A phase II study of encorafenib + binimetinib combination in Chinese patients with *BRAF*^{V600E} mutated metastatic non-small cell lung cancer.
First Author: Huaqiang Zhou, MD
- Board 431 **Abstract 8641:** A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.
First Author: Xiuning Le, MD, PhD
- Board 432 **Abstract 8642:** Comprehensive epigenomic profiling of plasma for non-invasive detection of MET activation to uncover MET-associated biology in patients with *EGFR*-mutated advanced NSCLC and progression on osimertinib.
First Author: Jonathan W. Riess, MD, MS
- Board 433 **Abstract 8643:** Clinical significance of *EGFR* amplification in patients with *EGFR*-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
First Author: Alessandro Di Federico, MD
- Board 434 **Abstract 8644:** Leptomeningeal disease in ALK-positive NSCLC: Survival impact of third-generation ALK inhibitors.
First Author: Kelsey Pan, MD, MPH
- Board 435 **Abstract 8645:** Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer.
First Author: Pranoti Pradhan
- Board 436 **Abstract 8646:** ALFA score as a predictor of long-term benefit with frontline brigatinib in ALK+ advanced NSCLC: A ctDNA-based composite biomarker from ALTA-1L.
First Author: Laura Mezquita, MD, PhD

- Board 437 **Abstract 8647:** Genomic determinants of resistance to BRAF/MEK inhibitors in *BRAF*^{V600E}-mutant non-small cell lung cancer.
First Author: Eleonora Gariazzo, MD
- Board 438 **Abstract 8648:** A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic *EGFR*-mutated non-small cell lung cancer (NSCLC).
First Author: Regan Michelle Memmott, PhD
- Board 439 **Abstract 8649:** Five-year outcomes of osimertinib-based treatment in a phase III study comparing *EGFR* tyrosine kinase inhibitor (*EGFR*-TKI) monotherapy and *EGFR*-TKI with inserted cisplatin plus pemetrexed as a first-line treatment for advanced non-squamous non-small-cell lung cancer harboring *EGFR* mutation (JCOG1404/WJOG8214L).
First Author: Shintaro Kanda, MD, PhD
- Board 440 **Abstract 8650:** Comprehensive profiling of *EGFR* PACC mutations and their co-mutation landscape in Chinese patients with non-small cell lung cancer: A large-scale NGS study of 2,360 cases.
First Author: Yuan Jiang
- Board 441 **Abstract 8651:** Efficacy and safety analysis of furmonertinib in the treatment of *EGFR*-mutated lung adenocarcinoma: A single-center real-world study based on high-risk stratification.
First Author: Aliya Aosiman, MA
- Board 442 **Abstract 8652:** Circulating tumor DNA dynamics following molecularly targeted therapy for non-small cell lung cancer.
First Author: Justin Jee, MD, PhD
- Board 443 **Abstract 8653:** Molecular and immune profiling of *BRAF*-mutated (*BRAF*^{MUT}) non-small cell lung cancer (NSCLC).
First Author: Roupen Odabashian, MD, FRCP
- Board 445 **Abstract 8655:** Correlation of CT changes, PET response, and histopathologic tumor regression in treated advanced *EGFR* mutant NSCLC before disease progression.
First Author: Pei Hsing Chen, MD
- Board 447 **Abstract 8657:** Efbemalenograstim alfa for prophylaxis in non-small cell lung cancer patients with chemotherapy-induced febrile neutropenia: A randomized, multicenter, exploratory clinical trial.
First Author: Mengjie Li
- Board 448 **Abstract 8658:** Genomic clonality analysis of patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC) who underwent double lung transplantation (DLT) across timepoints and tumor region.
First Author: Sang Hwa Kim, MD
- Board 449b **Abstract TPS8660:** SigVie-003: Phase 3 trial of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50%.
First Author: Martin Reck, MD, PhD
- Board 450a **Abstract TPS8661:** AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (*EGFR*)-mutated non-small cell lung cancer (NSCLC).
First Author: Adam Rock, MD
- Board 450b **Abstract TPS8662:** Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.
First Author: Paul K. Paik, MD
- Board 451a **Abstract TPS8663:** Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.
First Author: Yasushi Goto, MD
- Board 451b **Abstract TPS8664:** Combination of tulmimetostat and PD-1 blockade for patients with advanced non-small cell lung cancer who progressed from first or second line of treatments.
First Author: Daniel Sanghoon Shin, MD, PhD
- Board 452a **Abstract TPS8665:** Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01.
First Author: Martin Reck, MD, PhD
- Board 452b **Abstract TPS8666:** FUEL-IT Lung: Fasting to unleash and enhance lung cancer immunotherapy—A VA Lung Precision Oncology Program trial.
First Author: Razan Aljaras, MD
- Board 453a **Abstract TPS8667:** Phase III study of multidisciplinary therapy combining local ablative therapy with immune-checkpoint inhibitors for patients with synchronous oligometastatic NSCLC (J-OLIGO: WJOG20924L).
First Author: Taichi Miyawaki, MD, PhD
- Board 453b **Abstract TPS8668:** A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non-small cell lung cancer (NSCLC) (TeLuRide-008).
First Author: Dan Costin, MD, FACP
- Board 454a **Abstract TPS8669:** Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).
First Author: Saiama Naheed Waqar, MD, MS
- Board 454b **Abstract TPS8670:** INTERpath-013: A phase 2, randomized, double-blind study of intisieran autogene plus pembrolizumab and chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer.
First Author: Enriqueta Felip, MD, PhD
- Board 455a **Abstract TPS8671:** Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.
First Author: Andreas Nicholas Saltos, MD

- Board 455b **Abstract TPS8672:** A phase 3 study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard-of-care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress.
First Author: Tomasz Jankowski, MD, PhD
- Board 456a **Abstract TPS8673:** Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO).
First Author: Roy S. Herbst, MD, PhD, FACP, FASCO
- Board 456b **Abstract TPS8674:** A randomized phase III trial of chemo-immunotherapy vs immunotherapy alone for the vulnerable older adult with advanced non-small cell lung cancer: The ACHIEVE study—ECOG-ACRIN EA5221.
First Author: Megan Ann Baumgart, MD
- Board 457a **Abstract TPS8675:** ALPACCA: Phase 3 trial of firmonertinib vs investigator's choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006).
First Author: Xiuning Le, MD, PhD
- Board 457b **Abstract TPS8676:** Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound *EGFR*-mutated non-small cell lung cancer (WJOG17323L: AGEHA study).
First Author: Taichi Miyawaki, MD, PhD
- Board 458a **Abstract TPS8677:** A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with *EGFR*-mutant, *MET*-amplified stage IV or recurrent no-small cell lung cancer (Lung-MAP Sub-Study S1900G).
First Author: Sarah B. Goldberg, MD
- Board 458b **Abstract TPS8678:** First-in-human phase I, open-label, multicenter study of HJ-004, a novel *EGFR*-PROTAC degrader, in patients with advanced *EGFR*-mutated non-small cell lung cancer.
First Author: Xinru Chen, PhD, DM
- Board 459a **Abstract TPS8679:** KEYMAKER-U01J: Caldesasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with *KRAS* G12C mutations.
First Author: Qing Zhou, MD, PhD
- Board 459b **Abstract TPS8680:** A phase II study of amivantamab hyaluronidase in *MET* amplification-positive stage IV or recurrent non-small cell lung cancer (Lung-MAP Sub-Study).
First Author: Christian Diego Rolfo, MD, PhD, MBA
- Board 460a **Abstract TPS8681:** An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.
First Author: Neil Sankar, MD, MPH

9:00 AM-12:00 PM Poster Session

Melanoma/Skin Cancers

Location: Hall A—Posters and Exhibits

Posters by Topic

Advanced/Unresectable Melanoma: Board(s) 237-274, 480a-485a

Artificial Intelligence: Board(s) 275-277

Locoregional, Neoadjuvant, and Adjuvant Melanoma:

Board(s) 278-295, 485b-488a

Nonmelanoma Skin Cancers: Board(s) 296-305, 488b-490a

Outcomes/Quality: Board(s) 306-310, 479

- Board 237 **Abstract 9521:** Metabolic signatures of response: 2-hydroxybutyric acid as a biomarker in melanoma patients receiving ipilimumab–nivolumab.
First Author: Jean Henri Maselli-Schoueri, MD, PhD
- Board 238 **Abstract 9522:** Final results and correlative analysis of entinostat (E) plus pembrolizumab (P) in patients (Pts) with metastatic melanoma (MM) previously treated with anti-PD-(L)1 therapy (Tx).
First Author: Stergios J. Moschos, MD
- Board 239 **Abstract 9523:** Clinical characteristics, molecular features, and treatment of primary central nervous system melanoma.
First Author: Alexander Xiao, MD
- Board 240 **Abstract 9524:** A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
First Author: Caitlyn Balsay-Patel, MD, MS
- Board 241 **Abstract 9525:** A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [²¹²Pb]VMT01 melanocortin-1-receptor-targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.
First Author: Zachary Scott Morris, MD, PhD
- Board 242 **Abstract 9526:** Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in patients with CPI-refractory cutaneous melanoma: Promising results from an ongoing phase 1/2 study.
First Author: Meredith McKean, MD, MPH
- Board 243 **Abstract 9527:** Phase 1 evaluation of the PRAMETargeted ImmTAC brenetafusp in advanced melanoma (Mel).
First Author: Georgina V. Long, MD, PhD, FRACP, FASCO
- Board 244 **Abstract 9528:** Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
First Author: Michelle Ferreira, MD
- Board 245 **Abstract 9529:** Prospective, non-interventional, multisite evaluations of TRAQinform Immuno algorithmic quantitative treatment response analysis on treatment intent decisions in metastatic melanoma.
First Author: Ryan J. Sullivan, MD, FASCO

- Board 246 **Abstract 9530:** Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data. First Author: Hussein A. Tawbi, MD, PhD
- Board 247 **Abstract 9531:** Transposable elements and homotypic niches as drivers of immune dynamics and resistance in melanoma epigenetic-based immunotherapy. First Author: Teresa Maria Rosaria Noviello, PhD
- Board 248 **Abstract 9532:** Nivolumab + relatlimab (NIVO + RELA) in advanced melanoma: 5-year update of RELATIVITY-047. First Author: Hussein A. Tawbi, MD, PhD
- Board 249 **Abstract 9533:** Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma. First Author: Alyssa K. Steimle, MD
- Board 250 **Abstract 9534:** Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma. First Author: Vincent T. Ma, MD
- Board 251 **Abstract 9535:** Anti-PD-1 (PD-1) monotherapy versus combination with anti-CTLA-4 for metastatic uveal melanoma (MUM) patients (pts). First Author: Ines Esteves Domingues Pires da Silva, MD, PhD
- Board 252 **Abstract 9536:** Real-world experience with lifileucel, tumor selection, and dead-in therapy from a single-institution series. First Author: Theresa Medina, MD
- Board 253 **Abstract 9537:** Prognostic and therapeutic implications of HRR gene mutations in non-cutaneous melanoma: Association with anti-PD-1 efficacy. First Author: Yue Yang
- Board 254 **Abstract 9538:** Novel adaptive versus continuous dosing of encorafenib and binimetinib in combination with nivolumab in advanced *BRAF V600E* mutant melanoma. First Author: Zeynep Eroglu, MD
- Board 255 **Abstract 9539:** Pretreatment spatial immune architecture and 1-year clinical benefit to first-line ICB in advanced melanoma. First Author: Karim Amrane, MD, PhD
- Board 257 **Abstract 9541:** A phase III randomized study comparing BCD-201, a pembrolizumab biosimilar candidate, and reference pembrolizumab in patients with advanced melanoma. First Author: Kristina V. Orlova, MD, PhD
- Board 258 **Abstract 9542:** The prognostic and predictive role of FDG PET/CT in melanoma patients treated with immune checkpoint blockade: A meta-analysis. First Author: Isadora Mamede, MD
- Board 259 **Abstract 9543:** Botensilimab (BOT) ± balstilimab (BAL) in patients (pts) with advanced cutaneous melanoma (cMEL) refractory/resistant (R/R) to anti-PD-(L)1 ± CTLA-4: A phase 2 trial. First Author: Michael B. Atkins, MD, FASCO
- Board 260 **Abstract 9544:** Final results of the phase III OCTAVA trial: Clinical benefit of low-dose anti-CTLA-4 plus anti-PD-1 combination vs anti-PD-1 monotherapy in unresectable or metastatic melanoma. First Author: Lev V. Demidov, MD, PhD
- Board 261 **Abstract 9545:** Twenty years of metastatic uveal melanoma management: Real-world experience from a comprehensive cancer center in a low- and middle-income country (LMIC). First Author: Yacob Saleh, MD
- Board 262 **Abstract 9546:** Overall survival of patients with mucosal melanoma in the US before and after the advent of PD-1 based immune checkpoint inhibitor treatment. First Author: Olivia First, BA
- Board 263 **Abstract 9547:** Health-related quality of life following tumor-infiltrating lymphocyte (TIL) therapy with commercial lifileucel in metastatic melanoma: Real-world longitudinal patient-reported outcomes. First Author: Kimberly Ward, MPH
- Board 264 **Abstract 9548:** Real-world outcomes of dual checkpoint inhibition (nivolumab + ipilimumab) versus anti-PD-1 monotherapy in metastatic uveal melanoma: Impact of local therapy and adjusted survival analysis—A multicenter retrospective study in Russia. First Author: Zakhra R. Magomedova, MD
- Board 265 **Abstract 9549:** The clinical significance of *TET2*-driven clonal hematopoiesis (*TET2*-CH) in ICI-treated melanoma patients. First Author: Mason Nicholas Alford-Holloway, MD, MSc, MBA
- Board 266 **Abstract 9550:** Survival outcomes of adding stereotactic radiosurgery to dual immune checkpoint blockade in melanoma brain metastases: A systematic review and meta-analysis. First Author: Arturo Ortiz, MD
- Board 267 **Abstract 9551:** CD4 T-cell reconstitution and CD4:CD8 inversion following lymphodepleting chemotherapy for tumor-infiltrating lymphocyte therapy in metastatic melanoma. First Author: Arkadiusz Z. Dudek, MD, PhD
- Board 268 **Abstract 9552:** Real-world outcomes of lifileucel in advanced melanoma: A single-institution experience. First Author: Kelly Mahuron, MD
- Board 269 **Abstract 9553:** A phase II trial of olaparib in combination with pembrolizumab in metastatic uveal melanoma. First Author: Nikhil I. Khushalani, MD
- Board 270 **Abstract 9554:** Stage I results of a phase II study evaluating thymosin α1 combined with toripalimab in elderly patients with advanced melanoma. First Author: Xizhi Wen, MD, PhD
- Board 271 **Abstract 9555:** Risk and protective factors for acral, mucosal, and uveal melanoma in a multi-institutional cohort of veterans and civilians. First Author: Marc S. Hurlbert, PhD

- Board 272 **Abstract 9556:** Long term survival outcomes of immune checkpoint inhibitors in metastatic melanoma: Later relapse and long-term outcomes beyond 5 years.
First Author: Chantal Saberian, MD
- Board 273 **Abstract 9557:** Influence of peri-dose high-sensitivity troponin on clinically significant cardiac events and IL-2 interruption during post-TIL high-dose IL-2 therapy.
First Author: Jabra Zarka, MD
- Board 274 **Abstract 9558:** Real-world comparison of ipilimumab–nivolumab dosing strategies in melanoma brain metastases.
First Author: Dina Elantably, MD, MSc
- Board 275 **Abstract 9559:** Integrated AI-informed morphologic and spatial transcriptomics features from H&E slides to enable risk stratification of primary melanoma patients.
First Author: Bhakti Vilas Baheti
- Board 276 **Abstract 9560:** Systematic evaluation of machine learning optimization strategies for uveal melanoma detection using ultra-widefield photography.
First Author: Sanjay Ganesh, BS
- Board 277 **Abstract 9561:** Machine learning (ML) model integrating cell death pathways as a prognostic and predictive biomarker for patients with melanoma.
First Author: Erick F. Saldanha, MD
- Board 278 **Abstract 9562:** The efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma: A prospective, single-center, phase 2 trial.
First Author: Tu Hu
- Board 279 **Abstract 9563:** Survival outcomes of stage IIB/IIC cutaneous melanoma treated with wide local excision and adjuvant immunotherapy without sentinel lymph node biopsy.
First Author: Mahaasrei Ghosh
- Board 280 **Abstract 9564:** Intismeran autogene to induce de novo neoantigen-specific T cells as adjuvant therapy in melanoma.
First Author: Ryan J. Sullivan, MD, FASCO
- Board 281 **Abstract 9565:** Outcome of neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish nationwide population-based study (NEO-MEL).
First Author: Axel Nelson, MD, PhD
- Board 282 **Abstract 9566:** Adjuvant versus no adjuvant therapy after major pathological response to neoadjuvant immunotherapy in resectable melanoma: A Swedish nationwide population-based study (NEO-MEL).
First Author: Axel Nelson, MD, PhD
- Board 283 **Abstract 9567:** ADAPT-M: A tool to predict individualized benefit from adjuvant anti–PD-1 (PD-1) in resected high-risk melanoma.
First Author: Ines Esteves Domingues Pires da Silva, MD, PhD
- Board 284 **Abstract 9568:** Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.
First Author: Mohammad Saad Farooq, MD, MS
- Board 285 **Abstract 9569:** Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
First Author: Yang Wang, BPharm, FRACP, MBBS
- Board 286 **Abstract 9570:** 5-year overall survival after adjuvant treatment for stage III melanoma: An English nationwide registry-based study.
First Author: Mouhamad Hussein Ismail, MBBS
- Board 287 **Abstract 9571:** Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage III acral melanoma: Updated CAP 03-NEO trial results and external control comparison.
First Author: Xiaoting Wei
- Board 288 **Abstract 9572:** Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy.
First Author: Christoffer Gebhardt, MD
- Board 289 **Abstract 9573:** Linking T-cell receptor dynamics to outcomes in neoadjuvant-treated melanoma.
First Author: Ronen Stoff, MD
- Board 290 **Abstract 9574:** Surgical de-escalation in high-risk resectable melanoma with major pathologic response (MPR) after neoadjuvant immune checkpoint inhibition (ICI).
First Author: Meghan J. Mooradian, MD
- Board 291 **Abstract 9575:** Microbiome-derived bile acids and association with dietary fiber intake to anti-tumor responses in patients with melanoma receiving immune checkpoint blockade (ICB).
First Author: Nazli Dizman, MD
- Board 292 **Abstract 9576:** Outcome of adjuvant BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600K– compared to V600E-mutated melanoma.
First Author: Michael Weichenthal, MD
- Board 293 **Abstract 9577:** Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I–IIIB melanoma using a whole-genome sequencing–based ctDNA assay.
First Author: Karam Khaddour, MD, MS
- Board 294 **Abstract 9578:** Clinical validation of an AI-based prognostic assay for stage I-II cutaneous melanoma.
First Author: Christina Kanaan
- Board 295 **Abstract 9579:** Neoadjuvant anti–PD-1 prolgolimab monotherapy in resectable high-risk melanoma: Pathologic response and early event-free survival in a prospective single-arm phase II CRISTINA study.
First Author: Angelina Kuzmenko, PhD
- Board 296 **Abstract 9580:** Non-melanoma skin cancer–related mortality in the United States: A 25-year CDC WONDER analysis.
First Author: Shehdev Meghwar, MBBS
- Board 297 **Abstract 9581:** Anti-tumor activity of FF-10850 (liposomal topotecan) in patients with advanced Merkel cell carcinoma.
First Author: Vincent T. Ma, MD

- Board 298 **Abstract 9582:** Incidence of new keratinocyte cancers during pembrolizumab in resectable cutaneous squamous cell carcinoma: The De-Squamate study.
First Author: Rahul Ladwa, FRACP, MBChB, BSc, MPhil
- Board 299 **Abstract 9583:** Early burden reduction after two doses of cemiplimab in advanced non-melanoma skin cancer.
First Author: Lucrezia Raimondi, MD, PhD
- Board 300 **Abstract 9584:** Using stage-matched genomic analysis to support molecular similarity of unknown-primary Merkel cell carcinoma and identify ARID1B as a prognostic marker.
First Author: Furkan Bahar, MD
- Board 301 **Abstract 9585:** Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study.
First Author: Eva Muñoz Couselo, MD, PhD
- Board 302 **Abstract 9586:** Final analysis of the efficacy and safety of oral S-1 for locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma: A multicenter retrospective study.
First Author: Sadao Inoue, MD
- Board 303 **Abstract 9587:** Circulating tumor DNA (ctDNA) as a biomarker for pathologic response and clinical outcomes in patients with cutaneous squamous cell carcinoma (CSCC) receiving neoadjuvant anti-PD-1 therapy.
First Author: Luke Skyler Vest, MD
- Board 304 **Abstract 9588:** Survival outcomes following resistance to immune checkpoint inhibition in advanced cutaneous squamous cell carcinoma.
First Author: Samreen Iqbal
- Board 305 **Abstract 9589:** Outcomes of neoadjuvant immunotherapy (NeoIO) in Merkel cell carcinoma.
First Author: Lacey Mead, DO, MS
- Board 306 **Abstract 9590:** Characterization of germline pathogenic variants in melanoma patients.
First Author: Ye Tong Chua, BA
- Board 307 **Abstract 9591:** ctDNA clearance durability and progression-free survival in unresectable or metastatic cutaneous malignancies.
First Author: Joshua Espinola, BA
- Board 308 **Abstract 9592:** Long-term survivorship rates among previously treated advanced melanoma patients achieving objective response (OR) with lifileucel.
First Author: Peter Mohr, MD
- Board 309 **Abstract 9593:** Incidence and survival rates in pediatric and adolescent melanoma in the United States, 2001-2022.
First Author: Maimoona Maheen, MBBS
- Board 310 **Abstract 9594:** A propensity score-matched real-world analysis of immune checkpoint inhibitors in melanoma patients with autoimmune disease.
First Author: Shanawar Ali Waris, MD
- Board 479 **Abstract 9595:** First 1000 patients report of global practice patterns and clinical outcomes in the Collaborative Ocular Melanoma Natural History (OMNi) real-world database (NCT04588662).
First Author: Anthony M. Joshua, PhD, FRACP, MBBS
- Board 480a **Abstract TPS9596:** Clinical trial in progress: Phase I/II study of tebentafusp in combination with liver-directed therapies for the treatment of metastatic uveal melanoma.
First Author: Rino S. Seedor, MD
- Board 480b **Abstract TPS9597:** A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician's choice of therapy in patients with advanced melanoma that has progressed on anti-PD-1 and anti-CTLA-4 therapy (IGNYTE-3).
First Author: Yana G. Najjar, MD
- Board 481a **Abstract TPS9598:** A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
First Author: Marlana M. Orloff, MD
- Board 481b **Abstract TPS9599:** Phase 2 study of metronomic cyclophosphamide with pembrolizumab in checkpoint inhibitor-refractory melanoma.
First Author: Poorva Vaidya, MD
- Board 482a **Abstract TPS9600:** Phase 1b/2 trial of melphalan-percutaneous hepatic perfusion (PHP) therapy and nivolumab/relatlimab in patients with metastatic melanoma and liver metastasis.
First Author: Vincent T. Ma, MD
- Board 482b **Abstract TPS9601:** Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).
First Author: Bernardo Leon Rapoport, MD
- Board 483a **Abstract TPS9602:** A phase I/II clinical study of DOC1021 (dubodencel) dendritic cell immunotherapy for refractory melanoma.
First Author: Alexandra Haugh, MD
- Board 483b **Abstract TPS9603:** Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA) ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (MM) (TRINITY).
First Author: Elizabeth M. Burton, PhD, MBA
- Board 484a **Abstract TPS9604:** TrioMBM: A multicenter, phase II trial of relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases.
First Author: Allison Betof, MD, PhD, FASCO
- Board 484b **Abstract TPS9605:** Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan/hepatic delivery system followed by tebentafusp in the treatment of metastatic uveal melanoma.
First Author: Jonathan S. Zager, MD

- Board 485a **Abstract TPS9606:** SILVER (supplementing tebentafusp with subcutaneous IL-2 to verifiably eradicate radiological progression): A phase 1/2 trial of IL-2 with tebentafusp upon first radiological progression on first-line tebentafusp alone.
First Author: Anthony M. Joshua, PhD, FRACP, MBBS
- Board 485b **Abstract TPS9607:** Clinical trial in progress: Phase II trial of neoadjuvant tebentafusp in patients with locally advanced primary uveal melanoma.
First Author: Rino S. Seedor, MD
- Board 486a **Abstract TPS9608:** Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.
First Author: J. William Harbour, MD
- Board 486b **Abstract TPS9609:** A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519).
First Author: Maria Gonzalez, BN, BA
- Board 487a **Abstract TPS9610:** NeOLRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
First Author: Maria Gonzalez, BN, BA
- Board 487b **Abstract TPS9611:** EA6232: A phase II double-blind trial of sulforaphane for therapeutic prevention of melanoma in patients with multiple atypical nevi and a prior history of melanoma.
First Author: John M. Kirkwood, MD
- Board 488a **Abstract TPS9612:** A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.
First Author: Margaret Ottaviano, MD
- Board 488b **Abstract TPS9613:** A phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma.
First Author: Soo J. Park, MD
- Board 489a **Abstract TPS9614:** Spino-RT: A multicenter, randomized controlled phase III study of adjuvant radiotherapy versus surveillance in patients with cutaneous squamous cell carcinoma (cSCC) at high risk of recurrence.
First Author: Adeline Pêtre
- Board 489b **Abstract TPS9615:** Phase 2 study of ivonescimab in patients with cutaneous squamous cell carcinoma.
First Author: Neal Akhave, MD
- Board 490a **Abstract TPS9616:** A feasibility study of tumor-infiltrating lymphocytes (TIL) in patients with cutaneous squamous cell carcinoma and Merkel cell carcinoma after anti-PD-1 therapy.
First Author: Karam Khaddour, MD, MS

9:45 AM-11:00 AM Education Session

Caring for the Whole Patient: Integrative Medicine in Central Nervous System Malignancies

Location: E350

Margaret O. Johnson, MD, MPH

Duke University Medical Center

Evidence-Based Framework for Integrated (Holistic) Care of Patients With Central Nervous System Tumors

Heather Leeper, MD, MSc—Chair

The University of Chicago

Managing Dementia-Like Symptoms in Patients With Brain Tumors and Having Difficult Conversations

Helen Bulbeck, PhD

brainstrust - the brain cancer people

Voices From the Other Side: A Patient Advocate's Perspective on Care, Communication, and Compassion

Panel Question and Answer

9:45 AM-11:00 AM Education Session

State of the Art: Therapeutic Strategies on the Horizon for Gynecologic Malignancies

Location: E451

David M. O'Malley, MD—Chair

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Antibody-Drug Conjugates and Other New Agents in Ovarian Cancer: Managing Toxicities

Funda Meric-Bernstam, MD, FASCO

The University of Texas MD Anderson Cancer Center

Antibody-Drug Conjugates and Other New Agents in Endometrial Cancer: Overcoming Resistance

Ursula A. Matulonis, MD

Dana-Farber Cancer Institute

Antibody-Drug Conjugates and Other New Agents in Cervical Cancer: Drugs on the Horizon

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Tailoring Management for Invasive Lobular Carcinoma

Location: E450b

Rita A. Mukhtar, MD—Chair

University of California San Francisco

Surgical Right-Sizing in Invasive Lobular Carcinoma: Extent, Margins, and Nodes

Rinath Jeselsohn, MD

Dana-Farber Cancer Institute

Evidence and Exceptions in Systemic Therapy for Invasive Lobular Carcinoma

Matthew Covington, MD

Huntsman Cancer Institute at the University of Utah

Modern Imaging of Metastatic Invasive Lobular Carcinoma: Anatomic and Molecular

Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials

Location: Hall D1

Gabrielle Betty Rocque, MD, FASCO—Chair

O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham

9:45 AM Ethan Basch, MD, MSc, FASCO—Chair

The University of North Carolina at Chapel Hill
Understanding Patient-Reported Outcome Metrics: From Measurement to Regulatory Impact

9:57 AM Kelly Shanahan, MD

METAvisor
What Patient-Centered Outcomes Mean to Those Living With Cancer

10:09 AM Abstract 103: Long-term outcomes of ¹⁸F-fluoromisonidazole positron emission tomography (FMISO PET)-guided major radiation dose de-escalation in HPV-associated oropharyngeal cancer: The 30 ROC approach.
First Author: Nancy Y. Lee, MD

10:21 AM Abstract 104: Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific antibody) intraperitoneal infusion in advanced epithelial solid tumor with malignant ascites vs paracentesis.
First Author: Jianming Xu, MD

10:33 AM Abstract 105: Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial.
First Author: Jens Hoepfner, MD

10:45 AM Gabrielle Betty Rocque, MD, FASCO
O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham
Discussion of Abstract(s) 103-105: Measuring What Matters to Patients: The Role of Patient-Centered Outcomes in Shaping Clinical Practice and Modern Drug Development

10:57 AM Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

Oncology 2.0: How Artificial Intelligence Is Closing the Information Gap—Or Is It?

Location: S102

Richard F. Riedel, MD, FASCO—Chair

Duke Cancer Institute

Aakash Desai, MD, MPH, FASCO—Chair

O'Neal Comprehensive Cancer Center at The University of Alabama in Birmingham

9:45 AM Matthew Kurian, MD

St. Elizabeth Healthcare Cancer Center
The Artificial Intelligence Intersection: Evaluating Its Impact on Patients, Trainees, and Global Practice

9:57 AM Abstract 9000: Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis.
First Author: Pearl Subramanian, MD

10:09 AM Eleonora Teplinsky, MD, FASCO

Valley Health System
Discussion of Abstract(s) 9000: The Bot Will See You Now: Evaluating Artificial Intelligence-Generated Patient Education

10:21 AM Abstract 9001: Artificial intelligence (AI) in hematology and oncology fellowship (HOF) training: A multicenter survey of education, attitudes, and clinical use.
First Author: Evan Garrad, MD

10:33 AM Abstract 9002: Patterns of artificial intelligence use among physicians in Mexico: Implications for oncology practice.
First Author: Jeffrey Barragán Ortega

10:45 AM Debra A. Patt, MD, PhD, MBA, FASCO
Texas Oncology, The US Oncology Network
Discussion of Abstract(s) 9001-9002: Algorithms in Action: From Training to Practice

10:57 AM Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: E450a

Krina K. Patel, MD, MSc—Chair

The University of Texas MD Anderson Cancer Center

Brandon Jamaal Blue, MD—Chair

H. Lee Moffitt Cancer Center and Research Institute

9:45 AM Abstract 7509: Updated results from inMMycAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
First Author: P. Joy Ho, PhD, MBBS

9:51 AM Abstract 7510: Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Peter Forsberg, MD

9:57 AM Abstract 7511: Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma.
First Author: Joseph O'Brien, MD, MPH

10:03 AM Panel Question and Answer

10:15 AM Abstract 7512: Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study.
First Author: Evangelos Terpos, MD, PhD

10:21 AM Abstract 7513: Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.
First Author: Saad Z Usmani, MD, MBA, FRCP, FASCO

10:27 AM Abstract 7514: Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.
First Author: Prashant Kapoor, MD

Sunday, May 31, 2026

- 10:33 AM *Panel Question and Answer*
- 10:45 AM **Abstract 7515:** Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
First Author: Suzanne Trudel, MD
- 10:51 AM **Abstract 7516:** Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.
First Author: Albert Oriol Rocafiguera
- 10:57 AM **Abstract 7517:** Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
First Author: Jennifer H. Cooperrider, MD
- 11:03 AM *Panel Question and Answer*

9:45 AM-11:15 AM Rapid Oral Abstract Session

Prevention, Risk Reduction, and Genetics

Location: S403

Anita Kinney, PhD, RN—Chair

Rutgers Cancer Institute

Judy Ellen Garber, MD, MPH, FASCO—Chair

Dana-Farber Cancer Institute

- 9:45 AM **Abstract LBA10509:** Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.
First Author: Karthik Giridhar, MD
- 9:51 AM **Abstract 10510:** A randomized non-inferiority trial of an eHealth delivery alternative for cancer genetic testing for hereditary cancer (eREACH2).
First Author: Kimberley T. Lee, MD, MHS
- 9:57 AM **Abstract 10511:** Paired DNA and RNA sequencing from 860,000 consecutive individuals: Impact on yield in hereditary cancer genes and therapeutic options.
First Author: Magan Trottier, MSc, MS
- 10:03 AM *Panel Question and Answer*
- 10:15 AM **Abstract 10512:** Impact of population-based testing for pathogenic variants in breast cancer genes on screening recommendations in the WISDOM study.
First Author: Yiwey Shieh, MD
- 10:21 AM **Abstract 10513:** Real-world evaluation of germline pathogenic variants (PVs) in cancer-predisposition genes among unselected South Asian women with breast or ovarian cancer.
First Author: Siddhartha Yadav, MD
- 10:27 AM **Abstract 10514:** Fine-scaled genomic ancestry clusters to reveal population-specific cancer enrichments in the All of Us Research Program.
First Author: Hersh Gupta, MS
- 10:33 AM *Panel Question and Answer*
- 10:45 AM **Abstract 10515:** Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.
First Author: Andrea De Censi, MD

- 10:51 AM **Abstract 10516:** Clinical impact of *MSH3* loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types.
First Author: Emily Linda Alouani, MD
- 10:57 AM **Abstract 10517:** Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial.
First Author: Moran Amit, MD, PhD
- 11:03 AM *Panel Question and Answer*

11:30 AM-12:15 PM Award Lecture

Not Just for Cancer Immunotherapy: The Emergence of Cancer Immunoprevention

Location: S403

Philip E. Castle, PhD, MPH—Chair

National Cancer Institute, National Institutes of Health

Eduardo Vilar Sanchez, MD, PhD

The University of Texas MD Anderson Cancer Center
ASCO-American Cancer Society Cancer Prevention Award Recipient

Panel Question and Answer

11:30 AM-12:15 PM Award Lecture

Radiation Therapy, a Double-Edged Sword: Dulling the Normal Tissue Edge for Our Children With Cancer

Location: S504

Kirsten K. Ness, PhD, PT—Chair

St. Jude Children's Research Hospital

Louis S. Constine, MD, FASTRO

University of Rochester Medical Center, James P. Wilmot Cancer Institute

Pediatric Oncology Award Recipient

Panel Question and Answer

11:30 AM-12:45 PM Education Session

A New Era: Clinical Application of Evolving Technologies and Artificial Intelligence in Cancer Care

Location: S100a

Joseph A. Sparano, MD, FACP, FASCO

Icahn School of Medicine at Mount Sinai, Mount Sinai Tisch Cancer Center

Leveraging Clinical Trial Data and Biospecimens for Development and Validation of Molecular, Pathomic, and Artificial Intelligence-Based Diagnostics

Janice M. Lu, MD, PhD—Chair

Stanford University

Advancing Breast Cancer Diagnosis and Treatment Through the Integration of Artificial Intelligence With Genomics, Liquid Biopsy, and Imaging

Lee AD Cooper, PhD

Northwestern University Feinberg School of Medicine
A New Era of Health and Cancer Care With Artificial Intelligence-Driven Innovation

Panel Question and Answer

11:30 AM-12:45 PM Education Session

End-of-Life Choices Around the Globe: From Hospice Care to Medical Assistance in Dying

Location: E350

Charles D. Blanke, MD, FASCO—Chair

Oregon Health & Science University
Modern Approaches to Medical Assistance in Dying: Procedures and Pharmacological Protocols

Henry Ddungu, PhD, MBChB, MMed

Uganda Cancer Institute
Hospice and Palliative Care in Africa

Benjamin W. Corn, MD

Sharei Zedek Hospital
Navigating Ethical and Cross-Cultural Conversations on Medical Assistance in Dying: Global Views on Religion, Hope, and End-of-Life Decisions

Gary Rodin, MD

Princess Margaret Cancer Centre
Human-Centered Approach to End-of-Life Care

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Management of Bispecific Antibody Toxicities

Location: E450a

Eden Biltibo, MD

Vanderbilt University Medical Center
Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Management Inpatient and Outpatient

Rajshekhkar Chakraborty, MD

Columbia University Irving Medical Center
Beyond the First Month: Cytopenias and Infection

Michael Russell Bishop, MD, FACP, FASCO—Chair

Center for Translational Data at the University of Chicago
Long-Term Toxicities: Late Immune Events, Metabolic Syndrome, and Secondary Malignancies

Panel Question and Answer

11:30 AM-12:45 PM Education Session

State of the Art in New Treatment Paradigms of Neuroendocrine Tumors

Location: E451

Simron Singh, MD, MPH

Sunnybrook Hospital
Targeted Alpha Particle Therapies: Where Are We Now?

Jennifer A. Chan, MD, MPH—Chair

Dana-Farber Cancer Institute, Harvard Medical School
DII-4 Targeted Approaches and Treatment Considerations

Thorvardur Ragnar Halfdanarson, MD

Mayo Clinic
Emerging Targets in Pancreatic Neuroendocrine Tumors

Panel Question and Answer

11:30 AM-12:45 PM Education Session

What's New in Rare Cancers in Head and Neck, Including Adenoid Cystic Cancer, Thyroid Cancer, and Sinus Cancers

Location: S100bc

Bhumsuk Keam, MD, PhD

Seoul National University Hospital
ACcelerating Progress: Emerging Therapies in Adenoid Cystic Carcinoma

Sarimar Agosto Salgado, MD—Chair

Moffitt Cancer Center
From Guidelines to the Clinic: Redifferentiation and Other Emerging Options for Differentiated Thyroid Cancer

Nyall R. London Jr., MD, PhD

National Institute on Deafness and Other Communication Disorders, National Institutes of Health
At the Crossroads: New Directions in Sinonasal and Paranasal Sinus Cancer Management

Panel Question and Answer

11:30 AM-1:00 PM Rapid Oral Abstract Session

Breast Cancer—Metastatic

Location: Hall D1

Debora De Melo Gagliato, MD—Chair

Hospital Beneficência Portuguesa

Gregory A. Vidal, MD, PhD—Chair

West Cancer Center & Research Institute

11:30 AM Abstract 1013: ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC).
First Author: Sara M. Tolaney, MD, MPH, FASCO

11:36 AM Abstract 1014: ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).
First Author: Carlos H. Barrios, MD

11:42 AM Abstract 1015: Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.
First Author: Emily L. Podany, MD

Panel Question and Answer

12:00 PM Abstract 1016: Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i).
First Author: Komal L. Jhaveri, MD, FACP, FASCO

12:06 PM Abstract 1017: Effectiveness of first-line ET+CDK4/6i continuation beyond disease progression in a large cohort of patients with HR+/HER2– advanced breast cancer: Results from the multicenter, real-world, Italian study PALMARES-2.
First Author: Claudio Vernieri, MD, PhD

12:12 PM Abstract LBA1018: Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.
First Author: Yen-Shen Lu, MD, PhD

Sunday, May 31, 2026

- 12:18 PM *Panel Question and Answer*
- 12:30 PM **Abstract 1019:** Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.
First Author: Fumikata Hara, MD, PhD
- 12:36 PM **Abstract 1020:** Impact of bevacizumab on the efficacy of antibody–drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer.
First Author: Yin Liu
- 12:42 PM **Abstract 1021:** A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).
First Author: Yeon Hee Park, MD, PhD
- 12:48 PM *Panel Question and Answer*

1:00 PM-4:00 PM Plenary Session

Location: Hall B1

Eric J. Small, MD, FASCO—Chair
University of California San Francisco

Jo Chien, MD—Chair
University of California San Francisco

- 1:00 PM **Jo Chien, MD and Eric J. Small, MD, FASCO**
University of California San Francisco
Welcome and Introduction
- 1:05 PM **Abstract LBA1:** Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.
First Author: Mary-Ellen Taplin, MD, FASCO
- 1:17 PM **Declan G. Murphy, MD**
Peter MacCallum Cancer Centre
Discussion of Abstract LBA1
- 1:29 PM *Panel Question and Answer*
- 1:39 PM **Abstract LBA2:** SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark A. Dickson, MD
- 1:51 PM **Paolo G. Casali, MD**
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Discussion of Abstract LBA2
- 2:03 PM *Panel Question and Answer*
- 2:13 PM **Abstract LBA3:** Event-free survival with adjuvant seliperatinib in stage IB-IIIa *RET* fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
First Author: Jonathan W. Goldman, MD
- 2:25 PM **Christine M. Lovly, MD, PhD, FASCO**
City of Hope National Medical Center
Discussion of Abstract LBA3
- 2:37 PM *Panel Question and Answer*

- 2:47 PM **Abstract LBA4:** Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
First Author: Chen Zhiwei, MD/Presenter: Shun Lu, MD
- 2:59 PM **Julie R. Brahmer, MD, MSc, FASCO**
The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
Discussion of Abstract LBA4
- 3:11 PM *Panel Question and Answer*
- 3:21 PM **Abstract LBA5:** Daraxonasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
First Author: Brian M. Wolpin, MD, MPH
- 3:33 PM **Jennifer J. Knox, MD, MSc, MRCP**
Princess Margaret Cancer Centre, University Health Network
Discussion of LBA5
- 3:45 PM *Panel Question and Answer*

4:30 PM-5:45 PM Education Session

Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics

Location: Hall D2

Elisa Fontana, MD, PhD—Chair

Sarah Cannon Research Institute
RAS in Colorectal Cancer: Mechanisms of Action, Inhibition, and Resistance

Thomas Winder, MD, PhD

Swiss Tumor Molecular Institute
BRAF Biology in Colorectal Cancer: Current Evidence and Next Steps

Heinz-Josef Lenz, MD

University of Southern California Norris Comprehensive Cancer Center
Beyond RAS and RAF: Proven and Emerging Targets in Metastatic Colorectal Cancer

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Global Oncology: A Workforce Crisis—A Lancet Oncology Commission

Location: S102

David Collingridge—Chair

The Lancet Oncology
The Goal of Lancet Oncology Commissions and the Charge to the Global Cancer Workforce Commission

Patrick J. Loehrer Sr., MD, MD, FASCO

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
A Global Workforce Crisis: The Current and Projected Landscape

Zachary J. Ward, PhD, MPH

Harvard T.H. Chan School of Public Health
How Is the Workforce Measured? Qualitative and Quantitative Approaches

Hedvig Hricak, MD, PhD

Memorial Sloan Kettering Cancer Center
Charting a Path Forward: Results and Proposed Actions From the Lancet Oncology Commission

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter

Location: S100a

Christopher M. Booth, MD—Chair

Queen's University
Trials, Endpoints, and the Hippocratic Oath: Providing Care That Matters

Michelle Leah Tregear, PhD

National Breast Cancer Coalition
Treating More Than the Tumor: What Matters to Patients and Families

Rachel Riechelmann, MD

A.C. Camargo Cancer Center
From Guidelines and Trials to the Realities of Front-Line Care

Christopher G. C. A. Jackson, MBChB, FRACP

University of Otago
Caring for the Health System: Ensuring Systems and Providers Deliver Optimal Cancer Care

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Right-Sizing Locoregional Management of Breast Cancer in the Era of Neoadjuvant Therapy

Location: S100bc

Stephanie M. Wong, MD, MPH—Chair

Segal Cancer Centre, Jewish General Hospital
Approach to the Axilla After Neoadjuvant Therapy

Corey Wayne Speers, MD, PhD

University Hospitals Seidman Cancer Center and Case Western Reserve University
Response-Guided Adjuvant Radiation in Early-Stage Breast Cancer

Mark Schaverien, MD, MBChB, MSc, MEd, FRCS

University of Texas MD Anderson Cancer Center
Reconstruction in Context: Integrating Surgery, Radiation, and Systemic Therapy

Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Central Nervous System Tumors

Location: S403

Karisa C. Schreck, MD, PhD—Chair

Johns Hopkins University

James A. Balogun, MBBS—Chair

College of Medicine, University of Ibadan

4:30 PM Abstract 2009: SPECTRUM: Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory (R/R) primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)—The Korean Cancer Study Group LY22-07.
First Author: Jung Sun Kim, MD, MS

4:36 PM Abstract 2010: A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an *IDH1/2* mutation (INDIGO): Updated efficacy and safety.
First Author: Timothy Francis Cloughesy, MD

4:42 PM Abstract 2011: Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma (NCT05342883).
First Author: Clark C. Chen, MD, PhD

4:48 PM Panel Question and Answer

5:00 PM Abstract 2012: First-in-human study of AAV6-NeuroD1 trans-differentiation therapy in recurrent malignant glioma.
First Author: Yulun Huang, MD

5:06 PM Abstract 2013: Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).
First Author: Erin E. Hollander

5:12 PM Abstract 2014: Butaselen combined with radiotherapy for newly diagnosed H3K27M-mutant spinal diffuse midline glioma: A single-arm phase Ib trial.
First Author: Yuanhao Chang, MD

5:18 PM Panel Question and Answer

5:30 PM Abstract 2015: Azeliragon, a RAGE inhibitor, plus temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Final results from a dose-finding phase in the CAN-201 NDG trial.
First Author: Maria Martinez Garcia, MD, PhD

5:36 PM Abstract 2016: Change in relative cerebral blood volume as a biomarker for early response to bevacizumab in patients with recurrent glioblastoma: ECOG-ACRIN EAF151.
First Author: Jerrold L. Boxerman, MD, PhD

5:42 PM Abstract 2017: Recurrence patterns and site-level survival in the previous phase III study of IL13-PE38QQR: Implications for drug distribution variability.
First Author: Sandeep Kunwar, MD

5:48 PM Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Genitourinary Cancer—Prostate, Testicular, and Penile

Location: Hall D1

Jacob Orme, MD, PhD—Chair

Mayo Clinic Rochester

Daniel Castellano Gauna, MD—Chair

Hospital Universitario 12 de Octubre

- 4:30 PM Abstract LBA5012:** Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.
First Author: Nancy P. Mendenhall
- 4:36 PM Abstract 5013:** Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.
First Author: Daniel Keizman
- 4:42 PM Abstract 5014:** A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff, MD, FASCO
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 5015:** Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dingwei Ye, MD
- 5:06 PM Abstract 5016:** Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
First Author: Andrew J. Armstrong, MD, MS
- 5:12 PM Abstract 5017:** PROTRACT: A randomized phase II trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician’s choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).
First Author: Corinne Maurice-Dror, MD
- 5:18 PM Panel Question and Answer**
- 5:30 PM Abstract 5018:** Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
First Author: Susan Halabi, PhD, FASCO
- 5:36 PM Abstract 5019:** Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of ¹⁷⁷Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Kim N. Chi, MD
- 5:42 PM Abstract 5020:** Subgroup analyses by disease volume and de novo/recurrent mHSPC in the PSMAddition study of [¹⁷⁷Lu]Lu-PSMA-617.
First Author: Fred Saad, MD, FRCS
- 5:48 PM Panel Question and Answer**

4:30 PM-6:00 PM Rapid Oral Abstract Session

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Arie Crown Theater

C. S. Pramesh, MBBS, MS, FRCS—Chair

Tata Memorial Hospital

Melina Elpi Marmarelis, MD—Chair

University of Pennsylvania

- 4:30 PM Abstract 8009:** Complex segmentectomy versus lobectomy in small-sized peripheral non–small cell lung cancer: A post-hoc supplemental analysis of a multicenter, open-label, phase 3 trial (JCOG0802/WJOG4607L).
First Author: Atsushi Kamigaichi, MD
- 4:36 PM Abstract 8010:** Perioperative toripalimab in non-small cell lung cancer: Clinical outcomes and safety from a large prospective real-world study.
First Author: Pingping Song
- 4:42 PM Abstract 8011:** LuSato-1: Phase I study of ¹⁷⁷Lu-SSO110 with ⁶⁸Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).
First Author: Surein Arulananda, PhD, MBBS
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 8012:** Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFB β 2-armed DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.
First Author: Zhonglin Hao, MD, PhD
- 5:06 PM Abstract 8013:** Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage small-cell lung cancer: A randomized, controlled, open-label, single-center phase II clinical study.
First Author: Jiuwei Cui, MD, PhD
- 5:12 PM Abstract 8014:** Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).
First Author: Luis G. Paz-Ares, MD, PhD
- 5:18 PM Panel Question and Answer**
- 5:30 PM Abstract 8015:** Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
First Author: John V. Heymach, MD, PhD
- 5:36 PM Abstract 8016:** Tumor-naïve multimodal ctDNA MRD assay to predict recurrence in a prospective cohort of patients undergoing curative-intent lung cancer resection.
First Author: Di Lu
- 5:42 PM Abstract 8017:** Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer.
First Author: James R.M. Black, MD, PhD
- 5:48 PM Panel Question and Answer**

4:30 PM-6:00 PM Rapid Oral Abstract Session

Sarcoma

Location: S504

Kristen Nooshin Ganjoo, MD—Chair

Stanford University

Hiroataka Miyashita, MD, PhD—Chair

UC San Diego Moores Cancer Center

- 4:30 PM** **Abstract 11512:** Maintenance treatment with toripalimab and anlotinib after anthracycline-based chemotherapy in patients with advanced soft tissue sarcoma (TORANS): A single-arm, phase 2 trial.
First Author: Yaotiao Deng, MD, PhD
- 4:36 PM** **Abstract 11513:** Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study.
First Author: Tian Gao, PhD
- 4:42 PM** **Abstract 11514:** PEMBROCABOSARC: A phase II trial combining pembrolizumab and cabozantinib in patients with advanced undifferentiated pleomorphic sarcoma.
First Author: Maud Toulmonde, MD
- 4:48 PM** *Panel Question and Answer*
- 5:00 PM** **Abstract 11515:** Toxicity and efficacy characterization of doxorubicin and trabectedin association versus doxorubicin alone in patients over 70 years with leiomyosarcoma: Analysis from LMS02 and LMS04 studies.
First Author: Imen Ben-Ammar

- 5:06 PM** **Abstract 11516:** Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.
First Author: Dejka M. Araujo, MD
- 5:12 PM** **Abstract 11517:** Longitudinal plasma and CSF ctDNA profiling as used to define therapeutic landmarks and compartmentalized clonal evolution in rhabdomyosarcoma.
First Author: Yizhuo Zhang, MD
- 5:18 PM** *Panel Question and Answer*
- 5:30 PM** **Abstract 11518:** Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.
First Author: Julia Lynne Glade Bender, MD
- 5:36 PM** **Abstract 11519:** Association of NAB2–STAT6 distal fusion with risk level of metastatic disease and thoracic primary site.
First Author: Keerthana Sureshkumar, BS
- 5:42 PM** **Abstract 11520:** Efficacy of velzatinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.
First Author: Michael C. Heinrich, MD, FACP
- 5:48 PM** *Panel Question and Answer*

8:00 AM-9:00 AM Case-Based Panel

De Novo HER2 Metastatic Breast Cancer: Cure or Control?

Location: E451

Eric P. Winer, MD, FASCO—Chair

Yale Cancer Center
Moderator

Amy Sanders Clark, MD, MSCE

Abramson Cancer Center of the University of Pennsylvania
Medical Oncologist Perspective

Miriam Claire Mutebi, MD, MMed, MSc, FACS

Aga Khan University Hospital
Surgeon Perspective

Philip Poortmans, MD, PhD

Iridium Network
Radiation Oncologist Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Navigating Cervical Cancer Across the Globe: Neoadjuvant Chemotherapy, Radiation, and Immunotherapy

Location: E450a

Jyoti Mayadev, MD—Chair

University of California Davis Comprehensive Cancer Center
Moderator

Sudeep Gupta, MD, MBBS, DM

Tata Memorial Centre and Homi Bhabha National Institute
Medical Oncologist Perspective

Hannah Simonds, PhD, MBChB, MRCP, FRCR

Tygerberg Academic Hospital, Stellenbosch University
Radiation Oncologist and Implementation Perspective

Lilie L. Lin, MD

The University of Texas MD Anderson Cancer Center
Radiation Oncologist and Access Perspective

Panel Question and Answer

8:00 AM-9:15 AM Highlights Session

Highlights of the Year II

Location: Hall D1

Erika P. Hamilton, MD, FASCO—Chair

Sarah Cannon Research Institute

8:00 AM Kristen Keon Ciombor, MD, MS, FASCO

Vanderbilt University
Highlights of the Year in Colorectal Cancer: Improving Patient Outcomes Through Optimization of Molecularly Selected Therapies

8:15 AM Kevin Joseph Harrington, PhD, MBBS

City of Hope Comprehensive Cancer Center
Highlights of the Year: Exciting Advances in Rare and Not-so-Rare Head and Neck Cancers

8:30 AM To be determined

Highlights of the Year in Breast Cancer: Optimal Management With Antibody Drug Conjugates Across Breast Cancer Stages and Subtypes

8:45 AM Rashmi Chugh, MD, FASCO

Michigan Medicine
Highlights in New Targeted Therapies in Sarcoma: Desmoid, GIST, and Liposarcoma

9:00 AM Tanya B. Dorff, MD, FASCO

City of Hope Comprehensive Cancer Center
Highlights in Prostate Cancer: Moving Towards Personalized Treatment Across the Spectrum of Prostate Cancer

8:00 AM-9:15 AM Education Session

Big Breakthroughs for Young Patients: Newly Approved Drugs for Pediatric Brain Tumors

Location: S103

Eric Bouffet, MD, FRCPC—Chair

The Hospital for Sick Children, University of Toronto
BRAF Inhibitors for Low-Grade Gliomas

David Neal Franz, MD

Cincinnati Children's Hospital, University of Cincinnati College of Medicine

More Than 15 Years After Approval of Everolimus: How Has It Impacted the Care of Subependymal Giant Cell Astrocytoma Worldwide?

Isabel Arrillaga, MD, PhD

Massachusetts General Hospital
New U.S. Food and Drug Administration Approval for H3K27M-Mutant Tumors

Rakesh Jalali, MD

Tata Memorial Hospital
Access to Newer Therapeutic Agents in Low- and Middle-Income Countries

Panel Question and Answer

8:00 AM-9:15 AM Education Session

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy

Location: S102

Gareth Morgan, MD, PhD—Chair

Perlmutter Cancer Center, NYU Langone Health
Beyond Del(17p): A Modern Framework for Defining High-Risk Myeloma

Sagar Lonial, MD, FACP, FASCO

Winship Cancer Institute of Emory University
Frontline Therapy in High-Risk Myeloma: One Size Does Not Fit All

Jesus San-Miguel, MD, PhD

University of Navarra
Can Immunotherapy Level the Playing Field for High-Risk Myeloma?

Panel Question and Answer

8:00 AM-9:15 AM Education Session

New Horizons for Hereditary Cancer Syndromes

Location: S403

Olufunmilayo I. Olopade, MBBS, FACP, FASCO—Chair

The University of Chicago
Deploying Cascade Testing

Monday, June 1, 2026

Derek Wong, PhD

Children's Hospital of Philadelphia
Multicancer Detection, Liquid Biopsies, Artificial Intelligence, and More: Can Emerging Technologies Improve Upon Current Cancer Detection Strategies?

Susan M. Domchek, MD, FASCO

Abramson Cancer Center of the University of Pennsylvania
Reducing or Eliminating Risk: Preventive Agents

Rosa Maria Alvarez-Gomez, MD, PhD, MSc

Instituto Nacional de Cancerología
Addressing Hereditary Cancers in Resource Constrained Environments: The Low- and Middle-Income Countries Perspective

Panel Question and Answer

8:00 AM-9:15 AM Education Session

The Forgotten Symptom: Assessment and Management of Cognitive Impairment Across the Age Spectrum in Cancer Care

Location: E350

Allison Magnuson, DO, MS, FASCO—Chair

James P. Wilmot Cancer Center, University of Rochester Medical Center
Cognitive Assessment in Adults With Cancer: Why, When, and How?

Janette L. Vardy, MD, PhD, FRACP

Sydney Cancer Survivorship Centre
Assessment and Management of Treatment-Related Cognitive Impairment

Yin Ting Cheung

The Chinese University of Hong Kong
Integrating Cognitive Care Into Everyday Practice: Lessons From Pediatric Oncology for Clinicians Treating Older Adults

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Time to Activation in Oncology Clinical Trials: Challenges and Opportunities for Improvement

Location: S100a

Romeo Angelo M. DeClaro, MD—Chair

U.S. Food and Drug Administration
Setting the Stage for Clinical Trial Activation: From Non-Clinical to Investigational New Drug Submission

W. Kimryn Rathmell, MD, PhD, FASCO

The Ohio State University Comprehensive Cancer Center
The Cancer Center Perspective: Quantifying the "Activation Gap" and the Cost of Delay

Dee Anna Smith, BS

Sarah Cannon Research Institute
The Community Frontline: Scaling Rapid Activation for Real-World Impact

Anthony G. Letai, MD, PhD

National Cancer Institute
The Federal Mandate: National Strategies to Modernize the Clinical Trials Network

Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer

Location: E450b

Quynh-Thu Xuan Le, MD—Chair

Stanford University

Cristina P. Rodriguez, MD—Chair

University of Washington

8:00 AM Patrick Ha, MD

University of California San Francisco
Salivary Gland Cancers: Finding Precision in a Rare Landscape

8:12 AM Abstract 6009: Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.

First Author: Renata Ferrarotto, MD

8:24 AM Abstract 6010: Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.

First Author: Glenn J. Hanna, MD

8:36 AM Abstract 6011: Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial.

First Author: Ichiro Kinoshita, MD, PhD

8:48 AM Abstract 6012: A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy-naïve recurrent and/or metastatic androgen receptor (AR)-positive salivary gland cancer (ETCTN 10553).

First Author: Alan Loh Ho, MD, PhD

9:00 AM Laura D. Locati, MD

University of Pavia
Discussion of Abstract(s) 6009-6012: From Rare Targets to Real Impact

9:12 AM Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

To Boldly Deliver Where No Drug Has Gone Before: Antibody-Drug Conjugates in Sarcoma

Location: S504

Alberto S. Pappo, MD, FASCO—Chair

St. Jude Children's Research Hospital

Roberta Sanfilippo, MD—Chair

European Institute of Oncology

8:00 AM Vivek Subbiah, MD

Sarah Cannon Research Institute
Antibody-Drug Conjugates in Sarcomas: From Promise to Practice

8:12 AM Abstract 11509: Spatial RNA-protein profiling of antibody-drug conjugate (ADC) targets in leiomyosarcoma (LMS).

First Author: Carlos Torrado, MD, MS

8:24 AM Robert G. Maki, MD, PhD, FASCO

Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 11509: Biomarker-Guided Antibody-Drug Conjugates: Matching the Right Target to the Right Patient

- 8:36 AM** **Abstract 11510:** Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.
First Author: Lu Xie, MD, PhD
- 8:48 AM** **Abstract 11511:** Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.
First Author: Anthony Paul Conley, MD
- 9:00 AM** **Abha A. Gupta, MD**
Princess Margaret Cancer Centre, University Health Network
Discussion of Abstract(s) 11510-11511: Cracking the Code: Antibody-Drug Conjugates in Bone Sarcomas
- 9:12 AM** *Panel Question and Answer*

8:00 AM-9:30 AM Rapid Oral Abstract Session

Genitourinary Cancer—Kidney and Bladder

Location: Hall D2

Elizabeth Henry, MD—Chair

Loyola University

Benjamin Garmez, MD—Chair

Sarah Cannon Research Institute

- 8:00 AM** **Abstract 4514:** MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032901).
First Author: Shilpa Gupta, MD
- 8:06 AM** **Abstract 4515:** Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.
First Author: Emanuele Crupi, MD
- 8:12 AM** **Abstract 4624:** Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.
First Author: Maria De Santis, MD
- 8:18 AM** *Panel Question and Answer*
- 8:30 AM** **Abstract 4516:** Interim analysis results from Duravelo-2: Zelenectide pevvedotin (zele; BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC).
First Author: Yohann Loriot, MD, PhD
- 8:36 AM** **Abstract 4517:** Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
First Author: Xin Gao, MD
- 8:42 AM** **Abstract 4518:** Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.
First Author: Xinan Sheng, MD

- 8:48 AM** *Panel Question and Answer*
- 9:00 AM** **Abstract 4519:** Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade (ICB)–based first line therapies in metastatic renal cell carcinoma (mRCC).
First Author: Rahul Winayak, MD
- 9:06 AM** **Abstract 4520:** Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.
First Author: Pavlos Msaouel, MD, PhD
- 9:12 AM** **Abstract 4521:** Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non-clear cell renal cell carcinoma (nccRCC).
First Author: Darren R. Feldman, MD
- 9:18 AM** *Panel Question and Answer*

8:00 AM-11:00 AM Oral Abstract Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: Arie Crown Theater

Shivaani Kummar, MD, MBBS, FACP—Chair

Knight Cancer Institute

Collin M. Blakely, MD, PhD—Chair

UCSF Helen Diller Comprehensive Cancer Center

- 8:00 AM** **Abstract 3000:** DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial.
First Author: Hongyun Zhao, PhD
- 8:12 AM** **Abstract 3001:** Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors.
First Author: Wei Li
- 8:24 AM** **Abstract 3002:** First-in-human study of SYS6043, a novel B7-H3–targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies.
First Author: Li Zhang, MD
- 8:36 AM** **Abstract 3003:** T-Bren (BL-M07D1) in patients with recurrent or metastatic (R/M) ovarian cancer: Results from two phase II studies.
First Author: Gong-Yi Zhang, MD
- 8:48 AM** **Paolo Tarantino, MD, PhD**
Dana-Farber Cancer Institute, Harvard Medical School
Discussion of Abstract(s) 3000-3003: Making Sense of Antibody-Drug Conjugate Trials: Efficacy, Toxicity, and Patient Selection
- 9:00 AM** *Panel Question and Answer*
- 9:12 AM** **Abstract 3004:** Analysis of spatial atlas of ADC targets in immunotherapy-treated NSCLC to link compartment-specific target expression with tumor immune contexture, clinical outcome, and on-treatment remodeling.
First Author: Jean-Philippe Guegan

Monday, June 1, 2026

- 9:24 AM Abstract 3005:** Clinical utility of discordances between histomorphology and molecular biomarkers in precision oncology.
First Author: Gil Shamai, PhD
- 9:36 AM David L. Rimm, MD, PhD**
Yale School of Medicine
Discussion of Abstract(s) 3004-3005: Artificial Intelligence and Spatial Profiling: Redefining Predictive Biomarkers
- 9:48 AM Panel Question and Answer**
- 10:00 AM Abstract 3006:** Clinical activity and safety of RNK08954 in advanced non-small cell lung cancer (NSCLC) patients with KRAS G12D mutation (NCT06667544).
First Author: Zhengbo Song
- 10:12 AM Abstract 3007:** Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D-mutant solid tumors.
First Author: Yiyi Yu, PhD
- 10:24 AM Abstract 3008:** Preliminary efficacy of GFH375 in patients with advanced cholangiocarcinoma or colorectal cancer harboring KRAS G12D mutation.
First Author: Lingjun Zhu
- 10:36 AM Kathryn C. Arbour, MD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 3006-3008: "Cracking" KRAS G12D
- 10:48 AM Panel Question and Answer**

8:00 AM-11:00 AM Oral Abstract Session

Melanoma/Skin Cancers

Location: S100bc

Matias Rodrigo Chacon, MD—Chair

Alexander Fleming Institute

Barbara T. Ma, MD, MS—Chair

Weill Cornell Medicine, New York-Presbyterian Hospital

- 8:00 AM Abstract 9500:** Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
First Author: Matteo S. Carlino, PhD, MBBS, FRACP
- 8:12 AM Abstract 9501:** A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.
First Author: Ahmad Tarhini, MD, PhD
- 8:24 AM Abstract 9502:** A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi).
First Author: Georgina V. Long, MD, PhD, FRACP, FASCO
- 8:36 AM Rodrigo Ramella Munhoz, MD, PhD, FASCO**
Sírío Libanês Hospital
Discussion of Abstract(s) 9500-9502: Neo and Neo: Unraveling the Matrix of Adjuvant Neoantigen and Neoadjuvant Immunotherapy
- 8:48 AM Panel Question and Answer**

- 9:00 AM Abstract LBA9503:** Darovasertib plus crizotinib vs investigator's choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.
First Author: Marlana M. Orloff, MD
- 9:12 AM Abstract LBA9504:** ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
First Author: Shailender Bhatia, MD
- 9:24 AM Abstract 9506:** A phase II, multicenter, single-arm clinical trial of response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: RAMPART.
First Author: Christopher Andrew Barker, MD
- 9:36 AM Abstract LBA9505:** Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.
First Author: Janice M. Mehnert, MD
- 9:48 AM Jose Lutzky, MD**
Sylvester Comprehensive Cancer Center
Discussion of Abstract(s) LBA9503-9506: Are We Breaking Barriers in Uveal Melanoma and Nonmelanoma Skin Cancers?
- 10:00 AM Panel Question and Answer**
- 10:12 AM Abstract 9507:** OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.
First Author: Allison Betof, MD, PhD, FASCO
- 10:24 AM Abstract 9508:** Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
First Author: Diwakar Davar, MBBS, MSc
- 10:36 AM Charlotte Eielson Ariyan, MD, PhD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 9507-9508: Engineered T-Cells: Truly an Advantage for Cellular Therapy?
- 10:48 AM Panel Question and Answer**

9:00 AM-12:00 PM Poster Session

Gynecologic Cancer

Location: Hall A—Posters and Exhibits

Posters by Topic

- Artificial Intelligence:** Board(s) 184-186
Cervical Cancer: Board(s) 187-201, 203-205, 294a- 296a
Outcomes/Quality: Board(s) 206-211
Ovarian Cancer: Board(s) 212-274, 296b-302a
Uterine Cancer: Board(s) 275-291, 302b-303a
Other Gynecologic Cancer: Board(s) 292-293, 303b

- Board 184 **Abstract 5518:** Population-based prediction of cardiovascular mortality in gynecologic cancer survivors using machine learning (RISKHEART).
First Author: Luis Felipe Leite da Silva, MS

- Board 185 **Abstract 5519:** Feasibility and concordance of a large language model (ChatGPT-5) as a clinical decision support tool in gynecologic oncology tumor boards: A blinded, multi-observer study.
First Author: Hatice Asoglu, MD
- Board 186 **Abstract 5520:** Quantitative pathology biomarkers for platinum resistance in ovarian cancer.
First Author: Durga Vahini Sritharan, BS
- Board 187 **Abstract 5521:** Income inequality and cervical cancer: A comparative analysis of demographics and healthcare burden of women in the lowest and highest income quartiles.
First Author: Dhruvi Dipakkumar Pathak, MBBS
- Board 188 **Abstract 5522:** Treatment patterns and PD-L1 testing among persistent, recurrent, or metastatic cervical cancer patients in the United States community oncology setting.
First Author: Elizabeth A. Szamreta, PhD
- Board 189 **Abstract 5523:** Radiotherapy use among locally advanced cervical cancer patients (LACC) in the United States community oncology setting.
First Author: Elizabeth A. Szamreta, PhD
- Board 190 **Abstract 5524:** Targeting stromal FAK signaling to address chemotherapy and immunotherapy resistance in gastric-type endocervical adenocarcinoma.
First Author: Ting Peng, MD, MMedSc
- Board 191 **Abstract 5525:** Retrospective study of guideline concordance in cervical cancer screening surveillance by age, race, and ethnicity.
First Author: Maeve Fitzgerald Givens, BS
- Board 192 **Abstract 5526:** Efficacy and safety of cadonilimab (CD) in combination with disitamab vedotin (RC48) or nab-paclitaxel (NP) in the treatment of recurrent or metastatic cervical cancer (r/mCC): A prospective, double-cohort, multicenter, open-label, phase II clinical study.
First Author: Min Zheng, MD, PhD
- Board 193 **Abstract 5527:** Impact of adjuvant sequential chemoradiotherapy on long-term overall survival in early-stage cervical cancer: Final analysis of the STARS phase III randomized trial.
First Author: He Huang, MD
- Board 194 **Abstract 5528:** Impact of para-aortic lymphadenectomy on prognosis and quality of life in preoperative IB2-IIA2 cervical cancer: A multi-center cohort study.
First Author: Xinqu Qu
- Board 195 **Abstract 5529:** Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.
First Author: Meena Okera, MBBS
- Board 196 **Abstract 5530:** Global disparities in current clinical trials in cervical cancer.
First Author: Sneha Ahuja, BS
- Board 197 **Abstract 5531:** Genomic landscape and patient demographics in endocervical adenocarcinoma: Insights from the AACR Project GENIE.
First Author: Rechuma Hafter, BA
- Board 198 **Abstract 5532:** GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
First Author: Pin Wang, PhD
- Board 199 **Abstract 5533:** Neoadjuvant chemotherapy and individualized de-escalation surgery for fertility preservation in stage IB1-IIA2 cervical cancer: A multicenter prospective study (FIND study).
First Author: Yanling Feng
- Board 200 **Abstract 5534:** Quality of life outcomes following hypofractionated radiotherapy in locally advanced cervical cancer.
First Author: David Francisco Cantu De Leon
- Board 201 **Abstract 5535:** Trends in rural-urban disparities in U.S. cervical cancer mortality before and after the HPV vaccine introduction: A CDC analysis, 1999-2023.
First Author: Jasvinder Kumar, MD, MBBS
- Board 203 **Abstract 5537:** HPV-stratified tissue factor expression and multi-omic correlates of overall survival after tisotumab vedotin in cervical cancer.
First Author: Shaina Bruce, MD
- Board 204 **Abstract 5538:** The impact of re-adoption of open radical hysterectomy on postoperative outcomes in the United States: An interrupted time series analysis.
First Author: Alex Ede Rosenthal Powers, MD, ScM
- Board 205 **Abstract 5539:** Optimal adjuvant therapy for early-stage cervical cancer (ESCC) with intermediate-risk factors: A target trial emulation of GOG-0263 based on the NCDB.
First Author: Ifeyinwa Ejisoby-Nwosu
- Board 206 **Abstract 5540:** Evaluation of imiquimod treatment outcomes in vulvar melanoma.
First Author: Alyssa Osheim, BBA
- Board 207 **Abstract 5541:** Association of steroid exposure with overall survival and hypersensitivity reaction risk in paclitaxel-treated patients with gynecologic cancers.
First Author: Mohammad Harris Jalili, PharmD
- Board 208 **Abstract 5542:** Association of post-treatment vaginal structural changes with psychosexual dysfunction in young cervical cancer survivors: Evidence from a low- and middle-income country.
First Author: Suriana Sultana, MBBS
- Board 209 **Abstract 5543:** Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity: A propensity score matched analysis from a global federated health research network.
First Author: Yajur Arya, MD
- Board 210 **Abstract 5544:** A phase 1 dose-escalation and -expansion study of AFN0328, a novel mRNA-based immunotherapy, in patients with HPV16/18-associated high-grade squamous intraepithelial lesions.
First Author: Yunxia Cao
- Board 211 **Abstract 5545:** Limb compression therapy and chemotherapy-induced peripheral neuropathy in women with gynecologic cancers: A prospective self-controlled study (NEURO-GLOVE Trial)—Updated long-term analysis.
First Author: Kadriye Başkurt, MD

- Board 212 **Abstract 5546:** Systemic inflammation and tumor immune microenvironment biomarkers (FOXP3, CD68, CD163) stratified by BRCA/HRD status in high-grade serous ovarian carcinoma: Associations with PFS and OS.
First Author: Carolina Ibañez Caceres, MD
- Board 213 **Abstract 5547:** Genomic signature–based risk score for PARP inhibitor response in *BRCA*-mutated ovarian cancer: A whole-exome sequencing analysis.
First Author: Junhwan Kim, MD
- Board 214 **Abstract 5548:** ErbB family members as mediators of acquired resistance to immunotherapy in high-grade serous ovarian cancer.
First Author: Mengyao Xu, MD, PhD
- Board 215 **Abstract 5549:** Development of payload-resistant human ovarian cancer cell lines to better understand antibody-drug conjugate sequencing and resistance mechanisms.
First Author: Janina Pearce, MD, PhD
- Board 216 **Abstract 5550:** Geographical heterogeneity in modeled CA-125 KELIM values: Insights from more than 50,000 real-world calculations on the Biomarker Kinetics platform.
First Author: Benoit You, MD, PhD
- Board 217 **Abstract 5551:** YL205, a novel anti-Napi2b antibody drug conjugate (ADC), in patients with ovarian cancer: Preliminary result from a first-in-human trial.
First Author: Xiaohua Wu, MD
- Board 218 **Abstract 5552:** A first-of-its-kind multi-omic assay using lipids and proteins to identify early-stage ovarian cancer in symptomatic individuals.
First Author: Abigail McElhinny, PhD
- Board 219 **Abstract 5553:** Preoperative assessment of peritoneal carcinomatosis with [⁶⁸Ga]Ga-FAPI-46 PET/CT.
First Author: Ayca Arcay Ozturk, MD
- Board 220 **Abstract 5554:** Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)–expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/ APGOT-OV13) safety run-in (SRI).
First Author: Antonio Gonzalez Martin, MD, PhD
- Board 221 **Abstract 5555:** Integrating a small extracellular vesicle protein–based ovarian cancer score with O-RADS Ultrasound to improve preoperative risk stratification of adnexal masses.
First Author: Qunxian Rao, MD
- Board 222 **Abstract 5556:** Neoadjuvant disitamab vedotin plus carboplatin in HER2-expressing advanced ovarian cancer: A prospective, single-arm, phase II trial.
First Author: Yifan Meng
- Board 223 **Abstract 5557:** Understanding palliative care gaps in young adult ovarian cancer: A population-based study of 37,880 hospitalizations.
First Author: Rigved Virendra Jeurkar, MBBS
- Board 224 **Abstract 5558:** Ocular toxicity and safety profile of mirvetuximab soravtansine in ovarian cancer: A systematic review and meta-analysis of clinical trials and real-world studies.
First Author: Priyanka Nagdev, MD
- Board 225 **Abstract 5559:** Updated efficacy of dalpiciclib and nonsteroidal aromatase inhibitors (NSAIs) in estrogen receptor–positive (ER+) recurrent/metastatic (R/M) ovarian cancer and uterine neoplasms.
First Author: Huijuan Yang
- Board 226 **Abstract 5560:** Phase II study of sintilimab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.
First Author: Nan Zhang, MD
- Board 227 **Abstract 5561:** Treatment duration with avutometinib/defactinib in recurrent low-grade serous ovarian carcinoma by KRAS mutation status.
First Author: Anna Shvygin, MD
- Board 228 **Abstract 5562:** Circulating tumor DNA to add prognostic stratification beyond CA-125 in epithelial ovarian cancer.
First Author: Grace Gorecki, MD
- Board 229 **Abstract 5563:** The HER2 paradox in ovarian clear cell carcinoma: Expression and intrinsic resistance to trastuzumab deruxtecan (T-DXd).
First Author: Junsik Park, MD, PhD
- Board 230 **Abstract 5564:** A small extracellular vesicle protein-based model for ovarian cancer relapse detection and monitoring.
First Author: Zheng Feng
- Board 231 **Abstract 5565:** Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/ GOG-3012 trial.
First Author: Bradley J. Monk, MD
- Board 232 **Abstract 5566:** Platinum re-challenge in platinum-resistant ovarian cancer: Real-world patterns and outcomes.
First Author: Prakirthi Yerram, PharmD
- Board 233 **Abstract 5567:** Circulating tumor DNA to enhance detection of highrisk minimal residual disease in ovarian cancer relative to second look laparoscopy.
First Author: Helen D. Clark, MD
- Board 234 **Abstract 5568:** Dose-dense weekly versus standard three-weekly paclitaxel in combination with carboplatin for resectable stage II-IV epithelial ovarian carcinoma: A retrospective cohort study.
First Author: Sehrish Sarwar Baloch, MD, MBBS
- Board 235 **Abstract 5569:** Everolimus and aromatase inhibitors for advanced and recurrent low-grade serous ovarian carcinoma.
First Author: Halle Goodwin, MD

- Board 236 **Abstract 5570:** Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibody–drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).
First Author: Felipe K. Hurtado
- Board 237 **Abstract 5571:** Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a cadherin 6 (CDH6)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced ovarian cancer (OC) or renal cell carcinoma (RCC).
First Author: Felipe K. Hurtado
- Board 239 **Abstract 5573:** Multi-modal liquid biopsy integrating cfDNA fragmentomics and serum biomarkers for the differential diagnosis of ovarian tumors.
First Author: Zhoumei Liu
- Board 240 **Abstract 5574:** Realworld outcomes of olaparib with versus without bevacizumab in bevacizumabnaïve BRCA1/2mutated ovarian cancer.
First Author: Love Kumar, MD
- Board 241 **Abstract 5575:** A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).
First Author: Alessandro Santin, MD
- Board 242 **Abstract 5576:** Preliminary efficacy and safety of first-line anlotinib plus carboplatin/paclitaxel induction therapy followed by anlotinib maintenance in advanced ovarian cancer: Results from the ALTER-GO-010 phase II multicenter trial.
First Author: Wenjun Cheng
- Board 243 **Abstract 5577:** A novel prognostic index for survival prediction in ovarian cancer: Beyond FIGO staging.
First Author: Arya Prathap, MBBS, MS
- Board 244 **Abstract 5578:** Beyond survival: Understanding unmet needs among a diverse cohort of ovarian cancer survivors.
First Author: Caroline P. Shermoen, MD
- Board 245 **Abstract 5579:** Phase II study of utidelone plus fruquintinib for the treatment of platinum-resistant recurrent ovarian cancer (FRUTD trial).
First Author: Hao Wen
- Board 246 **Abstract 5580:** Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody–drug conjugate (ADC) in patients with advanced solid tumors.
First Author: Xiaohua Wu
- Board 247 **Abstract 5581:** Impact of organ-adjacent extracellular vesicle proteomics from uterine lavage on accurate detection and discrimination of ovarian cancer.
First Author: John A. Martignetti, MD, PhD
- Board 248 **Abstract 5582:** Fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) in ovarian, fallopian tube, and primary peritoneal cancers: Efficacy and safety results from the GINGA study.
First Author: Takashi Motohashi, MD
- Board 249 **Abstract 5583:** Differential impact of *TP53* and *KRAS* pathogenic variants on overall survival in advanced ovarian carcinoma.
First Author: Shreyas Kudrimoti, MD
- Board 250 **Abstract 5584:** Incidence and genomic characteristics of a low homologous recombination deficiency score subgroup in *BRCA*-mutant ovarian cancer.
First Author: Caiyan Liu
- Board 251 **Abstract 5585:** Virtual multiplex immunofluorescence characterization of spatial immune architectures and tertiary lymphoid structures in high-grade serous ovarian cancer.
First Author: Junhwan Kim, MD
- Board 252 **Abstract 5586:** Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial.
First Author: Huijuan Yang
- Board 253 **Abstract 5587:** IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
First Author: George Au-Yeung, PhD, MBBS
- Board 255 **Abstract 5589:** Budget impact analysis of heated intraperitoneal chemotherapy at interval cytoreductive surgery for stage III high grade serous carcinoma of tubo-ovarian origin.
First Author: Tal Milman, MD, BMedSci
- Board 256 **Abstract 5590:** Enhanced predictive value of KELIM for surgical resectability in HRD-positive high-grade serous ovarian cancer.
First Author: Mayerly Castrillón Sánchez
- Board 257 **Abstract 5591:** Impact of niraparib maintenance on progression-free survival and overall survival: An updated meta-analysis.
First Author: Roshan Mustafa Pathan, MBBS
- Board 258 **Abstract 5592:** Post-treatment ctDNA monitoring using a tumor-informed whole-genome sequencing-based assay in homologous recombination–proficient ovarian cancer.
First Author: Sophie Blakey-Cheung, MD
- Board 259 **Abstract 5593:** Spatial distribution and functional heterogeneity of CD56bright and CD56dim natural killer cells and the effects on the immune microenvironment in ovarian cancer.
First Author: Guo Huiming
- Board 260 **Abstract 5594:** Comprehensive profiling of antibody–drug conjugate target expression in epithelial ovarian cancer with pre- and post-ADC longitudinal assessment.
First Author: Yong jae Lee, MD, PhD
- Board 261 **Abstract 5595:** Primary analysis of pembrolizumab combined with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer: The NOGGO PERCEPTION phase II study.
First Author: Jalid Sehouli, MD
- Board 262 **Abstract 5596:** Update of the EORTC QLQ-Ovarian Cancer Module (EORTC-QLQ-OV28) phase I and II.
First Author: Vesna Bjelic-Radisic, PhD
- Board 263 **Abstract 5597:** Vididencel, an active immunotherapy in high-grade serous ovarian carcinoma patients: Analysis of tumor-directed immune responses post-primary treatment.
First Author: Annegé Vledder

- Board 265 **Abstract 5599:** Association of AI-based quantitative B7-H3 evaluation in the tumor microenvironment with molecular subtypes in high-grade serous ovarian carcinoma.
First Author: Ryusuke Murakami, PhD
- Board 266 **Abstract 5600:** Vaccine-induced immune responses, HLA genotyping, and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial).
First Author: Ana Veneziani, MD
- Board 268 **Abstract 5602:** Prognostic effect of neoadjuvant chemotherapy in gBRCA-mutated compared to gBRCA wild-type patients with advanced HGSOc treated with first-line PARP inhibitor maintenance: A large series propensity score–matching analysis.
First Author: Ilary Ruscito, MD
- Board 269 **Abstract 5603:** Onsite serial monitoring of high grade serous ovarian cancer (HGSOc) mutations in circulating tumor DNA (ctDNA) via droplet digital PCR.
First Author: John Nakayama, MD
- Board 270 **Abstract 5604:** The use of circulating tumor DNA to stratify the risk of recurrence after surgical debulking in epithelial ovarian cancer.
First Author: Muhammad Anees
- Board 271 **Abstract 5605:** Precision histopathologic classification of epithelial ovarian cancer subtypes using a computationally efficient multilayer perceptron framework with global validation.
First Author: Elangovan Krishnan, PhD, MBBS, MS
- Board 272 **Abstract 5606:** High-dimensional multiplex immunofluorescence to reveal immune microenvironment remodeling in matched primary and recurrent serous ovarian cancer.
First Author: Yookyung Lee
- Board 273 **Abstract 5607:** Bevacizumab rechallenge in platinum-resistant ovarian cancer: Evidence from a propensity score–matched analysis.
First Author: Celso Silva Sousa Filho
- Board 274 **Abstract 5608:** AI-driven multi-scale histopathologic classification of epithelial ovarian cancer to support precision oncology.
First Author: Yashwanth Kancharla, MBBS
- Board 275 **Abstract 5609:** The role of combined T cell and NK cell activity in immune checkpoint inhibitor (ICI) therapy in endometrial cancer (EC).
First Author: Danielle Greenberg, MD
- Board 276 **Abstract 5610:** Sequencing of fallopian tube p53 signature found concurrently with p53 mutant uterine cancers and their somatic mutation profiles.
First Author: Erika Joelle Lampert, MD
- Board 277 **Abstract 5611:** Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment.
First Author: Jeffrey Andrew How, MD, MS, MPH
- Board 278 **Abstract 5612:** Pembrolizumab–lenvatinib beyond immunotherapy progression in endometrial cancer: A real-world analysis.
First Author: Alberto Farolfi, MD, PhD
- Board 279 **Abstract 5613:** Circulating tumor DNA (ctDNA) from a phase II study of adjuvant dostarlimab with pelvic radiation in locally advanced, mismatch repair–deficient (MMR-D) endometrial cancer (D-RT study).
First Author: Gabriela Sotolongo, MD
- Board 280 **Abstract 5614:** Forecasting global disparities in cervix and corpus uteri cancers: GLOBOCAN 2022–2040 projections.
First Author: Sonia Babu, MD
- Board 281 **Abstract 5615:** A phase II trial of lenvatinib plus pembrolizumab in patients (pts) with endometrial or ovarian carcinosarcoma.
First Author: Sminu Bose, MD
- Board 282 **Abstract 5616:** Antibody-drug conjugate (ADC) biomarker targets in endometrial cancer (EC): Molecular characterization and implications for therapeutic decision-making.
First Author: Britt Kristina Erickson, MD
- Board 283 **Abstract 5617:** Accumulation of cholesterol, cortisol, and glutathione in mitochondria as a marker of metabolic adaptation in serous and clear cell endometrial carcinoma.
First Author: Anna Petrovna Menshenina
- Board 284 **Abstract 5618:** p53 R248Q upregulation of VTCN1 via dual mechanisms as a driver of immune evasion and adaptive resistance to CDK4/6 inhibitors: Rationale for combination immunotherapy in endometrial cancer.
First Author: Yan Ding
- Board 285 **Abstract 5619:** Preoperative endocrine treatment response in primary postmenopausal endometrial cancer.
First Author: Fabian Trillsch, MD
- Board 286 **Abstract 5620:** Racial disparities in endometrial cancer (EC) survival after molecular classification (MC).
First Author: Jill Roberts, MD
- Board 287 **Abstract 5621:** Aspirin use and survival outcomes in endometrial cancer.
First Author: Zachary Gentry, MD
- Board 288 **Abstract 5622:** MicroRNAs as surrogate biomarkers of future endometrial malignancy in women with endometrial hyperplasia without atypia and an open-label randomized trial of metformin, weight control, and exercise intervention.
First Author: Chyong-Huey Lai, MD
- Board 289 **Abstract 5623:** Whole-genome sequencing–based ctDNA testing for post-surgical monitoring and early detection of recurrence or progression in uterine cancer.
First Author: Abigail Barger, MD
- Board 290 **Abstract 5624:** Development of an endometrial cancer test from a vaginal swab.
First Author: Bridget Z. Gagrat
- Board 291 **Abstract 5625:** GLP-1 receptor expression in a molecularly characterized cohort of endometrial carcinoma: Results from the GEICO 163-T/ SPECTRUM study.
First Author: Carlos González-Merino

- Board 292 **Abstract 5626:** Examining the relationship between social support and inflammatory markers among patients with gynecologic cancer.
First Author: Oluwafemifola Oyedeji, MD, PhD, MPH
- Board 293 **Abstract 5627:** A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC).
First Author: Qi Zhou, MD
- Board 294a **Abstract TPS5628:** TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.
First Author: Brian M. Slomovitz, MD
- Board 294b **Abstract TPS5629:** Iparomlimab and tuvoralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer: A phase II umbrella trial.
First Author: Junjun Qiu Sr, PhD
- Board 295a **Abstract TPS5630:** A phase II trial of a FAK inhibitor combined with albumin-bound paclitaxel and an anti–PD-1/CTLA-4 bispecific antibody for metastatic, recurrent, or persistent gastric-type endocervical adenocarcinoma (GIFT Study).
First Author: Yingchao Zhao
- Board 295b **Abstract TPS5631:** Neoadjuvant chemioimmunotherapy before chemoradiation vs chemoradiation alone for stage IIB-IIIC1 carcinoma of the cervix: A phase II open-label randomized controlled trial (NeoCHIMERA).
First Author: Praveen Kumar Marimuthu, MBBS, DNB, DM
- Board 296a **Abstract TPS5632:** NRG-GY037: A phase III randomized trial of induction chemotherapy and pembrolizumab followed by chemoradiation and pembrolizumab maintenance versus standard chemoradiation and pembrolizumab maintenance in high-risk locally advanced cervical cancer.
First Author: Jyoti Mayadev, MD
- Board 296b **Abstract TPS5633:** A single-arm, phase 2 study of neoadjuvant mirvetuximab soravtansine and carboplatin for FR α -expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (M25-231; NCT06890338; GOG-3115).
First Author: Rebecca Arend
- Board 297a **Abstract TPS5634:** NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with *BRCA1/2*-mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.
First Author: Ying L. Liu, MD, MPH
- Board 297b **Abstract TPS5635:** A phase I, open-label, dose-finding, safety, tolerability, and exploratory trial of intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer.
First Author: Helen D. Clark, MD
- Board 298a **Abstract TPS5636:** TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.
First Author: Antonio Gonzalez Martin, MD, PhD
- Board 298b **Abstract TPS5637:** REJOICE-Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician's choice in patients with platinum-resistant ovarian cancer.
First Author: Debra L. Richardson, MD
- Board 299a **Abstract TPS5638:** A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.
First Author: Els Van Nieuwenhuysen, MD, PhD
- Board 299b **Abstract TPS5639:** A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.
First Author: Roisin Eilish O'Ceirbhail, MD
- Board 300a **Abstract TPS5640:** RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.
First Author: Benoit You, MD, PhD
- Board 300b **Abstract TPS5641:** RAINFOL-04 (ENGOT-OV96/GOG-3134): A phase 3, open-label, randomized study of rinatart sesutecan (Rina-S) plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.
First Author: Toon Van Gorp, MD, PhD
- Board 301a **Abstract TPS5642:** A phase 3, randomized, open-label study of INCB123667 versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer with cyclin E1 overexpression (MAESTRA 2, ENGOT-OV95, GOG-3137).
First Author: Rebecca Kristeleit, MD, PhD
- Board 301b **Abstract TPS5643:** Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS).
First Author: Myong Cheol Lim, MD, PhD
- Board 302a **Abstract TPS5644:** FRAMework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).
First Author: Isabelle Laure Ray-Coquard, MD, PhD

- Board 302b **Abstract TPS5645:** Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecán (HER2 ADC) versus investigator's choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC).
First Author: Floor Jenniskens Backes, MD
- Board 303a **Abstract TPS5646:** RAINFOL-03 (ENGOT-EN-31/GOG-3128): A global, phase 3, open-label, randomized study of rinatapar sesutecan (Rina-S) vs investigator's choice of chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and programmed death-ligand 1 inhibition.
First Author: Antonio Gonzalez Martin, MD, PhD
- Board 303b **Abstract TPS5647:** Puxitatum samrotecán (AZD8205) vs chemotherapy in patients with B7H4-selected advanced/metastatic endometrial cancer: The phase 3 randomized BluestarEndometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial.
First Author: Stephanie Gaillard, MD, PhD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Location: Hall A—Posters and Exhibits

Posters by Topic

Acute Leukemia: Board(s) 311-344, 392a-394a

Hematopoietic Stem Cell Transplantation and Other Cellular Therapies: Board(s) 345-358

Myelodysplastic Syndromes (MDS): Board(s) 359-364

Myeloproliferative Neoplasms (MPN) Including Chronic Leukemia and Mast Cell Disorders: Board(s) 365-382, 394b-396b

Outcomes/Quality: Board(s) 383-385

Other Leukemia and Myelodysplastic Syndromes: Board(s) 386-391

- Board 311 **Abstract 6518:** Early G-CSF after venetoclax-based induction for acute myeloid leukemia: Multicenter associations with infections, neutrophil recovery, and early mortality.
First Author: Randa Elzein, MBBS
- Board 312 **Abstract 6519:** Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.
First Author: Eno-obong Blessing Udoh, BS
- Board 313 **Abstract 6520:** The association of *IDH* co-mutations with treatment outcomes and overall survival in *TP53*-mutated acute myeloid leukemia.
First Author: Lukas Ronner, MD, MSc
- Board 314 **Abstract 6521:** A targeted phosphoproteomic assay to enable the prediction of response to intensive chemotherapy in acute myeloid leukemia.
First Author: Gabriel Ghiaur, MD, PhD
- Board 315 **Abstract 6522:** Investigation of the role of IFITM3 and the PI3K/Akt axis in the acute myeloid leukemia tumor microenvironment.
First Author: Fang Zhou, MD, PhD
- Board 316 **Abstract 6523:** Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.
First Author: Justin M. Watts, MD

- Board 317 **Abstract 6524:** Comparing induction strategies in acute myeloid leukemia: 10-year real-world experience with 7+3 and HMA/venetoclax.
First Author: Chandra Kakarala, MBBS
- Board 318 **Abstract 6525:** HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk-stratified analysis in 540 patients.
First Author: Sudhesh Kumar, MBBS
- Board 319 **Abstract 6526:** ASCERTAIN: Real-world asciminib (ASC) effectiveness in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
First Author: Marlise R. Luskin, MD
- Board 320 **Abstract 6527:** Response to HiDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
First Author: Apoorva Ravichandran, MD
- Board 321 **Abstract 6528:** Pharmacokinetic (PK) assessment of revumenib in patients with relapsed/refractory (R/R) acute leukemias harboring a *KMT2A* rearrangement (*KMT2Ar*) or *NPM1* mutation (*NPM1m*): Impact of food and concomitant medications.
First Author: Enoch Cobbina, PhD
- Board 322 **Abstract 6529:** Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia.
First Author: Daniel J. DeAngelo, MD, PhD
- Board 323 **Abstract 6530:** Older age as a predictor of post-transplant survival in newly diagnosed acute myeloid leukemia treated with HMA-venetoclax.
First Author: Momna Warraich, MBBS
- Board 324 **Abstract 6531:** Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT).
First Author: Naszrin Arani, MD
- Board 325 **Abstract 6532:** Impact of concomitant *NPM1* mutations on genomic and transcriptomic patterns of *PTPN11*-mutant myeloid leukemias.
First Author: Shivahamy Maheswaran, BA
- Board 326 **Abstract 6533:** Can transcriptome-based risk modeling improve survival stratification across cytogenetic groups in acute myeloid leukemia?
First Author: Amith Paruchuri, MBBS
- Board 327 **Abstract 6534:** Mutation landscape and pathway-level disparities in Black versus White patients with acute myeloid leukemia.
First Author: Chidiebube Ugwu, MD, MPH
- Board 328 **Abstract 6535:** Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome-negative (Ph-) B lymphoblastic leukemia (B-ALL).
First Author: Noam Edward Kopmar, MD
- Board 329 **Abstract 6536:** Impact of variant topography of *NPM1* mutations in acute myeloid leukemia.
First Author: Markie S. Zimmer, MD

- Board 330 **Abstract 6537:** Impact of transplant on *TP53^{MT}* configurational dynamics in myeloid neoplasms.
First Author: Dakshin Sitaram Padmanabhan, MD
- Board 331 **Abstract 6538:** Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without *FLT3* mutation.
First Author: Maher Albitar
- Board 332 **Abstract 6539:** Real-world outcomes of early unfractionated heparin use in NSTEMI patients with acute leukemia and severe thrombocytopenia.
First Author: Shanawar Ali Waris, MD
- Board 333 **Abstract 6540:** A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.
First Author: Jonathan Andreiadakis, MPH
- Board 334 **Abstract 6541:** Impact of cell-type-specific circadian disruption in pediatric B-ALL on clock-based biomarkers with implications for chronotherapy.
First Author: Angela Relógio, PhD
- Board 335 **Abstract 6542:** Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice.
First Author: Janvi Bhatia, BSc
- Board 336 **Abstract 6543:** Age and the genomic landscape of AML in precision oncology: An analysis using ASH HematOmics Program.
First Author: Pranav Singh, MBBS
- Board 337 **Abstract 6544:** From infancy to young adulthood: Exploring the divergent genomic mechanisms that drive AML.
First Author: Frank J. Scarpa, MSc
- Board 338 **Abstract 6545:** TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.
First Author: Alexandra Thalberg, BS
- Board 339 **Abstract 6546:** Induction failure (IF) as a prognostic marker in adult acute lymphoblastic leukemia (ALL).
First Author: Yosef Joseph Rene Amel Riazat Kesh, MBChB
- Board 340 **Abstract 6547:** Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.
First Author: Rafael Madero Marroquin, MD
- Board 341 **Abstract 6548:** Time to response with HMA/venetoclax as a predictor of survival in acute myeloid leukemia: Analysis of 1- vs 2-cycle responders.
First Author: Rafeh Safdar, MBBS
- Board 342 **Abstract 6549:** Cladribine/cyclophosphamide lymphodepletion efficacy and toxicity in CD19 CAR-T therapy for B-ALL.
First Author: Kriti Gera, MD
- Board 343 **Abstract 6550:** A phase II, single-arm study of romiplostim N01 for cancer treatment-induced thrombocytopenia in leukemia patients.
First Author: Aijie Huang
- Board 344 **Abstract 6551:** Comparative effectiveness and toxicity of CAR-T therapy versus blinatumomab in adult B-cell acute lymphoblastic leukemia: A real-world propensity-matched analysis.
First Author: Colton Davis, DO
- Board 345 **Abstract 6552:** Frailty-comorbidity discordance and non-relapse mortality after allogeneic hematopoietic cell transplantation.
First Author: Nihar Desai, MD, DM, MBBS
- Board 346 **Abstract 6553:** Clinical outcomes of *TP53*-mutated myeloid neoplasms after allogeneic hematopoietic cell transplantation: A Canadian multicenter propensity score-matched analysis.
First Author: Nihar Desai, MD, DM, MBBS
- Board 347 **Abstract 6554:** Allele-specific targeting of CD33 as a novel approach to enhance CAR-T selectivity in relapsed acute myeloid leukemia post-allogeneic transplantation.
First Author: Guido David Pelaez, MD
- Board 349 **Abstract 6556:** Pre-transplant MRD negativity and TP53 mutation status determine survival after CAR-T therapy bridged to allo-HSCT for refractory/relapse B-ALL.
First Author: Zhihui Li
- Board 350 **Abstract 6557:** MSNPseq: An NGS-based assay for chimerism detection and risk assessment in allogeneic HSCT.
First Author: Zhe Zou
- Board 351 **Abstract 6558:** Impact of Ori-TTV particles on in vivo CAR-T cell engineering for the treatment of hematologic malignancies.
First Author: Yongqin Li
- Board 352 **Abstract 6559:** Pharmacogenetic (PGx) markers of cardiovascular side effects (CVSEs) in allogeneic hematopoietic cell transplant (HCT) patients receiving post-transplant cyclophosphamide (PTCy).
First Author: Neha Deshpande, PhD
- Board 353 **Abstract 6560:** Outcomes after unrelated donor allogeneic hematopoietic cell transplantation in age ≥ 65 using post-transplant cyclophosphamide.
First Author: Amna Bint I Munir, MD
- Board 354 **Abstract 6561:** Post-prophylaxis CMV in the letermovir era: Incidence, risk factors, and outcomes following HCT.
First Author: Safah Khan, MD
- Board 355 **Abstract 6562:** Impact of *NPM1* co-mutation on post-transplant outcomes in MRG-mutated AML.
First Author: Yanal Mufeed Alnimer, MD
- Board 356 **Abstract 6563:** Myeloablative vs reduced-intensity conditioning in PTCy-based allogeneic HCT: A CIBMTR analysis.
First Author: Imran Khan, MD
- Board 357 **Abstract 6564:** Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.
First Author: John Behman, DO
- Board 358 **Abstract 6565:** Early neutrophil incompetence following allogeneic stem cell transplant.
First Author: Maria Lampou, MD

- Board 359 **Abstract 6566:** Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)-naïve patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS). First Author: Guillermo Garcia-Manero, MD
- Board 360 **Abstract 6567:** Impact of shallow whole genome sequencing on diagnostic yield and prognostic precision in myelodysplastic syndromes. First Author: Zhenling Li, MD
- Board 361 **Abstract 6568:** Phlebotomy, adherence, and hematocrit control in patients with polycythemia vera in the United States: Real-world analysis. First Author: Kristen M. Pettit, MD
- Board 362 **Abstract 6569:** Multimodal immunotherapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. First Author: Parveen Shiraz, MD
- Board 363 **Abstract 6570:** Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome. First Author: Alex Bataller
- Board 364 **Abstract 6571:** Multi-modal AI foundation models approach for diagnosis of myelodysplastic syndromes across whole bone marrow aspirate and biopsy slides. First Author: Palak Dave
- Board 365 **Abstract 6572:** Characterizing the genomic landscape of Langerhans cell histiocytosis using the AACR Project GENIE database. First Author: Amber Chang, BS
- Board 366 **Abstract 6573:** Updated analysis of overall survival (OS) with imetelstat (IME) in relapsed/refractory (R/R) myelofibrosis (MF) versus real-world (RW) data, and assessment of RW treatment (tx) patterns. First Author: Andrew Tucker Kuykendall, MD
- Board 367 **Abstract 6574:** Pregnancy outcomes in women with myeloproliferative neoplasms: A multicenter real-world analysis. First Author: Maryam Naser, MBBS
- Board 368 **Abstract 6575:** Treatment patterns and outcomes in pacritinib-treated patients with MF and higher platelet count: MY-PAC study. First Author: Douglas Tremblay
- Board 369 **Abstract 6576:** Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types. First Author: Ruben A. Mesa, MD
- Board 370 **Abstract 6577:** Activating MPN patients through empowering, patient-centered education. First Author: Aicha M. Diallo, MPH
- Board 371 **Abstract 6578:** Association of neutrophil-to-lymphocyte ratio and thrombotic events in US veterans with polycythemia vera. First Author: Mingfei Li, PhD
- Board 372 **Abstract 6579:** Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML. First Author: Muhammad Mujtaba Bhinder, MD
- Board 373 **Abstract 6580:** Clinical features, management, and outcomes of adolescents and young adults with myeloproliferative neoplasms. First Author: Sandro Pino-Ascencio, MD
- Board 374 **Abstract 6581:** Beyond haematological control: Long-term renal outcomes of imatinib therapy in chronic myeloid leukaemia. First Author: Rachana Chennamaneni, MD, DM
- Board 375 **Abstract 6582:** Durable treatment-free remission in CML beyond clinical trials: Lessons from a large single-center real-world experience. First Author: Sadashivudu Gundeti, MD, DM
- Board 376 **Abstract 6583:** ASC4FIRST wk 144 analysis: Efficacy and safety and tolerability with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed (ND) chronic myeloid leukemia in chronic phase (CML-CP). First Author: Jorge E. Cortes, MD
- Board 377 **Abstract 6584:** Upfront low-dose diet-modified nilotinib versus standard imatinib in Indian patients with newly diagnosed chronic-phase chronic myeloid leukemia: The NILLOW phase II randomised trial. First Author: Deepak Garg, DM
- Board 378 **Abstract 6585:** Clinical fidelity of large language models in chronic myeloid leukemia: A multimodel comparative study. First Author: Meenal Gehlawat, MD
- Board 379 **Abstract 6586:** Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting. First Author: Laneisha Maldonado Jaime, MD
- Board 380 **Abstract 6587:** Timing of TP53 mutation acquisition as a determinant of outcomes in patients with myeloproliferative neoplasms and myeloproliferative neoplasms/myelodysplastic syndromes. First Author: Lauren M. Granat, DO, MS
- Board 381 **Abstract 6588:** One vs. 2 vs. ≥ 3 *TET2* mutations in chronic myelomonocytic leukemia: Co-mutation patterns and prognostic correlates. First Author: Muhammad Yousuf, MBBS
- Board 382 **Abstract 6589:** Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia. First Author: Maria Hachem, MD, MS
- Board 383 **Abstract 6590:** Thromboelastography-guided platelet transfusion and associations with utilization and outcomes in patients with hematologic malignancies. First Author: Rana Mohamed, MD
- Board 384 **Abstract 6591:** Safety and efficacy of asciminib in veterans with chronic myeloid leukemia. First Author: Omar Shukri Yaghi, MD, MPH
- Board 385 **Abstract 6592:** Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes. First Author: Wei-Han Chen, MS

- Board 386 **Abstract 6593:** Clinical and genetic landscape of individuals evaluated in a CHIP cardiology clinic: A single-center experience, 2020 to 2025.
First Author: Ohad Oren, MD
- Board 387 **Abstract 6594:** Clinical outcomes in *TP53*-mutated clonal hematopoiesis: Single-center retrospective study.
First Author: Jacob Edward Herstein, MD
- Board 388 **Abstract 6595:** Genomic landscape and precision therapeutics in polycythemia vera: Insights from the AACR Project GENIE.
First Author: Alena Gagnon
- Board 389 **Abstract 6596:** Universal adipogenic and immunologic remodeling in the recurrent myeloid leukemia microenvironment of recurrent versus primary myeloid leukemias: An age-stratified analysis.
First Author: Karen Dong-Tran, MD
- Board 390 **Abstract 6597:** Molecular characteristics of therapy-related myeloid neoplasms in PARP inhibitor-treated patients.
First Author: Tamanna Haque, MD
- Board 391 **Abstract 6598:** Outcomes and responsiveness of standard tyrosine kinase inhibitor dose versus dose de-escalation in chronic myeloid leukemia: A single-center retrospective study.
First Author: Mark Pusung, MPH
- Board 392a **Abstract TPS6599:** A phase I study of HPB-092, a dual FLT3/IRAK4 inhibitor, in relapsed or refractory acute myeloid leukemia.
First Author: Mingyuan Sun, MD
- Board 392b **Abstract TPS6600:** A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed *NPM1*-mutated or *KMT2A*-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AML35-24/ACT-HOV-AML-002).
First Author: Geert Abraham Huls
- Board 393a **Abstract TPS6601:** Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes/neoplasms.
First Author: Dennise De Jesus Diaz, PhD
- Board 393b **Abstract TPS6602:** A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed *NPM1*-mutated acute myeloid leukemia (REVEAL-ND NPM1).
First Author: Eytan Stein, MD
- Board 394a **Abstract TPS6603:** A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for *IDH1*-mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).
First Author: Brian Andrew Jonas, MD, PhD
- Board 394b **Abstract TPS6604:** Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).
First Author: John Mascarenhas, MD
- Board 395a **Abstract TPS6605:** A phase 2 study to assess the safety and efficacy of bome demstat (IMG-7289) in combination with momelotinib in patients with myelofibrosis.
First Author: Ciro Roberto Rinaldi, MD, PhD
- Board 395b **Abstract TPS6606:** ASC4Kids-2: Asciminib in pediatric chronic myeloid leukemia with or without T3151.
First Author: Nobuko Hijya, MD
- Board 396a **Abstract TPS6607:** Phase Ib study of momelotinib during and following hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis.
First Author: Gabriela Hobbs, MD
- Board 396b **Abstract TPS6608:** A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.
First Author: Elias Jabbour, MD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 516-517

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL: Board(s) 518-539, 595a-595b

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell:

Board(s) 540-550, 596a-597a

Hodgkin Lymphoma: Board(s) 551-552

Non-Hodgkin Lymphoma: Board(s) 553-584, 597b-601a

Outcomes/Quality: Board(s) 585-590

Other Lymphoma: Board(s) 591-594

Board 516 **Abstract 7018:** Epigenetic profiling to identify aggressiveness markers in non-Hodgkin lymphoma via a targeted methylation-based multi-cancer early detection (MCED) blood test.
First Author: Xiang-Yu Zhao, MD, PhD

Board 517 **Abstract 7019:** Fragmentia AI—Lymphoma: A cfDNA language model for lymphoma detection using ultra-low-pass WGS.
First Author: Rui Liu, MSc

Board 518 **Abstract 7020:** Early corticosteroid dosing after anti-CD19 CAR-T therapy for large B-cell lymphoma: Multicenter associations with neurotoxicity, cytokine release syndrome, and survival.
First Author: Randa Elzein, MBBS

Board 519 **Abstract 7021:** Overcoming resistance to prior CAR-T therapy: Efficacy and safety of a sequential, multi-antigen targeted CAR T-cell strategy in B-cell NHL.
First Author: Guoai Su

Board 520 **Abstract 7022:** Late infectious complications after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphomas (LCBL): Real-world predictors and outcomes.
First Author: Daniel E. Goyco Vera, MD

- Board 521 **Abstract 7023:** Real-world patient characteristics, outcomes, and resource utilization of chimeric antigen receptor (CAR) T cell therapy across Foundation for the Accreditation of Cellular Therapy (FACT) and non-FACT treatment centers in large B-cell lymphoma (LBCL).
First Author: Renju V. Raj, MD
- Board 522 **Abstract 7024:** Real-world outcomes of lisocabtagene maraleucl (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.
First Author: Emily Tomasulo, DO
- Board 523 **Abstract 7025:** Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucl (liso-cel) in TRANSCEND FL.
First Author: Ariel Avilion
- Board 524 **Abstract 7026:** Outcomes of lisocabtagene maraleucl (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
First Author: Jennifer Jing Huang, MD, PhD
- Board 525 **Abstract 7027:** Efficacy of tocilizumab in resolving chimeric antigen receptor T-cell (CAR T)-induced cytokine release syndrome (CRS): A pooled clinical trial (CT) analysis of patients (pts) with B-cell lymphoma (BCL).
First Author: Soon Jye Kho, PhD
- Board 526 **Abstract 7028:** Long-term real-world outcomes of axicabtagene ciloleucl (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
First Author: Caron Alyce Jacobson, MD
- Board 527 **Abstract 7029:** Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.
First Author: Ian W. Flinn, MD, PhD
- Board 528 **Abstract 7030:** Pre-lymphodepletion CRP and ferritin risk stratification as a predictor of early immune toxicities and hematologic complications after CAR-T therapy: A propensity-matched cohort study.
First Author: Fayaz Aijaz Ahmed Khan, MBBS
- Board 529 **Abstract 7031:** Longitudinal safety of lisocabtagene maraleucl (liso-cel) in patients (pt) with second-line or later (2L+) large B-cell lymphoma (LBCL).
First Author: Manali Kirtikumar Kamdar, MD
- Board 530 **Abstract 7032:** Long-term cognitive impairment after CAR-T therapy compared with autologous stem cell transplantation.
First Author: Andrea Yun-En Sun, MD
- Board 531 **Abstract 7033:** Real-world toxicity of bispecific antibodies versus CAR-T cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.
First Author: Nanda Krishnan Siva, MD, MBA
- Board 532 **Abstract 7034:** The influence of advanced age on outcomes in patients with diffuse large B-cell lymphoma treated with CAR-T therapy.
First Author: Muqtasid Aftab Khan, MD
- Board 533 **Abstract 7035:** Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CAR T-cell therapy.
First Author: Samuel Yamshon, MD
- Board 534 **Abstract 7036:** Predictors of low- and high-grade ICANS after CAR-T: A nationwide analysis.
First Author: Ashish Nepal, MD
- Board 535 **Abstract 7037:** Real-world outcomes of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma: A TriNetX retrospective study.
First Author: Juhi Ardeshna-Chovatiya, MD
- Board 536 **Abstract 7038:** Baseline phosphoproteomic signatures in peripheral blood and prediction of durable response to CAR T-cell therapy in B-cell malignancies.
First Author: Christian A. Gordillo, MSc
- Board 537 **Abstract 7039:** Clonal hematopoiesis as a predictor of immune toxicity and efficacy after chimeric antigen receptor T-cell therapy: A systematic review and meta-analysis.
First Author: Adam Bowen
- Board 538 **Abstract 7040:** The impact of COVID19 mRNA vaccination on bispecific antibody outcomes in hematologic malignancies: A retrospective multicenter cohort study.
First Author: Mostafa Eysha, MD
- Board 539 **Abstract 7041:** Early toxicity, healthcare utilization, and survival after CAR T-cell therapy versus bispecific antibodies in DLBCL: A propensity-matched real-world analysis.
First Author: Jatin Thukral, MD, MBBS
- Board 540 **Abstract 7042:** Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL).
First Author: Michael Fradley
- Board 541 **Abstract 7043:** Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.
First Author: Constantine Si Lun Tam, MD, FRCPA, FRACP, MBBS
- Board 542 **Abstract 7044:** Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.
First Author: William G. Wierda, MD, PhD
- Board 543 **Abstract 7045:** Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States.
First Author: Ryan Jacobs

- Board 544 **Abstract 7046:** Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.
First Author: Constantine Si Lun Tam, MD, FRCPA, FRACP, MBBS
- Board 545 **Abstract 7047:** Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).
First Author: Daniel Arthur Ermann, MD
- Board 546 **Abstract 7048:** Targeted combination therapies for untreated chronic lymphocytic leukemia: A network meta-analysis of randomized trials.
First Author: Owais Gul, MD
- Board 547 **Abstract 7049:** Outcome comparison of once versus twice daily dosing of zanubrutinib.
First Author: Allison Kagerer, MD
- Board 548 **Abstract 7050:** Hematologic and cardiovascular outcomes of SGLT2 inhibitors in patients with chronic lymphocytic leukemia and type 2 diabetes: A real-world TriNetX analysis.
First Author: Safa Saadat Afridi, MBBS
- Board 549 **Abstract 7051:** Impact of SGLT2 inhibitors on clinical outcomes in diabetic patients with CLL receiving BTK inhibitors: A global propensity-matched study.
First Author: Angimar Uriepero-Palma, MD
- Board 550 **Abstract 7052:** Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.
First Author: Mariah Black, MS
- Board 551 **Abstract 7053:** Modern Hodgkin lymphoma treatments to reduce second cancer risks: Influence of risk-adapted screening.
First Author: Aislinn Macklin-Doherty, PhD, MBChB, MRCP
- Board 552 **Abstract 7054:** Invasive-field radiotherapy plus rituximab versus rituximab alone after response to immunochemotherapy in stage III follicular lymphoma: An open-label, multicenter, randomized clinical study.
First Author: Tongyu Lin, PhD
- Board 553 **Abstract 7055:** Single-cell analysis and functional profiling of galectin-3 in the tumor immune microenvironment in transformed follicular lymphoma.
First Author: Xiaohui Wang, MD
- Board 554 **Abstract 7056:** Diagnostic yield after pre-biopsy steroid administration in primary CNS high-grade B-cell lymphoma.
First Author: Charmi Trivedi, MD
- Board 555 **Abstract 7057:** Chemotherapy use and survival by demographic and socioeconomic factors in primary central nervous system lymphoma: A population-based SEER analysis.
First Author: Kevin Cheng Liang Wu, MS, DO
- Board 556 **Abstract 7058:** Navigating the post-covalent bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU).
First Author: Alvaro Jose Alencar, MD
- Board 557 **Abstract 7059:** Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
First Author: Xian Li
- Board 558 **Abstract 7060:** Diagnostic accuracy of circulating tumor DNA for post-remission surveillance in diffuse large B-cell lymphoma: A systematic review and meta-analysis.
First Author: Mohammad Ahsen Soomro
- Board 559 **Abstract 7061:** Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.
First Author: Yasmin Karimi, MD
- Board 560 **Abstract 7062:** A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.
First Author: Yucai Wang, MD, PhD
- Board 561 **Abstract 7063:** Signatures of biological heterogeneity associated with treatment outcome in diffuse large B-cell lymphoma.
First Author: Boya Wang, MD, PhD
- Board 562 **Abstract 7064:** Differential clinical and economic signatures of CAR T-cell therapy in DLBCL across demographic and payer strata: A national analysis.
First Author: Karnav Modi, MBBS
- Board 563 **Abstract 7065:** Frontline intensified vs standard immunochemotherapy in high-risk diffuse large B-cell lymphoma: A systematic review and meta-analysis.
First Author: Lauren Scarpetti, MD, MBA
- Board 564 **Abstract 7066:** Differences in outcomes for elderly patients with DLBCL treated at academic vs community programs: A 10-year survival analysis.
First Author: Carolina Velez-Mejia
- Board 565 **Abstract 7067:** Efficacy and tolerability of duvelisib in relapsed/refractory peripheral T-cell lymphoma: A multicenter real-world analysis.
First Author: Priyanka Pullarkat, MD
- Board 566 **Abstract 7068:** Comparative safety and efficacy of obinutuzumab versus rituximab in combination with chemotherapy for follicular lymphoma: A systematic review and meta-analysis.
First Author: Abdul Rafae Faisal
- Board 567 **Abstract 7069:** Survival and socioeconomic disparities in the elderly population with mycosis fungoides and Sézary syndrome: A comparative analysis of 2,690 patients by facility type.
First Author: Oscar Hinojosa, MD

- Board 568 **Abstract 7070:** Exploring improved prognostication using PET/CT radiomics in relapsed/refractory, TP53-aberrant diffuse large B-cell lymphoma (DLBCL).
First Author: Vincenzo Pizzuti, MD, MS
- Board 569 **Abstract 7071:** Conditional survival by primary extranodal site in diffuse large B-cell lymphoma: A population-based landmark analysis.
First Author: Muhammad Dawood Amir Sheikh, MBBS
- Board 570 **Abstract 7072:** Deep learning-based PET/CT radiomics-clinical model for prognostic stratification and immunotherapy exploration in natural killer/T-cell lymphoma.
First Author: Tongyu Lin, PhD
- Board 571 **Abstract 7073:** Efficacy and safety of mesutoclax (ICP-248) in combination with orelabrutinib in patients with B-cell malignancies: A pooled analysis.
First Author: Zhiming Li, MD
- Board 572 **Abstract 7074:** Effect of FDG-PET-based bone marrow assessment on prognostic accuracy compared to conventional histologic evaluation in patients with follicular lymphoma: A subanalysis of the FIL FOLL12 trial.
First Author: Stefano Luminari, MD
- Board 573 **Abstract 7075:** Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.
First Author: Adam Albitar, MD
- Board 574 **Abstract 7076:** Aberrant somatic hypermutation in large B-cell lymphomas and its relationship to mutational signatures, including a novel haloalkane pattern.
First Author: Nicholas J. Dcunha, MBBS
- Board 575 **Abstract 7077:** An exploratory study to assess the safety, immunogenicity, and preliminary anti-tumor activity of the EBV mRNA vaccine (WGc-043 injection) combined with PD-1 antibody in patients with relapsed or refractory ENKTL.
First Author: Xingchen Peng, MD, PhD
- Board 576 **Abstract 7078:** Safety and efficacy of GT719, an off-the-shelf CAR-NKT therapy, in adults with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Yarong Liu
- Board 577 **Abstract 7079:** First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies.
First Author: Yarong Liu
- Board 578 **Abstract 7080:** Zanubrutinib plus rituximab as front-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma: A single-arm, phase II study (ZAMA).
First Author: Yi Xia
- Board 579 **Abstract 7081:** Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.
First Author: Marek Trněný, MD
- Board 580 **Abstract 7082:** Chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with T follicular helper phenotype: Results of the phase II SWIFT trial.
First Author: Qingqing Cai, PhD
- Board 581 **Abstract 7083:** Prognostic impact of comorbidity burden on overall survival in patients with Waldenström macroglobulinemia in the United States.
First Author: Gaelle Haddad
- Board 582 **Abstract 7084:** Age and HIV status as survival predictors in HHV8-positive diffuse large B-cell lymphoma: The largest population-based analysis to date.
First Author: Gaelle Haddad
- Board 583 **Abstract 7085:** Genomic profiling of Burkitt lymphoma in adults: Novel molecular insights and implications for outcomes.
First Author: Manju Sengar, MD
- Board 584 **Abstract 7086:** iMARIX for primary and secondary central nervous system lymphomas.
First Author: Ekin Kircali
- Board 585 **Abstract 7087:** Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.
First Author: Mithunan Ravindran, MD
- Board 586 **Abstract 7088:** Survival outcomes of plasmablastic lymphoma according to immune status.
First Author: Hien Lau, MD
- Board 587 **Abstract 7089:** Survival of hematologic malignancy in patients with early-stage chronic kidney disease (SHIP-CKD).
First Author: Songphol Tungjitviboonkun, MD, MS
- Board 588 **Abstract 7090:** Comparative effectiveness of CAR-T and bispecific antibodies in relapsed/refractory large B-cell lymphoma: A network meta-analysis of phase III trials.
First Author: Aniq Baloch, MD
- Board 589 **Abstract 7091:** Utility of a modified geriatric assessment to identify impairments in adults of all ages with lymphoma: A prospective observational cohort study.
First Author: Christopher Edward Jensen, MD, MS
- Board 590 **Abstract 7092:** Temporal trends in ischemic heart disease mortality among lymphoma patients in the United States, 1999–2023: A 25-year nationwide analysis.
First Author: Prithvi Raghavan, MD, MBBS
- Board 591 **Abstract 7093:** Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO, and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL).
First Author: Matthew Matasar, MD
- Board 592 **Abstract 7094:** Ilofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.
First Author: Jarrod Longcor, MD, MBA, MMedSc, MPH
- Board 593 **Abstract 7095:** Analysis of sex-based differences in tumor microenvironments within hematopoietic and reticuloendothelial system malignancies.
First Author: Vera Vaz, BS

- Board 594 **Abstract 7096:** Real-world outcomes of mogamulizumab retreatment in cutaneous T-cell lymphoma: A single-center retrospective study. First Author: Shahzeem Bhayani, MBBS
- Board 595a **Abstract TPS7097:** Lisocabtagene maraleucel (liso-cel) as first-line (1L) therapy for transplant-ineligible patients (pt) with primary central nervous system lymphoma (PCNSL): The CAROLYN study. First Author: Allison Marie Winter, MD
- Board 595b **Abstract TPS7098:** KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). First Author: Saurabh Dahiya, MD, FACP
- Board 596a **Abstract TPS7099:** Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2). First Author: Mazyar Shadman, MD, MPH
- Board 596b **Abstract TPS7100:** ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). First Author: Anna Chen, PhD
- Board 597a **Abstract TPS7101:** A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress. First Author: Matthew Steven Davids, MD
- Board 597b **Abstract TPS7102:** Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator's choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study. First Author: Clémentine Sarkozy, MD
- Board 598a **Abstract TPS7103:** Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL). First Author: Martin Hutchings, MD, PhD
- Board 598b **Abstract TPS7104:** waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL). First Author: Max S. Topp, MD
- Board 599a **Abstract TPS7105:** AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for patients with hematologic malignancies. First Author: Michael A. Thompson, MD, PhD, FASCO
- Board 599b **Abstract TPS7106:** ROCK-2: An ongoing open-label, randomized, multicenter phase 2 study of rocrutinib versus investigator's choice of therapy in patients with R/R non-GCB DLBCL. First Author: Peng Liu
- Board 601a **Abstract TPS7107:** Phase 2 trial of lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma. First Author: Dai Chihara, MD, PhD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 397-402

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Disorders: Board(s) 403-424, 456a

Outcomes/Quality: Board(s) 425-431

Plasma Cell Neoplasms—Biology, Genomics: Board(s) 432-439

Other Therapeutic Strategies for Multiple Myeloma and Other Plasma Cell Disorders: Board(s) 440-455, 457a-458b

Board 397 **Abstract 7518:** Prediction of progression in MGUS using transformerbased survival timeseries modeling. First Author: Vaishnavi Kumbhar

Board 398 **Abstract 7519:** Early detection of multiple myeloma and MGUS progression risk using artificial intelligence and routine laboratory data. First Author: Ciro Roberto Rinaldi, MD, PhD

Board 399 **Abstract 7520:** Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma. First Author: Arjun Raj Rajanna, MSc

Board 400 **Abstract 7521:** AI-enabled multimodal adjudication of revised IMWG progression after BCMA CAR-T. First Author: David Kaldas, MD

Board 401 **Abstract 7522:** Echo cancer advisor: A modular AI framework for interpretable, patient-specific oncology decision support. First Author: Ariosto Silva

Board 402 **Abstract 7523:** Identifying high-risk cytogenetic subgroups in multiple myeloma using large language artificial intelligence models. First Author: John Culnan, PhD

Board 403 **Abstract 7524:** RP2R dose selection of Tal + Tec for the treatment of EMD patients in the RedirectTT-1 study. First Author: Nicholas Au, PhD, PharmD

Board 404 **Abstract 7525:** An integrated population pharmacokinetic/pharmacodynamic (popPK/PD) model to select the linvoseltamab (LINVO) dosing regimen in patients with high-risk smoldering multiple myeloma (HR-SMM). First Author: Brett Matzuka

Board 405 **Abstract 7526:** Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up. First Author: Hans C. Lee, MD

Board 406 **Abstract 7527:** Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma. First Author: Junmin Song, MD, MS

- Board 407 **Abstract 7528:** Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM).
First Author: Tanya Marya Wildes, MD, MSCI, FASCO
- Board 408 **Abstract 7529:** Association between survival outcomes in patients with multiple myeloma and treatment facility volume.
First Author: Carl Ola Landgren, MD, PhD
- Board 409 **Abstract 7530:** Gaps in access to chimeric antigen receptor T-cell (CAR-T) therapy post leukapheresis: Waiting time and postleukapheresis treatment patterns in relapsed/refractory multiple myeloma (RRMM)—Realworld evidence from U.S. claims.
First Author: Sikander Ailawadhi, MD
- Board 410 **Abstract 7531:** Targeting cfDNA and NETs with DNase I to augment CAR T-cell function and antitumor efficacy.
First Author: Alexey Stepanov, DPhil
- Board 411 **Abstract 7532:** Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).
First Author: Maen A. Hussein, MD
- Board 412 **Abstract 7533:** Immune effector cell–associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel–treated patients with RRMM in CARTITUDE clinical studies.
First Author: Yi Lin, MD, PhD
- Board 413 **Abstract 7534:** Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
First Author: Stefan Longobardi, MD
- Board 414 **Abstract 7535:** Age-stratified late outcomes following bispecific antibody therapy in multiple myeloma: A real-world 6-month landmark analysis.
First Author: Madhu Bhargavi Chandra, MD
- Board 415 **Abstract 7536:** Ciltacabtagene autoleucl in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.
First Author: Roberto Mina
- Board 416 **Abstract 7537:** CAR T-cell detection and clonality assessment in immune effector cell–associated enterocolitis following ciltacabtagene autoleucl.
First Author: Eric Matthew Jurgens, MD
- Board 417 **Abstract 7538:** How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.
First Author: Eva Duvalyan, MD, PharmD
- Board 418 **Abstract 7539:** Clinical outcomes following CAR T-cell therapy in relapsed or refractory multiple myeloma patients with baseline renal dysfunction: A TriNetX analysis.
First Author: Preetinder Singh Manshahia, MBBS
- Board 419 **Abstract 7540:** Expansion of a highly activated (HLA-DR+/CD38+) CAR T cell population after mezigdomide exposure post–idecabtagene vicleucl infusion in relapsed multiple myeloma.
First Author: Lawrence W. Liu, MD
- Board 420 **Abstract 7541:** CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.
First Author: Jayasree Krishnan, MD, MSPH
- Board 421 **Abstract 7542:** Dynamic changes in immune checkpoint and cell populations following lymphodepletion and CAR-T therapy in hematologic malignancies.
First Author: Zarina Brune, MD, PhD
- Board 422 **Abstract 7543:** Impact of prophylactic cyclophosphamide on ALC and delayed neurotoxicity after cilta-cel.
First Author: Melinda Tan, MD
- Board 423 **Abstract 7544:** Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.
First Author: Eli Zolotov, MD
- Board 424 **Abstract 7545:** Racial disparities in utilization of bispecific T-cell engager therapy for relapsed/refractory multiple myeloma: A TriNetX study.
First Author: Emmanuel Ekpenyong, MD
- Board 425 **Abstract 7546:** cfDNA WGS vs plasma proteomics for minimally invasive MRD assessment in multiple myeloma.
First Author: Dor Abelman, BS
- Board 426 **Abstract 7547:** Current threshold of measurable disease in AL amyloidosis clinical trials.
First Author: Eugene Brailovski, MD
- Board 427 **Abstract 7548:** Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: A propensity score–matched analysis from a global federated health research network.
First Author: Arshi Syal, MD
- Board 428 **Abstract 7549:** Duffy-null status and cytopenias following BCMA-directed CAR T therapy in multiple myeloma.
First Author: Christen Marie Dillard, MD
- Board 429 **Abstract 7550:** The future mortality trends in multiple myeloma (SEER analysis 2000–2030).
First Author: Muhammad Talha Shaukat
- Board 430 **Abstract 7551:** Machine learning to identify racial and socioeconomic disparities in the onset and tumor distribution of second primary malignancies in multiple myeloma.
First Author: Muhammad Talha Shaukat
- Board 431 **Abstract 7552:** Impact of human immunodeficiency virus on in-hospital outcomes among patients hospitalized with multiple myeloma: A National Inpatient Sample study, 2016–2022.
First Author: Sophio Kakabadze, MD
- Board 432 **Abstract 7553:** Single-cell analysis of plasma cell–centered inflammatory–immunosuppressive niches and response to daratumumab in primary light-chain amyloidosis.
First Author: Xuezhong Wang, MD
- Board 433 **Abstract 7554:** Copy number aberration profiling using shallow whole-genome sequencing-based LeukoPrint in multiple myeloma.
First Author: Li Gao, MD

- Board 434 **Abstract 7555:** Extrachromosomal DNA as a shaper of aggressive transcriptional states in multiple myeloma.
First Author: Hyunsoo Cho, MD, PhD
- Board 435 **Abstract 7556:** Enabling blood-based mass spectrometry MRD detection in multiple myeloma without archived serum samples.
First Author: Daniel Jesus Groso, BS
- Board 436 **Abstract 7557:** Circulating tumor DNA *NRAS* and *TP53* mutations to identify ultra-high-risk primary refractory myeloma patients.
First Author: Sridurga Mithraprabhu, PhD
- Board 437 **Abstract 7558:** A machine learning (ML)–based six-gene signature for risk stratification and therapeutic target identification in multiple myeloma.
First Author: Sriram Subramanian
- Board 438 **Abstract 7559:** SATMM: A systems genetic network analysis–based risk stratification tool validated across the disease trajectory of relapsed/refractory multiple myeloma.
First Author: Carl Murie
- Board 439 **Abstract 7560:** A common gene expression signature across multiple myeloma disease stages to identify high-risk of disease progression.
First Author: Claudio Cerchione, MD, PhD
- Board 440 **Abstract 7561:** Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.
First Author: Arthur Bobin, MD
- Board 441 **Abstract 7562:** ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
First Author: Andrew J. Yee, MD
- Board 442 **Abstract 7563:** Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.
First Author: Xavier P. Leleu, MD, PhD
- Board 443 **Abstract 7564:** Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
First Author: Marcelo Capra, MD
- Board 444 **Abstract 7565:** Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM8 longterm responder (LTR) analysis.
First Author: Meletios A. Dimopoulos, MD
- Board 445 **Abstract 7566:** PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Güldane Cengiz Seval
- Board 446 **Abstract 7567:** Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.
First Author: Okan Cetin, MD
- Board 447 **Abstract 7568:** Comparative efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs standard of care in patients with relapsed/refractory multiple myeloma (RRMM).
First Author: Joshua Ryan Richter, MD
- Board 448 **Abstract 7569:** Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).
First Author: Christopher P. Verner
- Board 449 **Abstract 7570:** Minimal residual disease dynamics in newly diagnosed multiple myeloma and impact on progression-free survival: A cohort study.
First Author: Panagiotis Malandrakis, MD
- Board 450 **Abstract 7571:** Exploratory associations between incretin-based therapies and plasma cell disorders in patients with type 2 diabetes: A real-world study.
First Author: Yousef Atewi
- Board 451 **Abstract 7572:** Incretin-based therapies and all-cause mortality and progression to multiple myeloma in patients with MGUS and type 2 diabetes: A real-world cohort study.
First Author: Yousef Atewi
- Board 452 **Abstract 7573:** Early intravenous immunoglobulin use in multiple myeloma patients treated with talquetamab: Effect on risk of infections and mortality.
First Author: Joseph OBrien, MD, MPH
- Board 453 **Abstract 7574:** Comparative safety and efficacy of DKRd versus DVRd regimens in multiple myeloma: A systematic review and meta-analysis.
First Author: M. Bakri Hammami, MD
- Board 454 **Abstract 7575:** Plasma exchange in myeloma-associated acute kidney injury: A multicenter propensity-matched cohort study.
First Author: Jarred Madison Boone, MD
- Board 455 **Abstract 7576:** Trends in frontline treatment patterns for multiple myeloma among US veterans, 1999–2025.
First Author: Byron Seiya Sigel, MSc
- Board 456a **Abstract TPS7577:** QUINTESENTIAL-2: A phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide.
First Author: Eyal Lebel, MD
- Board 457a **Abstract TPS7579:** MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM).
First Author: Binod Dhakal, MD

- Board 457b **Abstract TPS7580:** A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma.
First Author: Hans C. Lee, MD
- Board 458a **Abstract TPS7581:** Initial phase 1b/2 study results of purinostat mesylate (PM) in combination with pomalidomide (POM) and low dexamethasone (DEX) in patients with RRMM.
First Author: Lijuan Chen, PhD
- Board 458b **Abstract TPS7582:** A phase 1b/2 study of mirdametinib in combination with sirolimus for patients with RAS-mutated relapsed/refractory multiple myeloma.
First Author: Roshani Patel, MD

9:00 AM-12:00 PM Poster Session

Medical Education and Professional Development

Location: Hall A—Posters and Exhibits

Posters by Topic

Clinician Burnout and Wellness: Board(s) 479-482

Education Research: Board(s) 483-502, 514a

Leadership and Professional Development: Board(s) 503-509

Social Media Research: Board(s) 510-512

Workplace Issues and Workforce Development: Board(s) 513

- Board 479 **Abstract 9012:** The hidden struggle? Mental health burden among oncology physicians globally.
First Author: Coral Olazagasti, MD
- Board 480 **Abstract 9013:** Burnout among early-career oncologists in Latin America: A regional survey.
First Author: Sergio Cifuentes-Canaval, MD
- Board 481 **Abstract 9014:** Emotional burnout among oncology clinicians in Russia: Results of a national cross-sectional survey.
First Author: Anastasia Danilova, MD
- Board 482 **Abstract 9015:** Inspiring the next generation of medical oncologists: Passion, purpose, and preventing burnout.
First Author: Ruth Hutch, MD, MSc
- Board 483 **Abstract 9016:** Turning silence into rhythm: Outcomes of a school-based *Cancer Olympiad* in India.
First Author: Vangipuram Harshil Sai, MBBS
- Board 484 **Abstract 9017:** Preparedness of internal medicine residents for oncologic emergencies and end-of-life discussions in a community training environment.
First Author: Musa Kiyani, MD, MBA, MPH
- Board 485 **Abstract 9018:** Benefits of utilizing experiential learning in a medical school cancer survivorship course.
First Author: Yasheen Gao, BS
- Board 486 **Abstract 9019:** Utilizing large language models for lung cancer patient education compared to publicly available information.
First Author: Samantha Liu
- Board 487 **Abstract 9020:** Psychological burden and burnout among regional healthcare providers communicating hereditary tumor findings: A multi-institutional communication skills training implementation study.
First Author: Shuhei Suzuki, MD, PhD

- Board 488 **Abstract 9021:** Escape to learn: A team-based gamified educational experience for hematology/oncology fellows.
First Author: Emily Wolf, MD
- Board 489 **Abstract 9022:** Career destination effects of receipt of the American Society of Clinical Oncology Young Investigator Award.
First Author: Vince D. Cataldo, MD, FACP
- Board 490 **Abstract 9023:** Oncomovies: Cancer in cinema from early sound film to 2025.
First Author: Luciano de Fiore, PhD, MPhil
- Board 491 **Abstract 9024:** Training fellows in genomic oncology: A pilot team-based workshop.
First Author: Lauren O'Loughlin, MD
- Board 492 **Abstract 9025:** Experiences of a cancer survivorship elective in a US medical school: The first 10 years.
First Author: Lee Dong, BA
- Board 493 **Abstract 9026:** From pathophysiology to prognosis: An oncology curriculum for interdisciplinary palliative care specialists.
First Author: Sinthana Ramsey, DO, MS
- Board 495 **Abstract 9028:** Enhancing hematology-oncology education through a structured AI-based board review series: An ASCO Leadership Development Education Scholars initiative.
First Author: Manasi Ghatge, MD
- Board 496 **Abstract 9029:** Impact of liquid biopsy training on real-world testing practices for advanced NSCLC across Latin America: The OMEGA (LACOG 0424/GBOT) survey.
First Author: Leonardo Gil Santana, MD
- Board 497 **Abstract 9030:** Applying learning science principles (LSP) in a workshop (WS) for hematology and oncology (HemOnc) trainees (HOT) about how to use artificial intelligence (AI) in medical education (MedEd) and clinical practice (CP).
First Author: Guilherme Sacchi de Camargo Correia, MD
- Board 498 **Abstract 9031:** Enhancing oncology board exam readiness through a longitudinal review curriculum.
First Author: Sonia Godbole, MD
- Board 499 **Abstract 9032:** Bridging educational and research gaps among young oncologists in Latin America: Results from a multicenter survey.
First Author: Sergio Cifuentes-Canaval, MD
- Board 500 **Abstract 9033:** Collaborative education to advance equitable prostate cancer care in geographically diverse communities.
First Author: Erica Rusie, PharmD
- Board 501 **Abstract 9034:** Investigating interactions between pharmaceutical industry and oncologists in Africa: A secondary analysis of ONCOTRUST-2 study.
First Author: Imène Hadji, MD
- Board 502 **Abstract 9035:** Hematology-oncology bootcamp: Educational impact of an interactive, guideline-based "101" curriculum.
First Author: Chinmay Jani, MBBS

- Board 503 **Abstract 9036:** Empowering educators: An international virtual mentorship program for hematology/oncology medical educators.
First Author: Audrey M. Sigmund, MD
- Board 504 **Abstract 9037:** Determinants of leadership attainment among ASCO Leadership Development Program, 2009–2025.
First Author: Sarah Marie Abraham, BA, BS
- Board 505 **Abstract 9038:** Leader-member exchange (LMX) and workforce outcomes in radiation oncology: A preliminary generational comparison.
First Author: Christopher Mendez, MA
- Board 506 **Abstract 9039:** RECON: A trainee-led, needs-informed professional development and global connectivity model for young oncologists in low- and middle-income countries.
First Author: Muhammad Nawaz Khan, MBBS
- Board 507 **Abstract 9040:** The role of coaching in enhancing clinical oncology academic performance.
First Author: Amanda Woods Herron, PhD
- Board 508 **Abstract 9041:** Role expansion of advanced practice providers over 5 years at Hawai'i's NCI Community Oncology Research Program.
First Author: Christa M. Braun-Inglis, MS, FNP, APRN, AOCNP, DNP, APRN-BC
- Board 509 **Abstract 9042:** Placing oncology and conflicts of interest in a global context: Evidence from the large international ONCOTRUST-2 study.
First Author: Khalid El Bairi
- Board 510 **Abstract 9043:** Separating facts from feeds: An evaluation of social media videos on Barrett's esophagus.
First Author: Sean Bowden, MD
- Board 511 **Abstract 9044:** Digital information-seeking behavior in patients with cancer through storytelling.
First Author: Samantha Liu
- Board 512 **Abstract 9045:** AI-powered social media listening of oncologist conversations at ASCO 2025.
First Author: Sandeep Ghosal
- Board 513 **Abstract 9046:** Baseline bone marrow biopsy (BMBx) performance relative to a mastery-level standard: A SIM-BMBx interval analysis.
First Author: Max Farber Kelsten, MD
- Board 514a **Abstract TPS9047:** Improving internal medicine residents' confidence in oncology goals-of-care conversations.
First Author: Prathyusha Pandu, MD
- Board 1 **Abstract 11018:** Temporal trends in oncology clinical trial complexity and duration: A retrospective analysis of 5,261 industry-sponsored trials.
First Author: Andrew J. Yang, BS
- Board 2 **Abstract 11019:** A machine learning-enhanced analysis of temporal trends in biomarker-based eligibility restrictions in oncology clinical trials.
First Author: Luke Xiyu Zhao, MD
- Board 3 **Abstract 11020:** Restrictive eligibility criteria in FDA-approved oncology trials following ASCO Guideline updates.
First Author: Ryan Scott Imaikalani Kong, BS
- Board 4 **Abstract 11021:** Comparative effectiveness and safety of axicabtagene ciloleucel versus lisocabtagene maraleucel in large B-cell lymphoma: A real-world target trial emulation.
First Author: Mohammed Zuber, PharmD
- Board 5 **Abstract 11022:** AI-enabled clinical trial framework for end-to-end site recommendation and enrollment projection.
First Author: Stephen S. Yip, PhD
- Board 6 **Abstract 11023:** Exploring neural correlates of chemotherapy-induced peripheral neurotoxicity (CIPN) and the impact of exercise: A URCC NCORP nationwide phase II randomized controlled trial (RCT).
First Author: Thushini Manuweera, PhD
- Board 7 **Abstract 11024:** Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025).
First Author: Oliver Overheu, MD
- Board 8 **Abstract 11025:** Reducing effort through informatics-driven identification, recruitment, and data capture on a trial to improve adjuvant endocrine therapy adherence.
First Author: Ahauve Orusa
- Board 9 **Abstract 11026:** Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.
First Author: Raymond Mailhot Mailhot Vega, MD
- Board 10 **Abstract 11027:** Quantifying the impact of protocol design on enrollment and dropout rates in breast cancer clinical trials.
First Author: Evon Okidi, MSc, ScM
- Board 11 **Abstract 11028:** Assessing site-central baseline imaging discordance in oncology clinical trials.
First Author: Danielle Phillippi, PhD
- Board 12 **Abstract 11029:** Temporal trends in pregnancy-associated cancer mortality in the United States: A national analysis 2018-2023.
First Author: Diya Jayram, BA
- Board 13 **Abstract 11030:** Fair inclusion in clinical trials: Updated Good Pharma Scorecard evaluations of FDA oncology drugs approved by the FDA, 2018-2023.
First Author: Tanvee Varma, MD
- Board 14 **Abstract 11031:** Insurance and cost-related access barriers to specialty oral anticancer medications for blood cancers in a nationwide sample of Medicare and commercially insured patients.
First Author: Jalpa A. Doshi

9:00 AM-12:00 PM Poster Session

Quality Care/Health Services Research

Location: Hall A—Posters and Exhibits

Posters by Topic

Clinical Research Design: Board(s) 1-11, 182a-182b

Health and Regulatory Policy: Board(s) 12-16

Health Outcomes: Board(s) 17-27, 183a

Health Services Research: Board(s) 28-85

Patient Reported Outcomes: Board(s) 86-96

Quality Improvement: Board(s) 97-100

Real-World Data/Outcomes: Board(s) 101-181, 183b

- Board 15 **Abstract 11032:** Trends in cancer drug revenue retained by providers under buy-and-bill reimbursement, 2010-2024.
First Author: Aaron Philip Mitchell, MD, MPH
- Board 16 **Abstract 11033:** Association of Medicaid expansion with pre-diagnosis coverage continuity and 2-year overall survival in pediatric patients with blood cancer.
First Author: Rebecca Williamson Lewis, MPH
- Board 17 **Abstract 11034:** Association between low muscle mass assessed by bioelectrical impedance analysis and clinical outcomes in hospitalized cancer patients.
First Author: Diogo Toledo
- Board 18 **Abstract 11035:** Longitudinal changes in coping among early phase cancer clinical trial (EPCT) participants.
First Author: Anh B. Lam, DO, MBA
- Board 19 **Abstract 11036:** The association of baseline fatigue and severe cancer treatment toxicity by comorbid conditions: A pooled analysis.
First Author: Michael M. Caplan, MD
- Board 20 **Abstract 11037:** Decline in credit score and excess mortality risk among cancer patients: Evidence from Washington State.
First Author: Scott David Ramsey, MD, PhD
- Board 21 **Abstract 11038:** Cost-effectiveness analysis of teclistamab plus daratumumab in relapsed or refractory multiple myeloma.
First Author: Wing Fai Li, MD
- Board 22 **Abstract 11039:** Association of baseline clinical factors and treatment-related variables with survival in phase I solid tumor trials.
First Author: Jonathan Boiarsky, MD
- Board 23 **Abstract 11040:** Reduced treatment adherence and cancer mortality in patients with depression.
First Author: Edmund Men Qiao, MD
- Board 24 **Abstract 11041:** APS-TMA phenotypes as a failure-to-rescue signal during U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.
First Author: Tarek Tabbah
- Board 25 **Abstract 11042:** Premature cancer mortality in the United States, 1999–2023: Analysis of CDC WONDER data.
First Author: Kwame Adjei Sefah
- Board 26 **Abstract 11043:** Dose-response relationship of serum iron, ferritin, and transferrin saturation with cancer-related mortality: An analysis of population-based data.
First Author: Saima Gill, MD, MBBS
- Board 27 **Abstract 11044:** Predictors of mechanical ventilation in metastatic cancer hospitalizations: A National Inpatient Sample study.
First Author: Davin Turku, MD
- Board 28 **Abstract 11045:** Addressing housing instability as a quality-of-care determinant in cancer: A meta-analysis across national and Veterans Affairs cohorts.
First Author: Adarsh Vardhan Tangella, MBBS
- Board 29 **Abstract 11046:** Impact of symptom burden, psychological distress, and treatment accessibility on quality of life in people with cancer in Syria.
First Author: Mohamad Yousef Almawaz, MD
- Board 30 **Abstract 11047:** The AI paradox in precision oncology: Prospective blinded validation of large language models against molecular tumor board.
First Author: Arun Seshachalam, DM
- Board 31 **Abstract 11048:** Evolution of immune checkpoint inhibitor trials in oncology from 2011 to 2025: A cross-sectional study.
First Author: Runzhe Chen, MD
- Board 32 **Abstract 11049:** Baseline financial and credit status of participants enrolled in SWOG S1912CD.
First Author: Veena Shankaran, MD, MS
- Board 33 **Abstract 11050:** Palliative care for advanced cancer: Medicare Advantage and provider networks.
First Author: Xin Hu, PhD
- Board 34 **Abstract 11051:** Household costs of breast cancer and coping mechanisms in Kenya: A case of Kenyatta National Hospital.
First Author: Lyndah Kemunto Manoti, MBA, MBChB, MMed
- Board 35 **Abstract 11052:** Disparities in race and insurance status among hospitalized patients with pancreatic cancer and protein–energy malnutrition: A nationwide analysis, 2016–2022.
First Author: Alexandra Sueldo, MD
- Board 36 **Abstract 11053:** Malnutrition and cachexia as drivers of failure-to-rescue in gynecologic cancer hospitalizations, 2016–2023.
First Author: Charles Abraham Joseph Larson, BS
- Board 37 **Abstract 11054:** Comprehensive molecular profiling in advanced non–small cell lung cancer (NSCLC): Measurable survival and value impacts of implementation.
First Author: Stanley Ifeanyi Ozogbo, MD, MPH
- Board 38 **Abstract 11055:** Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies.
First Author: Hamlet Gasoyan, PhD
- Board 39 **Abstract 11056:** Impact of U.S. most-favored-nation (MFN) drug pricing on global oncology access.
First Author: Ariel Hammerman, PhD, RPh
- Board 40 **Abstract 11057:** When does time become a burden? Evaluating the association between time spent on cancer care and patient distress.
First Author: Sarah Boyle, MD
- Board 41 **Abstract 11058:** An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices.
First Author: Luis T. Campos, MD
- Board 42 **Abstract 11059:** Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
First Author: Aaron Philip Mitchell, MD, MPH

- Board 43 **Abstract 11060:** Format matters: Digital vs print delivery of a job retention intervention during breast cancer therapy.
First Author: Yashasvini Sampathkumar, MD
- Board 44 **Abstract 11061:** Co-creating patient partnership within a national cancer trials network: Experience from Cancer Trials Ireland in partnership with the Irish Cancer Society.
First Author: Emer Mulvaney
- Board 45 **Abstract 11062:** Commercial price variation in precision oncology testing across US hospitals.
First Author: Maryam Mooghali, MD, MSc
- Board 46 **Abstract 11063:** Economic evaluation of a designated oncology pharmacist in hemato-oncology outpatient care: A randomized clinical trial.
First Author: Areen Khateeb Alabbasi, PhD
- Board 47 **Abstract 11064:** Local and state paid sick leave policies and timeliness of treatment initiation among working-age patients with early-stage breast cancer.
First Author: Kewei Sylvia Shi, MPH
- Board 48 **Abstract 11065:** Association of facility type and metastatic burden with survival in gastric adenocarcinoma: A National Cancer Database study.
First Author: Yazmin Reategui-Almonacid, MD, MS
- Board 49 **Abstract 11066:** Shifting drivers of hospitalization in endometrial cancer: Toxicity-like organ failure phenotypes in the modern treatment era.
First Author: Sarah Peterson
- Board 50 **Abstract 11067:** Early-phase operational readiness gaps in oncology cell and gene therapy trials and implications for scalable trial infrastructure.
First Author: Meera Belur, BS
- Board 51 **Abstract 11068:** Prevalence and trends in rural patient enrollment in SWOG cancer clinical trials, 1992-2022.
First Author: Izumi Okado, PhD
- Board 52 **Abstract 11069:** Body mass index and mortality in immune checkpoint inhibitor–treated cancers: A real-world propensity-matched analysis.
First Author: Katherin Zambrano, MD
- Board 53 **Abstract 11070:** Burden and site-specific spectrum of second primary malignancies after adult acute myeloid leukemia: A population-based SEER standardized incidence ratio study with latency-stratified risk profiling (2000–2022).
First Author: Abat Khan, MD
- Board 54 **Abstract 11071:** Concordance of tissue and plasma NGS in early-stage non–small cell lung cancer.
First Author: Juhi Gor, MD
- Board 55 **Abstract 11072:** Clinical-stage AI-enabled therapeutic assets: An industry-wide analysis of scale, clinical progression, and company characteristics.
First Author: Waqas Haque, MD, MPH, MPhil
- Board 56 **Abstract 11073:** Impact of market entry of biosimilars in the US on cancer biologics’ pricing strategies, market share, and payer costs.
First Author: Xiaoyu Liu, MPH
- Board 57 **Abstract 11074:** Heart failure in hospitalizations for hematologic malignancies versus solid tumors: National burden and inpatient outcomes, 2018-2022.
First Author: Dylan Lee
- Board 58 **Abstract 11075:** Closing the information gap in oncology: A retrieval-augmented generation multi-modal AI platform for personalized patient education and physician efficiency.
First Author: Weiqi Liang, MD
- Board 59 **Abstract 11076:** The 2026 primary care oncology toolkit: An evolving shared-care framework for the implementation of prospective survivorship evidence.
First Author: Manila Sharma, MBBS
- Board 60 **Abstract 11077:** Inpatient burden and outcomes across gastrointestinal cancer subtypes among younger adults in the United States, 2018–2022.
First Author: Emaan Tiwana
- Board 61 **Abstract 11078:** Enhanced financial assistance intervention for unmet essential needs: A prospective pilot study to improve timely cancer treatment completion.
First Author: Justin Michael Barnes, MD, MS
- Board 62 **Abstract 11079:** Has racial and ethnic representation in oncology clinical trials changed?: A 30-year systematic analysis using artificial intelligence.
First Author: Rahman Adesoji Olusoji, MD
- Board 63 **Abstract 11080:** The Bermuda model: Achieving world-class, equitable, and efficient cancer care in a small island nation.
First Author: Ross Jarrett
- Board 64 **Abstract 11081:** Integrating AI-derived lung cancer risk and social determinants of health to improve risk stratification in a safety net lung cancer screening program.
First Author: Evan Garrad, MD
- Board 65 **Abstract 11082:** Closing the distance and the Specialist Nursing Optimal Placement Tool (SN-OPT): Strategic placement of specialist cancer nurses to achieve resource and geographic equity in Australia.
First Author: Rebecca Johnson, MN
- Board 66 **Abstract 11083:** Equity in breast cancer research authorship: Country, gender, and income representation in phase III trials presented at the ASCO Annual Meeting (2015–2025).
First Author: Sydney Johnson, MSc
- Board 67 **Abstract 11084:** Evaluating value in the age of accelerated approval: A pembrolizumab case study.
First Author: Jeffrey Mathew Boby, MBBS
- Board 68 **Abstract 11085:** Dysphagia-associated inpatient risk phenotypes and mortality in hospitalized head and neck cancer: A national analysis.
First Author: Manraj Dhillon, DO
- Board 69 **Abstract 11086:** PRIME-ROSE: A blueprint for implementing precision cancer medicine in Europe.
First Author: Gro Live Fagereng, PhD

- Board 70 **Abstract 11087:** Weekend admission and early in-hospital mortality among patients with hematologic malignancies admitted for febrile neutropenia.
First Author: Tarfa Verinumbe, MD, MPH
- Board 71 **Abstract 11088:** Reporting of sex-related data in landmark phase III solid tumor trials presented at ASCO 2025.
First Author: Marine Rushanyan, MD
- Board 72 **Abstract 11089:** Center-level delivery patterns and capacity during rapid CAR-T expansion in the United States (2021-2023).
First Author: Pranav Singh, MBBS
- Board 73 **Abstract 11090:** Safety-net coverage instability during cancer care and association with overall survival.
First Author: Liyang Yuan, MS, ScM
- Board 74 **Abstract 11091:** Real-world EGFR, ALK, and PD-L1 testing performance and end-to-end intervals in Colombian patients with non-small cell lung cancer.
First Author: Mateo Barros, MD
- Board 75 **Abstract 11092:** Investigating reasons patients do not join a cancer clinical trial.
First Author: Radhi Yagnik
- Board 76 **Abstract 11093:** Health shocks and advance care planning among U.S. older adults: Evidence from HRS 2012-2022.
First Author: Haofan Yang, MPH
- Board 77 **Abstract 11094:** Insights from initial scoring in the Health Equity Report Card (HERC) pilot in community oncology settings.
First Author: Taneal D. Carter, MPA, MS, DHSc
- Board 78 **Abstract 11095:** Same day/next day cancer care program: An early access program for patients with aggressive malignancies.
First Author: Artem Oganessian, MD
- Board 79 **Abstract 11096:** Empowering multidisciplinary teams in cancer survivorship: Results from the ASCO Project ECHO survivorship program in Brazil.
First Author: Luciana Castro Landeiro, MD, PhD
- Board 80 **Abstract 11097:** Admission acuity and inpatient outcomes across major gastrointestinal malignancies in the United States, 2018–2022.
First Author: Elaine Patricia Tupas, DO
- Board 81 **Abstract 11098:** Survival outcomes in individuals with cancer and pre-existing autoimmune disease receiving immune checkpoint inhibitors: A multicenter, propensity-matched real-world survival analysis.
First Author: Nehemias Guevara, MD
- Board 82 **Abstract 11099:** Racial and payer-based disparities in inpatient resource utilization and mortality among patients hospitalized with head and neck cancer in the United States, 2018 to 2022.
First Author: Sandhya Upreti
- Board 83 **Abstract 11100:** Consumer wearables and medical care utilization in gastrointestinal cancers: A Fitbit data analysis in NIH All of Us research program.
First Author: Osama Elkhider, MD, MBBS, MRCP
- Board 84 **Abstract 11101:** Recent trends in utilization of outpatient medical oncology services.
First Author: Carlos U. Muzlera, MD
- Board 85 **Abstract 11102:** Hidden advanced physiology in non-metastatic gastrointestinal cancer: Malnutrition/cachexia and in-patient failure-to-rescue.
First Author: Wei Ju Lin, DO
- Board 86 **Abstract 11103:** Quality of life among caregivers of patients with breast cancer in Mexico: A multicenter cross-sectional survey using the Caregiver Quality of Life Index–Cancer (CQOLI-C).
First Author: Carlos A. Gonzalez-Assad, MD
- Board 87 **Abstract 11104:** Patient-perceived caregiver burden after intense oncology treatment.
First Author: Virgil Junhui Guo
- Board 88 **Abstract 11105:** Patient trust in oncologists versus artificial intelligence for cancer-related questions.
First Author: Lyndon Huang, MD
- Board 89 **Abstract 11106:** Latent transitions of distress risk during cancer treatment and their concordance with anxiety, depression, and quality of life in a large multicenter cohort.
First Author: Cristiane Decat Bergerot, PhD, MS, FASCO
- Board 90 **Abstract 11107:** Clinical efficiency of remote symptom monitoring using electronic patient-reported outcome (ePRO) in lung cancer: Results of the prospective, multicenter REAL-MOOV-LUNG trial.
First Author: Nicolas Girard, MD, PhD
- Board 91 **Abstract 11108:** Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors.
First Author: Benjamin Avi Derman, MD
- Board 92 **Abstract 11109:** E-PROs in oncology: Improving treatment adherence to treatment while reducing emergency care and costs for patients with gastrointestinal malignancies receiving systemic therapy.
First Author: Patricia Rioja, MD
- Board 93 **Abstract 11110:** Determinants of cervical cancer awareness, procedural knowledge, and information sources among Nepali women undergoing HPV screening.
First Author: Jin Mou, MD, PhD, MSc, MPH
- Board 94 **Abstract 11111:** Digital oncology navigation based on ePROs: Effects on acute healthcare utilization and cost savings in a middle-income country setting.
First Author: Alessandra Menezes Morelle, MD, PhD
- Board 95 **Abstract 11112:** PROgress Tracker Breast Cancer Registry: Reporting worry of illness from a longitudinal peer-led, national patient-reported outcomes (PRO) registry.
First Author: Shaniah Leduc, RN
- Board 96 **Abstract 11113:** Text-based electronic patient-reported outcome monitoring in oncology: A 180-day longitudinal analysis of symptom burden changes in 701 cancer patients.
First Author: Pallav K. Mehta, MD

- Board 97 **Abstract 11114:** Advancing valuebased breast cancer screening in a safety-net health system: A multimodal approach to improving population health and system sustainability.
First Author: Shivani Agarwal, MD, MPH
- Board 98 **Abstract 11115:** Proactive response initiative for symptom management (PRISM): A multi-institutional symptom monitoring program for veterans receiving systemic cancer therapy.
First Author: Denaly Chen, MD
- Board 99 **Abstract 11116:** Factors associated with clinical trial failure and termination in non-small cell lung cancer immunotherapy: A ten-year review.
First Author: Arman Asatryan, MS
- Board 100 **Abstract 11117:** Evaluating the role of informal caregivers in metastatic cancer patients treated with oral anticancer therapy: A prospective observational study.
First Author: Barbara Salvo
- Board 101 **Abstract 11118:** Real-world utilization patterns and adverse events among patients receiving antibody-drug conjugates (ADCs) across the University of California health system.
First Author: Guanming Chen, PhD, MSc
- Board 102 **Abstract 11119:** Inpatient palliative care utilization and outcomes among decedent patients with metastatic cancer in the U.S.
First Author: Jiazhang Xing, MD
- Board 103 **Abstract 11120:** Risk of immune-related adverse events from checkpoint inhibitors in cancer patients with autoimmune disease: An emulated target trial.
First Author: Rotana M. Radwan
- Board 104 **Abstract 11121:** Trends in ivermectin medication records with cancer as the primary diagnosis following public attention: A national EHR analysis.
First Author: Changchuan Jiang, MD, MPH
- Board 105 **Abstract 11122:** Machine learning-based prognostic models for mortality prediction after unplanned hospitalization in cancer patients.
First Author: Taha Koray Sahin, MD
- Board 106 **Abstract 11123:** Mortality caused by coexisting malignant neoplasms and type 2 diabetes mellitus in U.S. adults: A CDC WONDER analysis (1999–2020).
First Author: Muhammad Abdullah, MBBS
- Board 107 **Abstract 11124:** Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis.
First Author: Chinemerem Martlin Emeasoba, MD
- Board 108 **Abstract 11125:** Natural language processing-assisted chart review to assess documented cannabis use in electronic medical records (EMR) of adults undergoing cancer infusion therapy.
First Author: Reina Haque, PhD
- Board 109 **Abstract 11126:** Breast cancer screening and detection after the 2024 USPSTF recommendation for women aged 40–49.
First Author: Karen Farrar
- Board 110 **Abstract 11127:** Safety and efficacy of immunotherapy rechallenge in solid tumors after discontinuation of immune checkpoint inhibitors for immune-related adverse events: A systematic review and meta-analysis.
First Author: Yu Fujiwara, MD
- Board 111 **Abstract 11128:** Overall survival after intravenous iron use in patients with cancer and iron deficiency: A propensity-matched real-world study.
First Author: Haris Sohail, MD
- Board 112 **Abstract 11129:** Impact of facility type and surgical management on survival outcomes in colon adenocarcinoma stratified by metastatic burden.
First Author: Yazmin Reategui-Almonacid, MD, MS
- Board 113 **Abstract 11130:** Integrated tumor-informed and tumor-agnostic ctDNA molecular residual disease (MRD) assessment with imaging in early breast cancer.
First Author: Tim Crook, MD, PhD
- Board 114 **Abstract 11131:** Role of iron supplementation in the efficacy of immune checkpoint inhibitors (ICIs): A real-world propensity-matched analysis.
First Author: Parth Sharma, MBBS
- Board 115 **Abstract 11132:** Pan-cancer discovery of clinical and genomic determinants of immune-related adverse events.
First Author: Ziad Bakouny, MD, MSc
- Board 116 **Abstract 11133:** Estimating survival in advanced cancer: A prospective single-center study on the accuracy of oncologists' prognostic accuracy (Pre-Sur).
First Author: Giulia Claire Giudice, MD
- Board 117 **Abstract 11134:** Trends and disparities in mortality from malignant neoplasms of male genital organs in the United States, 1999–2023.
First Author: Nikil Kumar, MBBS
- Board 118 **Abstract 11135:** Trends and disparities in mortality from malignant neoplasms of digestive system and renal failure in the United States, 1999–2023.
First Author: Nandni Kumari
- Board 119 **Abstract 11136:** Hospitalized oncology patients with diarrhea: Clinical outcomes and prognostic factors.
First Author: Güner Akgüner, MD
- Board 120 **Abstract 11137:** Beyond geography: The intersecting impact of rurality, race, and depression on breast cancer survival.
First Author: Ilias Jerrar, MD
- Board 121 **Abstract 11138:** A risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases.
First Author: Gabriela Esnaola, BA
- Board 122 **Abstract 11139:** Safety of glucagon-like peptide-1 receptor agonists in patients with breast cancer: A real-world multicenter cohort study.
First Author: Cho Han Chiang, MD, MSCI
- Board 123 **Abstract 11140:** The corticosteroid timing paradox in immune checkpoint inhibitor-treated solid tumors and its association with overall survival: A TriNetX retrospective cohort study.
First Author: Nikhil Kumar Kotla, MD

- Board 124 **Abstract 11141:** New-onset inflammatory bowel disease associated with immune checkpoint inhibitor therapy: A real-world multicenter analysis. First Author: Albert Ekow Orhin, MHS, MBChB
- Board 125 **Abstract 11142:** The impact of the COVID-19 pandemic on breast cancer stage at time of diagnosis at a major health system in New Jersey. First Author: Maureen Younan, MD, PharmD
- Board 126 **Abstract 11143:** Clinical associations of cannabis use among patients receiving immune checkpoint inhibitors: A real-world analysis. First Author: Qiuchen Li, BA
- Board 127 **Abstract 11144:** Relationship between immune-mediated adverse events and clinical outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors (ICIs): A retrospective real-world analysis. First Author: Leticia Escobar Vicentini, MD
- Board 128 **Abstract 11145:** Real-world outcomes with atezolizumab versus durvalumab plus chemotherapy for extensive-stage small cell lung cancer: A TriNetX propensity-matched analysis. First Author: Kevin Zhu, MD
- Board 129 **Abstract 11146:** Sinonasal adverse events of immune checkpoint inhibitors: Pharmacovigilance using FAERS. First Author: Kevin Zhu, MD
- Board 130 **Abstract 11147:** National trends in opioid-related hospitalizations among adult cancer patients: 2000-2022. First Author: Yongmei Huang, MD, DPH, DH
- Board 131 **Abstract 11148:** Long-term incidence of hypothyroidism and thyroiditis after CAR T-cell therapy versus standard chemotherapy in hematologic malignancies: A propensity-matched multi-institutional cohort study. First Author: Taha Hassan, MD
- Board 132 **Abstract 11149:** Risk of renal adverse events (RE-AE) and electrolyte changes with immunotherapy (IT) in a real-world cohort. First Author: Ameer Bawwab, MD
- Board 133 **Abstract 11150:** Immune checkpoint inhibitors and respiratory outcomes in cancer patients with pre-existing asthma: A TriNetX propensity-matched cohort study. First Author: Murad Alkharabsheh, MD
- Board 134 **Abstract 11151:** Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology. First Author: Shruti Prem Sudha, MD, MRCP
- Board 135 **Abstract 11152:** Association of β -blocker selectivity with survival and immune-related outcomes in melanoma and lung cancer patients treated with immune checkpoint inhibitors. First Author: Leen Alkuttob
- Board 136 **Abstract 11153:** Second-generation H1 antihistamine use with survival and immune-related outcomes in lung cancer and melanoma patients receiving immune checkpoint inhibitors. First Author: Leen Alkuttob
- Board 137 **Abstract 11154:** Trends in ischemic stroke and ischemic heart disease-related mortality among patients with malignancies in the United States: A 25-year CDC-WONDER analysis (1999-2023). First Author: Muhammad Saad, MD, MBBS
- Board 138 **Abstract 11155:** Five-year survival disparities in two population-based cohorts of adults with early-onset colorectal cancer. First Author: Lauren P. Wallner, PhD, MPH
- Board 139 **Abstract 11156:** Assessment of the role of rapid drug desensitization to treat cancer patient with infusion-related allergic reactions. First Author: Irene Palmieri, MD
- Board 140 **Abstract 11157:** Trends and racial disparities in pulmonary embolism-related mortality among older adults with neoplasms: A population-based retrospective study in the United States from 1999-2020. First Author: Chinenye Ekwuonwu, MD, MPH
- Board 141 **Abstract 11158:** Safety of immune checkpoint inhibitors in solid tumor patients with hepatitis C: A real-world analysis. First Author: Muhammad Yousaf, MD
- Board 142 **Abstract 11159:** Real-world resource use and cost in patients treated with originator or biosimilar rituximab in a large U.S. insurance claims database. First Author: Ruth Wangia Dixon, PhD
- Board 143 **Abstract 11160:** Impact of concomitant antibiotic exposure on overall survival in patients with esophagogastric cancer treated with immune checkpoint inhibitors: A real-world cohort study. First Author: Diptasree Mukherjee, MD
- Board 144 **Abstract 11161:** EU-OPEN: A novel approach for generating European oncology real-world evidence at scale. First Author: Kaushal Desai, PhD
- Board 145 **Abstract 11162:** Midday immune checkpoint inhibitor (ICI) infusion influence on survival in patients with metastatic cancer: A real-world chrono-immunotherapy study. First Author: Beliz Bahar Karaođlan, MD
- Board 146 **Abstract 11163:** Ischemic heart disease as a competing cause of death among patients with lung cancer in the United States: A multiple cause-of-death analysis, 1999–2023. First Author: Manish KC, MD
- Board 147 **Abstract 11164:** Real-world cost effectiveness of androgen receptor pathway inhibitors for metastatic hormone sensitive prostate cancer: An economic evaluation utilizing data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN). First Author: Rebecca Green, MS
- Board 148 **Abstract 11165:** Neurological immune-related adverse events and overall survival in patients with advanced solid tumors treated with immune checkpoint inhibitors in a global real-world analysis. First Author: Ahmed Abbasi, MD, MBBS
- Board 149 **Abstract 11166:** Pulmonary immune-related adverse events post-immune checkpoint inhibitors (ICI): Real-world experience. First Author: Maëlys Yepes, MD

- Board 150 **Abstract 11167:** Comparative real-world survival outcomes of ribociclib and abemaciclib in breast cancer.
First Author: Chinenye M. Okafor, MD, MPH
- Board 151 **Abstract 11168:** When autoimmunity meets immunotherapy: Immune checkpoint inhibitors in cancer patients with rheumatoid arthritis.
First Author: Rafi Aibani, MD
- Board 152 **Abstract 11169:** Sex differences in immune-related adverse events requiring hospitalization among patients with checkpoint inhibitor-sensitive malignancies: A national analysis.
First Author: Jeril Lasington, MD
- Board 153 **Abstract 11170:** Prevalence and fracture burden of osteoporosis among patients with colorectal cancer: A real-world analysis.
First Author: Anushree Venkatesh Murthy
- Board 154 **Abstract 11171:** Body mass index (BMI) and overall survival (OS) among Hispanic patients treated with immune checkpoint inhibitors (ICIs).
First Author: Matthew Barke, MD
- Board 155 **Abstract 11172:** Insurance and racial disparities in CAR T-cell therapy outcomes: A National Inpatient analysis.
First Author: Jeril Lasington, MD
- Board 156 **Abstract 11173:** Mental health and malignancy: Real-world associations between early-onset hormone-related cancers and mental illness.
First Author: Danielle Claire Thor, MA, DO
- Board 157 **Abstract 11174:** Mental health and malignancy: Real-world associations between early-onset gastrointestinal cancers and mental illness.
First Author: Danielle Claire Thor, MA, DO
- Board 158 **Abstract 11175:** Patterns and determinants of radiotherapy treatment default in a rural cancer centre: A retrospective observational study.
First Author: Darshana Kawale
- Board 159 **Abstract 11176:** Assessing burden and outcomes: Colon cancer survival across the U.S. safety-net spectrum.
First Author: David Othinoiyi, MD, PhD
- Board 160 **Abstract 11177:** Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.
First Author: Scott Kopetz, MD, PhD, FASCO
- Board 161 **Abstract 11178:** Predictors of tumor lysis syndrome in non-Hodgkin lymphoma hospitalizations.
First Author: Srijani Thannir, MD
- Board 162 **Abstract 11179:** Direct oral anticoagulants versus low-molecular-weight heparin in patients with liver metastases and cancer-associated thrombosis: A multi-center real-world analysis.
First Author: Jowan Al-Nusair, MD
- Board 163 **Abstract 11180:** Arrhythmia phenotype and 30-day readmission in selected cancers: Propensity-matched NRD study.
First Author: Mariana Marrero Castillo, MD
- Board 164 **Abstract 11181:** Trends and factors associated with glucagon-like peptide 1 receptor agonists prescription for cancer populations with type 2 diabetes.
First Author: Ilana Graetz, PhD
- Board 165 **Abstract 11182:** Organ-specific metastatic progression in non-small cell lung cancer treated with pembrolizumab versus atezolizumab: A TrinetX network analysis.
First Author: Athar Nawab, MD
- Board 166 **Abstract 11183:** Frailty among hospitalized patients with pancreatic cancer: A National Inpatient analysis.
First Author: Srijani Thannir, MD
- Board 167 **Abstract 11184:** Baseline corticosteroid use and outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors, stratified by indication.
First Author: Angelina Lim, BS
- Board 168 **Abstract 11185:** Cardiovascular-related adverse events (CVD-AEs) and echocardiographic (Echo) changes with immunotherapy (IT): A real-world experience.
First Author: Ahmed Nabil Mohamed, MD
- Board 169 **Abstract 11186:** Socioeconomic and treatment-related determinants of long-term cancer survival: A population-based SEER outcomes analysis.
First Author: Akhilesh Sharma, MBBS
- Board 170 **Abstract 11187:** Impact of diabetes on respiratory infection risk and hospitalization following immune checkpoint inhibitor initiation in non-small cell lung cancer: A propensity-matched retrospective cohort analysis.
First Author: Gurasis Singh Sodhi, MBBS
- Board 171 **Abstract 11188:** Association between selective serotonin reuptake inhibitor use and outcomes in metastatic melanoma treated with immune checkpoint inhibitors: A real-world cohort study.
First Author: Sandeep Kumar Jain, MD
- Board 172 **Abstract 11189:** Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.
First Author: Jay R. Hydrén, PhD
- Board 173 **Abstract 11190:** Trends and disparities in diabetes-associated cancer mortality in the United States, 1999–2020.
First Author: Kashish Magnani, MBBS
- Board 174 **Abstract 11191:** Time-dependent patterns of immune-related adverse events by obesity status following immune checkpoint inhibitor therapy: A real-world cohort analysis.
First Author: Bibek Shrestha, MD
- Board 175 **Abstract 11192:** Patterns of upper endoscopy use prior to gastric cancer diagnosis among high-risk populations.
First Author: Rohit Khullar, MD
- Board 176 **Abstract 11193:** Distinct patient and product-specific phenotypes associated with toxicity and resource utilization after CAR T-cell therapy: A Nationwide Inpatient analysis.
First Author: Ayodeji David Johnson, MD

Monday, June 1, 2026

- Board 177 **Abstract 11194:** Bridging the gap between clinical utility and coverage: Real-world impact of unreimbursed NGS testing.
First Author: Madhuri Paul, PhD
- Board 178 **Abstract 11195:** Early mortality and hospitalization following cholangiocarcinoma diagnosis by statin exposure: A TriNetX real-world analysis.
First Author: Reshma John
- Board 179 **Abstract 11196:** Osteoporosis and osteoporosis-related fractures among older male cancer patients: A nationwide study.
First Author: Tasneem Anagreh, MD
- Board 180 **Abstract 11197:** Sepsis severity and inpatient outcomes in metastatic cancer: A National Inpatient Sample study.
First Author: Davin Turku, MD
- Board 181 **Abstract 11198:** Real-world utilization and outcomes of lenalidomide in MDS with low blasts and isolated deletion 5q (MDS w 5q).
First Author: Krishna Sajeev, MBBS
- Board 182a **Abstract TPS11199:** A phase II, single-arm, exploratory study of GEMOX combined with tislelizumab and donafenib in the perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma with high recurrence risk.
First Author: Sulai Liu
- Board 182b **Abstract TPS11200:** Design of an innovative clinical development program using randomized controlled phase 2 trial data and real-world evidence from an expanded access protocol to assess mifomelotide (TCMCB07) in GI cancer cachexia.
First Author: Allison Gardner, PhD
- Board 183a **Abstract TPS11201:** Economic burden of nonapproved alternative therapies among patients with stage IV cancer: A prospective observational study.
First Author: Arpana Ashok, MD
- Board 183b **Abstract TPS11202:** A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.
First Author: Bradley J. Monk, MD

9:45 AM-10:45 AM Case-Based Panel

A Wealth of Options: Selecting Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Location: E451

Dana Rathkopf, MD—Chair

Memorial Sloan Kettering Cancer Center
Moderator

Andrew J. Armstrong, MD, MS

Duke University
Molecular Biomarker Perspective

Stuart M. Lichtman, MD, FASCO

University of Rochester
Patient and Quality-of-Life Perspective

Nicholas David James, PhD, MBBS, FRCP

Institute of Cancer Research
Radiation Perspective

Panel Question and Answer

9:45 AM-10:45 AM Case-Based Panel

Brain Metastases: Challenging Cases and Multidisciplinary Management

Location: S102

Iris C. Gibbs, MD—Chair

Stanford Cancer Institute
Moderator

Mariza Daras, MD

Virginia Commonwealth University Health
Neuro-Oncology Perspective

Evangelia Razis, MD, PhD, FASCO

Hellenic Cooperative Oncology Group
Medical Oncologist Perspective

Gelareh Zadeh, MD, PhD

Mayo Clinic Rochester
Neurosurgery Perspective

Panel Question and Answer

9:45 AM-10:45 AM Case-Based Panel

Navigating Thorny Issues When Providing Palliative Care

Location: E350

Areej El-Jawahri, MD, FASCO—Chair

Massachusetts General Hospital, Harvard Medical School
Moderator

Katharine Brock, MD, MS

Emory University School of Medicine
Pediatric Oncologist Perspective

Julia L. Agne, MD

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Palliative Care Perspective

Nahla Gafer, MD

Khartoum Oncology Hospital
Radiation Oncologist Perspective

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Accelerating the Cure: Perspectives From the AMA on Access to Targeted Immunotherapies

Location: S100a

Ashley Love Sumrall, MD, FACP, FASCO—Chair

Levine Cancer Institute

Bobby Mukkamala, MD

American Medical Association
Perspectives From the AMA on Access to Targeted Immunotherapies

Nita M. Kulkarni, MD

McLaren
Panelist

Panel Question and Answer

9:45 AM-11:00 AM Education Session

State of the Art: Desmoid Fibromatosis—Biology-Driven Management in a Shifting Treatment Landscape

Location: S504

Piotr Rutkowski, MD, PhD

Narodowy Instytut Onkologii im
“Do No Harm”: Active Surveillance and Imaging Strategies

Breelyn A. Wilky, MD—Chair

University of Colorado School of Medicine
Systemic Therapy in Desmoids: What to Use, When, and Why

Sean Tutton, MD

University of California San Diego
Nonsurgical Localized Approaches for Desmoids: Less Is More
 Panel Question and Answer

9:45 AM-11:00 AM Education Session

State of the Art: Emerging Treatments and Novel Modalities in Head and Neck Cancers

Location: E450b

Sue S. Yom, MD, PhD, FASTRO, FACR

UCSF Medical Center at Mount Zion
Novel Radiopharmaceuticals in Head and Neck Cancer

Kedar Kirtane, MD—Chair

Moffitt Cancer Center
Emerging Cell Therapies in Head and Neck Cancer

Anil K. Dacruz, MS, MBBS, DNB

Apollo Hospitals
Novel Therapies in the Neoadjuvant or Adjuvant Surgical Setting
 Panel Question and Answer

9:45 AM-11:00 AM Education Session

Tech That Scales: Artificial Intelligence and Digital Tools for Cancer Care in Low and Middle Income Countries and Counties

Location: S403

Arturo Loaiza-Bonilla, MD, MEd, FACP—Chair

St. Luke’s University Health Network
A Practical Playbook for Artificial Intelligence, Screening, and Remote Oncology in Resource-Constrained Settings

Partha Basu, MD, PhD

International Agency for Research on Cancer
HPV Self-Collection and Artificial Intelligence Triage: The Pave Strategy From Design to Deployment in Resource-Constrained Environments, Domestically, and Globally

Sanjeev Arora, MD, MACP

University of New Mexico
Scale Expertise, Not Just Apps: Project Echo and Remote Monitoring to Improve Rural Survivorship and Navigation
 Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

From Data to Decisions: Applying Artificial Intelligence for Smarter, More Accessible Cancer Care

Location: Hall D1

Kelsey H. Natsuhara, MD—Chair

University of California San Francisco

Caroline Chung, MD, FRCPC—Chair

The University of Texas MD Anderson Cancer Center

9:45 AM Julian C. Hong, MD, MS
 UCSF Helen Diller Family Comprehensive Cancer Center
Leveraging Artificial Intelligence in Oncology Care and Research: From Proof of Concept to Adoption—What Will It Take?

9:57 AM Abstract 106: An actionable machine learning–driven clinicogenomic model as a predictor of brain metastasis risk in breast cancer.
 First Author: Luke Roy George Pike, MD, DPhil

10:09 AM Abstract 107: External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.
 First Author: Corey Wayne Speers, MD, PhD

10:21 AM Abstract 108: An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
 First Author: Sebastian R. Medina, MSc

10:33 AM Abstract 109: Implementing a centralized navigator-led and AI-assisted platform to improve lung cancer screening rates and early detection: A 6-year health system analysis.
 First Author: Jun Zhang, MD, PhD

10:45 AM Caroline Chung, MD, FRCPC
 The University of Texas MD Anderson Cancer Center
Discussion of Abstract(s) 106-109: Harnessing Artificial Intelligence for More Personalized and Accessible Cancer Care: Are We There Yet?

10:57 AM Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall D2

Rebecca Arielle Shatsky, MD—Chair

University of California San Diego Medical Center

Coral Omene, MD, PhD—Chair

Rutgers Cancer Institute

9:45 AM Abstract 508: Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): A phase II clinical trial.
 First Author: Ruoxi Wang, MD

9:51 AM Abstract 509: Neoadjuvant pyrotinib vs pertuzumab therapy for HER2-positive early breast cancer: The HELEN HER-013 randomized clinical trial.
 First Author: Jiuju Zhu

Monday, June 1, 2026

- 9:57 AM Abstract LBA510:** Primary results of the BETTER-CARE trial: Implementation of a needs-adapted and individualized follow-up care after primary breast cancer.
First Author: Achim Woeckel
- 10:03 AM Panel Question and Answer**
- 10:15 AM Abstract 511:** The effects of Mediterranean diet, physical activity, and vitamin D on breast cancer recurrence and cardiometabolic health: A multicenter randomized trial.
First Author: Livia Augustin, PhD
- 10:21 AM Abstract 512:** Effect of elinzanetant on sleep disturbance and aspects of quality of life in women with breast cancer experiencing vasomotor symptoms: OASIS-4 subgroup analysis by type of endocrine therapy.
First Author: Claudio Soares, MD
- 10:27 AM Abstract 513:** Does resection of cavity shave margins impact survival in breast cancer patients?
First Author: Anees B. Chagpar, MD, MPH, MBA, MSc, MA, FACS, FRCS, FASCO
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract LBA514:** Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.
First Author: Ciara Catherine O'Sullivan, MD, MBBCh
- 10:51 AM Abstract LBA515:** Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.
First Author: Oleg Gluz, MD
- 10:57 AM Abstract 516:** Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).
First Author: Michael Untch, MD, PhD
- 11:03 AM Panel Question and Answer**

9:45 AM-12:45 PM Oral Abstract Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall B1

Robin Kate Kelley, MD, FASCO—Chair

UCSF Helen Diller Family Comprehensive Cancer Center

Antonella Cammarota, MD—Chair

Hepatobiliary Immunopathology Lab, IRCCS Humanitas Research Hospital

- 9:45 AM Abstract LBA4000:** Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
First Author: Ghassan K. Abou-Alfa, MD, PhD, MBA, JD, FASCO

- 9:57 AM Abstract 4001:** Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial.
First Author: Wei-Dong Jia
- 10:09 AM Abstract 4002:** IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).
First Author: Arndt Vogel, MD, PhD
- 10:21 AM Stephen Lam Chan, MD, FRCP, MRCP**
Prince of Wales Hospital
Discussion of Abstract(s) LBA4000-4002: Finding the Right Time and Place for Immunotherapy in Hepatocellular Carcinoma
- 10:33 AM Panel Question and Answer**
- 10:49 AM Abstract 4003:** First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study.
First Author: Xiaotian Zhang, MD
- 11:01 AM Abstract 4004:** A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003).
First Author: Chuan Hua Zhao
- 11:13 AM Robert H. Vonderheide, MD, DPhil**
University of Pennsylvania
Discussion of Abstract(s) 4003-4004: Better Together: Bispecific and Trispecific Antibodies in Gastrointestinal Cancers
- 11:25 AM Panel Question and Answer**
- 11:41 AM Abstract 4006:** Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
First Author: Do-Youn Oh, MD, PhD
- 11:53 AM Abstract 4007:** ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
First Author: Sung Hee Lim, MD
- 12:05 PM Abstract 4008:** Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
First Author: Zhihao Lu, MD
- 12:17 PM Sunnie S. Kim, MD**
University of Colorado Cancer Center
Discussion of Abstract(s) 4006-4008: New Directions in Gastroesophageal Cancers
- 12:29 PM Panel Question and Answer**

11:30 AM-12:15 PM Award Lecture

Assessing Real-World Outcomes in Breast Cancer: Opportunities, Challenges, and Lessons Learned

Location: Hall D2

Mariana Chavez Mac Gregor, MD, MSc, FASCO—Chair
The University of Texas MD Anderson Cancer Center

Sharon H. Giordano, MD, FASCO
The University of Texas MD Anderson Cancer Center
Gianni Bonadonna Breast Cancer Award Recipient

Panel Question and Answer

11:30 AM-12:30 PM Case-Based Panel

Consensus and Controversies in Well-Differentiated/Dedifferentiated Retroperitoneal Liposarcoma

Location: S504

Palma Dileo, MD—Chair
Istituto Ortopedico Rizzoli
Moderator

Mark Andrew Dickson, MD
Memorial Sloan Kettering Cancer Center
Medical Oncologist Perspective

Manpreet Bedi, MD
Cleveland Clinic Foundation
Radiation Oncologist Perspective

Dorian Yarih Garcia Ortega, MD, PhD, FACS, MSc, FSSO
National Cancer Institute (INCan Mexico)
Surgical Oncologist Perspective

Panel Question and Answer

11:30 AM-12:30 PM Case-Based Panel

Incorporating Immune Checkpoint Inhibitors in Locally Advanced Head and Neck Cancer

Location: E450b

Hyunseok Kang, MD, MPH, FACP—Chair
University of California San Francisco
Moderator

Christophe Le Tourneau, MD, PhD
Gustave Roussy
Medical Oncologist Perspective

Thomas James Galloway, MD
Fox Chase Cancer Center
Radiation Oncologist Perspective

Eleni M. Rettig, MD
Dana-Farber Cancer Institute
Surgeon Perspective

Panel Question and Answer

11:30 AM-12:45 PM Education Session

ASCO/ASPO Joint Session: The Coming Wave of Early-Onset Cancer

Location: S100a

Kimmie Ng, MD, MPH—Chair
Dana-Farber Cancer Institute
Understanding the Rising Incidence of Young-Onset Cancers

Cristiane Decat Bergerot, PhD, MS, FASCO

Grupo Oncoclínicas
Beyond Survival: Emotional and Psychosocial Wellbeing of Young Cancer Patients

Irene Su, MD, MSCE—Chair
Ideker Laboratory, UC San Diego School of Medicine
Oncofertility in Young People With Cancer: Preserving Hope Across Resource-Constrained Settings

Tara O. Henderson, MD, MPH, FASCO
Ann & Robert H. Lurie Children's Hospital of Chicago
Survivorship and Secondary Malignancies

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer

Location: Arie Crown Theater

Karim Olivier Fizazi, MD, PhD, BM—Chair
Centre Oscar Lambret, University of Paris-Saclay
First-Line Metastatic Castration-Resistant Prostate Cancer: One Size Doesn't Fit All

Louise Emmett, MD, PhD, MBChB, FRACP
St Vincent's Hospital Sydney
How to Better Personalize Treatment With Lu-PSMA

Biren Saraiya, MD
Rutgers Cancer Institute
Early Integration of Palliative and Supportive Care

Panel Question and Answer

11:30 AM-12:45 PM Education Session

When Less Is More: Balancing Cost, Toxicity, and Efficacy for Treatment of Lung Cancer in an Era of Sequencing and Combination Therapies

Location: Hall D1

Jordi Remon Masip, MD, PhD—Chair
Gustave Roussy
Didactic Lecture: Current Availability and Approval Status of Follow-On Targeted and Immunotherapy Drugs for Lung Cancer

Amol Patel, MD, DM
Indian Naval Hospital Ship
Debate (Pro Low-Dose Immunotherapy/Novel Follow-On Drugs): Yes—Let's Use the Opportunity to Reduce the Cost of Cancer Care

Marina Chiara Garassino, MD
University of Chicago
Debate (Pro Status Quo/Current Standard of Care): Yes—Newcomers and New Strategies Are Welcome but We Need More Data Before Implementation in Routine Clinical Care

Panel Question and Answer

11:30 AM-2:30 PM Oral Abstract Session

Symptom Science and Palliative Care

Location: S100bc

Nicholas Zdenkowski, PhD, MBBS, FRACP—Chair
University of Newcastle

Michelle Li, MBBS—Chair
Dana-Farber Cancer Institute

Monday, June 1, 2026

- 11:30 AM Abstract 12000:** Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.
First Author: Jian Zhang, MD
- 11:42 AM Abstract LBA12001:** Gabapentin plus tramadol versus tramadol alone for chemoradiotherapy-induced oral mucositis pain in head and neck cancer: Results of a randomized phase III trial.
First Author: Minit Jalan Shah, DM
- 11:54 AM Abstract LBA12002:** Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103.
First Author: Ryoichi Sadahiro, MD, PhD
- 12:06 PM Dame Idossa, MD**
Mayo Clinic Rochester
Discussion of Abstract(s) 12000-LBA12002: Repurposed Remedies: Old Drugs, New Tricks
- 12:18 PM Panel Question and Answer**
- 12:30 PM Abstract LBA12003:** Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results.
First Author: Luke Joseph Peppone, PhD
- 12:42 PM Abstract 12004:** YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors.
First Author: Yuri Choi, PhD, RN, MSN
- 12:54 PM Abstract 12005:** A phase III placebo controlled randomized controlled trial using combination therapy for treatment-related fatigue in patients with prostate cancer.
First Author: Sriram Yennu, MD
- 1:06 PM Michelle Riba, MD**
University of Michigan
Discussion of Abstract(s) LBA12003-12005: Sick of Being Tired: Strategies for Cancer-Related Fatigue
- 1:18 PM Panel Question and Answer**
- 1:30 PM Abstract 12006:** A digital health intervention to enhance well-being among adolescent and young adult survivors of cancer: Results from the EMPOWER full factorial trial.
First Author: John M. Salsman, PhD
- 1:42 PM Abstract 12007:** Impact of electronic patient-reported outcome measure (ePROM)–triggered, collaborative care (CC)–based symptom intervention on depression and anxiety in young adults (YAs) with cancer.
First Author: Michael H. Storandt, MD
- 1:54 PM Abstract LBA12008:** SUPPORT+ digital selfmanagement and clinical support for advanced cancer: A randomized controlled trial.
First Author: Wing-Lok Chan, MBBS
- 2:06 PM Tyler Murphy, MD**
Mayo Clinic in Arizona
Discussion of Abstract(s) 12006-LBA12008: Let's Get Digital: Reclaiming Quality of Life and Well-Being
- 2:18 PM Panel Question and Answer**

12:00 PM-1:00 PM Annual Business Meeting
ASCO Annual Business Meeting (ASCO Members Only)
Location: S103

1:15 PM-2:30 PM Education Session
Breaking the Immune Sanctuary: Targeting Metastatic Niches
Location: E450a

Raghav Sundar, MD, PhD—Chair
Yale School of Medicine
Foundations of Premetastatic Niche Formation

Emilie Le Rhun, MD, PhD
University Hospital Zurich
Targeting Metastatic Sanctuaries

Brian J. Czerniecki, MD, PhD
Moffitt Cancer Center
Intratumoral Immunotherapy and Local Immune Activation
Panel Question and Answer

1:15 PM-2:30 PM Education Session
Global Access to Quality Oncology Practice: The Role and Impact of Best Practices Model
Location: S102

Abdul Jazieh, MD, MPH, FASCO
Cincinnati Cancer Advisors
From Certification to Leadership: Expanding Quality Oncology Care in the Middle East

Naghib Bogere, MBChB, MBA, MMed
Uganda Cancer Institute
Applying Quality Oncology Practices in Africa: Lean Implementation, Real Impact

Gerardo Antonio Umazor, MD
Liga Contra El Cancer
Creating Regional Collaboratives: Quality Care as a Catalyst for Latin American Oncology

Jack O. Hensold, MD, FASCO—Chair
Bozeman Deaconess Health Group
Overcoming Barriers to Quality Oncology Care in Rural United States of America: Lessons for Globally Underserved Populations
Panel Question and Answer

1:15 PM-2:30 PM Education Session
How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer
Location: Arie Crown Theater

Nabil Adra, MD—Chair
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
First-Line Therapy for Patients With Poor Risk Testicular Cancer

Siamak Daneshmand, MD
Keck School of Medicine of USC
Management of Post-Chemotherapy Residual Masses in Poor-Risk Testicular Cancer

Patrizia Giannatempo, MD
IRCCS Foundation, National Cancer Institute
Salvage Therapy in Patients With Poor-Risk Testicular Cancer

Darren R. Feldman, MD
 Memorial Sloan Kettering Cancer Center
 Management of Brain Metastasis
 Panel Question and Answer

1:15 PM-2:30 PM Education Session

Integrating Artificial Intelligence Into Oncology Practice: Applications From the Clinic to Academic Research and Publication

Location: S100a

Jasmin Hundal, MD, MS, MPH—Chair

Cleveland Clinic
The Positive Impact of Artificial Intelligence in Daily Clinical Practice

Mohammad Hosseini, PhD

Northwestern University
Practical Considerations for the Use of Artificial Intelligence in Grant Submissions and Publications

Caroline Chung, MD, FRCPC

The University of Texas MD Anderson Cancer Center
The Artificial Intelligence Advantage—Easing the Path From Discovery to Delivery

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma

Location: E450b

Katy K. Tsai, MD

UCSF Helen Diller Family Comprehensive Cancer Center
The Art of Adjustment: Response-Guided Therapy in the Neoadjuvant/Adjuvant Setting

Daniel Olson, MD

University of Chicago Comprehensive Cancer Center
When to Push, When to Pull Back: Tailoring Therapy in Metastatic Melanoma

Geoffrey Thomas Gibney, MD, FASCO—Chair

Georgetown University's Lombardi Comprehensive Cancer Center
Melanoma Treatment Duration: Balancing Efficacy, Safety, Cost, and Quality of Life

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Updates on Management of Anal Cancer: A New Era Has Begun

Location: E451

Sheela Rao, MD, MBBS—Chair

The Royal Marsden NHS Foundation Trust
Latest Options for First-Line Treatment for Metastatic Anal Cancer

Van K. Morris II, MD

The University of Texas MD Anderson Cancer Center
Treatment Beyond First-Line Chemoimmunotherapy for Metastatic Anal Cancer

Cathy Eng, MD, FACP, FASCO

Vanderbilt Ingram Cancer Center
Current Landscape of Curative-Intent Anal Cancer Management

Panel Question and Answer

1:15 PM-2:45 PM Rapid Oral Abstract Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall D2

Peter Joel Hosein, MD—Chair

Sylvester Comprehensive Cancer Center, University of Miami

Kim Anna Reiss, MD—Chair

Abramson Cancer Center of the University of Pennsylvania

1:15 PM Abstract 4009: Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
 First Author: Lin Shen, MD

1:21 PM Abstract 4010: Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.
 First Author: Sun Young Rha, MD, PhD

1:27 PM Abstract 4011: A phase 2 pivotal study of savolitinib in patients with *MET*-amplified gastric cancer or gastroesophageal junction adenocarcinomas.
 First Author: Zhi Peng, MD

1:33 PM Panel Question and Answer

1:45 PM Abstract 4012: Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.
 First Author: Vincent Chung, MD

1:51 PM Abstract 4013: Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer.
 First Author: Vincent Chung, MD

1:57 PM Panel Question and Answer

2:09 PM Abstract 4014: Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.
 First Author: Hong Wu

2:15 PM Abstract 4015: Tegavivint, a downstream Wnt/ β -catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
 First Author: David Hsieh, MD

2:21 PM Abstract 4016: A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.
 First Author: Choong-kun Lee, MD, PhD

2:27 PM Abstract 4017: Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma (mCCA) with fibroblast growth factor receptor-2 (FGFR2) rearrangement: Phase 3 FIGHT-302 results.
 First Author: Tanios S. Bekaii-Saab, MD, FASCO

2:33 PM Panel Question and Answer

Monday, June 1, 2026

1:15 PM-4:15 PM Oral Abstract Session

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Hall D1

Patrick M. Forde, MD, PhD—Chair

Trinity St James's Cancer Institute, Trinity College Dublin

Laura Alder, MD—Chair

Duke University Medical Center

1:15 PM Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
First Author: Jamie E. Chaft, MD, FASCO

1:27 PM Abstract 8001: Adjuvant erlotinib versus observation after complete resection of *EGFR*-mutant NSCLC: Final overall survival results of Alliance A081105.
First Author: Ramaswamy Govindan, MD, FASCO

1:39 PM Abstract 8002: Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN).
First Author: Chao Zhang, MD, PhD

1:51 PM Mariano Provencio, MD, PhD
Hospital Universitario Puerta de Hierro
Discussion of Abstract(s) 8000-8002: Signals, Surprises, and Subtleties: Lessons From Early-Stage Lung Cancer Trials

2:03 PM Panel Question and Answer

2:15 PM Abstract 8003: Pollution and progression: Air quality and stage of lung cancer diagnosis across the U.S.
First Author: Raheem Bell, MD, MS

2:27 PM Abstract 8004: Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.
First Author: Brendan Heiden, MD, MS, MBA

2:39 PM Katharine A. Rendle, PhD, MPH, MSW
Perelman School of Medicine, University of Pennsylvania
Discussion of Abstract(s) 8003-8004: From Air to Awareness: Pollution and the Path to Early Detection

2:51 PM Panel Question and Answer

3:03 PM Abstract LBA8005: Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
First Author: Bjorn Henning Gronberg, MD, PhD

3:15 PM Abstract 8006: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
First Author: Giannis S. Mountzios, MD

3:27 PM Abstract 8007: Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, phase 2 study.
First Author: Yun Fan, MD

3:39 PM Abstract 8008: ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).
First Author: Lauren Averett Byers, MD, MSc

3:51 PM Misty Dawn Shields, MD, PhD
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Discussion of Abstract(s) LBA8005-8008: Bright Spots and Blind Alleys in Small Cell Lung Cancer Therapy

4:03 PM Panel Question and Answer

1:30 PM-4:30 PM Poster Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall A—Posters and Exhibits

Posters by Topic

Adjuvant Therapy: Board(s) 2-30, 127a-130a

Artificial Intelligence: Board(s) 31-45

Biologic Correlates: Board(s) 46-62, 130b

DCIS/LCIS/Premalignant Lesions: Board(s) 63-64

Local-Regional Therapy: Board(s) 65-75, 131a-132a

Neoadjuvant Therapy: Board(s) 76-110, 132b-134b

Outcomes/Quality: Board(s) 111-126, 135a-135b

Board 2 **Abstract 517:** International variation in diagnostic and treatment practices in patients with HER2+ EBC: The RWE PEARL-HER2 study.
First Author: Soraia Lobo-Martins, MD, MSc

Board 3 **Abstract 518:** Neoadjuvant atimociclib plus letrozole versus letrozole alone in HR+/HER2– breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.
First Author: Shom Goel, MD, PhD, FRACP, MBBS

Board 4 **Abstract 519:** Overall survival (OS) in premenopausal ER+/PR+, HER2– breast cancer (BC) treated with endocrine therapy (ET) ± chemotherapy (CT): A National Cancer Database (NCDB) analysis.
First Author: Lan Lei, MBBS, MS

Board 5 **Abstract 520:** Socioeconomic and racial disparities in receipt of treatment among early-stage ER+/PR+ HER2– breast cancer: Insights from invasive breast cancer OncoDX recurrence score database.
First Author: Lan Lei, MBBS, MS

Board 6 **Abstract 521:** Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.
First Author: Norah Lynn Henry, MD, PhD, FACP, FASCO

Board 7 **Abstract 522:** Tumor-associated macrophage (TAM) score as an independent predictor of recurrence in residual disease after neoadjuvant chemotherapy and for identification of high-risk patients for adjuvant escalation.
First Author: Aruna Korlimarla, PhD

Board 8 **Abstract 523:** Chemotherapy, endocrine therapy, and cognitive impairment in long-term breast cancer survivors.
First Author: Armaan Jamal, BS

- Board 10 **Abstract 525:** Adjuvant endocrine therapy omission in ER-positive breast cancer treated with neoadjuvant chemotherapy.
First Author: Grace Mei Yee Choong, MD
- Board 11 **Abstract 526:** Impact of *BRCA* pathogenic variants and novel targeted agents on ovarian reserve measured by anti-Müllerian hormone levels in young women with early breast cancer: A biomarker analysis of the PREFER study.
First Author: Luca Arecco, MD
- Board 12 **Abstract 527:** Impact of the Breast Cancer Index on extended endocrine therapy recommendations in patients from the BCI Registry study.
First Author: Tara B. Sanft, MD
- Board 14 **Abstract 529:** Platinum-based chemotherapy in early-stage, high-risk, triple-negative breast cancer: A systematic review and meta-analysis of randomized trials.
First Author: Jesse Lopes da Silva, PhD
- Board 15 **Abstract 530:** Real-world treatment patterns and adherence to adjuvant abemaciclib among patients with early hormone receptor-positive (HR+) breast cancer (BC).
First Author: Nimfon Jackson, MD, PhD, MPH
- Board 16 **Abstract 531:** Chemotherapy (CT) use by Oncotype DX (O-Dx) recurrence score (RS) in hormone receptor-positive, HER2-negative (HR+/HER2-) invasive lobular carcinoma (ILC): A contemporary National Cancer Database (NCDB) analysis.
First Author: Marija Sullivan, MD
- Board 18 **Abstract 533:** Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial.
First Author: Changjun Wang
- Board 19 **Abstract 534:** Real-world deployment of a multimodal artificial intelligence (AI) model for predicting response to neoadjuvant chemotherapy in early breast cancer.
First Author: Bareket Daniel, PhD
- Board 20 **Abstract 535:** Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations.
First Author: Paolo Tarantino, MD, PhD
- Board 21 **Abstract 536:** A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.
First Author: Keith L. Knutson, PhD
- Board 22 **Abstract 537:** Disparities in utilization of genomic risk assays in early-stage hormone-positive breast cancer: A retrospective analysis using National Cancer Database (NCDB).
First Author: Qi Jin Guo, MD, MS
- Board 23 **Abstract LBA538:** Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01).
First Author: Snehal Patel, MBA, MS
- Board 24 **Abstract 539:** Real-world post-APT trial adoption of de-escalated systemic therapy and outcomes in small HER2-positive breast cancer: An NCDB analysis.
First Author: Mengni Guo, MD
- Board 25 **Abstract 540:** Adjuvant chemotherapy (CT) benefit in invasive lobular carcinoma (ILC) by Oncotype DX Recurrence Score and menopausal status.
First Author: Arya Mariam Roy, MD
- Board 26 **Abstract 541:** Overall survival association of adjuvant endocrine therapy (ET) after pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in ER+/HER2+ early-stage breast cancer.
First Author: Mengni Guo, MD
- Board 27 **Abstract 542:** Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: A systematic review and meta-analysis.
First Author: Pedro C.A. Reis
- Board 28 **Abstract 543:** Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.
First Author: Anbarasan Sekar, MD, MBBS
- Board 29 **Abstract 544:** Chemotherapy use among women < 50 years with hormone receptor-positive breast cancer with low (≤ 15) Oncotype DX 21-gene recurrence score: A National Cancer Database (NCDB) analysis.
First Author: Mitali Shah, MD
- Board 30 **Abstract 545:** Comparative effectiveness of adjuvant chemotherapy on survival in node-positive (N2/N3), stage III ER+/HER2- invasive lobular breast cancer (ILC) versus invasive ductal cancer (IDC).
First Author: Sumeet K. Yadav, MD
- Board 31 **Abstract 546:** AI-based pre-screening of *BRCA1/2* mutation likelihood from routine H&E histopathology in unselected breast cancer cases using peakPredictBRCA.
First Author: Maher Sughayer, MD
- Board 32 **Abstract 547:** Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer, including early-onset disease.
First Author: Lilia Bouzit, MS
- Board 33 **Abstract 548:** AI-driven large language models for multimodal prediction of homologous recombination deficiency using clinical features and histopathological whole-slide images.
First Author: Zhao Sun

- Board 34 **Abstract 549:** Prediction of pathologic response using a taxane-based gene expression signature in RNA-sequencing data from breast cancer patients receiving neoadjuvant therapy.
First Author: Jan Nart, MSc
- Board 35 **Abstract 550:** Evaluating performance of an AI-based recurrence score in early breast cancer patients treated with chemoendocrine therapy: A secondary analysis of the UNIRAD trial.
First Author: Thomas Bachelot, MD, PhD
- Board 36 **Abstract 551:** Estimating individual benefit from adjuvant chemotherapy in hormone receptor–positive breast cancer using causal multimodal artificial intelligence.
First Author: Frederick Howard, MD
- Board 37 **Abstract 552:** Evaluating the prognostic performance of an AI-based model in clinically low-risk HR+/HER2– early breast cancer.
First Author: Dhruva Biswas, MD, PhD
- Board 38 **Abstract 553:** Standardized exam-style benchmarking of large language models in breast cancer clinical decision-making.
First Author: Mariam Haji, MD
- Board 39 **Abstract 554:** Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
First Author: Magali Lacroix-Triki, MD, PhD
- Board 40 **Abstract 555:** Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.
First Author: Johan Hartman, MD, PhD
- Board 41 **Abstract 556:** Deep learning–based classification of benign and malignant breast lesions on ultrasound using knowledge distillation with external validation and global deployment.
First Author: Jansi Rani Sethuraj, DNP
- Board 42 **Abstract 557:** Prospective-retrospective HeCOG phase III trial validation of Polaris TME for the prediction of TILs from whole-slide images in high-risk early breast cancer.
First Author: Elena Fountzilas, MD
- Board 43 **Abstract 558:** AI-driven risk stratification for distant recurrence in node-positive HR+/HER2– early breast cancer: Independent validation in the NSABP B-28 trial.
First Author: Priya Rastogi, MD
- Board 44 **Abstract 559:** Prognostic performance of a multimodal artificial intelligence histopathology-based tool versus the 21-gene recurrence score in early-stage breast cancer.
First Author: Shayna L. Showalter, MD, FACS
- Board 45 **Abstract 560:** Prognostic value of an MRI-derived recurrence assay in women with hormone receptor–positive, HER2-negative breast cancer: A retrospective, multi-center analysis.
First Author: Matthew P. Goetz, MD
- Board 46 **Abstract 561:** Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.
First Author: Steven J. Isakoff, MD, PhD
- Board 47 **Abstract 562:** Predicting recurrence and survival in hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC) with machine learning models: Optimization of model complexity.
First Author: Frederick Howard, MD
- Board 48 **Abstract 563:** Gut microbiome characteristics in patients with hormone receptor–positive (HR+) HER2– breast cancer treated with adjuvant abemaciclib: Biomarker analysis of the TRADE trial.
First Author: Ilana Schlam, MD, MPH
- Board 49 **Abstract 564:** Distinct late recurrence patterns and immune landscape of HER2-positive invasive lobular carcinoma (ILC): Analysis of NCCTG N9831 (Alliance) trial and real-world cohort.
First Author: Thiti Susirawatnanont, MD, MS
- Board 50 **Abstract 565:** Association of patient-reported stress and depression symptoms with ER-specific tumor transcriptional signatures in breast cancer (BC).
First Author: Shipra Gandhi, MD, MS
- Board 51 **Abstract 566:** Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106).
First Author: Meenakshi Anurag, PhD
- Board 52 **Abstract 567:** Spatial interactions between immune cells as a predictor of pCR to neoadjuvant chemotherapy (NACT) and nivolumab for ER+/HER2– breast cancer (BC): Analysis of the phase II GIADA trial.
First Author: Valentina Guarneri, MD, PhD
- Board 53 **Abstract 568:** Characteristics of cancer patients undergoing molecular residual disease testing with a tumor-informed assay.
First Author: Gargi D. Basu, PhD
- Board 54 **Abstract 569:** mTOR activation and racial disparity in early breast cancer survival.
First Author: Ekaterina Proskuriakova, MD
- Board 55 **Abstract 570:** Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial.
First Author: Andrew Dooley, MBChB
- Board 56 **Abstract 571:** Molecular profiling of male breast cancer in Brazil: Comprehensive genomic characterization of a Latin American cohort.
First Author: Elizabeth Santos
- Board 57 **Abstract 572:** Functional domain disruption to define the molecular and clinical spectrum of germline *RAD51* family variants in hereditary breast cancer (BC).
First Author: André Luiz Cicilini, MD
- Board 58 **Abstract 573:** Multi-omic profiling to identify RNA-protein concordance and post-transcriptional dysregulation in HER2+ breast cancer.
First Author: Pahini Pandya, PhD
- Board 59 **Abstract 574:** Exploring diversity and composition of sulfidogenic gut bacteria in breast cancer.
First Author: Tazeena Khan

- Board 60 **Abstract 575:** Beyond convolution: Attention-driven vision transformer modeling for breast cancer detection on mammography.
First Author: Tanzeela Mariam Shuja, MD
- Board 61 **Abstract 576:** ILCness to stratify lobular-like breast cancer biology and as an outcome independent of *CDH1* mutation in early ER-positive/HER2-negative breast cancer.
First Author: Masanori Oshi, MD, PhD
- Board 62 **Abstract 577:** Neighborhood disadvantage and correlation with differences in somatic mutations in a real-world breast cancer cohort.
First Author: Jacquelyn Dillon, MD
- Board 63 **Abstract 578:** Does surgery improve breast cancer-specific survival in low-grade DCIS?: A 20-year population-based analysis by nuclear grade.
First Author: Fatih Aydogan, MD
- Board 64 **Abstract 579:** Wire-guided versus radio-guided localization for non-palpable occult lesion in breast tissue: A systematic review and meta-analysis.
First Author: Mobeen Farooqi, MBBS
- Board 65 **Abstract 580:** Intraoperative precision margin assessment in breast-conserving surgery using handheld fluorescence microscopy.
First Author: Jing Wang, MD
- Board 66 **Abstract 581:** Impact of time-to-surgery on survival outcomes in Korean breast cancer patients: A nationwide population-based cohort study.
First Author: Je Hyun Chin, MD
- Board 67 **Abstract 582:** Can robotic surgery better preserve sensory function?: The significance and strategy of nerve preservation in axillary lymph node dissection.
First Author: Qiwen Liu
- Board 68 **Abstract 583:** Synergistic efficiency of methylene blue and carbon nanoparticles for sentinel lymph node biopsy in early breast cancer: A large-scale real-world cohort study of 1,355 patients.
First Author: Hongjin Liu, MD
- Board 69 **Abstract 584:** Oncological safety of oncoplastic breast conservation surgery: Experience of over a decade in early and locally advanced breast cancer from a tertiary care cancer center in India.
First Author: Shalaka Prakash Joshi, MS, DNB, MCh, MBBS
- Board 70 **Abstract 585:** Surgical outcomes and postoperative complications of robotic versus conventional nipple-sparing mastectomy in breast cancer: A meta-analysis.
First Author: Fahad Amin, MBBS
- Board 71 **Abstract 586:** Evaluation of a novel diagnostic kit using the semi-dry dot-blot method with an automated reader for detecting breast cancer metastases in sentinel lymph nodes: A combined analysis of two multicenter prospective studies in Japan.
First Author: Ryota Otsubo
- Board 72 **Abstract 587:** Distant recurrence-free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?
First Author: Jason A. Mouabbi, MD
- Board 73 **Abstract 588:** Can we omit surgical axillary staging in early-stage invasive lobular carcinoma?: Results from a large multicenter retrospective cohort study.
First Author: Massimo Ferrucci, MD, PhD
- Board 74 **Abstract 589:** Changes in metastatic breast cancer (MBC) bone lesions and SREs/fractures via a single intratumoral injection for a first-of-its-kind drug: Preliminary phase 2a results.
First Author: Manraj Heran, MD
- Board 75 **Abstract 590:** National real-world adoption of 5-fraction breast radiotherapy in the United States (2020–2023).
First Author: Pragya Jain, MBBS
- Board 76 **Abstract 591:** A response-adapted and genomically informed strategy to optimize neoadjuvant chemotherapy versus endocrine therapy plus CDK4/6 inhibition in high-risk HR+/HER2- breast cancer.
First Author: Zhengjun Yang, MD
- Board 77 **Abstract 592:** Impact of age on breast cancer outcomes in the neoadjuvant I-SPY2 trial.
First Author: Kelsey H. Natsuhara, MD
- Board 78 **Abstract 593:** Pathologic complete response in rare histologic subtypes of early-stage triple-negative breast cancer in the era of immunotherapy.
First Author: Maeve Hennessy, MBBS
- Board 79 **Abstract 594:** Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer.
First Author: Xianghui Zou, MD, PhD
- Board 80 **Abstract 595:** Neoadjuvant chemotherapy combined with toripalimab for triple-negative breast cancer: A prospective, single-arm, multi-center study (NEOTORCH-BREAST02).
First Author: Zhijun Dai
- Board 81 **Abstract 596:** Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.
First Author: Natasha Caminsky
- Board 82 **Abstract 597:** Evaluation of a taxane mRNA-based profile in neoadjuvant therapy across I-SPY2 investigational arms.
First Author: Jacob Niklassen, MSc
- Board 83 **Abstract 598:** Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.
First Author: Zhi-Ming Shao, PhD
- Board 84 **Abstract 599:** Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.
First Author: Maxim Ruban, MD
- Board 85 **Abstract 600:** Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: Updated efficacy and safety results from the phase II NeoTAPPL study.
First Author: Guozhi Zhang

- Board 86 **Abstract 601:** Outcomes after recurrence on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with high-risk early-stage triple-negative breast cancer (eTNBC).
First Author: Chiara Corti, MD
- Board 87 **Abstract 602:** Predicting chemotherapy benefit in premenopausal women with intermediate genomic scores using deep learning.
First Author: Arkadi Piven
- Board 88 **Abstract 603:** EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.
First Author: Nadine M. Tung, MD, FASCO
- Board 89 **Abstract 604:** Biological subtype discordance after neoadjuvant therapy in early breast cancer: Findings from a 1,500-patient cohort with residual disease.
First Author: Katarzyna Pogoda, PhD
- Board 90 **Abstract 605:** Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer.
First Author: Laura Burns Amin, MD
- Board 91 **Abstract 606:** Early results of neoadjuvant therapy with pyrotinib, subcutaneous trastuzumab, and capecitabine for HER2-positive early breast cancer from a prospective, single-arm, multicenter trial.
First Author: Lina Zhang, PhD
- Board 92 **Abstract 607:** Health-related quality of life with low-dose pembrolizumab plus chemotherapy in early triple-negative breast cancer: Findings from the PLANeT trial.
First Author: Adhip Arora, MD, DM
- Board 93 **Abstract 608:** Taxane and platinum combination as a predictor of pathologic complete response in I-SPY2 by gene expression breast cancer signatures.
First Author: Jacob Niklassen, MSc
- Board 94 **Abstract 609:** Delayed serplulimab combined with nab-paclitaxel and epirubicin in high-risk, early HR+/HER2- breast cancer (HELEN-B 018): A multicenter, single-arm, phase 2 trial.
First Author: Hao Dai, MD
- Board 95 **Abstract 610:** Impact of pembrolizumab infusion timing on outcomes in early-stage triple-negative breast cancer: A real-world exploratory analysis (Neo-Real).
First Author: Natalia Nunes
- Board 96 **Abstract 611:** DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients.
First Author: Xiaofei Huo, MD
- Board 97 **Abstract 612:** Development of a multivariable prognostic model for pathological response using anatomical and pathological variables in early triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: Initial results.
First Author: Dana Narvaez, MD
- Board 98 **Abstract 613:** Efficacy and safety of the pertuzumab biosimilar BCD178 versus the originator pertuzumab in patients with HER2-positive locally advanced breast cancer: Results from the international, double-blind, randomized, phase III PREFER trial.
First Author: Lyudmila Zhukova, MD, PhD
- Board 99 **Abstract 614:** Response to neoadjuvant chemotherapy in both the breast and lymph nodes in patients with inflammatory breast cancer.
First Author: Megan McClanahan, MD
- Board 100 **Abstract 615:** Preoperative combination radiotherapy (RT) and immune checkpoint inhibitor (ICI) in early-stage breast cancer: Influence of RT and ICI treatment sequencing (NCT04454528 post-hoc analysis).
First Author: Julia C. Tchou, MD, PhD
- Board 101 **Abstract 616:** De-escalation of neoadjuvant chemotherapy for HER2-positive breast cancer: A systematic review and meta-analysis.
First Author: Maria Clara Périco Perez
- Board 102 **Abstract 617:** Structural determinants compared with genetic ancestry and self-reported race in triple-negative breast cancer disparities: A multilevel analysis in an admixed population.
First Author: Patrick De Cerqueira, MD
- Board 103 **Abstract 618:** Predicting treatment effect on distant recurrence free survival from functional tumor volume change during neoadjuvant therapy: A Bayesian hierarchical model of I-SPY 2 MRI and survival data.
First Author: Keli Siqueiros Santos-Parker, MD, PhD
- Board 104 **Abstract 619:** Systemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and CDK4/6 inhibition in high-risk luminal breast cancer: Results from the GEICAM/2019-01-CARABELA trial.
First Author: Angel Guerrero-Zotano
- Board 105 **Abstract 620:** Neoadjuvant mitomycin C plus carboplatin followed by paclitaxel vs. standard doxorubicin-cyclophosphamide followed by paclitaxel-carboplatin in BRCA1/2-associated breast cancer.
First Author: Petr Krivorotko, MD, PhD
- Board 106 **Abstract 621:** Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.
First Author: David B. Page, MD, MS
- Board 108 **Abstract 623:** Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer.
First Author: Heather L. McArthur, MD, MPH, FASCO
- Board 110 **Abstract 625:** Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.
First Author: Kay T. Yeung, MD, PhD

- Board 111 **Abstract 626:** Maternal and neonatal complications associated with breast cancer systemic treatments: A VigiBase disproportionality analysis study.
First Author: Rayan Kabirian, MD
- Board 112 **Abstract 627:** Optimal timing of endocrine therapy interruption for pregnancy in young women with hormone receptor–positive early breast cancer.
First Author: Floriane Jochum
- Board 113 **Abstract 628:** GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis.
First Author: Dawit Hailemariam Yeshe, MD
- Board 114 **Abstract 629:** Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients.
First Author: Jasmine S. Sukumar, MD
- Board 115 **Abstract 630:** Real-world cumulative exposure of various endocrine-disrupting chemicals and association with breast cancer risk via common carcinogenic pathway.
First Author: Lijuan Tang, PhD
- Board 116 **Abstract 631:** Impact of fertility concerns on endocrine therapy.
First Author: Kathryn Jean Ruddy, MD, MPH, FASCO
- Board 117 **Abstract 632:** Long-term safety outcomes of pregnancy among young breast cancer survivors: Results from a prospective, multicenter cohort study.
First Author: Kimia Sorouri, MD, MPH
- Board 118 **Abstract 633:** Impact of an artificial intelligence–based management model on psychological and behavioral outcomes in breast cancer patients undergoing home CDK4/6 inhibitor therapy: A multicenter randomized controlled trial.
First Author: Li Zhang
- Board 119 **Abstract 634:** Temporal trends in adherence to adjuvant endocrine therapy across age groups in hormone receptor–positive breast cancer.
First Author: Michael M. Caplan, MD
- Board 120 **Abstract 635:** Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.
First Author: Kathryn Jean Ruddy, MD, MPH, FASCO
- Board 121 **Abstract 636:** Breast cancer–specific mortality in invasive lobular versus ductal carcinoma over 30 years.
First Author: Jose Pablo Leone, MD
- Board 123 **Abstract 638:** From treatment to survivorship: The CORE randomized study of a supervised exercise intervention in early-stage breast cancer.
First Author: Maria Torrente, MD, PhD
- Board 124 **Abstract 639:** Impact of GLP1 receptor agonists on survival of breast cancer patients.
First Author: Tim Prior, MD, PhD
- Board 125 **Abstract 640:** Lymphopenia in breast cancer and association with clinical outcomes: An analysis from over 30,000 patients.
First Author: Alexis Ann LeVee, MD
- Board 126 **Abstract 641:** Impact of social marginalization on stage at presentation and survival for invasive lobular versus ductal breast carcinoma.
First Author: David Wai Lim, PhD, MEd, MDCM
- Board 127a **Abstract TPS642:** HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor–positive breast cancer who are receiving adjuvant endocrine therapy.
First Author: Céline Bouchard, MD
- Board 127b **Abstract TPS643:** Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy.
First Author: Hatem Hussein Soliman, MD
- Board 128a **Abstract TPS644:** ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.
First Author: Payal Deepak Shah, MD
- Board 128b **Abstract TPS645:** NoLEEta: No chemotherapy in intermediate-risk HR+ HER2– early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.
First Author: Francois Clement Bidard, MD, PhD
- Board 129a **Abstract TPS646:** Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585).
First Author: Wolfgang Janni, MD, PhD
- Board 129b **Abstract TPS647:** PREDICT-RD: Postoperative molecular residual disease by ctDNA surveillance in TNBC with residual disease (TBCRC-071).
First Author: Yara Abdou, MD, MS
- Board 130a **Abstract TPS648:** SIGNAL-ER-101: Signatera-guided CDK4/6 inhibitor therapy in breast cancer.
First Author: Marla Lipsyc-Sharf, MD
- Board 130b **Abstract TPS649:** GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies.
First Author: Matthew E. Campbell, MD
- Board 131a **Abstract TPS650:** A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score \leq 25 (OFSET): NRG-BR009.
First Author: Eleftherios P. Mamounas, MD
- Board 131b **Abstract TPS651:** A randomized trial of sentinel node biopsy omission after neoadjuvant systemic therapy in clinically node-negative or selected node-positive breast cancer.
First Author: Ji-Jung Jung
- Board 132a **Abstract TPS652:** MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/BRA-NET/AGO-B-062; NCT05559411).
First Author: Maggie Banys-Paluchowski, PhD

- Board 132b **Abstract TPS653:** A molecular subtype-guided, chemotherapy-free neoadjuvant strategy using SHR-A1811 plus pertuzumab for hormone receptor-positive/HER2-positive breast cancer: A phase II trial in progress.
First Author: Zhengjun Yang, MD
- Board 133a **Abstract TPS654:** NOGA: Neoadjuvant treatment optimization via MRI-guided de-escalation in stage II-III TNBC—A phase 2 study.
First Author: Tal Sella, MD
- Board 133b **Abstract TPS655:** A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
First Author: Steven Quay, MD, PhD
- Board 134a **Abstract TPS656:** ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
First Author: Jose Pablo Leone, MD
- Board 134b **Abstract TPS657:** Stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitor and chemotherapy in early-stage treatment-naïve triple-negative breast cancer patients: A multicenter phase III clinical study.
First Author: Lei Liu, MD, PhD
- Board 135a **Abstract TPS658:** The SURVIVE study: Re-evaluating follow-up in early breast cancer.
First Author: Sophia T. Huesmann, MD
- Board 135b **Abstract TPS659:** Pre-operative chemotherapy versus surgery first with peri-operative interventions in early triple-negative and HER2-positive breast cancer: An open-label, phase 3, randomized controlled trial (PRACTISE).
First Author: Shalaka Prakash Joshi, MS, DNB, MCh, MBBS

1:30 PM-4:30 PM Poster Session

Breast Cancer—Metastatic

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 136-143

Biologic Correlates: Board(s) 144-154

HER2-Positive: Board(s) 155-173, 257a-259a

Hormone Receptor-Positive: Board(s) 174-216, 259b-263b

Non-Subtype-Specific Breast Cancer Therapies: Board(s) 217-222, 264a-265a

Outcomes/Quality: Board(s) 223-232, 265b

Triple-Negative: Board(s) 233-251, 266a-267b

Other Breast Cancer Subtypes: Board(s) 252-256, 268a-268b

- Board 136 **Abstract 1022:** Identifying patients with human epidermal growth factor receptor 2 (HER2)-low and -ultralow breast cancer (BC): Use of digital, artificial intelligence (AI)-based computational algorithms to assist HER2 scoring by pathologists.
First Author: Savitri Krishnamurthy, MD
- Board 137 **Abstract 1023:** Biology-informed predictive modeling and resistance monitoring in trastuzumab deruxtecan-treated metastatic breast cancer.
First Author: Josh Wheeler, MD, PhD

- Board 138 **Abstract 1024:** Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.
First Author: Guilherme Nader Marta, MD
- Board 139 **Abstract 1025:** Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i).
First Author: Michael Peng
- Board 140 **Abstract 1026:** Development and evaluation of a novel digital pathology image analysis pipeline for prediction of clinical outcomes with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in triplenegative breast cancer (TNBC).
First Author: Sara M. Tolaney, MD, MPH, FASCO
- Board 141 **Abstract 1027:** Antibody-drug conjugate (ADC) after ADC: Predicting survival in patients with HER2-low metastatic breast cancer with lung metastasis using artificial intelligence (AI) and radiomics.
First Author: Rishi Dakarapu
- Board 142 **Abstract 1028:** Cross-modality AI modeling of histopathology images to stratify outcomes among patients treated with hormonal or chemo-hormonal therapy in ER+/HER2- breast cancer.
First Author: Hassan Muhammad, PhD
- Board 143 **Abstract 1029:** Integrating artificial intelligence to evaluate outcomes and disparities in young-onset breast cancer: A SEER-based retrospective cohort study.
First Author: Jahnavi Ethakota, MD
- Board 144 **Abstract 1030:** Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
First Author: Shivani K. Thaker, MD, PhD
- Board 145 **Abstract 1031:** Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.
First Author: Ana Elisa Lohmann, MD, PhD
- Board 146 **Abstract 1032:** *TP53* status and licensing complex/IFN γ transcriptional profiles to stratify endocrine-related outcomes with CDK4/6i exposure in 10,833 real-world ER+/HER2- breast cancers and a treatment-naïve subset.
First Author: Alekya Raghavan, BS
- Board 147 **Abstract 1033:** Rapid digital patient-derived organoid testing for guiding therapy in patients with metastatic breast cancer receiving antibody drug conjugates (ADCs).
First Author: Yuan Yuan, MD, PhD
- Board 148 **Abstract 1034:** Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC).
First Author: Greydon Arthur, MD

- Board 149 **Abstract 1035:** Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.
First Author: Maher Albitar
- Board 150 **Abstract 1036:** Prognostic impact of *PIK3CA* amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).
First Author: Lorenzo Foffano, MD
- Board 151 **Abstract 1037:** HRD-positive breast cancer genomics: Cross-application of ovarian cancer HRD scores.
First Author: Xin Liu
- Board 152 **Abstract 1038:** Characterization of genomic alterations between local breast cancers and cutaneous metastases.
First Author: Francesca Thau, MD
- Board 153 **Abstract 1039:** Serum HER2 level as a predictor of treatment efficacy and prognosis in advanced breast cancer patients treated with trastuzumab deruxtecan (T-DXd).
First Author: Yehui Shi, PhD
- Board 154 **Abstract 1040:** PD-L1 upregulation as a reflection of distinct immune contexts in luminal and basal breast cancer.
First Author: Lynne Chapman Cook, MD
- Board 155 **Abstract 1041:** A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).
First Author: Yuan Huang, MD
- Board 156 **Abstract 1042:** Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.
First Author: Veronique C. Dieras, MD, MBBS
- Board 157 **Abstract 1043:** Risk factors and long-term prognostic impact of trastuzumab deruxtecan-related interstitial lung disease in metastatic breast cancer.
First Author: Takayuki Kobayashi, MD, PhD
- Board 158 **Abstract 1044:** Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.
First Author: Shigehisa Kitano, MD, PhD
- Board 159 **Abstract 1045:** Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.
First Author: Paolo Tarantino, MD, PhD
- Board 160 **Abstract 1046:** A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the 1L HER2-positive breast cancer cohort.
First Author: Wen Xia
- Board 161 **Abstract 1047:** Efficacy, safety, and immunogenicity of pertuzumab biosimilar versus reference pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer: A randomized, double-blind, multicenter, parallel group, phase III clinical trial.
First Author: P. K. Chaithanya
- Board 162 **Abstract 1048:** Phase Ia study of VRN101099, a brain-penetrant, highly selective covalent HER2 inhibitor, in HER2-positive or HER2-mutant advanced solid tumors.
First Author: Jee Hung Kim, MD, PhD
- Board 163 **Abstract 1049:** Phase II study of T-Bren (BL-M07D1) monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer.
First Author: He-Rui Yao, PhD
- Board 164 **Abstract 1050:** Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer.
First Author: Hui Cao
- Board 165 **Abstract 1051:** Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer.
First Author: Zunairah Shah, MD
- Board 166 **Abstract 1052:** Molecular imaging as a tool to predict patient outcomes in advanced HER2-low breast cancer on trastuzumab deruxtecan (T-DXd): The FHERAD trial.
First Author: Xiaoyi Guo
- Board 167 **Abstract 1053:** Intracranial efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer with central nervous system involvement: A systematic review and proportional meta-analysis.
First Author: Dua Azim, MD, MBBS
- Board 168 **Abstract 1054:** Neoadjuvant dalpiciclib combined with letrozole and dual HER2 blockade in HR+/HER2+ breast cancer: First-stage results of the HELEN HER2 017 trial.
First Author: JiuJun Zhu
- Board 169 **Abstract 1055:** Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)-permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial.
First Author: Nancy U. Lin, MD
- Board 170 **Abstract 1056:** TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses.
First Author: Erica Michelle Stringer-Reasor, MD, FASCO

- Board 171 **Abstract 1057:** Real-world cardiotoxicity with HER2 antibody–drug conjugates and survival after treatment continuation.
First Author: Sumbal Aziz, MD, MBBS
- Board 172 **Abstract 1058:** HER2-targeted tyrosine kinase inhibitors in breast cancer: Real-world analysis of gastrointestinal and musculoskeletal toxicities using the FAERS database.
First Author: Sneha Singh, MD
- Board 173 **Abstract 1059:** Dual HER2 blockade with or without taxane induction in HR+/HER2+ metastatic breast cancer: A comparative analysis of clinical outcomes.
First Author: Mariah Black, MS
- Board 174 **Abstract 1060:** Nanochemo-immunotherapy of ER-positive metastatic breast cancer (MBC) with PEG-liposomal doxorubicin (PLD) and pembrolizumab (PEM).
First Author: Alberto A. Gabizon, MD, PhD
- Board 175 **Abstract 1061:** Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2– advanced breast cancer in the real-world setting: Results from the PERFORM study.
First Author: Rupert Bartsch, MD
- Board 176 **Abstract 1062:** Clinical efficacy of a novel oral SERD TFX06 in prior fulvestrant-treated ER+/HER2– advanced breast cancer patients in a dose expansion study.
First Author: Wenxing Qin, MD, PhD
- Board 177 **Abstract 1063:** Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines (TMGs) on ILD/pneumonitis outcomes: A retrospective analysis of patients (pts) treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06 (DB-06).
First Author: Carla Mateo
- Board 178 **Abstract 1064:** CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with *PIK3CA*-mutant circulating DNA following CDK4/6 inhibition.
First Author: Eileen Geoghegan, MBBS
- Board 179 **Abstract 1065:** Subgroup analysis of participants (pts) with HER2 IHC0 in the ASCENT-07 study of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2– metastatic breast cancer (mBC).
First Author: Yeon Hee Park, MD, PhD
- Board 180 **Abstract 1066:** First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2– breast cancer (BC): A phase 1 safety expansion.
First Author: Shom Goel, MD, PhD, FRACP, MBBS
- Board 181 **Abstract 1067:** Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.
First Author: Rachel M. Layman, MD
- Board 182 **Abstract 1068:** Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2– metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended phase 3 dose (RP3D) of 5 mg once-daily (QD).
First Author: Rachel M. Layman, MD
- Board 183 **Abstract 1069:** HRS-8080, an oral selective estrogen receptor degrader (SERD), in ER+/HER2– advanced breast cancer (aBC) with *ESR1* mutations (*ESR1m*): Results from a first-in-human phase 1 trial.
First Author: Zefei Jiang, MD
- Board 184 **Abstract 1070:** Real-world survival benefit of glucagon-like peptide-1 receptor agonists (GLP-1 Ras) concomitant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy in hormone receptor-positive (HR+)/HER2– metastatic breast cancer: A large propensity-matched analysis.
First Author: Michela Palleschi
- Board 185 **Abstract 1071:** Beyond *ESR1*: Multi-pathway genomic drivers of endocrine resistance in HR+/HER2– breast cancer.
First Author: Humaid Obaid Al-Shamsi, MD, FRCPC
- Board 186 **Abstract 1072:** A phase 1/2 trial of tertsolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in *PIK3CA*-mutant advanced solid tumors: Updated results from PIKALO-1.
First Author: Komal L. Jhaveri, MD, FACP, FASCO
- Board 187 **Abstract 1073:** (RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.
First Author: VK Gadi, MD, PhD
- Board 189 **Abstract 1075:** Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atimociclib (ATI) in ER+/HER2– advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.
First Author: Melinda L. Telli, MD, FASCO
- Board 190 **Abstract 1076:** Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer after brain metastases: A multicenter, single-arm, phase II study.
First Author: Kuikui Jiang, MD
- Board 191 **Abstract 1077:** [¹⁸F] Fluoroestradiol PET/CT to guide second-line treatment decision-making in patients with estrogen receptor–positive, HER2-negative advanced breast cancer after progression on first-line aromatase inhibitor and CDK4/6 inhibitor: Primary results of ESTROTIMP.
First Author: Francois Clement Bidard, MD, PhD
- Board 192 **Abstract 1078:** BL0175, a novel nano-mediated polypeptide conjugate of protein degrader, in patients (pts) with locally advanced/metastatic HR+/HER2– breast cancer (HR+, HER2- LA/mBC): Initial results from a phase 1 study.
First Author: Nanya Wang

- Board 193 **Abstract 1079:** Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with *PIK3CA*-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).
First Author: Nicholas C. Turner, MD, PhD
- Board 194 **Abstract 1080:** Impact of FES-PET imaging in the management of estrogen receptor-positive breast cancer: Real-world experience.
First Author: Joanne E. Mortimer, MD, FASCO
- Board 195 **Abstract 1081:** Oral selective estrogen receptor degraders in HR+/HER2- advanced breast cancer and impact of ESR1 mutation status: A systematic review and meta-analysis.
First Author: Amal AlJuhani, MD, MBBS
- Board 196 **Abstract 1082:** Culmesticlib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2- advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial.
First Author: Tao Sun
- Board 197 **Abstract 1083:** Genomic markers of resistance to first-line (1L) therapy with a CDK4/6 inhibitor (CDKi) and endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).
First Author: Albert Grinshpun, MD, MSc
- Board 198 **Abstract 1084:** Impact of oral SERDs, including giredestrant, on survival in HR+ HER2- metastatic breast cancer: A meta-analysis.
First Author: Changtai Tian, MD
- Board 199 **Abstract 1085:** Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2- metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).
First Author: Olivia Benny
- Board 200 **Abstract 1086:** An early resistance genomic state (ERGS) as an identifier of primary CDK4/6 inhibitor failure in HR+/HER2- metastatic breast cancer.
First Author: Mobina Shrestha, MD
- Board 201 **Abstract 1087:** Oral estrogen receptor (ER) degraders compared to standard endocrine therapy (ET) in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC): A systematic review and meta-analysis.
First Author: Hadar Goldvaser, MD, MD
- Board 202 **Abstract 1088:** Capivasertib plus fulvestrant in Chinese patients with HR+/HER2- advanced breast cancer: Interim analysis of CAPtrue.
First Author: Peng Yuan, MD, PhD
- Board 203 **Abstract 1089:** *CBFβ* mutations as a predictive biomarker of endocrine therapy benefit in hormone receptor-positive (HR+) breast cancer: Discovery and validation in 3,799 patients.
First Author: Adar Yaacov, MD
- Board 204 **Abstract 1090:** First-line fovinaciclilb versus placebo combined with aromatase inhibitor for advanced breast cancer: A randomized, double-blind phase 3 study.
First Author: Peng Yuan, MD, PhD
- Board 205 **Abstract 1091:** Effects of SGLT2 inhibitor dapagliflozin on anticancer resistance and alpelisib- and fulvestrant-induced cardiomyocyte injury under hyperglycemic conditions.
First Author: Vincenzo Quagliariello
- Board 206 **Abstract 1092:** Prognostic impact of tumor recurrence dynamics in patients with HR+/HER2- advanced breast cancer treated with ET+CDK4/6i: Results from the multicenter, Italian study PALMARES-2.
First Author: Claudio Vernieri, MD, PhD
- Board 207 **Abstract 1093:** Association of *ESR1* amplification with survival and benefit from CDK4/6 inhibition in breast cancer.
First Author: George W. Sledge Jr, MD, FASCO
- Board 208 **Abstract 1094:** A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) and cyclin E1 (CCNE1)-amplified solid tumors: Updated safety and efficacy results.
First Author: Manish R. Patel, MD
- Board 209 **Abstract 1095:** Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i).
First Author: Daniel L. Abravanel, MD, PhD
- Board 210 **Abstract 1096:** Time on treatment for systemic therapies for patients with hormone receptor-positive breast cancer and *BRCA1*, *BRCA2*, or *PALB2* pathogenic variants.
First Author: Gerneiva Parkinson, MD, MHS
- Board 211 **Abstract 1097:** Influence of *TONSL* on tumor suppressor function of *RAD51* and resistance to CDK4/6 inhibitors in ER+ breast cancer.
First Author: Harikrishna Nakshatri, PhD
- Board 212 **Abstract 1098:** Elacestrant in combination with capivasertib in patients with ER+/HER2- advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.
First Author: Wassim McHayleh, MD, FACP, MBA
- Board 213 **Abstract 1099:** Real-world comparative safety and outcomes of ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: A propensity score-matched sensitivity analysis.
First Author: Noura Abbas, MD
- Board 214 **Abstract 1100:** Impact of GLP-1 receptor agonists in hormone receptor-positive breast cancer patients receiving CDK4/6 inhibitors.
First Author: Kiara Patino, PharmD

- Board 215 **Abstract 1101:** Fovinacliclib versus placebo combined with fulvestrant for advanced breast cancer after endocrine therapy: A randomized, double-blind phase 3 trial.
First Author: Xichun Hu, MD, PhD
- Board 216 **Abstract 1102:** Should CDK4/6 inhibitor plus endocrine therapy be standard of care for ER-low (1–10%) HR+/HER2– metastatic breast cancer? A multicenter registry cohort.
First Author: Kelvin K.H. Bao, FRCR, MBBChir, MA
- Board 217 **Abstract 1103:** Optimizing denosumab treatment strategies to balance skeletal-related events for prevention and osteonecrosis of the jaw risk in metastatic breast cancer patients: A Korean nationwide target trial emulation.
First Author: Ji Eun Lee, MD
- Board 218 **Abstract 1104:** Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: A retrospective analysis from two large university breast cancer centers.
First Author: Nikolas Tauber, MD
- Board 219 **Abstract 1105:** Final results of a phase II study of utidelone capsule, the first solid oral microtubule stabilizer, in metastatic breast cancer patients.
First Author: Binghe Xu, MD, PhD
- Board 220 **Abstract 1106:** ADAPT-T-DXd: Multi-institutional real-world study of dose-adapted trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
First Author: Minakshi Roy, DNB
- Board 221 **Abstract 1107:** Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
First Author: Saranya Chumsri, MD
- Board 222 **Abstract 1108:** Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
First Author: Chaitali Nangia, MD
- Board 223 **Abstract 1109:** Health-related quality of life.
First Author: Erinne Wasalski, PhD, MSHS
- Board 224 **Abstract 1110:** Potential BMI-dependent overall survival differences in postmenopausal breast cancer patients treated with CDK4/6 inhibitors: A Mayo Clinic platform study.
First Author: Chenyu Sun, MD, MSc, MMed
- Board 225 **Abstract 1111:** Baseline circulating tumor cells and association with early resistance in patients with metastatic breast cancer undergoing palbociclib therapy.
First Author: Qiang Zhang, MD, PhD
- Board 226 **Abstract 1112:** Prognostic impact of digitally quantified tumor-infiltrating lymphocytes in HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors.
First Author: Yeon Gil Jeong, MD
- Board 227 **Abstract 1113:** Analysis of information received and perceived by patients with metastatic breast cancer: Results of the Croyances et Réalités 3 French survey.
First Author: Claudia Lefevre-Plesse
- Board 228 **Abstract 1114:** Data-driven precision prognostic stratification in breast cancer leptomeningeal metastasis: The BC-LGPA model and treatment refinement.
First Author: Jian Zhang, MD
- Board 229 **Abstract 1115:** Clinicopathologic features, treatment patterns, and outcomes in young women with metastatic breast cancer: A National Cancer Database analysis.
First Author: Cher Ying Foo, MD
- Board 230 **Abstract 1116:** Temporal changes in mortality among adults with breast cancer and diabetes mellitus in the United States.
First Author: Sufia Ahmed, MBBS
- Board 231 **Abstract 1117:** Real-world analysis of the association between new-onset depression and outcomes in metastatic breast cancer.
First Author: Tornike Zabakhidze, MD
- Board 232 **Abstract 1118:** Breast cancer incidence and mortality in LGBTQ+ populations compared with cisgender heterosexual individuals: A comparative epidemiologic synthesis.
First Author: Manas Pustake, MD
- Board 233 **Abstract 1119:** The role of FOXM1 in regulating immune memory in triple-negative breast cancer and targeting FOXM1 to develop a therapeutic vaccine.
First Author: Jian Huang, BS
- Board 234 **Abstract 1120:** Rare histologic subtypes of triple-negative breast cancer: The impact of immunotherapy on outcomes for metastatic disease.
First Author: Jincong Q. Freeman, MPH, MS
- Board 235 **Abstract 1121:** Homologous recombination deficiency signature (HRDsig+) in older women with advanced breast cancer (ABC).
First Author: Tamar Kaminski, MD
- Board 236 **Abstract 1122:** AI-driven H&E plasma cell to predict pathological complete response in IO-treated triple-negative breast cancer (Yale; NCT02489448).
First Author: Amritpal Singh, MBBS, MS
- Board 237 **Abstract 1123:** JSKN016, a first-in-class anti-TROP2/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study.
First Author: Herui Yao, MD, PhD
- Board 238 **Abstract 1124:** Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.
First Author: Aleksandra Konieczna, MD
- Board 239 **Abstract 1125:** Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).
First Author: Shipra Gandhi, MD, MS
- Board 240 **Abstract 1126:** Single cell spatial profiling for identification of organ-specific immune features in the peritumoral microenvironment of triple-negative breast cancer with liver metastases.
First Author: Jin Sun Bitar, MD

- Board 241 **Abstract 1127:** Trends in immunotherapy use and survival outcomes by metastatic pattern in metastatic triple-negative breast cancer.
First Author: Michael Schwartz, MS
- Board 243 **Abstract 1129:** Long-term responders to sacituzumab govitecan in metastatic triple-negative breast cancer: Real-world outcomes and predictors from a multicenter Italian cohort.
First Author: Roberta Caputo, MD
- Board 245 **Abstract 1131:** Progression-free survival as a surrogate endpoint for overall survival in metastatic triple-negative breast cancer: A systematic review and meta-analysis.
First Author: Yashasvi Srivastava, MD
- Board 246 **Abstract 1132:** Measuring KEYNOTE-522 response from TNBC patient biopsies ex vivo using the E-slice assay.
First Author: Kyuson Yun, PhD
- Board 247 **Abstract 1133:** Determinants of triplenegative breast cancer among African patients: Early results from The African Cancer Atlas.
First Author: Emmanuella Amoako, MD
- Board 248 **Abstract 1134:** Immune infiltration features relative to cancer cell clumps as predictors of survival in triple-negative breast cancer.
First Author: Himangi Srivastava
- Board 249 **Abstract 1135:** Impact of protein-energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis.
First Author: Vaishali Deenadayalan, MD
- Board 250 **Abstract 1136:** Leveraging single-cell trajectory analysis and machine learning to build a robust prognostic classifier for triple-negative breast cancer to pinpoint CCDC171 as a master regulator.
First Author: Jialiang Feng, BCh
- Board 251 **Abstract 1137:** VISTA: Targeted combination immunotherapy for suppression of breast cancer metastasis and recurrence.
First Author: James Stuart Garner, MD
- Board 252 **Abstract 1138:** Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states.
First Author: Elyse R. Lopez, MD
- Board 254 **Abstract 1140:** Sequence of similar-payload ADCs: Does it make sense in real-world HER2-low advanced breast cancer?—The Portuguese national study.
First Author: Gonçalo Fernandes, MD
- Board 255 **Abstract 1141:** Clinical impact and temporal evolution of mutational signatures in metastatic lobular breast cancer.
First Author: Sherry Shen, MD
- Board 256 **Abstract 1142:** Phase II study of olaparib plus ATR inhibitor ceralasertib in patients with metastatic breast cancer and germline BRCA1/2 pathogenic variants who progressed on prior PARP inhibitor therapy.
First Author: Banu Arun, MD, FASCO
- Board 257a **Abstract TPS1143:** A phase II study evaluating treatment discontinuation of dual anti-HER2 therapy in metastatic HER2-positive breast cancer after five years of sustained complete response (FREEDOME-trial).
First Author: Albert Grinshpun, MD, MSc
- Board 257b **Abstract TPS1144:** A phase 1b/2 study of QLS1304, a novel, highly potent, and selective dual inhibitor of KAT6A/6B, plus endocrine therapy (ET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC).
First Author: Jiong Wu, MD, PhD
- Board 258a **Abstract TPS1145:** TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).
First Author: Diana Bello Roufai, MD, MSc
- Board 258b **Abstract TPS1146:** HER2-positive central nervous system (CNS) surveillance: A study of the feasibility of randomizing women and men with HER2-positive metastatic breast cancer to CNS surveillance versus no surveillance.
First Author: Talvinder Bhogal, MBChB
- Board 259a **Abstract TPS1147:** A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.
First Author: Stefania Morganti, MD
- Board 259b **Abstract TPS1148:** ReDiscover-2, a phase 3 study of zovogalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic *PIK3CA*-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
First Author: Hope S. Rugo, MD, FASCO
- Board 260a **Abstract TPS1149:** HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician's choice in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) unresectable locally advanced or metastatic breast cancer.
First Author: Barbara Pistilli, MD
- Board 260b **Abstract TPS1150:** Camizestrant plus ribociclib in hormone receptor-positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial.
First Author: Javier Cortes, MD, PhD
- Board 261a **Abstract TPS1151:** A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2- breast cancer.
First Author: Rafael Grochot, MD, MSc
- Board 261b **Abstract TPS1152:** OPERA-02: A phase 3 study of palaezestrant plus ribociclib as first-line treatment of ER+, HER2- advanced breast cancer.
First Author: Sara M. Tolaney, MD, MPH, FASCO

- Board 262a **Abstract TPS1153:** ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
First Author: Aditya Bardia, MD, MPH, FASCO
- Board 262b **Abstract TPS1154:** ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with *ESR1*-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
First Author: Antonio Llombart-Cussac, MD, PhD
- Board 263a **Abstract TPS1155:** ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2- breast cancer.
First Author: Nuhad K. Ibrahim, MD
- Board 263b **Abstract TPS1156:** CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)-positive breast cancer (TBCRC 070).
First Author: Kristina Fanucci, MD
- Board 264a **Abstract TPS1157:** AVATAR: Efficacy of personalized tumorogram-based therapy in breast cancer established from patient-derived organoids.
First Author: Luc Cabel, MD, PhD
- Board 264b **Abstract TPS1158:** Exploratory analysis of prognostic value of ctDNA monitoring among advanced breast cancer with oligometastatic disease: An ancillary biomarker study of JCOG 2110 (JCOG2110A1).
First Author: Takahiro Kogawa, MD, PhD
- Board 265a **Abstract TPS1159:** Phase II single-arm trial of low-dose capecitabine in patients with advanced breast cancer.
First Author: Humaira Sarfraz, MD, MBBS
- Board 265b **Abstract TPS1160:** Phase III trial of brain MRI surveillance in stage IV breast cancer.
First Author: Kamran A. Ahmed, MD
- Board 266a **Abstract TPS1161:** Evaluation of the safety and efficacy of TRC003 in metastatic triple-negative breast cancer: A prospective, open-label, multicenter, single-arm exploratory clinical trial.
First Author: Xiaorong Sun, MD
- Board 266b **Abstract TPS1162:** TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
First Author: Tiffany A. Traina, MD, FASCO
- Board 267a **Abstract TPS1163:** A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1-positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.
First Author: Kazuki Nozawa, MD

- Board 267b **Abstract TPS1164:** Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.
First Author: Adriana Matutino Kahn, MD, MHS
- Board 268a **Abstract TPS1165:** Phase IIa, open-label, multicenter study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399).
First Author: Mark Robson, MD, FASCO
- Board 268b **Abstract TPS1166:** IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)-positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC).
First Author: Jason A. Mouabbi, MD

1:30 PM-4:30 PM Poster Session

Central Nervous System Tumors

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 383-384

Brain Metastases: Board(s) 385-400, 457a-457b

Outcomes/Quality: Board(s) 401-405

Primary CNS Tumors—Glioma: Board(s) 406-450, 458a-464a

Primary CNS Tumors—Non-Glioma: Board(s) 451-456

- Board 383 **Abstract 2018:** Scaling deep learning for neuro-oncology: Knowledge-distilled EfficientNetB0 powered MRI classification of brain tumors with international expert validation.
First Author: Sophia Ahmed, MBBS
- Board 384 **Abstract 2019:** Enabling hybrid AI—radiologist endpoints in clinical trials imaging workflows.
First Author: Bharath Ramakrishna, PhD, MBA
- Board 385 **Abstract 2020:** Impact of genomic subtype on intracranial outcomes in treatment-naïve *EGFR*-mutant NSCLC with osimertinib (IGNITE).
First Author: Emily Wo, PharmD
- Board 386 **Abstract 2021:** Burden of mortality due to brain metastases secondary to lung cancer in the United States: A population-based study.
First Author: Dhivya Bharathi Govindaraj, MD
- Board 387 **Abstract 2022:** Risk of developing brain/central nervous system (CNS) metastases across multiple *ERBB2*-altered cancer types: Genotype as shaper of phenotype.
First Author: Aditya V. Shreenivas, MD, MS
- Board 388 **Abstract 2023:** AI-assisted prediction of radiation failure patterns and survival after stereotactic radiosurgery for brain metastases: A multicenter study.
First Author: Yuming Jiang, MD, PhD, MMed
- Board 389 **Abstract 2024:** Preclinical activity of homoharringtonine against melanoma leptomeningeal disease using patient-derived tumor cells.
First Author: Vincent Law

- Board 390 **Abstract 2025:** The impact of various radiation therapy options on plasminogen activation markers in the blood of patients with metastatic brain lesions.
First Author: Irina A. Goroshinskaya, PhD
- Board 391 **Abstract 2026:** Cerebrospinal fluid biomarker profiling in patients with non-small cell lung cancer and leptomeningeal disease.
First Author: Mark Yungjie Jeng, MD, PhD
- Board 392 **Abstract 2027:** Preclinical efficacy and brain uptake of an insulin-mediated nanoparticle co-delivering trastuzumab and pertuzumab (AxS007) in HER2+ breast cancer brain metastasis models.
First Author: Ayelet Zafran
- Board 393 **Abstract 2028:** Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
First Author: Atulya Aman Khosla, MD
- Board 394 **Abstract 2029:** Low-density lipoprotein receptor-related protein 1 overexpression as an identifier of brain metastasis and survival for patients with lung cancer.
First Author: Wendi Mo
- Board 395 **Abstract 2030:** Neoantigen prediction and reactivity of cerebrospinal fluid-human-derived tumor reactive T cells (CSF-TRT cells) in leptomeningeal disease (LMD) from solid tumors.
First Author: Yolanda Pina, MD
- Board 396 **Abstract 2031:** Intracranial pharmacokinetics and resistance mechanisms of tucatinib in patients with HER2+/mutant solid tumors and brain metastasis: Results from the WinHER2 study (NCT05892068).
First Author: Emanuela Ferraro, MD
- Board 397 **Abstract 2032:** Genomic correlates of leptomeningeal disease after brain metastasis resection.
First Author: Roshal R. Patel, MD
- Board 398 **Abstract 2033:** Distinct genomic and microenvironmental profiles of brain metastases in renal cell carcinoma: Insights into hypoxia-driven adaptation and therapeutic vulnerabilities.
First Author: Jorge Avila, MD
- Board 400 **Abstract 2035:** Central nervous system metastases in hereditary breast cancer according to germline pathogenic variants: A real-world cohort study.
First Author: Eduarda Mirela Da Silva Montiel, MD
- Board 401 **Abstract 2036:** Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
First Author: Atulya Aman Khosla, MD
- Board 402 **Abstract 2037:** Intrathecal (IT) therapy-associated pseudoprogression (PsP) in leptomeningeal metastases (LM) from solid tumors.
First Author: Zhenyu Pan, MD, PhD
- Board 403 **Abstract 2038:** Outcomes of CD-19-directed CAR-T therapy in patients with primary and secondary central nervous system lymphoma: A multi-center observational study.
First Author: Shilajeet Ray
- Board 404 **Abstract 2039:** The association of economic measures and patient outcomes with geographical disparities in access to a UCNS board-certified neuro-oncologist in the United States.
First Author: Maksym Horiachok
- Board 405 **Abstract 2040:** Use of knowledge-distilled EfficientNet to enable rapid, scalable glioma diagnosis.
First Author: Gowrishankar Palaniswamy, MD, MBBS
- Board 406 **Abstract 2041:** Phase 1, first-in-human (FIH) study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors.
First Author: Maria Vieito, MD
- Board 407 **Abstract 2042:** Initial analysis of adoptive neoantigen-specific T-cell immunotherapy for MGMT-unmethylated glioblastoma (TVI-AST-008): Signals amid control arm attrition.
First Author: Tolga Tuncer, MD
- Board 408 **Abstract 2043:** Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.
First Author: Wolfgang Wick, MD
- Board 409 **Abstract 2044:** Tumor treating fields therapy in patients with newly diagnosed glioblastoma and poor performance status: Real-world analysis of patients treated in the US.
First Author: Omar H. Butt, MD, PhD
- Board 410 **Abstract 2045:** Beyond survival: Longitudinal prognostication in glioblastoma using conditional survival—A population-based study.
First Author: Obuli Srinivasan Gurunathan, MD
- Board 411 **Abstract 2046:** A phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood).
First Author: Wenbin Li, MBBCh, BM
- Board 412 **Abstract 2047:** Interrupting HEG1/Cx43 interaction to promote cuproptosis via inhibiting gap junction to overcome glioblastoma radioresistance.
First Author: Lanlan Guo
- Board 414 **Abstract 2049:** Histopathology-verified comparison of FET PET and contrast-enhanced MRI for tumor visualization in glioblastoma.
First Author: Roman Stuerzl
- Board 415 **Abstract 2050:** Caregiver professional employment and its impact on glioblastoma patient survival: Results from two prospective studies.
First Author: Vincenzo Di Nunno, MD
- Board 416 **Abstract 2051:** Expression patterns of circulating microRNAs in classification models: New opportunities in brain tumor diagnosis.
First Author: Dmitry Yu. Gvaldin
- Board 417 **Abstract 2052:** Global validation of a brain cancer liquid biopsy.
First Author: James Munro Cameron, PhD
- Board 418 **Abstract 2053:** Genomic determinants of radiation necrosis in diffuse glioma patients.
First Author: Michael Kienhöfer, MD

Monday, June 1, 2026

- Board 419 **Abstract 2054:** Direct oral anticoagulants versus low-molecular-weight heparin for venous thromboembolism in primary brain tumors: A TriNetX real-world analysis.
First Author: Medina Esenbekova, MD
- Board 421 **Abstract 2056:** Development of human B7H3/IL13Ra2 bispecific armored CAR-T for treatment of glioblastoma.
First Author: Keming Zhang, MD, MSc
- Board 422 **Abstract 2057:** Which treatment is best? A systematic review and Bayesian network meta-analysis of adjuvant treatments for low-grade glioma.
First Author: Amit Kumar Chowdhry, MD, PhD
- Board 423 **Abstract 2058:** Characterization of contemporary practice patterns in the management of *IDH*-mutant glioma: A multidisciplinary multi-institutional survey.
First Author: Luis Nicolas Gonzalez Castro, MD, PhD
- Board 424 **Abstract 2059:** Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial.
First Author: Bryan D. Choi, MD, PhD
- Board 425 **Abstract 2060:** Real-world outcomes from 3D-PREDICT glioma chemosensitivity testing of primary CNS tumors.
First Author: Aidan Jones
- Board 426 **Abstract 2061:** Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: A prospective phase II clinical study.
First Author: Cheng-Cheng Guo
- Board 427 **Abstract 2062:** An alternative approach to limiting surgical and radiation stress in patients with glioblastoma.
First Author: Eduard E. Rostorguev
- Board 428 **Abstract 2063:** Management of first recurrence from *IDH*-wildtype glioblastoma with re-resection or stereotactic radiosurgery: A retrospective, international, multicenter study.
First Author: Nico Teske, MD, DSc, MS
- Board 429 **Abstract 2064:** Phase II trial evaluating nivolumab in patients with recurrent *IDH*-mutant gliomas with and without hypermutation phenotype.
First Author: Jing Wu, MD, PhD
- Board 430 **Abstract 2065:** A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂ combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.
First Author: Samuel A. Goldlust, MD
- Board 431 **Abstract 2066:** Mapping the exhausted and tolerized myeloid populations in the glioblastoma tumor microenvironment.
First Author: Yu-Ting Tsai, PhD
- Board 432 **Abstract 2067:** A 3D tumorwide multi-omic atlas of intratumoral heterogeneity in *IDH*-mutant glioma.
First Author: Benjamin Joshua Lerman, MD, MS
- Board 433 **Abstract 2068:** Identification of prognostically relevant residual tumor burden in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs [¹⁸F]FET PET.
First Author: Jens Blobner
- Board 434 **Abstract 2069:** Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas.
First Author: Matthias Holdhoff, MD, PhD
- Board 435 **Abstract 2070:** Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma.
First Author: Nicholas Alfred Blondin, MD
- Board 436 **Abstract 2071:** Suicide gene therapy for recurrent glioblastoma using allogeneic bone marrow-derived mesenchymal stem cell gene delivery (MSC/CD): A first-in-human, dose-escalation phase I clinical trial.
First Author: Jaejoon Lim
- Board 437 **Abstract 2072:** Intrathecal iPSC-derived natural killer cells combined with the Stupp regimen for newly diagnosed WHO grade 4 glioma: A phase I trial.
First Author: Yulun Huang, MD
- Board 438 **Abstract 2073:** Comparative response assessment using PET-RANO 1.0 and RANO 2.0 in vorasidenib-treated *IDH*-mutant gliomas: The VORAFET study.
First Author: Alberto Bosio
- Board 439 **Abstract 2074:** Phase II clinical study of ACT001 combined with radiotherapy in newly diagnosed pediatric diffuse intrinsic pontine glioma.
First Author: Jing Zhang
- Board 440 **Abstract 2075:** Application of PET RANO 1.0 criteria and associations with outcome in *IDH*-mutant gliomas: A retrospective cohort study.
First Author: Maximilian Mair, MD, PhD
- Board 441 **Abstract 2076:** Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.
First Author: Jay-Jiguang Zhu, MD, PhD
- Board 442 **Abstract 2077:** INB-200: Phase I study and characterization of gene-modified autologous gamma delta ($\gamma\delta$) T cells in newly diagnosed glioblastoma multiforme (GBM).
First Author: Louis B. Nabors, MD
- Board 443 **Abstract 2078:** Regorafenib in recurrent glioblastoma: Real-world outcomes from a Colombian cohort (REGOMA-COL).
First Author: Javier Jacobo, MD
- Board 444 **Abstract 2079:** Lucicebtide (ST101) plus chemoradiation in newly diagnosed GBM patients: Efficacy, pharmacodynamics, and safety from phase 2 window-of-opportunity study.
First Author: Fabio M. Iwamoto, MD
- Board 445 **Abstract 2080:** Tumor recurrence or treatment effect? Large multi-institutional evaluation of an AI risk assessment model in glioma and brain metastases.
First Author: Dheerendranath Battalapalli

- Board 446 **Abstract 2081:** Decision support for treatment of patients with glioblastoma: A systems biology approach enabled by explainable AI.
First Author: Thomas D. Brown, MD, MBA
- Board 447 **Abstract 2082:** Germline HLA class II diversity as a predictor of survival selectively in MHC-silenced gliomas.
First Author: Om H. Gandhi, MS
- Board 448 **Abstract 2083:** Knowledge distillation for glioma diagnosis: ResNet-based deep learning for WHO grade stratification with real-world deployment optimization.
First Author: Sravani Bhavanam, MBBS
- Board 449 **Abstract 2084:** Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.
First Author: Amirhossein Zare
- Board 450 **Abstract 2085:** Gene-treatment interaction modeling to identify temozolomide-sensitive *IDH*-mutant diffuse gliomas.
First Author: Seyed Reza Salarikia
- Board 451 **Abstract 2086:** Preclinical evaluation of intrathecal TRP1-targeted CAR T cells: Effects on durable antitumor immunity in melanoma leptomeningeal disease.
First Author: Peter A.J. Forsyth, MD
- Board 452 **Abstract 2087:** Efficacy of high-dose chemotherapy in adult patients with relapsed or refractory medulloblastoma.
First Author: Nurlan Mammadzada, MD
- Board 453 **Abstract 2088:** Molecular characterization of WHO grade II atypical meningioma using the AACR Project GENIE database.
First Author: Aden V. Chudziak
- Board 454 **Abstract 2089:** Long term outcomes of central neurocytoma in a multi-institutional cohort: The role of radiotherapy and Ki-67.
First Author: Yufan Yang
- Board 455 **Abstract 2090:** Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [¹⁷⁷Lu]Lu-DOTA-TATE and [⁶⁸Ga]Ga-DOTA-TATE in adults with advanced intracranial meningioma.
First Author: Sylvia Christine Kurz, MD, PhD
- Board 456 **Abstract 2091:** Long-term outcomes of CNS lymphoma patients treated with glucarpidase.
First Author: Lauren Webb
- Board 457b **Abstract TPS2093:** Phase I trial of trastuzumab deruxtecan in combination with stereotactic radiosurgery for brain metastases from HER2-positive breast cancer.
First Author: Zouina Sarfraz, MBBS
- Board 458a **Abstract TPS2094:** Randomized phase 2 trial of ruxolitinib in combination with radiation and temozolomide compared to radiation and temozolomide for newly diagnosed glioblastoma.
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 458b **Abstract TPS2095:** CLARITY-GBM: A phase II, multi-centered, open-label, single-arm study to evaluate the safety and efficacy of cetuximab and lomustine (CCNU) in adult patients with recurrent high-grade glioblastoma.
First Author: Zoya Peelay, PhD
- Board 459a **Abstract TPS2096:** TTFIELDS with maintenance temozolomide (TMZ) and pembrolizumab versus TTFIELDS with maintenance TMZ and placebo for newly diagnosed glioblastoma: The phase 3 EF-41/KEYNOTE D58 trial.
First Author: David D. Tran, MD, PhD
- Board 459b **Abstract TPS2097:** Resection and intracranial implant of (Z)-*n*-butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial.
First Author: Clark C. Chen
- Board 460a **Abstract TPS2098:** Randomized phase 2 study to evaluate the efficacy and safety of silevetinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma.
First Author: Patrick Y. Wen, MD
- Board 460b **Abstract TPS2099:** Targeting macrophage migration inhibitory factor: A phase 2 and pharmacodynamic study of sitagliptin in patients with progressive grade 4 gliomas.
First Author: David M. Peereboom, MD
- Board 461a **Abstract TPS2100:** A trial to evaluate CSF ctDNA and safety of plicorafenib alone or with retifanlimab in patients with BRAF-altered glioma.
First Author: Karisa C. Schreck, MD, PhD
- Board 461b **Abstract TPS2101:** Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy.
First Author: Seema Nagpal, MD
- Board 462a **Abstract TPS2102:** Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.
First Author: Nader Sanai, MD
- Board 462b **Abstract TPS2103:** Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in *IDH*-mutated newly diagnosed grade 3 astrocytoma (VORTEX).
First Author: Ugonma Nnenna Chukwueke, MD, MPH
- Board 463a **Abstract TPS2104:** A phase 3 randomized trial comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 diffuse gliomas in adults.
First Author: Nandini Sharrel Menon, MD, DNB, MBBS
- Board 463b **Abstract TPS2105:** BRIDGES: A phase 3 randomized trial of immediate postoperative cesium131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma (NCT07195591).
First Author: Clark C. Chen, MD, PhD

Board 464a **Abstract TPS2106:** Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE).
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO

1:30 PM-4:30 PM Poster Session

Pediatric Oncology

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 269

Leukemia/Lymphoma: Board(s) 271-272

Multiple Cancer Types: Board(s) 273-275

Outcomes/Quality: Board(s) 276

Pediatric Solid Tumors: Board(s) 277-295, 308a-308b

Survivorship: Board(s) 296-302

Symptom Management/Supportive Care/Palliative Care:
Board(s) 303-307

Board 269 **Abstract 10018:** Integrating genomics, imaging, and clinical data for late-onset cardiomyopathy prediction in pediatric cancer survivors: A multi-modal machine-learning comparison using St. Jude Cloud.
First Author: Masab Mansoor, MBA

Board 271 **Abstract 10020:** Longitudinal genomic characterization of pediatric acute myeloid leukemia at diagnosis and relapse.
First Author: Jagdish Prasad Meena, MD

Board 272 **Abstract 10021:** Distinct immunologic vs progenitor landscapes in myeloid leukemia recurrence: Adaptive immune persistence in pediatrics vs niche exhaustion in adults.
First Author: Karen Dong-Tran, MD

Board 273 **Abstract 10022:** The burden of childhood cancers in the South Asian Association for Regional Cooperation (SAARC) region: A GLOBOCAN 2022 analysis.
First Author: Tara Pattilachan Menon, BS

Board 274 **Abstract 10023:** A capacity assessment of pediatric oncology research biorepositories across a regional collaborative group in the Middle East, North Africa, and Asia.
First Author: Sushmitha Grama Srinivasan, MBBS

Board 275 **Abstract 10024:** Cancer outcome among adolescents in Canada.
First Author: Samuel Sassine, MD, MSc

Board 276 **Abstract 10025:** Beyond translation: Leveraging interpreter expertise to enhance clinician training and language equity in pediatric oncology.
First Author: Joseph S. Kang, BS

Board 277 **Abstract 10026:** Immunogenicity profiles in pediatric extra-cranial rhabdoid tumors: A framework for future risk stratification.
First Author: Omnia Al Qadi, MD, MBBS

Board 278 **Abstract 10027:** Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE in pediatric, adolescent, and young adult neuroendocrine tumors: A single-center experience from Bambino Gesù Children's Hospital.
First Author: Maria Debora De Pasquale, MD, PhD

Board 279 **Abstract 10028:** Clinical impact of panel-based next-generation sequencing in a real-world cohort of neuroblastoma patients.
First Author: Samantha Martin, MD

Board 280 **Abstract 10029:** Results of a phase II trial of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-deficient cancers.
First Author: Suzanne J. Forrest, MD

Board 281 **Abstract 10030:** Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS).
First Author: Michael W. Bishop, MD, MS

Board 282 **Abstract 10031:** Long term effects of treatment with dabrafenib (D) and/or trametinib (T) in pediatric patients with MAPK pathway-activated tumors.
First Author: Eric Bouffet, MD, FRCPC

Board 283 **Abstract 10032:** Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium.
First Author: Emanuela Palmerini, MD, PhD

Board 284 **Abstract 10033:** Association of response with survival in patients with relapsed/refractory high-risk neuroblastoma: A report from NANT Consortium.
First Author: Michael Migotsky, MD

Board 285 **Abstract 10034:** HopeMove: Feasibility and acceptability of a mobile exercise app for pediatric patients undergoing cancer treatment.
First Author: Rejin Kebudi, MD

Board 286 **Abstract 10035:** Concurrent RNA- and DNA-NGS testing for the detection of clinically-relevant fusions in pediatric solid-tumor patients.
First Author: Lisa Gai, DPhil

Board 287 **Abstract 10036:** Precision oncology in practice: Real-world multicenter experience with larotrectinib in pediatric extracranial NTRK fusion-positive tumors.
First Author: Rejin Kebudi, MD

Board 288 **Abstract 10037:** Dinutuximab beta in combination with chemotherapy in patients with refractory or relapsed neuroblastoma: A national prospective study (2020/ABM/01/00055).
First Author: Aleksandra Wieczorek, MD, PhD

Board 289 **Abstract 10038:** A study of the safety, efficacy, and pharmacokinetics of SPJ-101CA as maintenance therapy for newly diagnosed high-risk neuroblastoma.
First Author: Atsushi Makimoto

Board 290 **Abstract 10039:** Phase I study of the LiViT regimen (liposomal irinotecan, vincristine, and temozolomide) in pediatric patients with relapsed/refractory solid tumors.
First Author: Feifei Sun, MD

Board 291 **Abstract 10040:** Changes in the incidence of second malignant neoplasms in neuroblastoma over time: An updated SEER database analysis.
First Author: Arhanti Sadanand, MD

- Board 292 **Abstract 10041:** Interrogation of fibrolamellar cancer to provide clinically relevant insights into therapeutic vulnerabilities.
First Author: Sabina A. Schneider
- Board 293 **Abstract 10042:** Prognostic significance of CD8+T lymphocytes and CD68+ macrophages in assessing pathologic response in pediatric soft tissue sarcomas.
First Author: Djamila Polatova, PhD
- Board 294 **Abstract 10043:** Utilization and outcomes of minimally invasive resection in patients with neuroblastoma and Wilms tumor in a national cohort.
First Author: Courtney N. Day
- Board 295 **Abstract 10044:** Impact of central review process on response rates in neuroblastoma clinical trials: A report from NANT Consortium.
First Author: Michael Migotsky, MD
- Board 296 **Abstract 10045:** Evaluating satisfactory testing versus transcript grade performance between childhood cancer survivors and healthy controls.
First Author: Raymond Mailhot Mailhot Vega, MD
- Board 297 **Abstract 10046:** Neurosensory deficits and functional outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).
First Author: Chiara Papini, PhD, MPH
- Board 298 **Abstract 10047:** Comparison of different metrics for estimating kidney radiation exposure during treatment for childhood cancer: A report from the St. Jude Lifetime Cohort Study.
First Author: Daniel M. Green, MD
- Board 299 **Abstract 10048:** Opportunities for breast cancer prevention among pediatric lymphoma survivors treated with chest radiation: Projected gap in breast cancer deaths with real-world uptake rates.
First Author: Jenna R. Rogers, BS
- Board 300 **Abstract 10049:** Early-onset chronic and metabolic morbidity among survivors of childhood acute lymphoblastic leukemia: Evidence from Middle Eastern real-world data.
First Author: Samah Hayek, DrPH
- Board 301 **Abstract 10050:** Symptom-based individual risk prediction for late mortality: A report from the Childhood Cancer Survivor Study study (CCSS).
First Author: Elyse Zhang, PhD
- Board 302 **Abstract 10051:** Perceptions of Medicaid coverage and care experiences among long-term survivors of childhood cancer: Qualitative interviews from the Childhood Cancer Survivor study (CCSS).
First Author: Xu Ji, PhD
- Board 303 **Abstract 10052:** Effects of delayed sodium thiosulfate on cisplatin-induced ototoxicity in pediatric and adolescent patients with cancer: Results from the Japanese Children's Cancer Group STS-J01 study.
First Author: Eiso Hiyama, MD, PhD
- Board 304 **Abstract 10053:** Olanzapine for weight gain in children undergoing chemotherapy for solid-organ malignancies: An investigator-initiated, open-label, multicenter, phase III randomized controlled trial (SNOWMAN).
First Author: Shubham Sahni, MD, MBBS
- Board 305 **Abstract 10054:** Neuropsychiatric symptom and biomarker changes with electroacupuncture in adolescent and young adult (AYA) cancer survivors: Results from a randomized controlled trial.
First Author: Alexandre Chan, PharmD, BCOP, FCCP, MPH
- Board 306 **Abstract 10055:** Barriers and enablers to pediatric palliative care integration in low- and middle-income countries: A systematic review and meta-synthesis.
First Author: Mohd Faizan Siddiqui, MD, PhD
- Board 307 **Abstract 10056:** Development and early implementation of a statewide comprehensive childhood cancer network to support pediatric oncology care and research.
First Author: Chris Hagemeyer, PhD
- Board 308a **Abstract TPS10057:** A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma.
First Author: Emily K. Slotkin, MD
- Board 308b **Abstract TPS10058:** Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.
First Author: Samantha Martin, MD
-
- 1:30 PM-4:30 PM Poster Session**
Prevention, Risk Reduction, and Genetics
Location: Hall A—Posters and Exhibits
- Posters by Topic**
Cancer Prevention, Risk Reduction, and Early Detection: Board(s) 479-543, 589a-591a
Etiology/Epidemiology of Cancer Risk and Development: Board(s) 544-563
Germline Genetic Risk Evaluation: Board(s) 564-575
Hereditary Cancer Syndromes: Board(s) 576-582
Modifiable/Behavioral Risk Factors: Board(s) 583-588
- Board 479 **Abstract 10518:** Global development and validation of the Lung Cancer Prevention Score (LCPS): A quantitative framework linking policy strength, incidence, and outcomes across 40 countries.
First Author: Adarsh Vardhan Tangella, MBBS
- Board 480 **Abstract 10519:** Family cancer history and perceived value of multi-cancer early detection tests in a national U.S. sample.
First Author: Chinenye Egwuonwu, MD, MPH
- Board 481 **Abstract 10520:** GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety.
First Author: Nico-al Paolo Gotera, MPH, DO
- Board 482 **Abstract 10521:** A SEER-based Joinpoint analysis investigating the effect of shared decision-making on prostate cancer stage at diagnosis.
First Author: Noah Ritschard, BS

- Board 483 **Abstract 10522:** Glucagon-like peptide-1 receptor agonist for primary prevention of hepatocellular carcinoma in high-risk patients: A real-world analysis across metabolic, viral, alcoholic, and hereditary liver disease.
First Author: Colton Jones, MD
- Board 484 **Abstract 10523:** Integrating multi-cancer early detection into cancer screening programs in the United States: A cost-effectiveness modeling study.
First Author: Shuaipeng Geng, MSc
- Board 485 **Abstract 10524:** Time-restricted eating and metformin (TEAM) in invasive breast cancer or DCIS: A randomized, phase IIb, window-of-opportunity presurgical trial.
First Author: Parijatham S. Thomas, MD
- Board 486 **Abstract 10525:** Cost-effective colorectal cancer screening in the United States: Comparative analyses of four molecular tests.
First Author: Yinyin Chang, MSc
- Board 487 **Abstract 10526:** Using digital screening to increase early identification of hereditary breast and ovarian cancer syndrome: A multicenter cluster-randomized trial.
First Author: Dorothee Speiser
- Board 488 **Abstract 10527:** Incorporating CA19-9 testing in a prospective study of pancreatic cancer surveillance (PCS) among high-risk individuals (HRIs).
First Author: Asaf Maoz, MD
- Board 489 **Abstract 10528:** Correlates of patient enrollment in a population-based randomized controlled trial of cascade genetic testing in families with hereditary cancer susceptibility.
First Author: Steven J. Katz, MD, MPH
- Board 490 **Abstract 10529:** Clinical characteristics and risk factors of individuals ineligible for lung cancer screening at a tertiary care center.
First Author: Julian A. Marin-Acevedo, MD
- Board 491 **Abstract 10530:** Disparities in cancer screening across disease sites for transgender and gender-diverse patients.
First Author: Peter James Stanfield, BA
- Board 492 **Abstract 10531:** Development and validation of a multidimensional cfDNA assay for cancer detection and tissue-of-origin prediction.
First Author: Hua Bao, PhD
- Board 493 **Abstract 10532:** Implementation of a multi-cancer early detection (MCED) test in a private practice: Adoption, performance, and repeat-testing patterns.
First Author: Eric Sue
- Board 494 **Abstract 10533:** Generalizable cancer detection from ultra-low-pass whole-genome sequencing of cell-free DNA using a sequentially fine-tuned transformer framework.
First Author: Rui Liu, MSc
- Board 495 **Abstract 10534:** Beyond detection: Five-year screening behaviors and patient-reported perceptions in DETECT-A participants.
First Author: Tomasz M. Beer, MD
- Board 496 **Abstract 10535:** Evaluation of a novel blood-based lung cancer screening test in elevated-risk subjects.
First Author: Dawn R. Mattoon, PhD
- Board 497 **Abstract 10536:** Next-generation multi-cancer early detection (MCED) assay: Independent blinded validation of a locked serum multi-omics NMR test with stage I sensitivity.
First Author: Patrick C. Strasser, MSc
- Board 498 **Abstract 10537:** Precision risk stratification for lung cancer in COPD: Evidence from the All of Us Program.
First Author: Muhammad Rafiqul Islam, MD, MBBS, FACP, MSPH
- Board 499 **Abstract 10538:** Impact of AI-based risk stratification integrating routine laboratory data with age on screening volume and multi-cancer early detection yield.
First Author: Mao Mao, MD, PhD
- Board 500 **Abstract 10539:** Machine learning–optimized multi-biomarker panel for discriminating lung cancer from LDCT-positive benign pulmonary nodules.
First Author: Sungjoon Park, MD
- Board 501 **Abstract 10540:** Association of high postoperative physical activity with ctDNA MRD positivity and recurrence-free survival across solid tumors: The SCRUM-MONSTAR LIFELOG study.
First Author: Shugo Yajima, MD
- Board 502 **Abstract 10541:** The PROFOUND study: A large-scale prospective multicenter case-control trial of a multi-cancer early detection (MCED) test in China.
First Author: Kezhong Chen, MD
- Board 503 **Abstract 10542:** Prospective evaluation of the psychological impact of multicancer early detection (MCED) blood testing: A smartphone-based patient-reported outcomes study.
First Author: Ronan Joseph Kelly, MD, MBA, FASCO
- Board 504 **Abstract 10543:** Performance of a cfDNA methylation–based MCED test in patients with clinicoradiologic suspicion of cancer.
First Author: Elie Massaad, MD, MSc
- Board 505 **Abstract 10544:** A phase II open-label, single-arm study to evaluate the efficacy of pembrolizumab for leukoplakia.
First Author: Maria Antonia Velez Velez, MD, MS
- Board 506 **Abstract 10545:** Risk prediction models for familial breast cancer: A Cochrane systematic review and meta-analysis.
First Author: Sarah A. McGarrigle, PhD
- Board 507 **Abstract 10546:** Evaluating the impact of the 2021 USPSTF age expansion (50–54 years) on racial disparities in early-stage lung cancer diagnosis.
First Author: Shubhangi Sharma, MBBS
- Board 508 **Abstract 10547:** Evaluation of a novel blood-based lung nodule triage test in elevated-risk subjects.
First Author: Dawn R. Mattoon, PhD
- Board 509 **Abstract 10548:** GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.
First Author: Zunairah Shah, MD
- Board 510 **Abstract 10549:** Evaluation of intervention strategies to improve follow-up after FIT/FOBT tests: A systematic review and meta-analysis.
First Author: Wei Yu Chua, MBBS

- Board 511 **Abstract 10550:** Contemporary trends in early-stage non–small cell lung cancer diagnosis and disparities, 2018–2022.
First Author: Ahmed Minhas, MD
- Board 512 **Abstract 10551:** Oncoseek 2.0: An updated blood-based assay for multi-cancer early detection.
First Author: Shiyong Li
- Board 513 **Abstract 10552:** A Korea–USA multicenter study of duodenal pancreatic fluid–derived exosomal CES1 and MAN2A1 as pancreas-proximal biomarkers for early pancreatic cancer detection.
First Author: Do Hyun Park, MD, PhD
- Board 514 **Abstract 10553:** Clinical outcomes and cumulative cost of preventive surveillance versus treatment in Li–Fraumeni syndrome: Results from the European PREVENTABLE project.
First Author: Marion Rolain Jr
- Board 515 **Abstract 10554:** Prenatal hormonal imprinting reflected by anogenital distance and risk of breast cancer: A case-control study of 839 women.
First Author: Domingo Antonio Sánchez Martínez Sr, PhD
- Board 516 **Abstract 10555:** K-ACCELERATE: A multi-center prospective trial to evaluate the utility of a ctDNA-based assay for accelerating multi-cancer diagnosis among high-risk symptomatic participants.
First Author: Le Son Tran, PhD
- Board 517 **Abstract 10556:** Association of clonal hematopoiesis driven by mosaic chromosomal alterations with epigenetic age in the PLCO trial.
First Author: Corey Young, PhD, MS
- Board 518 **Abstract 10557:** Use of multiplex digital profiling of DNA methylation heterogeneity to enable sensitive early detection of non–small cell lung cancer from low-volume liquid biopsies.
First Author: Christine O’Hersey, PhD
- Board 519 **Abstract 10558:** Development of an oncology generative AI foundation model trained on more than a million longitudinal patient journeys across the United States.
First Author: Wilson Lau, PhD
- Board 520 **Abstract 10559:** Clinical impact of GLP-1 receptor agonist use on lung cancer incidence in high-risk patients: A real-world analysis.
First Author: Ariana N. Neely, MD
- Board 522 **Abstract 10561:** Multimodal risk phenotyping of early-onset colorectal cancer.
First Author: Azza Sarfraz, MBBS
- Board 523 **Abstract 10562:** Evidence of clonal stability in a 5-year longitudinal prospective cohort of cancer survivors with serial NGS analysis.
First Author: Anmol Goyal, MD
- Board 524 **Abstract 10563:** Mammography utilization and male breast cancer in BRCA1/2 carriers.
First Author: Meredith Davies
- Board 525 **Abstract 10564:** Refining breast cancer risk stratification for selection of women at intermediate to high risk for supplemental MRI screening using artificial intelligence.
First Author: Eun Kyung Park, MD, PhD
- Board 526 **Abstract 10565:** Real-world experiences with a multi-cancer detection (MCD) blood test.
First Author: Julius Chiang-Boeckmann
- Board 527 **Abstract 10566:** Spatial organization of immune surveillance by germline mutation status in the Breast Cancer Family Registry.
First Author: Marni Blair McClure, MD, PhD
- Board 528 **Abstract 10567:** Quantifying the macroeconomic burden of tobacco-attributable cancers in 2023: Global disparities in value-of-lost-welfare (VLW) in 189 countries.
First Author: Mansha Gupta, MD, MBBS
- Board 529 **Abstract 10568:** Effect of breast density reporting on supplemental MRI and ultrasound use.
First Author: Gianna Aliberti, MD
- Board 530 **Abstract 10569:** Circulating cadherin17 (CA17) in blood as a diagnostic biomarker for gastric cancer.
First Author: Tsz Chun Hon, MMedSc
- Board 531 **Abstract 10570:** Transdermal drug delivery to the normal and the radiated breast: Determinants of individual variation in skin permeation.
First Author: Natalie Pulliam, MS
- Board 533 **Abstract 10572:** Embedding germline genetic testing into African oncology care: Early results from the Genetic Cancer Families (GenCAF) program.
First Author: Sulin Wu, MD, PhD
- Board 534 **Abstract 10573:** Missed by the guidelines: A meta-analysis of USPSTF lung cancer screening ineligibility among patients diagnosed with lung cancer.
First Author: Khalid Ahmad Qidwai
- Board 535 **Abstract 10574:** Reproducible modulation of tissue Ki-67 across lung and prostate cancer interception trials.
First Author: Sri Pranita Cherukuri, MPH
- Board 536 **Abstract 10575:** Elevated red blood cell distribution width-to-albumin ratio and incident cancer risk: A prospective cohort study.
First Author: Parham Habibzadeh, MD, MS
- Board 537 **Abstract 10576:** Pancreatic cancer incidence and survival in lean and obese adults with type 2 diabetes: A propensity matched analysis.
First Author: Vasu Bansal, MBBS
- Board 538 **Abstract 10577:** Diagnostic accuracy of blood-based cfDNA fragmentomic assays for lung cancer detection: A meta-analysis of clinically validated cohorts.
First Author: Khalid Ahmad Qidwai
- Board 539 **Abstract 10578:** Enterprise-wide implementation of multicancer detection testing across a large academic health system.
First Author: Aditya Kumar Ghosh, MD
- Board 540 **Abstract 10579:** Structural disparities in early-onset colorectal cancer mortality: A national county-level analysis.
First Author: Varshini Odayar, MS
- Board 541 **Abstract 10580:** Quantifying the macroeconomic burden of cancer: Global disparities in value-of-lost-welfare (VLW).
First Author: Sai Varun Gadde, MBBS

- Board 542 **Abstract 10581:** Multimodal profiling of STIC lesions to identify precursor states with genomic features of high grade serous ovarian cancer.
First Author: Duaa Al-Rawi, MD, PhD
- Board 543 **Abstract 10582:** Texture and color enhancement imaging (TXI) for polyp detection in colorectal neoplasia screening: A meta-analysis of randomized controlled trials.
First Author: Haroon Alamy, MD
- Board 544 **Abstract 10583:** GLP-1 receptor agonist therapy and cancer risk and mortality in patients with moderate CKD: A national matched cohort study of 58,000 patients.
First Author: Muneeb Asad, BS
- Board 545 **Abstract 10584:** Non-random patterns of multiple primary malignancies in the era of cancer survival.
First Author: Thomas George, MBBS
- Board 546 **Abstract 10585:** Differential risk patterns of secondary breast cancer in medullary versus papillary thyroid carcinoma survivors: A SEER-based analysis.
First Author: Li Liu, MB, MS
- Board 547 **Abstract 10586:** Association of prior SARS-CoV-2 infection with advanced cancer presentation in newly diagnosed solid tumors: A real-world data analysis.
First Author: Anushreddy Muddasani, MD
- Board 548 **Abstract 10587:** Distinct immunogenomic features of cancers arising in solid organ transplant recipients.
First Author: Shyfuiddin Ahmed, PhD
- Board 549 **Abstract 10588:** PCSK9 inhibitors and association with lower risk of metastasis.
First Author: Gin Yi Lee, MD
- Board 550 **Abstract 10589:** The effects of the COVID-19 pandemic on cancer incidence and cancer-specific mortality.
First Author: Reba Dhillon, DO
- Board 551 **Abstract 10590:** Association of SGLT2 inhibitors and GLP-1 receptor agonists or DPP-4 inhibitors with incident cancer in patients with type 2 diabetes.
First Author: Nikitha Vobugari, MD, MBBS
- Board 552 **Abstract 10591:** Predictors of EGFR-mutant primary lung adenocarcinoma.
First Author: Lauren Kriger Groner
- Board 553 **Abstract 10592:** Association of sociodemographic, environmental, and health factors with early-onset cancer in a diverse urban cohort.
First Author: Devon Kathleen Dietrich, BA
- Board 554 **Abstract 10593:** Racial differences in clinical, genomic, and survival outcomes in colorectal cancer.
First Author: Nour Maher Mustafa, MD
- Board 555 **Abstract 10594:** Progestin-only implant and breast cancer risk in adolescents and premenopausal women: A systematic review and meta-analysis.
First Author: Angela Theresa Zuffo Yabrude, MD
- Board 556 **Abstract 10595:** Endocrine therapy non-adherence and recurrence risk in patients with breast cancer and major depressive disorder.
First Author: Maya Aboumrad, PhD, MPH
- Board 557 **Abstract 10596:** Hair relaxer use and breast cancer risk by tumor molecular subtypes.
First Author: Kaitlin White, BS
- Board 558 **Abstract 10597:** Prevalence of oral and genital HPV-45 and non-vaccine-targeted HPV-35 among U.S. adults.
First Author: Morgan C. Byrd, PhD, MPH
- Board 559 **Abstract 10598:** Genome-wide association and Mendelian randomization analyses of body mass index and breast cancer risk in women of African ancestry.
First Author: Wenji Guo, MD, DPhil
- Board 560 **Abstract 10599:** Genetic correlation and causal associations between metabolic traits and lung cancer risk.
First Author: Knightess Oyibo
- Board 561 **Abstract 10600:** Lung cancer incidence and PM2.5: Evaluating the association with varying spatial scales and durations of exposure estimates.
First Author: George Carey, MD
- Board 562 **Abstract 10601:** Quantifying equal-producing and beta-glucuronidating gut bacteria in breast cancer using 16S rDNA sequencing methods.
First Author: Kathryn Zamiela, MS
- Board 563 **Abstract 10602:** Early lessons from the implementation of a pan-African clinico-genomic cancer platform: The African Cancer Atlas.
First Author: Emmanuella Amoako, MD
- Board 564 **Abstract 10603:** Variants of uncertain significance and contralateral risk-reducing mastectomy in early-stage breast cancer across safety-net and private hospital settings.
First Author: Vineeth Kommidi, MD
- Board 565 **Abstract 10604:** A pilot study of a digital, patient-directed consent process for MSK-IMPACT tumor-normal genetic testing in gynecologic cancer.
First Author: Varshini Gali, MD
- Board 566 **Abstract 10605:** Germline testing in Asian American and Pacific Islander women with breast cancer.
First Author: Jennifer Tseng, MD
- Board 567 **Abstract 10606:** Impact of germline BRCA pathogenic or likely pathogenic variants on fertility potential and reproductive outcomes in young women with breast cancer: A systematic review and meta-analysis.
First Author: Luca Arecco, MD
- Board 568 **Abstract 10607:** Longitudinal follow-up after identification of variants of uncertain significance in highly penetrant cancer predisposition genes.
First Author: Bridget Kiely, MD
- Board 569 **Abstract 10608:** Intensity of chemotherapy regimens for patients with Lynch syndrome and colorectal cancer.
First Author: Christine M. Veenstra, MD, MS
- Board 570 **Abstract 10609:** Clinical implementation of an online family cascade genetic testing platform: The Preventive Risk Outreach and Cascade Testing (PROACT) initiative.
First Author: Jennifer Lee Caswell-Jin, MD

- Board 571 **Abstract 10610:** Initial findings from the PROMISE Registry, a US decentralized, prospective prostate cancer genetic registry.
First Author: Heather H. Cheng, MD, PhD
- Board 572 **Abstract 10611:** Actionable germline findings in endometrial cancer from a large multigene panel tested cohort.
First Author: Adela Rodriguez Hernandez, MD
- Board 573 **Abstract 10612:** Expanded germline genetic testing of patients with hematologic malignancies to identify high proportion with hereditary cancer predisposition.
First Author: Ozge Ceyhan-Birsoy
- Board 574 **Abstract 10613:** Prevalence of microsatellite stable Lynch syndrome and universal germline testing: A pan-cancer analysis of 246,694 patients.
First Author: Casey Cosgrove, MD
- Board 575 **Abstract 10614:** Spectrum of germline pathogenic and novel BRCA1 and BRCA2 gene mutations in a cohort of 1780 breast and ovarian carcinoma patients from east India.
First Author: Amit Roy Chowdhury, PhD, MSc
- Board 576 **Abstract 10615:** Association of thymic epithelial tumors (TETs) with Lynch syndrome (LS) per germline genetic testing and molecular tumor analysis.
First Author: Megan Dwyer
- Board 577 **Abstract 10616:** Population-based analysis of cancer disparities and social determinants of health in hereditary cancer syndrome carriers: A Healthy Nevada Project study.
First Author: Haley Nadone, MD
- Board 578 **Abstract 10617:** Evidence supporting *RPS20* as a colorectal cancer susceptibility gene from a case-control MGPT study.
First Author: Sarah Nielsen Young, MS, CGC
- Board 579 **Abstract 10618:** Feasibility of a novel oncologist-led diagnostic algorithm for Lynch syndrome in colorectal cancer patients: The ItaLynch study.
First Author: Alberto Puccini, MD
- Board 580 **Abstract 10619:** A randomized controlled trial of a multilingual digital genetic cancer risk assessment tool in a diverse patient population.
First Author: Tina Karimaghaie, BA
- Board 581 **Abstract 10620:** Age-stratified evaluation of subsequent primary malignancy risk in patients with primary Lynch syndrome—spectrum cancers.
First Author: Vinit Singh, MBBS
- Board 582 **Abstract 10621:** Prevalence, tumor characteristics, and clinical impact of LZTR1 pathogenic variants in a large, pan-cancer cohort.
First Author: Anushri Soni, MBBS
- Board 583 **Abstract 10622:** Diabetes risk reduction diet and mortality outcomes following breast cancer diagnosis in Black women.
First Author: Lawrence Deng, BS
- Board 584 **Abstract 10623:** Leisure-time physical activity among US cancer survivors, 2020-2024.
First Author: Ruixuan Wang, PhD, MPP
- Board 585 **Abstract 10624:** Alcohol-related hospitalizations among patients with cancer in the United States: Trends and associated risk factors.
First Author: Anna Mehlich, MD
- Board 586 **Abstract 10625:** Association of proton pump inhibitor use with cancer-specific mortality in a nationally representative U.S. cohort (NHANES, 1999–2018).
First Author: Albine Djeagou F., MD
- Board 587 **Abstract 10626:** The impact of high body-mass index on cancer mortality in the United States: An emerging public health challenge.
First Author: Charbel Fadi Matar, MD
- Board 588 **Abstract 10627:** Oxybutynin for vasomotor symptoms across cancer-related and menopause-associated settings: A systematic review and meta-analysis of randomised control trials and observational studies.
First Author: Arundhati Sharma
- Board 589a **Abstract TPS10628:** CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.
First Author: Gregory Idos, MD, MS
- Board 589b **Abstract TPS10629:** Cancer recognition and assessment through non-invasive evaluation (CRANE): A prospective clinical validation study of a multi-biomarker class multi-cancer early detection (MCED) test in Japan.
First Author: Takeaki Yamazaki
- Board 590a **Abstract TPS10630:** BRCA-P: Can denosumab reduce breast cancer risk in *BRCA1* mutation carriers?
First Author: Christian F. Singer, MD, MPH
- Board 590b **Abstract TPS10631:** Lung cancer screening for early detection of suspicious lung nodules in Latin America (LUCAS-LATAM).
First Author: Luis Corrales, MD
- Board 591a **Abstract TPS10632:** SOLAR: A post-approval study evaluating longitudinal performance of a blood-based test for screening individuals at average risk for colorectal cancer (CRC).
First Author: Sam Asgarian, MD, MBA

1:30 PM-4:30 PM Poster Session

Sarcoma

Location: Hall A—Posters and Exhibits

Posters by Topic

Artificial Intelligence: Board(s) 311-312

Bone Tumors: Board(s) 313-322, 376a-376b

Gastrointestinal Stromal Tumors (GIST): Board(s) 323-329, 377a-377b

Molecular Targets/Biomarkers/Tumor Biology: Board(s) 330-340, 378a-378b

Outcomes/Quality: Board(s) 341-347

Soft Tissue Tumors: Board(s) 348-375, 379a-382b

- Board 311 **Abstract 11521:** Feasibility of constructing an external control arm for early efficacy assessment in phase 1a: Methodological framework from the INVOKE trial.
First Author: Nicolas Loiseau, MSc
- Board 312 **Abstract 11522:** AI-assisted systematic review and pooled analysis of anthracycline- versus taxane-based chemotherapy in advanced or metastatic angiosarcoma.
First Author: Annarita Peddio
- Board 313 **Abstract 11523:** Efficacy and safety of continuous intra-arterial cisplatin and recombinant human endostatin combined with systemic chemotherapy in osteosarcoma: A phase II study.
First Author: Hongtao Li, MD
- Board 314 **Abstract 11524:** ICONIC (Improving Outcomes Through Collaboration in Osteosarcoma): Insights from a national prospective cohort trial for newly diagnosed osteosarcoma patients.
First Author: Sandra J. Strauss, MD, PhD
- Board 315 **Abstract 11525:** Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.
First Author: Hui Li
- Board 316 **Abstract 11526:** Efficacy and safety of perioperative anlotinib combined with cisplatin and doxorubicin in treatment-naive stage IIB classic osteosarcoma of the extremity: Updated results from the ALTER-S002 trial.
First Author: Minxun Lu
- Board 317 **Abstract 11527:** A phase 2 trial of cetuximab for patients with locally advanced/metastatic chordoma.
First Author: Anthony Paul Conley, MD
- Board 318 **Abstract 11528:** Genomic characterization of conventional, dedifferentiated, and mesenchymal chondrosarcoma: A 550-patient multicenter analysis.
First Author: Luyuan Li, MD, PhD
- Board 319 **Abstract 11529:** Low-dose apatinib combination with first-line chemotherapy rechallenge in advanced osteosarcoma: A single-center ambispective cohort study.
First Author: Jing Chen, MD, PhD
- Board 320 **Abstract 11530:** First-in-human dose escalation trial of an engineered salmonella delivering L-methioninase in advanced bone and soft tissue sarcomas.
First Author: Hongtao Li, MD
- Board 322 **Abstract 11532:** Efficacy and safety of DR4/DR5 agonist aponermin monotherapy in advanced chondrosarcoma: Preliminary report from a prospective, multicenter study.
First Author: Mengxiang Sun
- Board 323 **Abstract 11533:** Benefit of adjuvant therapy in high-risk GIST: A large-scale real-world analysis of 2,166 patients (DEEPSARC study).
First Author: Nicolas Penel, MD, PhD, MBA
- Board 324 **Abstract 11534:** Standard-dose ripretinib plus sunitinib versus ripretinib dose escalation in advanced GIST after progression on four prior therapies: Preliminary results of a multicenter cohort study.
First Author: Hao Xu, MD
- Board 325 **Abstract 11535:** Oncologic equivalence of brand-name vs generic imatinib in neoadjuvant *KIT* exon 11 GIST: A real-world international cohort study.
First Author: Tannaz Ranjbarian
- Board 326 **Abstract 11536:** Artificial intelligence–based predictive models for recurrence and recurrence-free survival in gastrointestinal stromal tumors: A contemporary systematic review.
First Author: Elizaveta Bodrova, MD
- Board 327 **Abstract 11537:** Ripretinib as preoperative therapy in patients with potentially resectable advanced gastrointestinal stromal tumors after imatinib failure: Final analysis of a prospective, multicenter study.
First Author: Linxi Yang
- Board 328 **Abstract 11538:** Clinical characteristics and outcomes of germline and sporadic NF1-associated gastrointestinal stromal tumors: Insights from a real-world patient registry.
First Author: Denisse Evans, MS
- Board 329 **Abstract 11539:** Updated clinical and translational results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)–deficient tumors.
First Author: Haibo Qiu, MD, PhD
- Board 330 **Abstract 11540:** Circulating tumor DNA monitoring for early detection of disease recurrence in bone/soft tissue sarcoma.
First Author: Maggie Yuxi Zhou, MD
- Board 331 **Abstract 11541:** Cell proliferation, immune cell infiltration, and survival outcomes in sarcomas with high cancer-associated fibroblast expression.
First Author: Olivia Martin
- Board 332 **Abstract 11542:** Myxoid/round cell liposarcoma misdiagnosis incidence, etiology, and importance of NY-ESO-1 testing: Retrospective analysis of the Tempus database.
First Author: Michael Jason Nathenson, MD
- Board 333 **Abstract 11543:** Synovial sarcoma misdiagnosis and potential utility of NGS testing patient identification for autologous T cell therapy: Retrospective analysis of Tempus database.
First Author: Michael Jason Nathenson, MD
- Board 334 **Abstract 11544:** Ultra-sensitive whole-genome sequencing–based molecular residual disease detection in resectable sarcoma in MONSTAR-SCREEN-3.
First Author: Toru Wakamatsu, MD, PhD
- Board 335 **Abstract 11545:** Identification of checkpoint inhibitor resistance mechanisms in leiomyosarcoma through enrichment of active chromatin-associated cell-free DNA.
First Author: Carlos Diego Holanda Lopes, MD
- Board 336 **Abstract 11546:** Prognostic biomarkers in retroperitoneal dedifferentiated liposarcoma and their clinical impact on patient management.
First Author: Ilaria Tortorelli, MD, PhD

- Board 337 **Abstract 11547:** Unsupervised clustering of RNA-Seq data to identify molecular subtypes of sarcomas.
First Author: Michael J. Robinson, MD, MSCI
- Board 338 **Abstract 11548:** A subset analysis of clinical activity and pharmacodynamic biomarkers in patients with sarcomas in the phase 1 dose-escalation study of STC-15, a METTL3 inhibitor.
First Author: Justin C. Moser, MD
- Board 339 **Abstract 11549:** Use of subtype-specific patterns of clinically relevant antibody–drug conjugate targets in sarcoma to guide precision oncology strategies.
First Author: Sohil Reddy
- Board 340 **Abstract 11550:** Distinct prognostic roles of *IDH* mutation and high-risk genomic alterations in patients with primary chondrosarcoma.
First Author: Akshee Batra, MBBS
- Board 341 **Abstract 11551:** Survival outcomes of cabozantinib treatment with and without immune checkpoint inhibition in patients with heavily pretreated advanced sarcoma.
First Author: Lauren Li
- Board 342 **Abstract 11552:** Phase 2 study integrating early palliative care in advanced sarcoma patients for enhanced quality of life (SARQUALITY Trial: NCT06805669): An interim analysis.
First Author: Catherine S. Weadick, MRCP, MBBCh, MSc
- Board 343 **Abstract 11553:** Impact of concomitant medications on immune checkpoint inhibitor outcomes in sarcoma.
First Author: Adel Shahnam, MD, MPH
- Board 344 **Abstract 11554:** Patient-reported global health to predict negative health outcomes in patients with advanced sarcoma.
First Author: Marium Husain, MD, MPH
- Board 345 **Abstract 11555:** Neoadjuvant versus adjuvant chemotherapy in cardiac tumor resection: A propensity-matched analysis of perioperative and long-term outcomes.
First Author: Fadi Abualhommos, MD
- Board 346 **Abstract 11556:** Impact of regorafenib treatment on overall survival (OS) in advanced sarcoma patients.
First Author: Clemence Leguillotte
- Board 347 **Abstract 11557:** Prevalence of post-traumatic stress disorder and associated factors among adult sarcoma patients.
First Author: Sang Minh Nguyen, MD, PhD
- Board 348 **Abstract 11558:** Enhanced local and systemic efficacy in refractory solid tumors via integrated intra-tumoral injection and radiotherapy: A study of the 'R-ISV-RO' modality.
First Author: Wang Xiaolu, MD
- Board 349 **Abstract 11559:** A phase II, multi-cohort study with pemetrexed plus cisplatin combination in patients with relapsed or refractory advanced soft tissue sarcoma: Leiomyosarcoma cohort (ALBATROSS-SARC-LMS01).
First Author: Hyo Song Kim, MD, PhD
- Board 350 **Abstract 11560:** Efficacy and safety results of tazemetostat in Japanese patients with advanced epithelioid sarcoma: The phase 2 TAZETTA trial (NCCH2107).
First Author: Kenji Tsuchihashi, MD, PhD
- Board 351 **Abstract 11561:** Neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma: Clinical outcomes and multi-omics analysis from a phase II study.
First Author: Wei Sun
- Board 352 **Abstract 11562:** Triplet combination of anlotinib plus nab-paclitaxel and gemcitabine (AG) as a first-line strategy for advanced primary cardiac angiosarcoma: A high-volume center experience.
First Author: Xi Guo
- Board 353 **Abstract 11563:** Outpatient rehabilitation for adults with soft tissue sarcoma: Examining real-world service utilization and outcomes.
First Author: Kelley C. Wood, PhD, MS
- Board 354 **Abstract 11564:** The investigator-initiated trial (IIT) of GO306 injection, a recombinant oncolytic vaccinia virus, in patients with advanced soft tissue sarcomas.
First Author: Qiujuan Zhang
- Board 355 **Abstract 11565:** Cardiac safety of aldorubicin compared to doxorubicin: Integrated results from two randomized studies in advanced soft tissue sarcoma.
First Author: Philip Sager
- Board 356 **Abstract 11566:** Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery: The NARIS trial for extremity soft tissue sarcoma.
First Author: Rutian Li, PhD
- Board 357 **Abstract 11567:** Effect of pamicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.
First Author: Gabriel Tinoco, MD
- Board 358 **Abstract 11568:** Longer-term safety of pamicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.
First Author: Hans Gelderblom, MD
- Board 359 **Abstract 11569:** Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma.
First Author: Amy E. Armstrong, MD
- Board 360 **Abstract 11570:** Outcomes of malignant peripheral nerve sheath tumors in neurofibromatosis type 1 and sporadic patients: A 25-year experience from a sarcoma referral center.
First Author: Clio Coste, MSc, BM
- Board 361 **Abstract 11571:** Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pamicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.
First Author: Vinod Ravi, MD

Monday, June 1, 2026

- Board 362 **Abstract 11572:** Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study. First Author: Javier Martin Broto, MD, PhD
- Board 363 **Abstract 11573:** Who really benefits from chemotherapy in high-risk localized soft tissue sarcoma? A virtual twin analysis of ISG-ST5 1001. First Author: Fahima Dossa, MD, PhD
- Board 364 **Abstract 11574:** Sintilimab (PD-1 antibody) plus gemcitabine and docetaxel (GT) as first-line or later-line therapy in patients with advanced epithelioid sarcoma: A prospective, multicenter, single-arm, phase II clinical study. First Author: Xiaowei Zhang
- Board 365 **Abstract 11575:** Preliminary results of pegylated liposomal doxorubicin, dacarbazine, and toripalimab in patients with advanced primary cardiac sarcoma: An interim analysis. First Author: Zhichao Tan, MD
- Board 366 **Abstract 11576:** Impact of modern systemic and multimodality treatments on post-relapse survival in retroperitoneal soft-tissue sarcoma: A digital-twin target trial emulation study. First Author: Roberta Sanfilippo, MD
- Board 367 **Abstract 11577:** Real-world outcomes of doxorubicin and paclitaxel in advanced Kaposi sarcoma: A TriNetX retrospective cohort study. First Author: Keun Lee, MD
- Board 368 **Abstract 11578:** Phase I trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with *TSC1/2* alterations: Preliminary results. First Author: Elise F. Nassif Haddad, MD, PhD, MS
- Board 369 **Abstract 11579:** Efficacy and safety analysis of intraoperative radiotherapy for soft tissue sarcoma: The largest-sample, single-center, real-world data review. First Author: Zhichao Liao Sr
- Board 370 **Abstract 11580:** Secondary genomic alterations and clinical outcomes in myxoid liposarcoma: A multi-institutional analysis. First Author: Daniel Reinhorn, MD
- Board 371 **Abstract 11581:** Integrating personalized ctDNA into clinical surveillance of soft tissue sarcoma: Performance, timing, and histologic insights. First Author: Amrit Paudel, MD
- Board 372 **Abstract 11582:** Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. First Author: Ajay Katwala
- Board 373 **Abstract 11583:** Investigating the molecular characteristics underlying desmoid tumor clinical trajectory. First Author: Robert Lawrence Dilley, MD, PhD
- Board 374 **Abstract 11584:** Phase II pilot study of pembrolizumab (PEM) and neoadjuvant radiation therapy (nRT) in high-risk soft tissue sarcomas (STS). First Author: Lee D. Cranmer, MD, PhD
- Board 375 **Abstract 11585:** Neoadjuvant versus adjuvant chemotherapy for resectable high-grade soft tissue sarcoma: A real-world propensity-matched survival analysis. First Author: Mohammed Aloqaily
- Board 376a **Abstract TPS11586:** A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER). First Author: Thomas Cash, MD, MSc
- Board 376b **Abstract TPS11587:** A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRR15-targeted ¹⁷⁷Lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma. First Author: Noah Federman, MD
- Board 377a **Abstract TPS11588:** StrateGIST 3: A randomized, phase 3 study of velzatinib (IDRX-42) versus sunitinib in patients with advanced gastrointestinal stromal tumors after imatinib therapy. First Author: Suzanne George, MD
- Board 377b **Abstract TPS11589:** Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure. First Author: Mark Agulnik, MD
- Board 378a **Abstract TPS11590:** Clinical feasibility of 68Ga-DOTATATE PET/CT to identify SSTR-positive soft tissue sarcoma for PRRT selection. First Author: Gabriel Tinoco, MD
- Board 378b **Abstract TPS11591:** SARC045: A phase 2 trial of tebentafusp in HLA-A*02:01-positive patients with advanced clear cell sarcoma. First Author: Andrea Napolitano, MD, PhD
- Board 379a **Abstract TPS11592:** SARC046: A phase II trial of nab-sirolimus in patients with progressing or symptomatic epithelioid hemangioendothelioma. First Author: Michael J. Wagner, MD
- Board 379b **Abstract TPS11593:** Investigator-initiated phase II trial of ABSK043, an oral PD-L1 inhibitor, in patients with angiogenic sarcoma. First Author: Changsu Lawrence Park, MD
- Board 380a **Abstract TPS11594:** A phase Ib/II study of mirdametinib in combination with palbociclib in patients with advanced dedifferentiated liposarcoma. First Author: Olayode Babatunde, MD
- Board 380b **Abstract TPS11595:** SATURN-ST5: Phase II study of neoadjuvant atezolizumab with doxorubicin, concurrent atezolizumab with pre-operative radiation therapy and adjuvant atezolizumab in patients with high-risk surgically resectable extremity and truncal soft tissue sarcoma. First Author: Ahsan Saleem Farooqi, MD, PhD

- Board 381a **Abstract TPS11596:** Maintenance pegylated liposomal doxorubicin (PLD) versus active surveillance for advanced soft tissue sarcoma patients who had controlled disease after standard anthracycline-based treatment (MELODY).
First Author: Tom Wei-Wu Chen, MD, PhD
- Board 381b **Abstract TPS11597:** STARS (NCT 07265661): Surgical timing after preoperative hypofractionated radiotherapy for patients with primary localized soft tissue sarcoma of the extremity and trunk—A randomized phase 2 clinical trial.
First Author: Marco Baia, MD
- Board 382a **Abstract TPS11598:** The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.
First Author: Sandra P. D'Angelo, MD
- Board 382b **Abstract TPS11599:** A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab, for advanced soft tissue sarcomas (NCT05876715).
First Author: Samantha Jeffrey, BS

3:00 PM-4:15 PM Education Session

ASCO/ECO Joint Session: Cancer Screening and Early Detection—New Approaches in a Changing Environment
Location: S100a

Eric J. Small, MD, FASCO—Chair
University of California San Francisco
Welcome and Introductory Remarks From ASCO President

Isabel Rubio—Chair
Clinica Universidad de Navarra
Welcome and Introductory Remarks From ECO President

Zainab Shinkafi-Bagudu, MBBS
Medicaid Cancer Foundation
Addressing Barriers to Implementing Global Cancer Screening

Tanja Spanic, PhD
Europa Donna Slovenia
Implementing Age-Specific Cancer Screening

Fabio Y. Moraes, MD, PhD
Kingston Health Sciences Centre
Adapting New Screening Technologies and Approaches to Maximize Global Impact

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Navigating a Successful Career in Academic Oncology: Strategies Throughout Your Many Chapters
Location: E350

Kristen A. Marrone, MD, FASCO—Chair
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Moderator/Fellowship Director

Brian Russell, MD
Beth Israel Deaconess Medical Center
Moderated Panel: Trainee Perspective

Gilberto Lopes, MD, MBA, FASCO

Sylvester Comprehensive Cancer Center, University of Miami
Miller School of Medicine
International Medical Graduate Perspective

Dineo Khabele, MD

Washington University in St. Louis School of Medicine
Senior Career Perspective: Gynecologic Oncologist
Panel Question and Answer

3:00 PM-4:15 PM Education Session

New Approaches in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia for Adolescent/Young Adult and Elderly Patients

Location: S504

Josep-Maria Ribera

Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute
Upfront Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Ali Bazarbachi, MD, PhD

American University of Beirut
Rethinking Transplant in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Nicholas James Short, MD—Chair

The University of Texas MD Anderson Cancer Center
Treatment of Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Panel Question and Answer

3:00 PM-4:30 PM Clinical Science Symposium

Making It Personal: Targeting Tumor Neoantigens

Location: Hall D2

Hatem Hussein Soliman, MD—Chair

Moffitt Cancer Center

Margaret E. Gatti-Mays, MD, MPH, FACP—Chair

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

3:00 PM To be determined

Making It Understandable: Shared Versus Personalized Vaccine Approaches

3:12 PM

Abstract 2509: An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.
First Author: Xinjing Wang, MD, PhD

3:24 PM

Abstract 2510: Synthetic lethality–informed neoantigen prioritisation to support mechanism-specific therapeutic strategies across human cancers.
First Author: Michael E. Bryan, BSc

3:36 PM

Elena Garraïda, MD, PhD
Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO)
Discussion of Abstract(s) 2509-2510: Making It Lethal: Exploiting Tumor Vulnerabilities

Monday, June 1, 2026

- 3:48 PM Abstract 2511:** Personalized neoantigen vaccine as adjuvant therapy in high-risk postoperative esophageal carcinoma.
First Author: Ming Wu, PhD
- 4:00 PM Mark Yarchoan, MD**
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Discussion of Abstract(s) 2511: Making It Promising: Overcoming Historic Resistance
- 4:12 PM Panel Question and Answer**

3:00 PM-4:30 PM Clinical Science Symposium

Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer

Location: Arie Crown Theater

Sophia C. Kamran, MD—Chair

Massachusetts General Hospital, Harvard Medical School

Andrei Iagaru, MD—Chair

Stanford University

- 3:00 PM To be determined**
Radioligand Revolutions: Where We Are Now and Where We Are Going
- 3:12 PM Abstract LBA5009:** Safety and dosimetry of ¹⁷⁷Lu-rosopitamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global study.
First Author: Pedro C. Barata, MD, MSc, FACP
- 3:24 PM Karolien Goffin, MD, PhD**
University Hospitals Leuven
Discussion of Abstract(s) LBA5009: Switching Gears: Tuning the Targeting Moiety of Prostate-Specific Membrane Antigen-Directed Targeted Radioligand Therapy
- 3:36 PM Abstract 5010:** AcTION: Phase 1 study of [²²⁵Ac]Ac-PSMA-617 (²²⁵Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [¹⁷⁷Lu]Lu-PSMA (¹⁷⁷Lu-PSMA) radioligand therapy (RLT).
First Author: Louise Emmett, MD, PhD, MBChB, FRACP
- 3:48 PM Abstract 5011:** CONVERGE-01 part 3: Ac-225 rosopitamab tetraxetan (CONV01-α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris, MD, FASCO
- 4:00 PM Jeremie Calais, MD, PhD**
University of California Los Angeles
Discussion of Abstract(s) 5010-5011: Moving Beyond Beta-Emitters: The Next-Generation Radioligand Therapies in Prostate Cancer
- 4:12 PM Panel Question and Answer**

3:00 PM-6:00 PM Oral Abstract Session

Care Delivery/Models of Care

Location: S100bc

Alejandro Recio, MD—Chair

The University of Arizona Cancer Center

Heather B. Neuman, MD—Chair

University of Wisconsin School of Medicine and Public Health

- 3:00 PM Abstract 1500:** Impact of access to effective post-progression therapies on survival outcomes in first-line randomized oncology trials.
First Author: João Pedro Apolinário, MD
- 3:12 PM Abstract 1501:** Expert validation of an artificial intelligence-enabled trial matching solution using real-world data from patients with cancer.
First Author: Jai Narendra Patel, PharmD
- 3:24 PM Abstract 1502:** Development and external validation of a computational approach for accelerated read out of randomized clinical trials in metastatic prostate cancer.
First Author: Ali Sabbagh, MD
- 3:36 PM Megan Othus, PhD**
Fred Hutch Cancer Center
Discussion of Abstract(s) 1500-1502: Enhancing Design, Conduct, and Analysis Across the Protocol Life Cycle in Clinical Trials
- 3:48 PM Panel Question and Answer**
- 4:00 PM Abstract 1503:** Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies.
First Author: Susanna Goggans Bowen, MD
- 4:12 PM Abstract 1504:** Outcomes of patients with cancer admitted to a dedicated oncology service within a multisite home hospital program.
First Author: Thomas J. Roberts, MD, MBA
- 4:24 PM Abstract 1505:** Impact of remote symptom monitoring on acute care utilization in phase I cancer patients: Secondary analysis of a randomized clinical trial.
First Author: Jack Stover, MD
- 4:36 PM Amy Iarrobino Laughlin, MD**
Orlando Health Cancer Institute
Discussion of Abstract(s) 1503-1505: Cancer Care at Home: Navigating Complexity and Utilization in Decentralized Care
- 4:48 PM Panel Question and Answer**
- 5:00 PM Abstract 1506:** Analysis of an oral anticancer repository program and the impact on access to care.
First Author: Allyson Waller, PharmD
- 5:12 PM Abstract 1507:** Follow-up of outpatients taking oral anticancer drugs in the multidisciplinary community hospital ONCORAL care plan.
First Author: Anissa Guillemin
- 5:24 PM Abstract 1508:** Essential but unaffordable: Real-world costs of WHO essential cancer medicines in a low-income setting.
First Author: Vivek Ghosh, MD
- 5:36 PM Bishal Gyawali, MD, PhD, FASCO**
Queen's University
Discussion of Abstract(s) 1506-1508: Access, Affordability, and Availability of Anticancer Drugs
- 5:48 PM Panel Question and Answer**

4:30 PM-6:00 PM Clinical Science Symposium

Accelerating Adoptive Cell Therapy in Melanoma: Are We Sold on Cells?

Location: E451

Ravi K. Amaravadi, MD—Chair
Abramson Cancer Center

Allison Betof, MD, PhD, FASCO—Chair
Stanford Cancer Center

- 4:30 PM** **Stephanie L. Goff, MD, FACS**
National Institutes of Health
The Evolution and Revolution of Tumor Infiltrating Lymphocyte Therapy
- 4:42 PM** **Marco Donia, MD, PhD**
National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital
TILs, CARs, and TCRs, Oh My! What Are the Types of Cell Therapy in Melanoma?
- 4:54 PM** **Abstract LBA9509:** A multicenter, randomized, controlled, open-label, phase II trial of autologous tumor-infiltrating lymphocytes (GC101 TIL) in patients with advanced melanoma.
First Author: Lu Si, MD, PhD
- 5:06 PM** **Abstract 9510:** Real-world safety of adoptive cellular therapy with lifileuceel in patients with advanced melanoma.
First Author: Alexandra Haugh, MD
- 5:18 PM** **Abstract 9511:** Immunologic determinants in procured melanoma tissue as drivers of durable response to tumor-infiltrating lymphocyte therapy.
First Author: Lilit Karapetyan, MD, MSc
- 5:30 PM** **Alexander Shoushtari, MD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) LBA9509-9511: How Can We Translate New Tumor-Infiltrating Lymphocyte Research Into Patient Benefit?
- 5:42 PM** *Panel Question and Answer*

4:30 PM-6:00 PM Rapid Oral Abstract Session

Head and Neck Cancer

Location: Hall D1

Jason Y.K. Chan, MBBS—Chair
The Chinese University of Hong Kong

Parth Anil Desai, MD, MBBS—Chair
Fox Chase Cancer Center

- 4:30 PM** **Abstract 6013:** Induction chemotherapy with nab-paclitaxel and cisplatin versus docetaxel, cisplatin, and fluorouracil followed by chemoradiotherapy in patients with stage III–IVA nasopharyngeal carcinoma: An open-label, noninferiority, randomized, controlled, phase 3 trial.
First Author: Xing Lyu, PhD
- 4:36 PM** **Abstract 6014:** Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study.
First Author: Kunyu Yang, PhD

- 4:42 PM** **Abstract 6015:** Timing of postoperative chemoradiotherapy and survival outcomes in high-risk locally advanced head and neck squamous cell carcinoma: A supplementary analysis of JCOG1008.
First Author: Yoshinori Imamura, MD, PhD
- 4:48 PM** *Panel Question and Answer*
- 5:00 PM** **Abstract 6016:** Phase II randomized trial of radiotherapy with pembrolizumab vs. cisplatin for unfavorable-risk p16+ head and neck squamous cell carcinoma (KEYCHAIN).
First Author: Loren K. Mell, MD
- 5:06 PM** **Abstract 6017:** Final analysis of the investigator-initiated randomized study of anti-PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
First Author: Anna Spreafico, MD, PhD
- 5:12 PM** **Abstract 6018:** Randomized phase I/II trial adjuvant CD40.HVAC, an immunotherapy engaging dendritic cells (DC), in patients with HPV16+ oropharyngeal carcinoma (OPC).
First Author: Caroline Even
- 5:18 PM** *Panel Question and Answer*
- 5:30 PM** **Abstract 6019:** Phase II study of izalontamab (SI-B001) in combination with paclitaxel or docetaxel in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Ye Guo, MD
- 5:36 PM** **Abstract 6020:** FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Guilherme Rabinowits, MD
- 5:42 PM** **Abstract 6021:** Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: Results of the phase 2 NAVIGATION study.
First Author: Makoto Tahara, MD, PhD
- 5:48 PM** *Panel Question and Answer*

4:45 PM-6:00 PM Education Session

Advancing Immune Checkpoint Inhibitor Therapy in High-Risk Populations

Location: E450a

Matteo S. Carlino, PhD, MBBS, FRACP—Chair
Melanoma Institute Australia

Rechallenging Immune Checkpoint Inhibitor After a Major Immune-Related Adverse Event

Ann W. Silk, MD

Dana-Farber Cancer Institute, Mass General Brigham Cancer
Role of Immune Checkpoint Inhibitors in Patients With Solid Organ Transplants

Matthew R. Zibelman, MD

Fox Chase Cancer Center
Optimizing Toxicity Management of Combination Immune Checkpoint Inhibitor Therapies

Panel Question and Answer

Monday, June 1, 2026

4:45 PM-6:00 PM Education Session

From Passion to Persistence: Nurturing Idealistic Roots to Extinguish Burnout

Location: E350

Sabe S. Sabesan, MBBS, FRCP—Chair

Townsville Cancer Care Centre

Sustaining the Calling: Preserving Idealism and Purpose in Oncology Practice

Fay J. Hlubocky, PhD, MA, FASCO

The University of Chicago

Fueling the Fire: Understanding Burnout and Other Work Traumas

Wendy Oldenmenger, PhD

Erasmus MC Cancer Institute

Battling the Blaze: Tools to Protect Joy and Combat Burnout

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Modern Management of Mantle Cell Lymphoma

Location: S102

Martin H. Dreyling, MD, PhD—Chair

Ludwig Maximilians University Hospital

Standard of Care for “Transplant Eligible” Mantle Cell Lymphoma

Anita Kumar, MD

Memorial Sloan Kettering Cancer Center

New Options for “Transplant Ineligible” Mantle Cell Lymphoma

Toby Andrew Eyre, MBChB, MRCP

Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust

Approach to Relapsed/Refractory Mantle Cell Lymphoma

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Optimizing Management of Non-Clear Cell Renal Cell Carcinoma: Focus on Papillary Renal Cell Carcinoma

Location: Arie Crown Theater

Ramaprasad Srinivasan, MD, PhD

National Cancer Institute, National Institutes of Health

Biology and Molecular Characteristics of Papillary Renal Cell Carcinoma

Arpita Desai, MD—Chair

UCSF Helen Diller Family Comprehensive Cancer Center

Subsequent Lines and Novel Therapeutic Approaches in Papillary Renal Cell Carcinoma

Charles B. Nguyen, MD

City of Hope Comprehensive Cancer Center

Frontline Treatment Strategies in Papillary Renal Cell Carcinoma

Panel Question and Answer

4:45 PM-6:00 PM Education Session

State of the Art: Updates in Supportive Care in Pediatric Oncology—Early Intervention to Prevent Long-Term Morbidities

Location: S504

Karen Cristly Burns, MD

Cincinnati Children’s Hospital Medical Center

Oncofertility, New Technology, and Benefits of Establishing a Formal Program

Etan Orgel, MD, MS—Chair

Children’s Hospital Los Angeles

Predicting and Preventing Platinum-Induced Hearing Loss in Pediatric Oncology

Lisa Kahalley, PhD

Baylor College of Medicine

Preserving Neurocognition After Cranial Radiation in Pediatric Oncology

Panel Question and Answer

4:45 PM-6:00 PM Education Session

The Exposome, Cancer Risk, and Cancer Care: Understanding the Environmental Impact on Malignancy

Location: S403

Robert Allan Hiatt, MD, PhD—Chair

University of California San Francisco

A New Threat: How the Environment Impacts Cancer Risk and Care

Jeff Burgess, MD, MS, MPH

University of Arizona

Mitigating Occupational and Environmental Toxic Exposure: A Risk Reduction Approach for First Responders

Leticia M. Nogueira, PhD, MPH

American Cancer Society

Food, Climate Change, and Cancer Care

Prashant Mathur

National Centre for Disease Informatics and Research

Environmental Causes of Cancer and Cancer Control in India

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Treatment Decisions After Neoadjuvant Therapy for Non–Small Cell Lung Cancer: Should Further Adjuvant Therapy be Administered?

Location: S100a

Tina Cascone, MD, PhD

The University of Texas MD Anderson Cancer Center

Perioperative Immunotherapy: Is More Always Better?

Jonathan Spicer, MD, PhD, FRCPC

McGill University Health Centre

Neoadjuvant-Only Immunotherapy: Enough to Achieve Cure?

José F. Corona-Cruz, MD—Chair

Instituto Nacional de Cancerología

Surgical Considerations in the Integration of Neoadjuvant and Perioperative Systemic Therapies

Panel Question and Answer

8:00 AM-9:15 AM Highlights Session

Highlights of the Year III

Location: Hall D1

Mariana Chavez Mac Gregor, MD, MSc, FASCO—Chair

The University of Texas MD Anderson Cancer Center

- 8:00 AM Kelsey Klute, MD**
University of Nebraska Medical Center
Highlights in Upper Gastrointestinal Cancer, Hepatobiliary, and Pancreas Cancers
- 8:15 AM Abdul Rafeh Naqash, MD, FASCO**
Stephenson Cancer Center at The University of Oklahoma Health Sciences Center
Highlights of the Year in Lung Cancer: From Data to Decisions in Integrating Advances in the Last One Year Into Practice
- 8:30 AM Matias Rodrigo Chacon, MD**
Alexander Fleming Institute
Highlights of the Year in Melanoma and Skin Cancer: Where Are We Going Next With New Immunotherapy and Targeted Therapy Strategies?
- 8:45 AM Sonali M. Smith, MD, FASCO**
University of Chicago
Highlights in Lymphoma
- 9:00 AM Michelle E. Melisko, MD**
University of California San Francisco
Highlights in Symptom Science and Palliative Care

8:00 AM-9:15 AM Education Session

Global Cancer Prevention: Current Approaches and Future Directions

Location: S102

Isabelle Soerjomataram—Chair

International Agency for Research on Cancer
Global Estimations of Cancer Attributable to Preventable Factors: Harnessing Data to Inform Prevention Policies

Karen Canfell, PhD, DPhil

Cancer Council NSW
Elimination of Vaccine-Preventable Cancers: Lessons From Global HPV-Prevention Strategies

Clement Adebamowo, MD, ScD, FASCO

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Evidence-Based Cancer Control in Africa: Advancing Prevention Through Research, Policy, and Capacity Building

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Navigating Treatment Decisions in Early-Stage Hormone Receptor–Positive Breast Cancer

Location: E450a

Erin Frances Cobain, MD

Michigan Medicine
ctDNA Surveillance in Early Breast Cancer: Handling Requests and Results

Kevin Kalinsky, MD, MS, FASCO—Chair

Winship Cancer Institute of Emory University
Genomic Scores in Node-Positive Premenopausal Disease: When to Test, How to Act

Eitan Amir, PhD, MBChB

Princess Margaret Cancer Centre
Treatment Decision-Making in Locally Advanced, Favorable Biology Breast Cancer

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Selecting Optimal Therapies for Chronic Lymphocytic Leukemia Across the Disease Spectrum: Worldwide Perspectives

Location: S100a

Anna Maria Frustaci, MD

Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda

Selecting the Best Frontline Therapy for Your Patient With Chronic Lymphocytic Leukemia

Michael J. Hallek, MD

University of Cologne, University Hospital Cologne and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf
Treatment in Second-Line Chronic Lymphocytic Leukemia: What Is the Best Sequencing Strategy?

Susan Mary O'Brien, MD—Chair

UCI Health Chao Family Comprehensive Cancer Center
Treatment Options for Double-Exposed Chronic Lymphocytic Leukemia

Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Gastrointestinal Cancer—Colorectal and Anal

Location: S100bc

Chloe E. Atreya, MD, PhD, FASCO—Chair

University of California San Francisco

Christopher G. Cann, MD—Chair

Vanderbilt University Medical Center

- 8:00 AM Abstract LBA3509:** A phase III, randomized, open-label study of tunlmetinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated *BRAF*^{V600E}-mutant metastatic colorectal cancer.
First Author: Ting Xu, MD
- 8:06 AM Abstract 3510:** Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.
First Author: Heinz-Josef Lenz, MD
- 8:12 AM Abstract 3511:** Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in *KRAS* G12C-mutated colorectal cancer (mCRC): Results from phase 3 CodeBreak 300.
First Author: Filippo Pietrantonio, MD
- 8:18 AM Panel Question and Answer**

- 8:30 AM Abstract 3512:** Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer. First Author: Ramon Salazar, MD, PhD
- 8:36 AM Abstract 3513:** Development of a computational histology artificial intelligence (CHAI)-powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT). First Author: Paolo Ciraci, MD
- 8:42 AM Abstract 3514:** Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases. First Author: Hangyu Zhang, MD
- 8:48 AM Panel Question and Answer**
- 9:00 AM Abstract 3516:** Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI). First Author: Hannah Ruth Robinson, MD
- 9:06 AM Panel Question and Answer**

9:45 AM-11:00 AM Education Session

Immunotherapy in Early-Stage Colorectal Cancer: Paradigm Shift in Cure and Nonoperative Management

Location: S102

Kai-Keen Shiu, PhD, FRCP

University College London Hospitals NHS Foundation Trust
Neoadjuvant vs Adjuvant Immunotherapy for Microsatellite Instability-High Colon Cancer

Stacey A. Cohen, MD

Fred Hutch Cancer Center, University of Washington
Is There a Role for Immunotherapy in Localized Microsatellite-Stable Colorectal Cancer?

Christopher Lieu, MD, FASCO—Chair

University of Colorado, Anschutz School of Medicine
Nonoperative Management After Neoadjuvant Immunotherapy in Microsatellite Instability-High Localized Colorectal Cancer—One Size Fits All?

Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: E451

Christos Vaklavas, MD—Chair

Huntsman Cancer Institute, University of Utah

Cynthia X. Ma, MD, PhD—Chair

Washington University School of Medicine

- 9:45 AM Abstract 3009:** Integrin $\alpha v\beta 3$ -targeted radionuclide therapy with ^{177}Lu -AB-3PRGD2 in multiple advanced metastatic solid tumors: A prospective, single-arm, single-center, investigator-initiated clinical trial. First Author: Hao Fu, PhD
- 9:51 AM Abstract 3010:** Phase Ib results from the phase Ib/II study of [^{177}Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer. First Author: Stephen V. Liu, MD
- 9:57 AM Abstract 3011:** An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors. First Author: Xueying Zhang, MD
- 10:03 AM Panel Question and Answer**
- 10:15 AM Abstract 3013:** First-in-human study of BG-C9074 (B7-H4-targeting ADC) in advanced solid tumors: Dose escalation and safety expansion. First Author: Binghe Xu, MD, PhD
- 10:21 AM Abstract 3014:** First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in *EGFR*-mutant (*EGFRm*) NSCLC. First Author: Xiuning Le, MD, PhD
- 10:27 AM Panel Question and Answer**
- 10:39 AM Abstract 3015:** Genomically personalized radiation dose de-escalation: A phase II basket radiation study in patients with pathogenic mutations in *ATM*. First Author: Amy Xu, MD, PhD
- 10:45 AM Abstract 3016:** A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data. First Author: Hong Jae Chon, MD, PhD
- 10:51 AM Abstract 3017:** Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial. First Author: Wenbin Li
- 10:57 AM Panel Question and Answer**

9:45 AM-12:45 PM Oral Abstract Session

Breast Cancer—Metastatic

Location: Hall D1

Bora Lim, MD—Chair

The University of Texas MD Anderson Cancer Center

Amy Sanders Clark, MD, MSCE—Chair

Abramson Cancer Center of the University of Pennsylvania

- 9:45 AM Abstract LBA1000:** Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro. First Author: Kevin Kalinsky, MD, MS, FASCO

- 9:57 AM Abstract 1001:** Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo).
First Author: Sara A. Hurvitz, MD, FACP
- 10:09 AM Abstract 1002:** First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
First Author: David W. Cescon, MD, PhD, FRCPC
- 10:21 AM Meredith M. Regan, ScD, FASCO**
Dana-Farber Cancer Institute and IBCSG Statistical Center
Discussion of Abstract(s) LBA1000-1002: Promise and Pitfalls of PFS2
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract LBA1003:** Izalontamab brengitecan (iza-bren) versus physician's choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.
First Author: Jiong Wu, MD, PhD
- 10:57 AM Abstract 1004:** Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUCE.
First Author: Roger Anton Fredy Von Moos, MD
- 11:09 AM Abstract 1005:** Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
First Author: Erika P. Hamilton, MD, FASCO
- 11:21 AM Valentina Guarneri, MD, PhD**
University of Padua and Division of Oncology 2, Istituto Oncologico Veneto IRCCS
Discussion of Abstract(s) LBA1003-1005: Diverse Approaches and Shared Challenges in Metastatic Breast Cancer
- 11:33 AM Panel Question and Answer**
- 11:45 AM Abstract LBA1006:** Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2- LA/mBC): Primary analysis of the phase III persevera BC trial.
First Author: Nicholas C. Turner, MD, PhD
- 11:57 AM Abstract LBA1007:** First-line (1L) camizestrant (CAMI) for emergent *ESR1* mutations (*ESR1m*) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.
First Author: Francois Clement Bidard, MD, PhD
- 12:09 PM To be determined**

- 12:21 PM Matthew P. Goetz, MD**
Mayo Clinic Rochester
Discussion of Abstract(s) LBA1006-LBA1008: Getting It Right Early in HR+ Metastatic Breast Cancer
- 12:33 PM Panel Question and Answer**

9:45 AM-12:45 PM Oral Abstract Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Location: S100a

Amer Methqal Zeidan, MBBS—Chair
Yale School of Medicine

Sandrine Niyongere, MD—Chair
University of Maryland Marlene and Stewart Greenebaum Cancer Center

- 9:45 AM Abstract LBA6500:** Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial.
First Author: John Mascarenhas, MD
- 9:57 AM Abstract 6501:** RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
First Author: Naseema Gangat, MBBS
- 10:09 AM Abstract 6502:** A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.
First Author: Hannah Goulart, MD
- 10:21 AM Andrew Tucker Kuykendall, MD**
H. Lee Moffitt Cancer Center and Research Institute
Discussion of Abstract(s) LBA6500-6502: Breaking Boundaries in Myeloproliferative Neoplasms and Blastic Plasmacytoid Dendritic Cell Neoplasms
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract 6503:** A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in *IDH1*-mutated acute myeloid leukemia (AML).
First Author: Jennifer Marvin-Peek, MD
- 10:57 AM Abstract 6504:** Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory *FLT3*-mutated AML.
First Author: Musa Yilmaz, MD
- 11:09 AM Abstract 6505:** Revumenib as maintenance for AML following allogeneic stem cell transplantation.
First Author: Hannah Goulart, MD
- 11:21 AM Catherine Choy Smith, MD**
UCSF Helen Diller Family Comprehensive Cancer Center
Discussion of Abstract(s) 6503-6505: Rewriting the Rules of Targeted Therapies in Acute Myeloid Leukemia
- 11:33 AM Panel Question and Answer**
- 11:45 AM Abstract 6506:** Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies.
First Author: Huaifeng Wang

Tuesday, June 2, 2026

- 11:57 AM Abstract 6507:** Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).
First Author: Mendel Goldfinger, MD
- 12:09 PM Abstract 6508:** First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.
First Author: Meng Lv, MD, PhD
- 12:21 PM Maximilian Stahl, MD**
Yale School of Medicine
Discussion of Abstract(s) 6506-6508: Expanding the Arsenal Against Leukemia and Myelodysplastic Syndromes
- 12:33 PM Panel Question and Answer**

9:45 AM-12:45 PM Oral Abstract Session

Prevention, Risk Reduction, and Genetics

Location: S100bc

Jennifer Lee Caswell-Jin, MD—Chair
Stanford Cancer Institute

Nadine M. Tung, MD, FASCO—Chair
Beth Israel Deaconess Medical Center

- 9:45 AM Abstract 10500:** Allostatic load as a mediator of exposomic risk pathways to early-onset cancer: A cross-cohort validation study.
First Author: Ravi Bharat Parikh, MD, MPP
- 9:57 AM Abstract 10501:** Predicting multi-cancer risk from EHR data using multi-agent LLMs.
First Author: Sihang Zeng
- 10:09 AM Abstract 10502:** Beyond hematologic malignancies: Clonal hematopoiesis of indeterminate potential and the risk of solid tumors in the UK biobank.
First Author: Parham Habibzadeh, MD, MS
- 10:21 AM Payal Deepak Shah, MD**
Abramson Cancer Center of the University of Pennsylvania
Discussion of Abstract(s) 10500-10502: Nature Meets Nurture: Unconventional Approaches to Understanding Cancer Risk
- 10:33 AM Panel Question and Answer**
- 10:45 AM Abstract 10503:** Effect of type and location of *BRCA2* deleterious variant on prognosis and survival in metastatic prostate cancer: A longitudinal, international, cohort study from hormone-sensitive to castration-resistant settings.
First Author: Lorena Incorvaia, MD, PhD
- 10:57 AM Abstract 10504:** Association between the rs72725854(A>T) allele and prostate cancer in males of African ancestry in a US population-based database.
First Author: Jeffrey Shevach, MD, MSCE

- 11:09 AM Abstract 10505:** Prospective prostate cancer screening in germline pathogenic variant carriers: The PATROL study.
First Author: Daniel Lee, MD

11:21 AM Veda N. Giri, MD, FASCO
Yale Cancer Center, Yale School of Medicine
Discussion of Abstract(s) 10503-10505: Genetic Prostate Cancer Risk: Beyond Borrowed Biology

11:33 AM Panel Question and Answer

- 11:45 AM Abstract 10506:** Association of GLP-1 agonists with breast cancer incidence in women.
First Author: Elizabeth Susan McDonald, MD, PhD

11:57 AM Abstract 10507: Primary prevention of acute leukemias in high-risk patients: The therapeutic promise of GLP-1 receptor agonists.
First Author: Jonathan Dao

12:09 PM Abstract 10508: Comparative analysis of tirzepatide versus metformin and insulin in type 2 diabetes patients across the 13 most common cancers.
First Author: Viraj R. Shah, MBBS

12:21 PM Rayjean Hung, MD
Lunenfeld-Tanenbaum Research Institute, Sinai Health
Discussion of Abstract(s) 10506-10508: Weighing the Evidence: GLP-1 Receptor Agonists and Cancer Risk

12:33 PM Panel Question and Answer

11:30 AM-12:45 PM Education Session

Expanding Synthetic Lethality Strategies Beyond PARP

Location: E451

Timothy A. Yap, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center
Going Beyond Immunotherapy for the Treatment of Microsatellite Instable Tumors Through the Development of Werner Helicase Inhibitors

Sophie Postel-Vinay, MD, PhD

Institut Gustav Roussy
Advances in MTA-Cooperative PRMT5 and MAT2A Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers

Fiona Simpkins, MD

University of Pennsylvania Health System
Targeting of CCNE1 Amplified Tumors With Novel PKMYT1 Inhibitors and/or WEE1 Inhibitors

Panel Question and Answer